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Hypothesis and aims of thesis 
 
The overall hypothesis of this thesis is that p38δ MAPK plays a role in the 
tumourigenicity of oesophageal cancer and may serve as a potential future 
therapeutic target. 
 
Since their discovery, the p38 mitogen-activated protein kinase (MAPK) family of 
kinases have been increasingly associated with processes involved in cellular 
transformation such as proliferation, migration and apoptosis [1]. However these 
observations relate only to the effects of the p38 MAPK family as a whole or to p38α 
MAPK. While p38α MAPK has been characterised as both a tumour promoter and a 
tumour suppressor [2, 3], information regarding the role(s) p38δ MAPK plays in 
tumourigenicity are seriously lacking. Subsequent to reporting a role for p38δ in 
inhibition of cell growth in renal clear cell carcinoma (RCC) [4], our group 
examined p38 MAPK isoform expression in a panel of cancer cell lines. Preliminary 
data indicates that p38δ MAPK, as opposed to –α, -β and –γ isoforms is 
differentially expressed in a variety of human malignancies. Approximately 75% of 
cancer cell lines examined fail to express p38δ MAPK yet consistently express the 
other p38 MAPK family members. A lack of p38δ MAPK expression was detected 
in renal, prostate, lung, liver and oesophageal cancer cell lines (Figure A.1). This 
thesis focuses on providing novel insights into specific roles for p38δ MAPK in 
several aspects of cancer progression, particularly in oesophageal carcinoma. 
However it is important to note that our findings may be translatable to other cancers 
which lack p38δ MAPK expression. 
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Figure A.1 p38 MAPK isoform expression analysis in cancer primary and 
metastatic cell lines. Western blot analysis of p38α, -β, -γ and –δ expression in HRE 
(normal human renal epithelium); 786-0, ACHN, A-498 and Caki-1 (Renal cell 
carcinoma); Huh-7 (liver carcinoma); A-549 (lung carcinoma); PC-3 (prostate 
carcinoma), HT-29 (colon carcinoma) and KE-3 (oesophageal squamous cell 
carcinoma). Aliquots of 30μg protein lysate for each cell line were loaded on a 10% 
SDS-PAGE gel and analysed by immunoblot using antibodies specific for p38α, -β, -
γ, or –δ. β-actin analysis served as a loading control. The results shown are 
representative of four independent experiments.  
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To achieve this overall goal of identifying how p38δ MAPK contributes to the 
tumourigenicity of oesophageal squamous cell carcinoma (OESCC), the project was 
divided into a number of specific aims: 
 
(1) The first specific aim of this thesis is to develop a method of examining not 
only the effects of p38δ MAPK expression in OESCC but also the 
consequences of expressing constitutively active p-p38δ MAPK. In Chapter 
3, an approach of enzyme-substrate fusion is utilised to generate a 
constitutively active form of p38δ MAPK for use in subsequent experiments.  
 
(2) The second specific aim is to evaluate the roles for p38δ MAPK in processes 
essential for OESCC progression such as proliferation, migration and 
anchorage independent growth. This will be addressed in Chapter 4 using 
stably transfected OESCC cell lines expressing p38δ and p-p38δ MAPK. 
 
(3) Chapter 5 will aim to outline the effect p38δ MAPK has on OESCC response 
to conventional and novel chemotherapeutic drug combinations and also to 
delineate the specific apoptotic pathways involved.  
 
(4) As discussed above, p38δ MAPK is differentially expressed in various cancer 
cell lines. Chapter 6 aims to uncover how p38δ MAPK expression is lost in 
these cells. Here genetic and epigenetic mechanisms of gene silencing are 
examined.  
 
 xxxii 
 
(5) Finally, as p38α MAPK is a known regulator of the cell cycle, Chapter 7 
aims to elucidate a specific contribution for p38δ MAPK to cell cycle 
progression in OESCC using a human cell cycle PCR array.  
 
In summary, this thesis aims to uncover and explain new roles for p38δ MAPK, 
particularly in OESCC progression and chemosensitivity and in doing so, 
evaluate its potential as a therapeutic target for OESCC. 
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Abstract 
 
Oesophageal cancer is an aggressive malignancy which is resistant to conventional 
therapy and has a poor prognosis. A greater understanding of the underlying 
molecular biology of oesophageal cancer and the identification of novel targets is 
necessary for the future treatment of this disease. This thesis focuses specifically on 
the ill-defined and understudied p38δ mitogen-activated protein kinase (MAPK) and 
its function(s) in oesophageal squamous cell carcinoma (OESCC). In contrast to the 
three other p38 isoforms (p38α, -β and –γ which have to-date been relatively well-
studied), p38δ MAPK signalling is poorly understood. Thus, this research elucidates 
some of the role(s) played by p38δ MAPK in cancer progression. This work outlines 
how loss of p38δ MAPK expression confers greater tumourigenicity in oesophageal 
cancer. Restoration of p38δ MAPK expression, however, has anti-proliferative and 
anti-migratory effects and decreases OESCC capacity for anchorage-independent 
growth. Using a novel application of an enzyme-substrate fusion approach, the effect 
of phosphorylated p38δ (p-p38δ) MAPK expression is also considered. The work 
goes onto describe the effect(s) of p38δ MAPK status on the chemosensitivity of 
OESCC to conventional cisplatin and 5-fluorouracil (CF) versus the effectiveness of 
doxorubicin, cisplatin and 5-fluorouracil (ACF). ACF treatment of p38δ MAPK-
negative OESCC results in decreased proliferation, migration and recovery, and 
increased apoptosis when compared with CF treatment. This thesis examines the 
potential mechanisms by which p38δ MAPK expression is lost in OESCC and 
identifies epigenetic regulation as the probable cause of differential p38δ MAPK 
expression. Also analysed is the role p38δ MAPK and p-p38δ MAPK play in the cell 
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cycle. In summary, this research identifies p38δ MAPK as a possible molecular 
target and a potential predictor of response to chemotherapy in OESCC patients.  
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1.1 Hallmarks of cancer 
 
The World Health Organisation (WHO) defines cancer as a group of diseases that 
can affect any part of the body and are characterised by the rapid creation of 
abnormal cells that grow beyond their usual boundaries [1]. This definition however 
lacks the complexity required to fully explain this intricate and multifaceted disease. 
The seminal article ‘The Hallmarks of Cancer’ identified six capabilities which 
normal cells acquire as they evolve progressively to invasive cancer cells. These are 
self-sufficiency in growth signals, evasion of growth suppressors, invasion and 
metastasis, unlimited replicative potential, angiogenesis, and evasion of cell death. 
[2] These hallmarks are essential for most forms of cancer, enabling cells to become 
tumourigenic and malignant. However tumours are now known to consist of more 
than just cancer cells. The contribution of the ‘tumour microenvironment’ to 
tumourigenesis must also be considered. As a result, two further acquired 
characteristics are now being considered as emerging hallmarks of cancer cells [3]. 
The ability of cancer cells to evade destruction by immune cells and the modification 
of cellular energetics in order to effectively support cancer cell proliferation may 
also be crucial to the pathogenesis of some if not most cancers [3]. Underlying the 
acquisition of these hallmark characteristics are genome instability and mutation of 
DNA monitoring and repair systems as well as tumour promoting inflammation. 
These enabling characteristics represent the means by which pre-malignant cells 
reach the hallmark capabilities detailed above [3]. To date targeted therapies for the 
treatment of human cancers have focused on molecular targets which are involved in 
enabling specific hallmark capabilities, some examples of which are outlined in 
Table 1.1. However this has often led to adaptation of cancer cells to alternative 
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pathways and/or increased dependence on another hallmark capability. It is possible 
however that co-targeting of multiple hallmarks and enabling characteristics may in 
the future provide more effective therapeutics for cancer. 
 
 
Table 1.1 Therapeutic targeting of the acquired capabilities necessary for 
cancer [3]. 
Hallmark/enabling charateristic Targeted therapy 
Self-sufficiency in growth signals Receptor tyrosine kinase inhibitors 
Evasion of growth suppressors Cyclin-dependent kinase inhibitors 
Invasion and metastasis HGF/c-Met inhibitors 
Unlimited replicative potential Telomerase inhibitors 
Angiogenesis Inhibitors of VEGF signalling 
Evasion of cell death Proapoptotic BH3 mimetics 
Avoidance of immune destruction Anti-CTLA4 mAb 
Deregulation of cellular energetic Aerobic glycolysis inhibitors 
Genome instability and mutation PARP inhibitors 
Tumour promoting inflammation Anti-inflammatory drugs 
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1.2 Oesophageal cancer 
 
Oesophageal cancer is an aggressive disease which responds poorly to both 
chemotherapy and radiation therapy and has a poor prognosis – the five-year survival 
rate in Ireland is ~15% [4]. Worldwide, it is the eighth most common cancer and the 
sixth leading cause of death from cancer [5]. Despite recent advances in surgical 
techniques, the lack of adequate preventative strategies, screening techniques, and 
most significantly, effective therapeutic agents all contribute to the poor outcome. 
The molecular mechanisms underlying oesophageal carcinoma are not well 
understood and as a result novel therapeutic targets are lacking. Thus, a greater 
understanding of the biology of oesophageal cancer is needed in order to identify 
new effective targeted therapies. 
 
 
1.2.1 Incidence 
In Ireland, oesophageal cancer is the fourteenth most common cancer diagnosed and 
the sixth leading cause of invasive cancer related death with an average of 372 new 
cases each year and 333 deaths in 2010 [4]. The lifetime risk (to age 75 years) of 
oesophageal cancer diagnosis is 0.4% for women and 1.0% for men. Risk increases 
with age, with a median age at diagnosis of 69 years [4]. Universally, oesophageal 
cancer is more common in men than women. Approximately 80% of cases 
worldwide occur in less developed regions. The highest incidence rates are found in 
Eastern Asia and Southern and Eastern Africa, followed by Northern Europe [5]. 
There are two main histologic forms of oesophageal cancer: squamous carcinoma 
(OESCC) which is most commonly found in the middle-third of the oesophagus and 
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adenocarcinoma (OEAC) which usually occurs in the distal oesophagus [6]. OESCC 
is dominant in most parts of the world, particularly in high-risk areas such as China; 
however OESCC incidence rates are declining in most Western countries. In 
contrast, incidence trends for OEAC are increasing in developed countries [7].   
 
 
1.2.2 Etiology 
Oesophageal cancer is a multifactorial disease. Increased risk of both OESCC and 
OEAC is most closely associated with smoking. Occurrence of oesophageal cancer 
correlates directly with both the quantity of cigarettes smoked per day and the 
duration of smoking [8, 9]. Smoking cessation can cause a considerable decrease in 
the risk of developing OESCC but does not appear to impact on the risk of OEAC 
[10, 11]. Risk factors for both OESCC and OEAC are discussed below and 
summarised in Table 1.1 
 
OESCC 
Factors which cause irritation and inflammation of the oesophageal mucosa appear 
to contribute greatly to the occurrence of OESCC. These include substantial alcohol 
intake (particularly in combination with smoking), achalasia, and frequent 
consumption of hot beverages [9, 12-14]. The autosomal dominant disorder 
nonepidermolytic palmoplantar keratoderma (tylosis) confers up to a 95% risk of 
OESCC by the age of 70 years in affected families [15, 16]. Incidence of OESCC is 
also associated with a low socioeconomic status. The reasons for this are not well 
understood but are thought to include poor nutrition and low intake of fruit and 
vegetables [9]. Human papilloma virus (HPV) infection is thought to be associated 
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with the development of OESCC. A recent meta-analysis identified an increased risk 
of OESCC in patients with HPV infection while the prevalence of HPV in OESCC 
was found to be 24.8% [17] 
 
OEAC 
Chronic gastrointestinal reflux is a major risk factor for OEAC. Patients with 
recurring reflux have an eight-fold increase in risk of developing OEAC [18]. 
Barrett’s Esophagus (BE), which develops in 5-8% of patients with gastrointestinal 
reflux disease but can also occur in patients without symptoms of reflux, appears to 
be a significant risk factor for OEAC [19, 20]. BE is characterised by a change of the 
oesophageal epithelium from squamous to columnar mucosa and the risk of 
transformation to adenocarcinoma is estimated to be 0.5% per patient, per year [21]. 
Obesity, especially visceral obesity, is also a risk factor for OEAC [22]. It has been 
estimated that obesity accounts for 23% of OEAC cases [23]. The worldwide 
increase in obesity rates in recent years is thought to be the major contributor to the 
increasing incidence of OEAC. 
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Table 1.2 Risk factors for oesophageal cancer 
Risk Factor OESCC OEAC 
Smoking/Tobacco X X 
Alcohol X  
Obesity  X 
Reflux  X 
Barrett’s Oesophagus (BE)  X 
Poverty X  
Hot beverages X  
Nonepidermolytic palmoplantar keratoderma X  
HPV X  
 
 
1.2.3 Staging, prognosis and treatment 
Oesophageal cancer is classified according to the tumour-node-metastases (TNM) 
system which describes the primary tumour, regional node metastases and distant 
metastases [24]. At the time of presentation more than 50% of patients have 
unresectable disease or distant metastases [25]. The five-year survival rate has 
improved over time from 4% to 14% and improves further following complete 
surgical removal of the tumour [26]. In terms of survival benefit for patients there is 
currently no clear optimal adjuvant or neoadjuvant treatment regimen [27]. 
Preoperative chemotherapy or chemoradiotherapy is the standard treatment for 
locally advanced disease. For management of advanced (stage IV) disease, 
chemotherapy is palliative and improves quality of life and dysphagia [25]. 
Chemotherapy may be given as a single agent or in combination, generally in a 
fluoropyrimidine/platinum regimen. Combination chemotherapy tends to achieve 
greater tumour reduction than single-drug treatments, however the median survival 
time remains unchanged and the potential for toxicity is increased [25]. 
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1.2.4 Targeted therapy for oesophageal cancer 
In this era of targeted therapy, the identification of molecular markers and 
therapeutic targets for oesophageal cancer lags significantly behind that of other 
malignancies. Although a small number of novel targets have been discovered, the 
underlying molecular mechanisms governing oesophageal carcinoma remain unclear. 
Promising molecular targets are generally considered to be genes mutated at a high 
frequency, regulators of key cancer phenotypes, or receptors overexpressed in cancer 
cells [25]. Several molecular targets which are commonly found in other cancers 
have been evaluated for efficacy in oesophageal cancer. These include epidermal 
growth factor receptors EGFR and HER-2/Neu as well as regulators of angiogenesis 
(vascular epithelial growth factor, VEGF), inflammation (Cox-2), apoptosis (p53, 
Bcl-2) and cell cycle control (p16, p21) [25]. Although therapies targeting these 
molecules in oesophageal cancer continue to undergo phase I/II clinical trials, they 
have shown limited effectiveness to date [25, 28]. As such the development of novel 
diagnostic markers and molecular targeted therapies is urgently required.  
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1.3 p38δ MAPK – emerging roles of a neglected isoform 
 
p38δ MAPK is a unique stress responsive protein kinase. While the p38 MAPK 
family as a whole has been implicated in a wide variety of biological processes, a 
specific role for p38δ MAPK in cellular signalling and its contribution to both 
physiological and pathological conditions are presently lacking. Recent emerging 
evidence, however, provides some insights into specific p38δ MAPK signalling. 
Importantly, these studies have helped to highlight functional similarities as well as 
differences between p38δ MAPK and the other members of the p38 MAPK family of 
kinases. Here we discuss the current understanding of the molecular mechanisms 
underlying p38δ MAPK activity. We outline a role for p38δ MAPK in important 
cellular processes such as differentiation and apoptosis as well as pathological 
conditions such as neurodegenerative disorders, diabetes, and inflammatory disease. 
Interestingly, disparate roles for p38δ MAPK in tumour development have also 
recently been reported. Thus, we consider evidence which characterises p38δ MAPK 
as both a tumour promoter and a tumour suppressor. In summary, while our 
knowledge of p38δ MAPK has progressed somewhat since its identification in 1997, 
our understanding of this particular isoform in many cellular processes still strikingly 
lags behind that of its counterparts. 
 
 
1.3.1 p38 MAPK isoform evolution 
The first and now archetypal member of the p38 MAPK family, p38α MAPK, was 
identified by four independent groups in 1994. It was isolated as a 38 kDa protein 
rapidly tyrosine phosphorylated in response to lipopolysaccharide (LPS) stimulation 
 10 
 
[29], as a molecule that binds pyridinyl-imidazole drugs which inhibit the synthesis 
of proinflammatory cytokines [30] and as an activator of MAPK activated protein 
kinase 2 (MAPKAP-K2/MK2) and small heat shock proteins in cells stimulated with 
heat shock or interleukin- (IL-) 1 [31, 32]. This was followed by the subsequent 
identification of p38β MAPK in the same year, p38γ MAPK in 1996, and lastly p38δ 
MAPK in 1997 [33-37]. The product of the S. cerevisiae HOG1 gene, an important 
component of osmoregulation and the cell cycle, was found to be a homologue of 
p38 MAPK [38]. This conservation from yeast to mammals is significant as it 
indicates that the p38 family is responsible for critical cellular processes. A study of 
the evolutionary history of MAPKs suggests that each p38 MAPK family member 
evolved from a single ancestor. In fact it appears that MAPK12 (p38γ) arose from a 
tandem duplication of MAPK11 (p38β) on chromosome 22 while MAPK14 (p38α) 
and MAPK13 (p38δ) subsequently resulted from a single segmental duplication of 
theMAPK11-MAPK12 gene unit on chromosome 6 [39]. These gene duplications 
appear to have occurred before the species separation of nematodes but after the 
species separation of arthropods. Interestingly, unlike the other p38 isoforms, 
MAPK13 has not been identified in teleosts [39]. This indicates that a MAPK13 
gene deletion event may have occurred subsequent to gene duplication in the 
evolution of these species. Duplicated genes are generally assumed to be functionally 
redundant at the time of origin and are eventually silenced. The evolutionary 
preservation of the four p38 MAPK isoforms therefore suggests functional 
differentiation of the individual family members. Thus, while the majority of 
research to date has focused on p38α and p38β MAPKs, each isoform is an 
important kinase in its own right with distinct cellular functions. This chapter aims to 
highlight components of the previously neglected p38δ MAPK signalling pathway 
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and emphasises recent progress in our understanding of p38δ MAPK involvement in 
diverse physiological as well as pathological processes.  
 
The use of pyridinyl-imidazole inhibitors has largely driven the advancement in our 
understanding of p38α and p38β MAPK signalling, functions, and substrates. Both 
p38α and p38β MAPK are highly sensitive to inhibition by SB203580, SB202190, 
and newer compounds such as L-167307 [30, 33, 40]. In contrast, the observation 
that p38δ MAPK is insensitive to inhibition by pyridinyl-imidazole compounds has 
hindered its study in cellular events [35, 37].The differential sensitivity to these 
drugs can be attributed to amino acid sequence variability at the ATP binding pocket 
where these compounds bind competitively, facilitated by interactions with nearby 
amino acids. Thr106 of p38α and p38β MAPK has been identified as the major 
determinant for imidazole inhibitor specificity as it orientates the drug to interact 
with His107 and Leu108 thereby preventing ATP binding [41]. The equivalent 
residue in p38δ MAPK is a methionine (Met), the large side chain of which prevents 
binding of these inhibitors. In fact, substitution of Met106 in p38δ MAPK with Thr 
was found to confer some sensitivity to inhibition by SB203580 [42]. Conversely, 
p38α MAPK mutants in which Thr106 is replaced with Met displayed reduced 
sensitivity to inhibition by SB203580 [43]. It is unfortunate that no potent p38δ 
MAPK specific inhibitor has been identified to date. Although the diaryl urea 
compound BIRB796 allosterically inhibits p38δ MAPK at high concentrations, it is 
also a powerful inhibitor of p38α, -β, and -γ MAPK [44]. While varying the 
concentration of BIRB796 and combining it with SB203580 may be of some use in 
identifying p38δ MAPK specific signalling pathways, the possible influence of the 
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other p38 MAPK isoforms, in particular p38γ MAPK, must be considered when 
interpreting any results. 
 
 
1.3.2 p38δ MAPK expression and activation 
Unsurprisingly, p38δ MAPK shares highly similar protein sequences with the other 
p38 MAPK isoforms. It displays 61%, 59%, and 65% amino acid identity to p38α, -
β, and –γ MAPKs, respectively [35]. Differences in sequence between p38δ MAPK 
and the other p38 MAPK family members can be observed in the ATP binding 
pocket. This has consequences for inhibitor sensitivity and contributes to substrate 
specificity. On the other hand, the greatest sequence similarities lie in the highly 
conserved kinase domains, where the four isoforms share >90% amino acid identity 
[45]. Within kinase subdomain VIII (of XI), p38δ MAPK possesses a Thr-Gly-Tyr 
(TGY) dual phosphorylation motif which is the hallmark of p38 MAPKs and is 
conserved among all known mammalian p38 isoforms [35-37, 46]. p38δ MAPK has 
a distinct distribution profile in human tissue that is relatively limited compared to 
that of p38α and p38β MAPK isoforms which are largely ubiquitously expressed 
[36]. High levels of p38δ messenger RNA (mRNA) have been detected in endocrine 
tissues such as salivary, pituitary, prostate, and adrenal glands, while more modest 
levels are expressed in the stomach, colon, trachea, pancreas, skin, kidney, and lung 
[36]. This differential expression in different cell and tissue types is indicative of a 
specific biological effect of p38δ MAPK activation in these cell types, distinct from 
that of the other p38 family members. 
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The murine p38δ MAPK amino acid sequence is 92% identical to the human 
sequence and the adult mouse displays a broadly similar pattern of p38δ MAPK 
expression to that seen in human tissue, that is, lung, testis, kidney, and gut 
epithelium [46]. Murine p38δ MAPK expression varies at different stages in the 
developing mouse embryo. At 9.5 days it is primarily expressed in the developing 
gut and septum transversum, while by 15.5 days its expression expands to most 
developing epithelia [46]. This suggests that p38δ MAPK has a role in embryonic 
development. However, knock-out of p38δ MAPK results in mice which are both 
viable and fertile and exhibit a normal phenotype [47]. Moreover, while p38β- and 
p38γ-null mice as well as p38γ/p38δ double knockout (KO) mice are also 
phenotypically normal [47, 48], genetic ablation of p38α MAPK is embryonic lethal 
at day 10.5–11.5 [49]. Functional redundancy among the p38 isoforms is a likely 
explanation with p38α, -β, or -γ compensating for the loss of p38δ MAPK activity 
during development. However, it appears that p38α MAPK plays a critical role in 
early development where its loss cannot be overcome.  
 
p38α, -β, and -γ MAPK isoforms are activated by alterations in the physical and 
chemical properties of the extracellular environment with diverse triggers including 
environmental stress signals, inflammatory cytokines, and mitogenic stimuli [29, 33, 
34, 50]. Using transiently expressed epitope-tagged p38δ MAPK, a similar activation 
profile has been defined for p38δ MAPK [35-37]. It is strongly activated by 
environmental alterations in osmolarity, ultraviolet (UV) irradiation, and oxidation. 
It is also moderately activated by chemical stressors and proinflammatory cytokines 
including arsenite, anisomycin, tumour necrosis factor- (TNF-)  , and IL-1. Despite 
their similar activation profiles, differences in the levels of activation of p38δ MAPK 
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and the other p38 MAPK isoforms have been reported. For example, while 
hyperosmolarity appears to stimulate both p38α and p38δ MAPK to a similar degree, 
under hypoosmotic conditions, p38α MAPK is more strongly activated than p38δ 
MAPK [35]. A range of mitogen-activated protein kinase kinase kinases (MAP3Ks) 
have been implicated in the activation of the p38 MAPK pathway, including  mixed-
lineage kinases (MLKs), transforming growth factor β activated kinase 1 (TAK1), 
apoptosis signal-regulating kinase 1 (ASK1), thousand-and one amino acid (TAO), 
dual-leucine-zipper-bearing kinase 1 (DLK1), MAPK/ERK kinase kinases 
(MEKKs), and leucine zipper and sterile-  motif kinase 1 (ZAK1) (Figure 1.1). To 
date their individual contribution to p38δ MAPK signalling in particular is not yet 
understood [51-56]. Further upstream of the MAP3Ks is a complex network 
involving members of the Ras/Rho family of small GTP-binding proteins and 
heterotrimeric G-protein coupled receptors (GPCR) [57, 58]. This adds to the 
diversity of signalling from various stimuli contributing to the crosstalk between p38 
MAPKs and other signalling pathways.  
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Figure 1.1 Schematic representation of the current understanding of p38δ 
MAPK signalling and activation. A variety of extracellular stimuli can activate the 
MAPK signalling pathway resulting in dual phosphorylation of p38δ MAPK. Known 
substrates of active p38δ MAPK include transcription factors, structural proteins, 
kinases, and translation repressors. Phosphorylated substrates affect several cellular 
processes and contribute to the pathogenesis of diseases such as cancer, diabetes, and 
neurodegenerative and inflammatory conditions. 
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The upstream direct activators responsible for dual phosphorylation of the p38 
MAPK TGY motif are the MAPK kinases (MKKs). p38δ MAPK is unique as it can 
be activated by four separate MKKs: the p38 MAPK specific MKK3 and MKK6 and 
also the JNK MKKs-4 and -7 [35-37, 46]. However, information regarding the 
specific contributions of these individual MKKs to p38δ MAPK activation in 
different cell types and under diverse conditions is lacking. Current evidence 
suggests that activation of p38δ MAPK is significantly influenced by both the nature 
and the strength of the stimulus as well as the cell type involved. This may be the 
result of varying levels of expression of upstream components of the MAPK 
signalling cascade in different cell types. For example, MKK3 is the major direct 
activator of p38δ MAPK phosphorylation in response to UV radiation, hyperosmotic 
shock, and TNFα in mouse embryonic fibroblast (MEF) cells [59]. It also appears to 
be the primary kinase responsible for p38δ MAPK activation in response to 
transforming growth factor-β1 (TGF-β1) as MKK3 deficiency impairs endogenous 
p38δ activation by TGF-β1 in murine glomerular mesangial cells [60]. On the other 
hand, MKK6 was identified as the major activator of p38δ MAPK in KB (HeLa) 
cells subjected to IL-1, anisomycin, or osmotic stress [37]. Furthermore, MKK7 is 
reported to be responsible for the activation of p38δ MAPK in 293T cells under 
peroxide stress, mediated by the scaffolding action of islet brain-2 [61]. Further 
complicating the current understanding of p38δ MAPK activation is the likelihood 
that, in some cases, the cooperation of two MKKs may be necessary. While MKK4 
preferentially phosphorylates JNK on Tyr, MKK7 preferentially phosphorylates JNK 
on Thr [62-64]. Therefore it must be considered possible that the combined activity 
of these two MKKs may be required to fully phosphorylate p38δ MAPK on both the 
Tyr and the Thr residues. Interestingly, two reports outline a MKK independent 
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mechanism of activation for p38α MAPK via autophosphorylation [65, 66]. While 
autophosphorylation activity is detected in intrinsically active p38δ mutants [67, 68], 
no such pathway has been observed which activates the endogenous p38δ MAPK 
isoform. 
 
An important factor in determining the biological consequences of p38δ MAPK 
phosphorylation is the strength and duration of the activation signal. p38δ MAPK 
activation is largely transient with activation and downregulation occurring within 
minutes of stimulation [45]. This is due to the regulatory action of protein 
phosphatases which again appears to be cell-type specific. While MAPK 
phosphatase 1 inactivates p38δ MAPK in HEK293FT cells, it does not interact with 
p38δ MAPK in the NIH3T3 cell line [69, 70]. The protein serine/threonine 
phosphatases PP1 and PP2A have also been shown to be involved in p38δ MAPK 
phosphorylation as okadaic acid (OA), a PP1/PP2A inhibitor, causes increased p38δ 
MAPK activity in human epidermal keratinocytes [71]. 
 
 
1.3.3 Novel p38δ MAPK substrates 
While p38 MAPKs are proline-directed kinases, substrate specificity is also 
determined by docking domains both in the MAPK itself and in the target protein 
[72]. Therefore, although p38δ MAPK substrate specificity overlaps to some extent 
with that of p38α, -β, and -γ MAPKs, there are a number of notable differences. 
Common substrates of p38 MAPKs include MBP, PHAS-1, and transcription factors 
ATF2, SAP1, Elk-1, and p53 (Figure 1.1). In contrast, however, substrates such as 
MAPK activated protein kinase 2 (MAPKAP-K2) and MAPKAP-K3 which are the 
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major downstream kinases of p38α and p38β MAPK are not phosphorylated by p38δ 
MAPK [35-37, 73] (Table 1.2). 
 
Tau  
At the time p38δ MAPK was first described the microtubule-associated protein tau 
was identified as a strong in vitro substrate for p38δ MAPK [74]. Tau is a 
component of the cytoskeleton network and under normal conditions it stabilises 
microtubule assembly by binding to β-tubulin. Phosphorylation of tau at T50 by 
p38δ MAPK causes it to be functionally modified and enhances its capacity to 
promote microtubule assembly. This effect is seen in neuroblastoma in response to 
osmotic shock where tau T50 phosphorylation occurs soon after p38δ MAPK 
activation, aiding the adaptive response of neurons to changes in osmolarity [74]. It 
appears, however, that subsequent hyperphosphorylation of tau at additional sites 
causes it to dissociate from the cytoskeleton, thereby promoting its self-assembly 
[75]. This aggregation destabilises the microtubule network and contributes to the 
development of neurofibrillary tangles [76]. Notably, Alzheimer’s disease and other 
neurodegenerative disorders known as tauopathies are characterised by the 
aggregation in the brain of these neurofilament structures [77]. There is therefore a 
clearly defined role for p38δ MAPK in the pathogenesis of neurodegenerative 
disease, making it a good potential therapeutic target for these disorders. 
 
Stathmin 
There is further evidence of a role for p38δ MAPK in cytoskeleton regulation as the 
microtubule associated protein stathmin has also been characterised as a good p38δ 
MAPK substrate in vitro and in transfected cells exposed to osmotic shock [78]. The 
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normal physiological role of stathmin is to sequester free tubulin and increase 
depolymerisation of microtubules [79, 80]. It is possible that phosphorylation of 
stathmin by p38δ MAPK blocks its ability to destabilise microtubules and as a result 
promotes microtubule polymerisation and enhances cell survival under stress 
conditions. 
 
eEF2K 
In response to anisomycin stimulation, p38δ MAPK has been shown to be the main 
p38 MAPK isoform which phosphorylates eukaryotic elongation factor 2 kinase 
(eEF2K) [81]. Phosphorylation of eEF2K on Ser359 inactivates the kinase and as a 
result removes its inhibitory phosphorylation of eukaryotic elongation factor 2 
(eEF2). eEF2 in turn promotes the movement of the ribosome along mRNA during 
translation [82]. This suggests that, by inhibiting eEF2K and consequently activating 
eEF2, p38δ MAPK is responsible for driving the translation of proteins associated 
with stress responses. Consistent with this hypothesis is the observation that the 
MKK3/6-p38δ MAPK/eEF2K pathway in myeloid cells is implicated in the 
production of the proinflammatory cytokine TNFα in bacterial LPS induced acute 
liver disease [83]. These differences in substrate specificity in combination with its 
unique tissue distribution profile demonstrate that despite similarities in stimuli the 
consequences of p38δ MAPK can potentially be significantly different to those of 
the other p38 MAPK isoforms. 
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Table 1.3 Known p38δ MAPK substrates and their biochemical functions 
Substrate Function Consequences of phosphorylation 
AP1 Transcription factor Activation of transcription, involcurin 
expression, keratinocyte differentiation [84] 
ATF2 Transcription factor Activation of transcription [35, 37] 
C/EBP Transcription factor Keratinocyte differentiation [85] 
c-myb Transcription factor c-myb degradation [86] 
eEF2K Inhibitory kinase eEF2 activation, protein synthesis [81] 
Elk1 Transcription factor Activation of transcription [35, 37] 
p53 Transcription factor p21 expression, G1 phase arrest [37, 87] 
PHAS-1 Translation repressor Dissociation from eIF4E, activation of 
translation [35] 
PKD1 Serine-threonine kinase Inhibition of PRKD1 activity [88] 
SAP-1 Transcription factor Activation of transcription [37] 
SAP-2 Transcription factor Activation of transcription [37] 
Stathmin Microtubule protein  Cytoskeleton reorganisation [78] 
Tau Microtubule protein Microtubule assembly, tau self-aggregation 
[74] 
TonEBP/ 
OREBP 
Transcription factor Impaired TonEBP/OREBP transcriptional 
activity [69] 
AP1: activator protein 1; ATF2: activating transcription factor 2; C/EBP: CCAAT 
(cytosine-cytosine-adenosine-adenosine-thymidine)-enhancer-binding protein; myb: 
myeloblastosis; eEF2K: eukaryotic elongation factor 2 kinase; eEF2: eukaryotic 
elongation factor 2; PHAS-1: Phosphorylated heat- and acid-stable protein 1; PKD1: 
protein kinase D 1; SAP: Serum Response Factor Accessory Protein; eIF4E: 
eukaryotic translation initiation factor 4E  
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1.3.4 p38δ MAPK function and new roles in human disease 
Since the discovery of p38δ MAPK in 1997 it has been implicated in a range of 
diverse physiological events, namely, differentiation, apoptosis, and cytokine 
production (Figure 1.1). The greatest understanding of its involvement in these 
cellular processes has been achieved from work using keratinocytes and the majority 
of these studies have previously been reviewed [89, 90]. Research is now emerging 
which establishes p38δ MAPK as a regulator of these processes in other cell types. 
As a result in the past five years p38δ MAPK has also been implicated in the 
pathogenesis of diabetes, inflammatory diseases, and cancer. This progress has been 
achieved with the development of p38δ MAPK KO mouse models which are proving 
to be a useful tool in elucidating novel roles for p38δ MAPK in vivo. 
 
Differentiation and psoriasis  
A number of different studies have identified a role for p38δ MAPK in keratinocyte 
differentiation, a process critical for the precise control of normal epidermal 
homeostasis. p38δ MAPK induces keratinocyte differentiation by regulating the 
expression of involucrin, a marker of keratinocyte terminal differentiation [84, 85, 
91]. p38δ MAPK activation by 12-otetradecanoylphorbol-13-acetate (TPA), calcium, 
OA, or green tea polyphenol corresponds with increased involcurin promoter 
activity, mRNA, and protein expression, as well as increased levels and activity of 
AP1 and C/EBP transcription factors [84, 85, 92]. Importantly, these responses are 
observed in the presence of a p38α/β MAPK inhibitor. In addition p38γ MAPK is 
poorly expressed in keratinocytes [91] confirming a specific role for p38δ MAPK. 
Involucrin expression can also be further upregulated in keratinocytes coexpressing 
p38δ MAPK and protein kinase C (PKC) -η, -δ or ε isoforms [85]. Of note 
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cholesterol depleting agents and overexpression of MKK6/MKK7 have previously 
been shown to induce involucrin expression via activation of p38α MAPK [91, 93, 
94]. This highlights the significance of the stimulus type in determining p38 MAPK 
isoform activation. A further role for p38δ MAPK in keratinocyte differentiation was 
recently identified. p38δ MAPK can regulate expression of ZO-1, an epidermal tight 
junction membrane protein associated with keratinocyte differentiation [95]. 
Inhibition of p38δ MAPK results in depletion of ZO-1 protein in calcium induced 
differentiating keratinocytes while other junction proteins remain unaffected [95]. 
Psoriasis is a benign, chronic inflammatory skin condition that is characterised by 
hyperproliferation and differentiation of keratinocytes as well as increased 
expression of inflammatory cytokines. Given the significant role p38δ MAPK plays 
in keratinocyte differentiation, it is no surprise that aberrant p38δ MAPK signalling 
has been implicated in the pathogenesis of psoriasis. Expression of the MAPK13 
gene is commonly upregulated in psoriasis [96]. Furthermore, an increase in p38δ (as 
well as -α and -β) MAPK activity has been detected in psoriatic lesions compared to 
nonlesional psoriatic skin. After treatment for psoriasis, phosphorylated p38 MAPK 
levels return to those of uninvolved skin [97]. 
 
Further to its role in keratinocyte differentiation p38δ MAPK is also implicated in 
hematopoiesis. In human primary erythroid cells, p38δ MAPK mRNA is only 
expressed in late-stage differentiation where along with p38α MAPK it is 
increasingly activated [98]. This may suggest a functional role for p38δ MAPK in 
erythrocyte membrane remodelling and enucleation. Interestingly, an increase in 
p38δ MAPK mRNA and protein expression is observed as blood monocytes 
differentiate to macrophages [99]. This suggests a role for p38δ MAPK in functions 
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gained by mature macrophages. A possible candidate is phagocytosis given that the 
microtubule associated protein stathmin is such a strong p38δ MAPK substrate. 
 
Most recently, p38δ MAPK has been identified as a component of differentiation in 
bone repair [100]. In bone cell differentiation during wound healing, wild type (WT) 
monocytes differentiate to calcifying/bone-forming monoosteophils upon treatment 
with the peptide LL-37. p38δ MAPK protein and mRNA is highly expressed in 
monoosteophils compared to undifferentiated monocytes. Monocytes from p38δ 
MAPK KO mice are incapable of this differentiation, suggesting a critical role for 
p38δ MAPK in this process [100]. 
 
Apoptosis and diabetes  
As well as its significant role in keratinocyte differentiation, p38δ MAPK has also 
been identified as a regulator of keratinocyte apoptosis. This dual functional role 
may be attributed to the overlap of differentiation and apoptosis signalling pathways 
[101]. As well as inducing involucrin expression [92], OA simultaneously causes 
disruption of mitochondrial membrane potential and caspase-dependent apoptosis 
[71]. Overexpression of p38δ MAPK enhances this OA driven apoptotic 
morphology. This response is specific to p38δ MAPK activation as it occurred in the 
presence of the p38α/β MAPK inhibitor SB203580 [71]. Furthermore, p38δ MAPK 
coexpressed with either MEK6 or PKCδ, both upstream p38 MAPK activators, 
elicited an apoptotic response similar to that induced by OA but in the absence of an 
external stimulus. This was also independent of SB203580, again ruling out a 
contribution from other p38 MAPK isoforms [102]. Interestingly, concurrent p38δ 
MAPK activation and inactivation of the proproliferative MAPK extracellular-
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regulated kinase (ERK) 1/2 were observed with OA stimulation and PKCδ/p38δ 
MAPK coexpression [71, 92, 102]. In fact a reduction in ERK1/2 activation appears 
to be critical for apoptosis as its constitutive activation inhibited PKCδ/p38δ MAPK 
mediated apoptosis [102]. Therefore, it is likely that a specific balance between 
prosurvival ERK1/2 and proapoptotic p38δ MAPK is essential in determining 
keratinocyte fate. In regulating this balance, p38δ MAPK and ERK1/2 form a 
complex that is translocated to the nucleus upon stimulation by PKCδ. This nuclear 
localisation facilitates ERK1/2 inactivation by nuclear phosphatases, while 
maintaining p38δ MAPK activation [102]. 
 
A role for p38δ MAPK in apoptosis has recently been demonstrated in vivo using 
p38δ MAPK KO mice. Mice deficient in p38δ MAPK displayed a fivefold lower rate 
of pancreatic β cell death in response to oxidative stress than WT mice and are 
afforded protection against insulin resistance induced by a high-fat diet [88]. This 
would appear to link p38δ MAPK to the pathogenesis of diabetes mellitus, a disease 
characterised by reduced insulin sensitivity and a decrease in insulin-producing 
pancreatic β cells [88]. Increased p38 MAPK pathway activity has indeed been 
observed in both type 1 and type 2 diabetes and is correlated with late complications 
of hyperglycaemia, including neuropathy and nephropathy [103, 104]. p38δ MAPK 
specifically has also been implicated in the regulation of insulin secretion. 
Phosphorylation by p38δ MAPK negatively regulates the activity of protein 
kinaseD1 (PKD1), a known positive regulator of neuroendocrine cell secretion [88]. 
Thus, pronounced activation of PKD1 has been observed in pancreatic β cells 
lacking p38δ MAPK. As p38δ MAPK is normally quite highly expressed in the 
pancreas this can contribute to heightened insulin secretion and improved glucose 
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tolerance in p38δ MAPK-null mice [88]. The pivotal role p38δ MAPK plays in 
integrating insulin secretion and survival of pancreatic β cells makes it an attractive 
potential therapeutic target for the treatment of human diabetes. 
 
Cytokine production and inflammatory diseases  
One of the pathways by which p38α MAPK was discovered was via its identification 
as a regulator of proinflammatory cytokine biosynthesis [30]. Thus, its role in 
cytokine signalling and cytokine-dependent inflammatory diseases is well 
characterised. Consequently, some recent research using p38δ MAPK KO mouse 
models has focused on identifying specific roles for p38δ MAPK in inflammation. A 
study of p38δ MAPK KO mice as well as myeloid-restricted deletion of p38δ MAPK 
in mice has shown that p38δ MAPK is required for the recruitment of neutrophils to 
sites of inflammation [105]. p38δ MAPK and its downstream target protein kinase D 
(PKD) 1 conversely regulate phosphatase and tensin homolog (PTEN) activity to 
control neutrophil extravasation and chemotaxis. The accumulation of neutrophils at 
inflammatory sites is known to trigger inflammation-induced acute lung injury (ALI) 
which can cause acute respiratory distress syndrome (ARDS), a condition with a 
high mortality rate [106]. Therefore, abnormal p38δ-PKD1 signalling may play an 
important role in both ALI and ARDS in humans. 
 
Rheumatoid arthritis is a typical example of an inflammatory disease involving 
chronic synthesis of proinflammatory cytokines which result in synovial hyperplasia 
and joint destruction [107]. While p38δ MAPK (along with -α, -β, and -γ) is 
expressed in the synovium of rheumatoid arthritis patients its level of activation is 
lower than that of the four other p38 MAPK isoforms [108]. Despite this low level of 
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activation new research has identified p38δ MAPK as an essential component of 
joint damage in a collagen-induced model of arthritis. p38γ/δ−/− mice displayed 
reduced arthritis severity compared to WT mice [109]. The decrease in joint 
destruction was associated with lower expression of IL-1β and TNFα as well as a 
reduction in T cell proliferation, interferon (IFN) -γ, and IL-17 production.  Lack of 
either p38γ or p38δ MAPK alone yielded intermediate effects, suggesting significant 
roles for both isoforms in arthritis pathogenesis. 
 
Proinflammatory cytokines also play a significant role in the pathogenesis of 
inflammatory airway diseases, including asthma, chronic obstructive pulmonary 
disease (COPD), and cystic fibrosis. While increased mucus production is linked to 
the morbidity and mortality of such diseases the underlying molecular mechanisms 
remain somewhat unclear [110]. The critical driver of mucus production is thought 
to be IL-13 production by immune cells which results in mucin gene expression 
[111, 112]. In the last few years p38δ MAPK has been implicated in the signalling 
pathway responsible for controlling IL-13 driven excess mucus production. 
Increased MAPK13 gene expression is evident in the lungs of patients with severe 
COPD [113]. Novel inhibitors with increased activity against p38δ MAPK blocked 
mucus production by IL-13 in human airway epithelial cells [113].Thus, in patients 
with hypersensitivity airway diseases there exists a potential opportunity for 
therapeutic intervention should specific p38δ MAPK inhibitors become clinically 
available. 
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1.3.5 p38δ MAPK and cancer 
In recent years, the function of the p38 MAPK signalling pathway in malignant 
transformation has been intensively studied. As a result, the best characterised 
isoform, p38α MAPK, has been identified as both a tumour promoter [114-116] and 
a tumour suppressor [117-119]. Recent studies have now also implicated p38δ 
MAPK in cancer development and progression. Like p38α MAPK, p38δ MAPK 
would also appear to have both pro- and anti-oncogenic roles, depending on the cell 
type studied. 
 
Interest in p38δ MAPK as a potential tumour promoter is based on the evidence that 
p38δ MAPK expression and activation are significantly increased in a variety of 
carcinoma cell lines such as human primary cutaneous squamous carcinoma cells  
[96], head and neck squamous carcinoma cells and tumours [115], 
cholangiocarcinoma (CC), and liver cancer cell lines [120]. p38δ MAPK was first 
shown to promote a malignant phenotype (over eight years ago) in head and neck 
squamous cell carcinoma (HNSCC) [115]. It was shown to regulate HNSCC 
invasion and proliferation through controlling expression of 
matrixmetalloproteinase-1 and -13 [115, 121]. Moreover the expression of dominant-
negative (DN) p38δ MAPK impaired the ability of cutaneous HNSCC cells to 
implant in the skin of immunodeficiency mice as well as inhibiting the growth of 
xenografts [115]. 
 
p38δ MAPK-null mice have been utilised to demonstrate that p38δ MAPK is 
required for the development of multistage chemical skin carcinogenesis in vivo. 
When compared with WT mice, p38δ MAPK-deficient mice displayed reduced 
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susceptibility to 7, 12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-
acetate induced skin carcinoma with a significant delay in tumour development 
[122]. Furthermore, both tumour numbers and size were significantly decreased 
compared with WT mice [122]. This decreased carcinogenesis was associated with 
reduced levels of proproliferative ERK1/2-AP1 signalling and decreased activation 
of signal transducer and activator of transcription 3 (Stat3) [122]. The ERK1/2-AP1 
pathway is a key cancer promoting cascade previously implicated in skin 
carcinogenesis [123, 124]. Stat3 meanwhile is an oncogenic transcription factor 
involved in chemical and UVB-induced transformation [125]. It is also 
proproliferative and plays a role in angiogenesis and invasion [126, 127]. Therefore 
p38δ MAPK promotion of proliferation via Stat3 may be a significant mechanism in 
the promotion of carcinogenesis by p38δ MAPK. Similarly, p38δ MAPK KO mice 
have reduced susceptibility to development of K-ras driven lung tumourigenesis. 
Compared with WT mice, p38δ−/−/KRasG12D+/− mice displayed significantly 
decreased tumour numbers, average tumour volume, and total tumour volume per 
lung [122]. This is in contrast to p38α MAPK-deficient mice which display 
hyperproliferation of lung epithelium and increased K-Ras-induced lung tumour 
development [118]. This highlights once again the distinct and often opposing 
functions of the individual p38 MAPK isoforms. 
 
In contrast to the relatively well characterised role of p38δ MAPK as a tumour 
promoter an increasing number of reports since 2011 outline its activity as a tumour 
suppressor. The first indication of a tumour suppressive role for p38δ MAPK was 
observed in MEFs. p38δ−/− (and p38γ−/−) MEFs displayed increased cell motility 
compared to WT cells [128]. Furthermore, while WT fibroblasts ceased to proliferate 
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after reaching 100% confluency, p38δ−/− MEFs continued to grow, forming foci 
rather than a monolayer [128]. This deregulation of contact inhibition is significant 
as it is a hallmark of malignant transformation [3]. Further supporting the hypothesis 
that loss of p38δ MAPK confers a survival advantage, p38δ MAPK expression was 
found to be downregulated in brain metastases of triple-negative breast cancer 
(TNBC). Abolition of p38δ MAPK expression in TNBC induced cell growth, while 
overexpression of p38δ MAPK in brain metastases reduced growth rates [129]. 
 
Cancer genomes are increasingly associated with epigenetic alterations whereby 
tumour suppressor genes exhibit promoter hypermethylation. Interestingly, 
hypermethylation of the MAPK13 gene promoter region has recently been 
characterised in both malignant pleural mesothelioma [130] and primary cutaneous 
melanoma [131]. This methylation was associated with downregulation of p38δ 
MAPK mRNA and protein expression. Melanoma cell lines displaying MAPK13 
gene promoter methylation do not express significant levels of p38δ MAPK when 
compared to fibroblasts, melanocytes, and melanoma cell lines with unmethylated 
MAPK13 promoters. Furthermore, treatment of melanoma cells with the 
demethylating agent 5-aza-2’-deoxycytidine significantly increases the expression of 
the MAPK13 gene [131, 132]. Importantly, reestablishment of p38δ MAPK 
expression in melanoma cells with MAPK13 hypermethylation suppressed cell 
proliferation. The effect was further enhanced upon expression of a constitutively 
active form of p38δ MAPK. Interestingly, however, overexpression of p38δ MAPK 
or its constitutively active form in cells in which MAPK13 was not epigenetically 
silenced only marginally affected proliferation [131]. 
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1.4 Summary 
 
Oesophageal cancer is one of the deadliest cancers worldwide with a five-year 
survival rate of less than 15 % [26]. It is an aggressive disease and is highly 
insensitive to conventional chemotherapy [133]. Despite this, it remains one of the 
least studied of all cancer types and the underlying molecular mechanisms which 
govern oesophageal cancer development and progression are poorly understood. This 
contributes to the poor prognosis and high-mortality rate of oesophageal cancer as 
specific tumour markers and effective molecular therapeutic targets are seriously 
lacking. The p38 MAPK family of kinases has in recent years emerged as important 
regulators of cellular processes which are critical for tumourigenesis such cell 
proliferation, migration and apoptosis [134]. As such, these kinases have been 
characterised as both tumour promoters and tumour suppressors and therefore 
represent important potential therapeutic targets for a host of cancers. However, 
much of the research to date has focused p38α MAPK, or examines the p38 MAPK 
family as a whole. It is now becoming increasingly clear that conclusions drawn 
from p38α MAPK (and to an extent p38β MAPK) studies cannot be automatically 
applied to the most recently discovered isoform, p38δ MAPK, due to their different 
expression patterns, substrate specificities, and sensitivity to chemical inhibitors. As 
a result, the p38δ MAPK isoform remains under-studied and its cellular functions are 
ill-defined. The limited information available regarding p38δ MAPK suggests 
however that it may also play opposing roles in tumourigenesis, depending on cell 
type. Therefore the aims of this thesis are to provide insights into how this unique 
isoform contributes to tumourigenicity in OESCC and to evaluate its potential as a 
much needed therapeutic target for this disease.  
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2.1 Materials 
 
2.1.1 Reagents 
All chemicals, reagents and solvents were obtained from Sigma Aldrich Ireland Ltd 
(Arklow, Ireland) unless otherwise stated. All reagents were stored and prepared 
according to manufacturer’s directions.  
 
Cell culture reagents 
Media (RPMI-1640, Dulbecco’s modified eagle’s medium (DMEM), F12 (Ham) 
nutrient mixture) and supplements (heat inactivated foetal bovine serum (FBS), 
penicillin/streptomycin solution), as well as trypsin-EDTA and Dulbecco’s 
phosphate buffered saline were purchased from Sigma Aldrich Ireland Ltd (Arklow, 
Ireland). Geneticin was supplied by Gibco® (Life Technologies, Grand Island, NY, 
USA). 
 
Immunoblotting reagents 
Primary antibodies for immunoblotting were as outlined in Table 2.1. Secondary 
antibodies for Western blotting were horseradish peroxidase (HRP)-conjugated 
polyclonal goat anti-rabbit or rabbit anti-mouse immunoglobulins from Dako 
Diagnostics Ireland Ltd. (Dublin, Ireland) and anti-biotin HRP linked antibody from 
Cell Signaling Technologies (Hertfordshire, UK). 
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Table 2.1 Primary antibodies used for detection of proteins by Western blot 
Target antigen 
(human) 
Molecular 
Weight 
(kDa) 
Supplier Source Optimal 
Dilution 
Incubation 
β-Actin 42 Sigma Aldrich Mouse 1:5000 1 hr @ RT 
Bad 23 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Bak 25 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Bax 20 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
BID 15, 22 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Bik 20 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Bim 12, 15, 23 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Caspase-3 (8G10) 17, 19, 35 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Caspase-6 15, 35 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Caspase-7 (D2Q3L) 20, 35 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Caspase-8 (1C12)  18, 43, 57  Cell Signaling  Mouse 1:1000 Overnight @ 4°C 
Caspase-9 (C9) 47, 37, 35 Cell Signaling  Mouse 1:1000 Overnight @ 4°C 
COX-2 72 Cayman 
Chemical 
Mouse 1:1000 Overnight @ 4°C 
eEF2 95 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Fas (C-20) 48 Santa Cruz  Rabbit 1:1000 1 hr @ RT 
Fas-L 26, 40 Santa Cruz  Rabbit 1:1000 1 hr @ RT 
FLAG®  <10 Sigma Aldrich Mouse 1:1000 30 min @ RT 
MKK3b 40 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
MKK6 38 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
MKK7 48 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
p38α MAPK 43 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
p38β MAPK  40 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
p38γ MAPK 46 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
p38δ MAPK 43 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
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p44/42 MAPK 
(Erk1/2) 
42, 44 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
p53 (7F5) 53 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
PARP 89, 116 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
PARP 85, 116 BD Biosciences Mouse 1:2000 Overnight @ 4°C 
Paxillin 68 Chemicon Rabbit 1:1000 Overnight @ 4°C 
p-eEF2K 105 Santa Cruz Rabbit 1:1000 1 hr @ RT 
Phospho-eEF2 95 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Phospho-Bad 
(Ser112)(40A9) 
23 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Phospo-
MKK3/MKK6 
40, 41 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Phospho-p38MAPK 
(Thr180/Try182) 
43 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Phopsho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
42, 44 Cell Signaling  Rabbit 1:1000 Overnight @ 4°C 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
46, 54 Cell Signaling Rabbit 1:1000 Overnight @ 4°C 
Puma 23 Cell Signaling Rabbit 1:1000 Overnight @ 4°C 
SAPK4  
(H-60) 
43 Santa Cruz Rabbit 1:1000  
SEK1/MKK4 44 Cell Signaling Rabbit 1:1000 Overnight @ 4°C 
TRAIL 34, 20 Santa Cruz Rabbit 1:1000 1 hr @ RT 
Wip-1 67 Santa Cruz Rabbit 1:1000 1 hr @ RT 
(Cayman Chemical, Ann Arbor, MI, USA; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA; BD BioSciences, San Diego, CA, USA). 
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Molecular biology reagents 
All restriction enzymes were purchased from New England BioLabs (Hertfordshire, 
UK). DNA polymerases Phusion®, DreamTaqTM and Platinum® Taq were 
purchased from New England BioLabs (Hertfordshire, UK), Fermentas (Thermo 
Fisher Scientific, Waltham, MA, USA) and Life Technologies, Grand Island, NY, 
USA) respectively.  
 
 
2.1.2 Cell lines 
KE cell lines 
The following KE cell lines were kind gifts from Professor T. Fujii, Kurume 
University School of Medicine, Japan [1-3]. All KE cell lines were established prior 
to chemotherapy or radiation treatment. KE cell line features are summarised in 
Table 2.2. 
 KE-3 human oesophageal squamous cell carcinoma cell line was established 
from a moderately differentiated oesophageal squamous cell carcinoma 
resected from the lower thoracic oesophagus of a 62 year old male. 
 KE-4 human oesophageal squamous cell carcinoma cell line was established 
from a poorly differentiated oesophageal squamous cell carcinoma resected 
from the middle and upper thoracic oesophagus of a 50 year old male. 
 KE-5 human oesophageal squamous cell carcinoma cell line was established 
from a well differentiated oesophageal squamous cell carcinoma resected 
from the middle thoracic oesophagus of a 69 year old male. 
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 KE-6 human oesophageal squamous cell carcinoma cell line was established 
from a well differentiated oesophageal squamous cell carcinoma resected 
from the lower thoracic oesophagus of a 61 year old male. 
 KE-8 human oesophageal squamous cell carcinoma cell line was established 
from a poorly differentiated oesophageal squamous cell carcinoma resected 
from the middle thoracic oesophagus of a 71 year old female. 
 KE-10 human oesophageal squamous cell carcinoma cell line was established 
from a moderately differentiated oesophageal squamous cell carcinoma 
resected from a (skip) metastatic site in the stomach of a 58 year old female. 
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Table 2.2 KE (OESCC) cell line features 
KE Features      
Sex 
 Male      KE-3, -4, -5, -6   
     Female     KE-8, -10 
Age       Median 67 (50 to 71) years 
TNM7 stage 
 T stage 
  T1     KE-10 
  T3     KE-3, -5, -6, -8 
  T4     KE-4     
N stage 
  N0     KE-5 
  N1     KE-3, -4, -6, -8, -10 
Histological grade 
 Well differentiated    KE-5, -6 
 Moderately differentiated   KE-3, -10 
 Poorly differentiated    KE-4, -8 
KE features are summarised based on gender, age, TNM7 stage and histological 
stage. Based on the TNM7 categorization for oesophageal cancer. 
 
 
OC cell lines 
The following OC cell lines were kind gifts from the Cork Cancer Research Centre, 
Biosciences Institute, National University of Ireland, Cork, Ireland. They have been 
previously used by us [4] and characterised [5]. 
 OC-1 oesophageal squamous cell carcinoma cell line was established from 
malignant ascites of a patient with oesophageal cancer. 
 OC-3 oesophageal adenocarcinoma cell line was established from a 
metastatic lymph node of a Barrett’s oesophageal lesion. 
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Commercially available cell lines 
 KYSE-70 is a human oesophageal squamous cell carcinoma and is available 
from the European Collection of Cell Cultures (ECACC). The KYSE-70 cell 
line was established from a poorly differentiated invasive oesophageal 
squamous cell carcinoma resected from the middle intra-thoracic oesophagus 
of a 77 year old Japanese man prior to treatment.  
 KYSE-450 human oesophageal squamous cell carcinoma is available from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH 
(German Collection of Microorganisms and Cell Cultures). The KYSE-450 
cell line was established from a well differentiated invasive oesophageal 
squamous cell carcinoma resected from the middle intra-thoracic oesophagus 
of a 59 year old Japanese man prior to treatment (depth of invasion was not 
beyond the submucosa).  
 OE-19 human oesophageal adenocarcinoma cell line is available from 
ECACC. The OE-19 cell line, also known as JROECL19, was established 
from a moderately differentiated adenocarcinoma of the gastric 
cardia/oesophageal gastric junction of a 72 year old Caucasian male. 
 OE-21 human oesophageal squamous cell carcinoma is available from 
ECACC. The OE-21 cell line, also known as JROECL21, was established 
from a moderately differentiated squamous carcinoma of the mid oesophagus 
of a 74 year old Caucasian male.  
 OE-33 human oesophageal carcinoma is available from ECACC. The OE-33 
cell line, also known as JROECL33, was established from a poorly 
differentiated adenocarcinoma of the lower oesophagus (Barrett’s metaplasia) 
of a 73 year old Caucasian female.  
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2.1.3 Plasmids 
Two different plasmids pcDNA3-MKK6b(E) and pcDNA3-FLAG-p38δ  were a kind 
gift from Professor J. Han, Scripps Research Institute, La Jolla, CA, USA and have 
previously been described [6]. pcDNA3 vector was obtained from Invitrogen (Life 
Technologies, Grand Island, NY, USA). Nucleotide sequence of each plasmid is 
detailed in Appendix I. All other plasmids used for this research project were 
generated by us and are detailed in Chapter 3.  
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2.2 General methods 
 
General methods used in multiple chapters are discussed here. Supplementary 
techniques used in individual chapters are outlined in the relevant chapter as per 
Table 2.3  
 
Table 2.3 Relevant chapters for experimental techniques 
Experimental technique Outlined in 
Agarose gel electrophoresis Chapter 2 
Antibody array Chapter 4 
Bisulfite sequencing PCR Chapter 6 
Boyden chamber cell migration assay Chapter 2 
cDNA synthesis Chapter 2 
Cell culture Chapter 2 
Cloning Chapter 3 
Clonogenic assay Chapter 5 
Colony forming assay Chapter 4 
DNA purification Chapter 2 
DNA sequencing Chapter 2 
Drug treatment Chapter 5 
ELISA Chapter 4 
Ethics Chapter 2 
Immunoblotting Chapter 2 
Immunohistochemistry Chapter 4 
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Ligation Chapter 3 
Methylation specific PCR Chapter 6 
Mitochondrial membrane potential assay Chapter 5 
MTT staining Chapter 2 
Nuclear and cytosolic protein extraction Chapter 4 
Nucleic acid isolation Chapter 2 
PCR/rt-PCR Chapter 2 
Plasmid prep Chapter 3 
Preparation of whole cell lysates Chapter 2 
Quantitation of total protein concentration Chapter 2 
Quantitative rt-PCR Chapter 6 
Restriction digest Chapter 2 
SDS-PAGE Chapter 2 
siRNA transfection Chapter 4 
Site-directed mutagenesis Chapter 3 
Sodium bisulfite conversion Chapter 6 
Stable transfection Chapter 4 
Statistical analysis Chapter 2 
Transformation Chapter 3 
Transient transfection Chapter 3 
Trypan blue proliferation assay Chapter 4 
Western blotting Chapter 2 
Wound-healing assay Chapter 2 
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2.2.1 Cell culture 
Media and supplements 
All cell culture procedures were performed using aseptic technique in a Holten 
LaminAir (Thermo Fisher Scientific, Waltham, MA, USA) laminar flow tissue 
culture hood. All cell cultures were incubated at 37°C in a 5% CO2 atmosphere in a 
Forma Scientific Infrared CO2 incubator (Thermo Fisher Scientific, Waltham, MA, 
USA). KE, OE and KYSE-70 cells were maintained in RPMI-1640 medium 
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin (1% 
penicillin/streptomycin). OC-1 and OC-3 cells were routinely grown in Dulbecco’s 
modified eagle’s medium (DMEM) containing 10% FBS and 1% 
penicillin/streptomycin. KYSE-450 cells were maintained in 45% RPMI-1640/45% 
F-12 Ham, with 10% FBS and 1% penicillin/streptomycin. Generation of stable cell 
lines is outlined in Chapter 4. Once established stably transfected cell lines were 
grown in the appropriate media supplemented with 10% FBS and 400 μg/ml 
Geneticin (Gibco®, Life Technologies, Grand Island, NY, USA). 
 
Reconstitution of frozen cells 
25 ml of the appropriate medium was added to a T150 flask and incubated at 37°C, 
5% CO2. Cryovials were removed from liquid nitrogen storage and transferred to a 
37°C waterbath until contents were fully thawed (1-2 min). Contents of cryovials 
were pipetted slowly into the 150 ml flasks containing the pre-warmed medium.  
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Passaging/maintenance of cells 
In general cell lines were maintained at ≤70% confluency. Medium was removed 
from flasks and cells were washed with 20 ml Dulbecco’s phosphate buffered saline 
(PBS). Cells were incubated with 10 ml Trypsin-EDTA solution per T150 flask, at 
37°C, 5% CO2 for 5-7 min. Flasks were periodically examined under a microscope 
to determine if cells were detached from the surface. Once cells were observed to be 
detached from the surface, the contents of the flask were transferred to a 15 ml 
centrifuge tube. Cells were centrifuged at a speed of 1100 rpm for 5 min. 
Supernatant was removed from the pelleted cells. Cells were resuspended in 5 ml of 
the appropriate medium. 1 ml cell suspension was added to 25 ml medium in a fresh 
flask. 
 
Preparation of liquid N2 stocks 
Cells were pelleted by centrifugation at 1100 rpm for 5 min and supernatant was 
discarded. Cell pellet was resuspended in the appropriate volume of freezing medium 
(90% FBS, 10% dimethyl-sulfoxide (DMSO)) to yield a suspension of 1-2x10
6
 
cells/ml. Cell suspension was divided into 1 ml aliquots in cryovials and frozen at -
80°C overnight in a Nalgene® Cryo 1°C Freezing Container (Thermo Fisher 
Scientific, Waltham, MA, USA) before being transferred to liquid N2 storage. 
 
 
2.2.2 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
staining 
The MTT assay depends on the ability of viable cells to reduce the MTT to a 
coloured formazan product as previously described [7]. MTT was dissolved at a final 
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concentration of 0.25 mg/ml in complete culture medium. 2ml MTT solution was 
added per well of a 6-well plate. Cells were incubated at 37°C, 5% CO2 for 30 min. 
Medium was aspirated and the MTT-formazan precipitate was dissolved with 1 ml 
DMSO per well. Absorbance was measured at 540 nm using a Sunrise
TM
 
spectrophotometric plate reader and analysed using the XRead software program 
(Tecan Group Ltd., Männedorf, Switzerland). 
 
 
2.2.3 Cell migration 
Boyden chamber cell migration assay 
Migration of untransfected and transfected KE-3 (KE-3 pcDNA3, KE-3 p38δ, KE-3 
p-p38δ, KE-3 p-p38δDN) cells was assessed using a Boyden Chamber assay. Cells 
were plated in starvation medium at a density of 3 × 10
4
 cells/well into a 96-well 
plate of the upper chamber. The bottom chamber contained 10% FBS as the 
chemoattractant. Cells were left migrate for 24 hr through the matrigel filter (8 m). 
Migrated cells were treated with MTT as described above to calculate viable cell 
numbers. 
 
Wound-healing assay 
Cell migration was assessed by in vitro wound-healing assay as previously described 
[8]. A linear wound track was made by use of a sterile tip through confluent cells. 
Cells migrating into the wound were photographed under a phase-contrast 
microscope 24 hr and 48 hr after wounding. Migration was determined using the 
ImageJ (National Institutes of Health, Bethesda, Maryland, USA) program as an 
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average closed area of the wound relative to the initial wound area at 24 hr and 48 hr 
after wounding. 
 
 
2.2.4 Protein preparation and immunoblot analysis 
Preparation of whole cell lysates 
Cells cultured in 6-well plates were washed twice with cold PBS and plates frozen at 
-80°C. Plates were thawed on ice for 10 min. Lysis buffer consisted of 1X Protease 
Inhibitor Cocktail (2mM AEBSF, 0.3μM Aprotinin, 130μM Bestatin, 14mM E-64, 
1mM Leupeptin, 1mM EDTA) supplemented with 10 mM Sodium Fluoride (NaF) 
and 25mM Sodium Pyrophosphate (Na4P2O7). 100 μl lysis buffer was added to each 
well and incubated on ice for 45 min. Cells were scraped into the lysis buffer and 
collected. Lysates were sonicated twice for 10 pulses on ice at 50% duty cycle for 
0.5 s with a 30 s rest period (Ultrasonic Homogenizer 4710 series; Cole-Parmer 
Instrument Co., Chicago, IL, USA). Following centrifugation at 12 000 rpm for 5 
min, ≤ 4°C, supernatants were removed and stored at -20°C. 
 
Quantitation of total protein concentration of samples 
Total protein concentration of lysates was quantitated using a Micro BCA™ Protein 
Assay Kit (Pierce Biotechnology, Rockford, IL, USA). A set of diluted BSA 
standards ranging from 0.5-40 μg/ml and a blank of ddH2O only were prepared. Cell 
lysates were diluted 1:50 and 1:100. 500 μl of each standard, blank and lysate 
dilution was added to 500 μl Micro BCA Working Reagent (25 parts reagent MA + 
24 parts reagent MB + 1 part reagent MC) and incubated in a 60°C water bath for 1 
hr. 200 μl of each sample was transferred in triplicate to a 96-well plate and 
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absorbance at 562 nm was measured using a Sunrise
TM
 spectrophotometric plate 
reader and analysed using the XRead software program. A standard curve (Figure 
2.1) was generated by plotting the Blank-corrected average absorbance reading for 
each of the standards versus their concentrations in μg/ml. The protein concentration 
of each unknown sample was determined using this standard curve according to the 
following equation: 
       
 
where y = blank-corrected absorbance reading at 562 nm, m = the slope of the 
standard curve and x = concentration in μg/ml. 
 
 
 
Figure 2.1 Standard curve for determination of protein concentration of 
unknown samples. Standard curve generated by plotting the absorbance of a series 
of standards (40-0.5 μg/ml) at 562 nm versus their concentration. Results shown are 
from a single experiment and are representative of all experiments. 
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SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
1X Laemmli loading buffer (2% w/v SDS, 10% v/v glycerol, 60 mM Tris-HCL (pH 
6.8), 0.002% w/v Bromophenol Blue, 0.64 M β-mercaptoethanol) was added to 15-
35 μg of each protein lysate and samples were incubated at 95°C for 5 min. Proteins 
were separated by SDS-Polyacrylamide Gel Electrophoresis (SDS PAGE) using a 
Mini-PROTEAN® system (Bio-Rad, Hercules, CA, USA). Gels consisted of a 
resolving gel of 10%, to give a linear range of separation of 16-68 kD, overlaid by a 
5% stacking gel with components outlined in Table 2.4 [9].  
 
Table 2.4 Solutions for preparing gels for SDS-PAGE [9]  
Component 5% Stacking Gel 10% Resolving Gel 
H2O 2.7 ml 4.0 ml 
30% acrylamide/bis mix 29:1 670 μl 3.3 ml 
Tris HCl 500 μl 1.0 M, pH 6.8 2.5 ml 1.5 M, pH 8.8 
10% SDS 40 μl 100 μl 
10% ammonium persulphate 40 μl 100 μl 
TEMED 4 μl 4 μl 
 
 
Electrophoresis was carried out at 80 V in running buffer  (25 mM Tris base, 192 
mM Glycine, 0.01% w/v SDS) until the dye front entered the resolving gel, then 
performed at 120 V until 30 min after the dye front had reached the bottom of the 
gel, generally taking a total of 3.5-4 hr. A biotinylated protein ladder (Cell Signaling 
Technologies, Hertfordshire, UK) was used as a molecular weight marker. 1X 
Laemmli loading buffer was loaded into any unused wells. 
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Western blotting 
Resolved proteins were electrophoretically transferred onto nitrocellulose membrane 
(GE Healthcare, Buckinghamshire, UK) using a SemiPhor semi-dry transfer unit 
(Hoefer, Holliston, MA, USA) for 1 hr at 200 mAmp or a Trans-Blot® TurboTM 
Semi Dry Transfer System (Bio-Rad, Hercules, CA, USA) for 30 min @ 25 V, 1.0 
A. Blotting paper, cellophane, nitrocellulose and SDS-PAGE resolving gels were 
initially equilibrated in transfer buffer (25 mM Tris base, 192 mM Glycine, 0.01% 
w/v SDS, 20% v/v MeOH). Protein transfer was confirmed with Ponceau S staining. 
 
Protein detection/probing 
Non-specific binding to the nitrocellulose was blocked by incubation in 1X Tris 
buffered saline (50 mM Tris Base, 0.25 M NaCl, pH adjusted to 7.6 with 5 N HCl), 
0.1% v/v TWEEN (TBS-T) containing 5% w/v marvel milk powder (Premier Foods, 
Hertfordshire, UK) for 1 hr at RT. Membranes were then washed three times with 
TBS-T over 15 min. Incubation with primary antibodies (Table 2.1) was performed 
as per manufacturer’s instructions/optimised conditions for each individual antibody. 
 
Secondary antibodies were diluted 1:1000 in TBS-T. After washing three times with 
TBS-T over 15 min, membranes were incubated with appropriate secondary 
antibodies for 1 hr at RT, followed by another three 5 min washes with TBS-T. 
Luminol/Enhancer solution and Peroxidase Buffer (SuperSignal West Dura 
Extended Duration Substrate, Pierce Biotechnology, Rockford, IL, USA) were 
mixed at a 1:1 ratio and incubated on membranes for 3 min. After removing excess 
reagent and covering with plastic, membranes were exposed using an LAS-3000 Lite 
Intelligent Dark Box (Fujifilm, Dublin, Ireland) or G:Box ChemiXR5 Gel 
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Documentation System (Syngene Europe, Cambridge, UK). Images were quantified 
using ImageJ software. Occasionally membranes were stripped by incubation with 
Restore
TM
 Western Blot Stripping Buffer (Thermo Fisher Scientific, Waltham, MA, 
USA) at 37°C for 45 min before being blocked and re-probed as above. 
 
 
2.2.5 Nucleic acid isolation and cDNA synthesis 
DNA isolation 
Genomic DNA (gDNA) was isolated from cultured cells using magnetic bead 
technology with a Magna Pure LC Total Nucleic Acid Isolation Kit (Roche 
Diagnostics Ltd., West Sussex, UK) according to manufacturer’s instructions. 1 x 
10
6
 cells were resuspended in PBS and incubated with a chaotropic salt lysis/binding 
buffer to release nucleic acids and denature nucleases. The automated Magna Pure 
LC instrument performs the remainder of steps. Proteinase K is added to digest 
proteins. Magnetic Glass Particles (MGPs) are added and nucleic acids in the sample 
bind to their silica surface. MGPs with bound nucleic acids are magnetically 
separated from the residual sample and washed repeatedly with wash buffer to 
remove unbound substances. Purified nucleic acids are eluted in a low-salt buffer. 
DNA concentration and quality was determined spectrophotometrically with a 
BioPhotometer (Eppendorf AG, Hamburg, Germany). 
 
RNA isolation  
RNA was isolated from cultured cells with a RNeasy Mini Kit (Qiagen, Manchester, 
UK) using a silica membrane based purification protocol. 1 x 10
6
 cells per sample 
were washed with PBS and pelleted by centrifugation at 1200 rpm for 5 min. Cell 
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pellets were resuspended in 350 μl Buffer RLT and homogenized by vortexing for 1 
min. Cell lysates were stored at -80°C. For RNA isolation, frozen lysates were 
thawed in a 37°C water bath and RNA was extracted as follows according to the 
Spin Technology protocol. One volume (350 μl) of 70% ethanol was added to the 
lysate and mixed by pipetting. The sample (700 μl) was loaded into an RNeasy spin 
column in a 2 ml collection tube and centrifuged at ≥ 10 000 rpm for 15 s. 350 μl 
Buffer RW1 was added to the RNeasy spin column and centrifuged for 15 s at          
≥ 10 000 rpm.  DNaseI was incubated on the column membrane at RT for 15 min. 
350 μl Buffer RW1 was added to the RNeasy spin column and centrifuged for 15 s at 
≥ 10 000 rpm. Spin column membrane was washed twice with Buffer RPE, with 
centrifugations at ≥ 10 000 rpm for 15 s and 2 min. The spin column was placed in a 
new 2 ml collection tube and centrifuged for 1 min at ≥ 10 000 rpm to eliminate any 
possible carryover of ethanol. RNA was eluted in RNase-free water by centrifugation 
for 1 min at ≥ 10 000 rpm. Eluted RNA was stored at -80°C. RNA concentration and 
quality was determined spectrophotometrically with a BioPhotometer. 
 
cDNA synthesis 
First-strand complementary DNA (cDNA) was synthesised using SuperScript® 
VILO™ cDNA Synthesis Kit (Life Technologies, NY, USA). For a single reaction, 
SuperScript® Enzyme Mix (including SuperScript® III reverse transcriptase an 
engineered version of M-MLV reverse transcriptase, RNaseOUT™ Recombinant 
Ribonuclease Inhibitor, and a helper protein), VILO™ Reaction Mix (including 
random primers, MgCl2, and dNTPs) and up to 2.5 μg RNA were combined in a total 
volume of 20 μl. Samples were incubated at 25°C for 10 min, 42°C for 60 min, and 
85°C for 5 min. cDNA was stored at -20°C. 
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2.2.6 PCR and rt-PCR  
Primers for PCR and reverse transcription PCR (rt-PCR) (Table 2.5) were designed 
with the aid of online primer design tools, including Primer3Plus [10] and Integrated 
DNA Technologies online OligoAnalyzer 
http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/. Specificity of primers 
was determined by BLAST analysis of the primer sequences against the RefSeq 
Homo sapiens mRNA database [11]. Primers were synthesised by Sigma Aldrich or 
Eurofins Genomics (Ebersberg, Germany). 
 
 
Table 2.5 Primers for PCR and rt-PCR 
Primer Sequence (5’→3’) Tm° 
P001F CCACGTTAAACTGCCCATCT 66.0 
P001R CCGCCACAAGCTAAAAAGAG 64.0 
P002F CCGGAAAAAGGGCTTCTACAA 63.8 
P002R GACGTTCTCATGCTGCATGT 63.6 
P003F CCGCGCTTTAAAGGCGAGGGCGAGGGCGAGGGCGAGG
GCGAGATGGACTACAAGGACGACGAT 
97.1 
P003R TTGATCTTTAAATTATTACAGCTTCATGCCACTTCGT 72.8 
P009F CGAGATCGGGTGCCCGGGAT 65.5 
P017R TCAGCTTCTTGATGGCCACCTTCTC 64.6 
SP6 CATTTAGGTGACACTATAG 50.2 
T7 TAATACGACTCACTATAGGG 53.2 
Tm° = value provided by manufacturer. 
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PCR and rt-PCR reactions were carried out in a 50 μl final volume and included 
components listed in Table 2.6. For each PCR/rt-PCR reaction a negative control 
was included in which the template was replaced with the equivalent volume of H2O 
in order to identify any non-specific DNA amplification. 
 
 
Table 2.6 PCR/rt-PCR reaction components 
Reaction Component Final Concentration  
PCR Reaction Buffer  1X 
Deoxynucleotide (dNTP) Mix  0.2 mM 
MgCl2 1.5 mM 
Forward Primer 0.2 μM 
Reverse Primer 0.2 μM 
Template variable 
DNA Polymerase 1-2 units 
H2O to total reaction volume of 50 μl 
Template: cDNA = 1 μl; gDNA ≤ 100 ng; plasmid DNA ≤ 10 ng. 
 
 
PCR and rt-PCR reactions were performed in a GeneAmp PCR System 2700 
(Applied Biosystems, Life Technologies, NY, USA) under the conditions described 
in Table 2.7. 
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Table 2.7 PCR/rt-PCR reaction conditions 
Step Temperature °C Time Number of cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 50 s 35 
Annealing lowest primer Tm° -5 50 s 
Extension 72 1 min/kb 
Final Extension 72 10 min 1 
 
 
2.2.7 Restriction digest 
All restriction enzymes were purchased from New England Biolabs (Hertfordshire, 
UK). Restriction enzymes used as well as their recognition sequences and incubation 
temperatures are listed in Table 2.8.  
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Table 2.8 Incubation temperatures and recognition specificities for restriction 
enzymes 
Restriction Enzyme Recognition Sequence Incubation Temperature 
BamHI G^GATCC 37°C 
BsaAI YAC^GTR 37°C 
BstXI CCANNNNN^NTGG 37°C 
DraI TTT^AAA 37°C 
HindIII A^AGCTT 37°C 
MfeI C^AATTG 37°C 
SwaI ATTT^AAAT 25°C 
XbaI T^CTAGA 37°C 
XhoI C^TCGAG 37°C 
Y = C or T, R = A or G, N = A or G or C or T. ^ denotes point of cleavage. 
 
 
Typical restriction digest reaction conditions are outlined in Table 2.9 as advised by 
New England BioLabs (Hertfordshire, UK) to overcome variability in DNA source, 
quantity, and purity. 
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Table 2.9 Restriction digest reaction components and conditions 
Component Condition 
Restriction enzyme 10 units 
DNA 1 μg 
10X buffer 5 μl 
Total reaction volume 50 μl 
Incubation time 16 hr 
Incubation temperature Enzyme dependent 
 
 
2.2.8 Agarose gel electrophoresis 
0.8 – 1.0% gels were prepared with agarose and 1X TBE (89 mM Trizma base, 89 
mM boric acid, 2 mM EDTA) or TAE (40 mM Trizma base, 20 mM glacial acetic 
acid, 1 mM EDTA) Buffer. SafeView nucleic acid stain (NBS Biologicals, 
Cambridgeshire, UK) was used for the detection of DNA and RNA. Samples were 
loaded using 1X DNA loading dye (New England BioLabs, Hertfordshire, UK). 
Various DNA Ladder molecular weight markers were used depending on the 
expected size of the product according to Table 2.10.  
 
 
 
 
 
 
 
 
 
 65 
 
Table 2.10 DNA ladder molecular weight markers 
Sizing range DNA Ladder Supplier 
50-1000 bp GeneRuler
TM
 50bp DNA ladder Fermentas, Thermo Fisher 
Scientific, Waltham, MA, USA 
250-10 000 bp GeneRuler
TM
 1kb DNA ladder Fermentas, Thermo Fisher 
Scientific, Waltham, MA, USA 
500-10 000 bp 1 kb DNA ladder New England BioLabs, 
Hertfordshire, UK 
 
 
2.2.9 DNA purification 
Products were purified from PCR and restriction digest reactions using an Illustra 
GFX PCR DNA & Gel Band Purification Kit (GE Healthcare, Buckinghamshire, 
UK) according to manufacturer’s instructions. Briefly, the PCR/enzyme reaction was 
combined with capture buffer and transferred to a GFX MicroSpin column in a 
collection tube and centrifuged at 16 000 x g for 30 s. Following two wash steps, 
DNA was eluted in nuclease-free H2O by centrifugation at 16 000 x g for 1 min. 
 
 
2.2.10 DNA sequencing 
Plasmids and purified PCR products were routinely sent for DNA sequence analysis. 
All DNA sequencing was performed by Eurofins Genomics using their ‘Value Read’ 
modified dideoxychain termination sequencing service. The relevant PCR primers 
were generally used for sequencing of PCR products. Additional primers for DNA 
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Sequencing (Table 2.11) were synthesised by Eurofins Genomics (Ebersberg, 
Germany) and designed using their ‘Design A Primer’ tool. 
 
Table 2.11 Additional primers for DNA sequence analysis 
Primer Sequence (5’-3’) 
T7 TAATACGACTCACTATAGGG 
SP6 CATTTAGGTGACACTATAG 
SeqP1 CTCTCGGTCAAGTGAAGATGTG 
SeqP2 AGCTGGATGCACTACAACCAGAC 
SeqP3 AGACATCCAGGAGCCCAATG 
SeqP4 GGATATTTCCATGAGGACGGTG 
SeqP5 CTGCTGAAGCACATGCAGCATGAG 
SeqP6 TTGGATATTTCCATGAGGACGG 
 
 
2.2.11 Ethics 
This research was approved by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals. 
 
 
2.2.12 Statistical analysis 
Results are expressed as mean ± SE. Statistical comparisons were made by analysis 
of variance with subsequent application of Student’s t-test, as appropriate. The non-
parametric Mann-Whitney U-test pairwise comparisons were also performed. As the 
results obtained using both methods were in agreement, only results for the Student’s 
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t-test are shown. GraphPad InStat 3 software (GraphPad Software, Inc., La Jolla, 
CA, USA) was used for statistical analysis also. 
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Chapter 3  
 
Generation and expression of three different 
plasmids: 
(i) pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ 
(ii) pcDNA3-MKK6b-(Gly-Glu)5-FLAG-p38δ 
(iii) pcDNA3-MKK6b(E) -(Gly-Glu)5-FLAG-p38DN  
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3.1 Abstract 
 
p38 MAPK isoforms are emerging as important regulators of a host of cellular 
processes and as a result may be considered as possible therapeutic targets for a 
variety of diseases. The functions of p38α and -β MAPK in cell differentiation, cell 
growth and cell death have to-date been well characterised. Recently, additional 
functions have been ascribed to these isoforms as both pro- and anti-tumourigenic in 
depending on the cell type. In contrast, the most recently identified isoform, p38δ 
MAPK, has been poorly studied to-date. Investigation of the role p38δ MAPK plays 
in tumourigenesis has been hindered by the lack of specific chemical activators and 
constitutively active mutants. To create a constitutively active form of p38δ MAPK 
we fused it to an active mutant of its upstream regulator MKK6 in a single vector. 
Expression of this fusion plasmid in an OESCC cell line resulted in the expression of 
a single polypeptide and constitutive specific phosphorylation of p38δ MAPK. We 
also generated control fusion plasmids expressing either inactive MKK6 or a 
dominant-negative p38δ MAPK mutant. These results indicate that the MKK6-p38δ 
MAPK fusion protein is a constitutively active kinase and will facilitate future study 
on the specific effects of p38δ MAPK phosphorylation in OESCC.  
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3.2 Hypothesis and aims 
 
The hypothesis for this chapter is that physical linking of p38δ MAPK to MKK6 in a 
single peptide will result in specific and constitutive phosphorylation of p38δ 
MAPK. 
 
To examine this hypothesis the aims for this chapter are as follows: 
 
 To generate plasmids expressing MKK6b(E) or MKK6 joined to p38δ via a 
peptide linker. 
 
 To generate a control plasmid expressing MKK6b(E) joined to a non-
phosphorylatable p38δ MAPK mutant, p38δDN.  
 
 To evaluate p-p38δ MAPK expression in oesophageal squamous carcinoma 
cells transiently transfected with the plasmids detailed above. 
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3.3 Introduction 
 
Conventional chemo- and radiotherapy for oesophageal cancer is largely ineffective 
– its 5 year survival rate is as low as 15% [1]. Therefore, the identification of novel 
molecular targets is likely to be crucial to the future of oesophageal cancer treatment. 
The p38 family of mitogen-activated protein kinases is one such potential molecular 
target. p38 MAPK isoforms –α, -β, -γ and –δ are signalling kinases which 
incorporate extracellular signals into a variety of cellular processes including 
proliferation, differentiation, transformation and apoptosis [2]. Roles for p38α 
MAPK in tumourigenesis are now well established and it has been characterised as 
both a tumour promoter [3, 4] and a tumour suppressor [5, 6]. The limited 
knowledge which exists in relation to p38δ MAPK also suggests pro- and anti-
tumourigenic functions, depending on cell type [3, 7, 8]. Our group has previously 
reported a role for p38δ MAPK in the inhibition of cell growth in renal clear cell 
carcinoma. Introduction of p38δ MAPK into the RCC 786-0 cell line which does not 
express it abrogated apoptosis [9]. This prompted an examination of p38 MAPK 
isoform expression in various other cancer cell lines (see Aims of thesis). In 75% of 
cell lines examined i.e. renal, liver and lung cells, as well as OESCC cell lines, p38δ 
MAPK is differentially expressed. 
 
As the main aim of this thesis is to investigate any potential role for p38δ MAPK in 
the tumourigenesis of OESCC, it will therefore be necessary to examine not only the 
effect of p38δ MAPK expression but also the consequences of its activation 
(phosphorylation). Of note, p38δ MAPK is inactive in the non-phosphorylated state. 
While transfection with FLAG-tagged p38δ MAPK in a pcDNA3 vector  [10] will 
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facilitate stable expression of p38δ MAPK, expression of active p38δ MAPK 
presents a greater challenge. Activation of p38δ MAPK requires dual-
phosphorylation of Thr and Tyr residues within a conserved regulatory loop [11]. To 
date, no external artificial stimulus, such as a pharmacological agent, has been 
identified which will specifically phosphorylate p38δ MAPK and not simultaneously 
affect p38α, -β or –γ MAPK activation. p38δ MAPK is directly activated by 
members of the dual-specificity MAP kinase kinases family, predominately MKK3 
and MKK6, although p38δ MAPK phosphorylation by MKK4 and MKK7 has also 
been reported [12-14]. Overexpression of an MKK however, as a means of 
specifically activating p38δ MAPK would have multiple downstream effectors, 
possibly resulting in non-specific MAPK activation:  MKK3 also phosphorylates 
p38α and –γ MAPK, MKK4 can phosphorylate p38α MAPK and JNK, MKK6 
phosphorylates all 4 p38 MAPK isoforms and MKK7 phosphorylates JNKs [13, 15-
17]. 
 
Attempts have previously been made to generate constitutively active p38δ MAPK 
kinase mutants [18, 19]. Mutants were designed on the basis of information obtained 
from biochemical and structural analysis of naturally occurring activating mutations 
in the yeast MAPK HOGI gene and previously synthesised p38α MAPK mutants 
[19-21]. While the majority of p38δ MAPK mutants generated were inactive, a 
p38δF324S mutant reached an activity level of 13.5% in comparison to that of dually 
phosphorylated active p38δWT [18] However, dual phosphorylation cannot be 
mimicked with intrinsically active kinase variants and no p38δ MAPK mutant has 
been identified which reaches the level of phosphorylation obtained by co-expression 
of p38δ MAPK with active MKK6 [18, 19]. Therefore the approach of enzyme-
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substrate fusion as previously described for p38α, p38γ, ERK2 and JNK1 MAPKs 
would appear to be a more useful tool for investigating the function of p-p38δ 
MAPK in oesophageal carcinoma as it more closely represents endogenous MAPK 
signalling [22-24].  
 
The rate of an enzymatic reaction is greatly influenced by the proximity between the 
enzyme and its substrate. In eukaryotic cells, the specificity and efficiency of signal 
transduction is often enhanced by the activity of scaffold proteins. These adaptor 
proteins organise several components of a signalling pathway to aid the formation of 
signalling complexes. In fact, p38δ MAPK has been shown to interact with such a 
scaffold protein, JNK-interacting protein (JIP) 2 [25].  The technique of enzyme-
substrate fusion was chosen under the assumption that p38δ MAPK may become 
specifically and constitutively active if physically linked to its upstream activator 
MKK6. To achieve this, polypeptides were designed which comprised of MKK6b or 
constitutively active MKK6 (MKK6b(E)) and p38δ MAPK combined in the same 
vector. In summary, this chapter outlines that expression of these MKK6b-p38δ and 
MKK6b(E)-p38δ fusion proteins facilitate specific and constitutive in vitro 
phosphorylation of p38δ MAPK in the absence of an external stimulus. These fusion 
proteins will be valuable tools in elucidating the roles of p38δ MAPK activation in 
OESCC tumourigenesis as outlined in Chapters 4 and 7.   
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3.4 Materials and methods 
 
3.4.1 Cloning strategy for pcDNA3-MKK6b(E)(Gly-Glu)5FLAG--p38δ fusion 
plasmid 
A constitutively active mutant form of MKK6 i.e. MKK6b(E) in a pcDNA3 vector 
[10] was chosen as the backbone of the fusion construct. To maintain the open-
reading frame and allow translation proceed from MKK6b(E) through to the carboxy 
terminus of p38δ MAPK it was necessary to replace the TAA stop codon of 
MKK6b(E) with another amino acid. Site-directed mutagenesis to replace TAA with 
Phe (TTT) facilitated the introduction of a unique SwaI recognition sequence. This 
new site allowed for a blunt-end cloning strategy. 
 
The gift of the plasmid pcDNA3-FLAG-p38δ [10] provided a template from which 
to amplify FLAG-tagged p38δ MAPK by PCR. To allow the principal components 
of the fusion protein to interact, a protein linker was needed to provide a flexible 
region and facilitate protein folding. A decapeptide linker composed of alternating 
glycine and glutamate (Gly-Glu)5 was designed to be included 5’ of the amplified 
FLAG-p38δ sequence (Figure 3.1) [23].  
 
Finally, DraI restriction sites were designed 5’ and 3’ of the (Gly-Glu)5-FLAG-p38δ 
product to allow the blunt-ended product resulting from digestion to be ligated in-
frame to the SwaI linearised pcDNA3-MKK6b(E) vector. Figure 3.2 provides a 
detailed overview of the processes involved in the generation of the fusion construct. 
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Figure 3.1 Schematic of the MKK6b(E)-(Gly-Glu)5-FLAG-p38δ fusion protein. 
The (Gly-Glu)5 linker allows for protein folding, facilitating the interaction between 
MKK6b(E) and p38δ MAPK (adapted from [23]). 
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Figure 3.2 Steps involved in generating pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-
p38δ fusion construct. Abbreviations; FL: FLAG; SAP: shrimp alkaline 
phosphatase. 
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The second plasmid to be designed, pcDNA3-MKK6b-FLAG-p38δ, lacks 
constitutive MKK6b activation as it consists of wild-type MKK6b fused to FLAG-
p38δ MAPK in a pcDNA3 vector. To achieve this, the MKK6b(E) activating 
mutations Glu
151
 and Glu
155
 were replaced with the endogenous MKK6b amino acids 
in these positions, Ser
151
 and Thr
155
. A control plasmid was also designed. In this 
pcDNA3-MKK6b(E)-FLAG-p38δDN plasmid, wild-type p38δ MAPK was replaced 
with a kinase-inactive mutant form.   
 
 
3.4.2 Site-directed mutagenesis 
Site-Directed Mutagenesis was performed using QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies UK Limited, Cheshire, UK). 
Primers for Site-Directed Mutagenesis (Table 3.1) were designed using the Agilent 
Technologies web-based QuikChange Primer Design program, 
www.agilent.com/genomics/qcpd; and were synthesised by Eurofins Genomics 
(Ebersberg, Germany). 
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Table 3.1 Primers for site-directed mutagenesis 
Primer Orientation Sequence (5’→3’) Tm° 
SDM1 sense CATCTTTTGTAAAACTGATTCTTGGAGAA
TTTAAATCAGTGGACTTAATCGGTTGACC
CTACTG 
73.9 
SDM1 antisense CAGTAGGGTCAACCGATTAAGTCCACTG
ATTTAAATTCTCCAAGAATCAGTTTTACA
AAAGATG 
73.9 
SDM2 sense TGGAATCAGTGGCTATTTGGTGGACTCTG
TTGCTAAAACAATTGATGCAGGTTGCAA
ACCATAC 
79.2 
SDM2 antisense GTATGGTTTGCAACCTGCATCAATTGTTT
TAGCAACAGAGTCCACCAAATAGCCACT
GATTCCA 
79.2 
SDM3 sense GACGCCGAGATGGCTGGCTTCGTGGTGA
CCCG 
81.1 
SDM3 antisense CGGGTCACCACGAAGCCAGCCATCTCGG
CGTC 
81.1 
Tm° = value provided by Eurofins Genomics 
 
Components of a single mutant strand synthesis (thermal cycling) reaction were as 
outlined in Table 3.2. 
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Table 3.2 Site-directed mutagenesis reaction components 
Reaction Component Final Concentration in 50μl reaction 
10X Reaction Buffer 1X 
Plasmid DNA 1 ng/μl 
Sense primer 125 ng 
Antisense primer 125 ng 
dNTP Mix 1 μl 
QuikSolution Reagent 1.5 μl 
QuikChange Lightning Enzyme 1 μl 
 
Picomol concentration of 125 ng of each primer was calculated using the formula 
provided in the QuikChange Lightning Site-Directed Mutagenesis Kit protocol, i.e. 
 
                    
            
                         
       
 
The mutant strand synthesis reaction was cycled in a GeneAmp PCR System 2700 
according to the conditions outlined in Table 3.3. 
 
Table 3.3 Mutant strand synthesis reaction conditions 
Temperature °C Time Number of cycles 
95 2 min 1 
95 20 s 30 
55 10 s 
68 30 s/kb of plasmid length 
65 5 min 1 
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Following temperature cycling, newly synthesized mutation-containing DNA was 
selected for by digestion of methylated and hemimethylated parental (template) 
DNA with DpnI endonuclease. DpnI treated DNA was transformed into SURE 2 
Supercompetent cells (Agilent Technologies UK Limited, Cheshire, UK) and 
plasmid DNA was extracted as outlined below. Presence of mutations was confirmed 
by restriction digest and DNA sequencing as described in Chapter 2. 
 
 
3.4.3 PCR generation of (Gly-Glu)5-FLAG-p38δ fragment 
The (Gly-Glu)5-FLAG-p38δ insert for the fusion plasmid was amplified from 
pcDNA3-FLAG-p38δ by PCR using Phusion® DNA polymerase (New England 
BioLabs, Hertfordshire , UK). Other reaction components were as listed in Table 2.6. 
5’ oligonucleotide (P003F) for PCR included DraI recognition sequence as well as 
the (Gly-Glu)5 sequence (5’-CCGCGCTTTAAAGGCGAGGGCGAGGGCGAGGG 
CGAGGGCGAGATGGATACAAGGACGACGAT-3’). 3’ primer (P003R) also 
included a DraI restriction site (5’- TTGATCTTTAAATTATTACAGCTTCATGC 
CACTTCGT-3’). PCR was performed in a GeneAmp PCR System 2700 under the 
conditions described in Table 3.4. 
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Table 3.4 PCR reaction conditions for amplification of (Gly-Glu)5-FLAG-p38δ. 
Step Temperature °C Time Number of 
cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 30 s 5 
Annealing 65.3 30 s 
Extension 72 30 s 
Denaturation 95 30 s 30 
Extension 72 30 s 
Final Extension 72 10 min 1 
 
The PCR reaction was analysed by agarose gel electrophoresis before being column 
purified with an Illustra GFX PCR DNA & Gel Band Purification Kit (as described 
in Chapter 2). The purified product was analysed by DNA sequencing as described 
in Chapter 2. 
 
The purified PCR product was then digested with DraI (as described in Chapter 2). 
The (Gly-Glu)5-FLAG-p38δ insert was gel-purified from the restriction enzyme 
reaction using an Illustra GFX PCR DNA & Gel Band Purification Kit according to 
manufacturer’s instructions. The restriction digest products were separated by 
agarose gel electrophoresis as described in Chapter 2. Under long wavelength UV 
light and with minimal exposure time, the band of interest was excised from the gel 
using a sterile scalpel. The excised band was placed in a 1.5 ml microcentrifuge tube 
containing Capture buffer type 3 and incubated at 60°C for 15-30 min until the 
agarose was completely dissolved. The sample mix was transferred to a GFX 
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MicroSpin column in a collection tube and centrifuged at 16 000 x g for 30 s. 
Following two wash steps, DNA was eluted in 10 mM Tris-HCl, pH 8.0 by 
centrifugation at 16 000 x g for 1 min. 
 
 
3.4.4 Ligation  
The pcDNA3-MKK6b(E) vector (linearised by digestion with SwaI as described in 
Chapter 2) and (Gly-Glu)5-FLAG-p38δ insert were ligated with insert:vector ratios 
of 3:1, 6:1 and 10:1 by incubation with T4 DNA Ligase (New England BioLabs, 
Hertfordshire, UK) at 16°C overnight. Insert:vector ratios were calculated using the 
following formula: 
 
           
                             
                 
                 
      
      
 
 
Ligation products were transformed into SURE2 Supercompetent Cells  as described 
below. Plasmids prepared by miniprep (outlined below) were analysed by restriction 
enzyme digestion followed by agarose gel electrophoresis as described in Chapter 2 
to confirm ligation and determine the orientation of the insert. Plasmids positive for 
ligation with the insert in a sense orientation were analysed by DNA sequencing with 
custom SeqP4 primer (5’-GGATATTTCCATGAGGACGGTG-3’). 
 
 
3.4.5 Transformation 
Transformations were performed with SURE 2 Supercompetent cells according to 
manufacturer’s protocols. Cells were thawed on ice and 100 μl was aliquoted to a 
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pre-chilled tube with 2 μl β-mercaptoethanol. After a 10 min incubation on ice, 2 μl 
ligation reaction was added to cells and tubes were incubated on ice for 30 min. Cells 
were heat-pulsed in a 42°C water bath for 30 s then incubated on ice for 2 min. 900 
μl pre-heated (42°C) NZY+ broth (Lab M, Lancashire, UK) was added and tubes 
were incubated at 37°C for 1 hr with shaking at 225 rpm. 50 μl transformation 
mixture was plated on luria broth (LB) agar (InvivoGen, Toulouse, France) plates 
and incubated overnight at 37°C. Controls performed included transformation with 
0.01 ng pUC18 and with no DNA added. 
 
 
3.4.6 Miniprep 
A QIAprep Miniprep Kit (Qiagen, Manchester, UK) was used to purify up to 20 μg 
molecular biology grade plasmid DNA from bacterial cultures. A single bacterial 
colony was picked from a freshly streaked agar plate and inoculated in terrific broth 
(TB) medium (InvivoGen, Toulouse, France) containing the appropriate antibiotic. 
Cultures were incubated overnight at 37°C with shaking. Bacterial cells were 
harvested by centrifugation ≥8000 rpm for 3 min. Using the QIAprep Miniprep Kit, 
bacteria were lysed under alkaline conditions [26]. Lysate was then neutralised and 
adjusted to high salt binding conditions. DNA was adsorbed onto the QIAprep silica 
membrane and purified by a series of wash steps. Plasmid DNA was then eluted 
from the QIAprep column in Tris buffer. Plasmid DNA concentration and quality 
was determined spectrophotometrically with a BioPhotometer.  
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3.4.7 Maxiprep 
Transfection-grade plasmid DNA was prepared using an Endofree® Plasmid Maxi 
Kit (Qiagen, Manchester, UK). A single colony was picked from a freshly streaked 
selective plate and inoculated in a starter culture of 5 ml TB medium containing the 
appropriate selective antibiotic. Culture was incubated for 8 hr at 37°C with shaking 
at 220 rpm. The starter culture was diluted 1/500 into 100 ml selective TB medium 
and incubated overnight (16 hr) at 37°C with shaking at 220 rpm. Bacterial cells 
were harvested by centrifugation at 6000 x g for 15 min at 4°C. The bacterial pellet 
was resuspended in a buffer containing RNaseA. Cells were lysed by addition of an 
alkaline lysis buffer and incubation at RT for 5 min. Genomic DNA, proteins, cell 
debris and potassium dodecyl sulphate were precipitated by addition of a 
neutralisation buffer. Lysate was separated from precipitate by passing through a 
QIAfilter Maxi cartridge. Endotoxin removal buffer was added to the filtered lysate 
and incubated on ice for 30 min. Filtered lysate was then applied to the Qiagen-Tip 
and allowed to enter the Qiagen resin by gravity-flow to facilitate DNA binding. 
Contaminants were removed by two medium salt washes. DNA was eluted in a high-
salt buffer before being concentrated and desalted by isopropanol precipitation. DNA 
was redissolved in Buffer TE. 
 
 
3.4.8 Cell culture 
The KE-3 and KE-6 oesophageal cancer cell lines were cultured as described in 
Chapter 2. 
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3.4.9 Transient transfection 
24 hr before transfection, cells were seeded at a density of 2 x 10
5
 cells/well in a 6-
well tissue culture plate in the appropriate growth medium without antibiotics. Cells 
were transfected at 80-90% confluency. For each well, 10 μl LipofectamineTM 2000 
transfection reagent (Life Technologies, NY, USA) and 4 μg plasmid DNA were 
each diluted in 250 μl serum-free media and incubated for 5 min at RT. Diluted 
Lipofectamine
TM
 2000 and diluted DNA were combined, mixed gently and 
incubated for 20 min at RT. The DNA and Lipofectamine
TM
 2000 complex was 
added to each well containing cells and 2 ml antibiotic-free medium. 24 hr following 
transfection, cells were harvested to prepare protein lysates as described in Chapter 
2. 
 
 
3.4.10 Immunoblot analysis 
Supernatants were used for immunoblotting with specific antibodies, p38δ MAPK, 
phospho-p38 MAPK and MKK6, as detailed in Chapter 2 and as previously 
described by us [27, 28]. 
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3.5 Results 
 
3.5.1 A vector for the fusion construct was created from pcDNA3-MKK6b(E) 
A pcDNA3-MKK6b(E) vector was created by substituting the MKK6b(E) TAA stop 
codon in pcDNA3-MKK6b(E) with Phe (TTT) by site directed mutagenesis. 
Oligonucleotide primers used were P004F: 5’-CATCTTTTGTAAAACTGATTCTT 
GGAGAATTTAAATCAGTGGACTTAATCGGTTGACCCTACTG-3’ (sense) and 
P004R: 5’-CAGTAGGGTCAACCGATTAAGTCCACTGATTTAAATTCTCCAA 
GAATCAGTTTTACAAAAGATG-3’ (antisense) (mismatches underlined). Three 
plasmids were amplified from bacterial colonies generated from the transformation 
reaction following site directed mutagenesis. Plasmids were tested for the presence 
of the mutation by restriction digest with SwaI (successful site directed mutagenesis 
should have introduced a unique SwaI restriction site (ATTTAAAT)). As a positive 
control for linearization, plasmids were also digested with HindIII of which there is a 
single recognition site in pcDNA3-MKK6b(E). Agarose gel electrophoresis of 
restriction digest products identified a linear plasmid product following digestion of 
Plasmid 1 with SwaI (Figure 3.3A), indicating the presence of a unique SwaI 
restriction site and successful site directed mutagenesis. Plasmids 2 and 3 were 
undigested following incubation with SwaI (Figure 3.3A), suggesting site directed 
mutagenesis was unsuccessful in these plasmids.  
 
To confirm the restriction digest results all three plasmids were sent for DNA 
sequence analysis by Eurofins MWG Operon with custom primer SeqP1 (5’-
CTCTCGGTCAAGTGAAGATGTG-3’). Sequence reads were aligned to the 
original pcDNA3-MKK6b(E) nucleotide sequence using Multalin [29]. The 
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sequences generated for plasmids 2 and 3 correspond to the sequence of the original 
pcDNA3-MKK6b(E) plasmid and therefore do not contain the desired mutation 
(Figure 3.3B). The sequence generated for plasmid 1 contains the expected mutation 
and indicates successful site directed mutagenesis (Figure 3.3B). A further mutation 
after the site-directed mutagenesis site was deemed to be silent. Plasmid 1 was 
therefore used as the vector in all further experiments. 
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Figure 3.3 Confirmation of site-directed mutagensis. (A) Agarose gel 
electrophoresis of SwaI digestion products to confirm site directed mutagenesis of 
pcDNA3-MKK6b(E). (B) DNA sequence analysis to confirm site directed 
mutagenesis of pcDNA3-MKK6b(E). Residues identical to the reference sequence 
(pcDNA3-MKK6b(E)) residue at the same position are represented by a point (•), 
residues which differ are in uppercase. Expected mutation sites following successful 
site-directed mutagenesis are highlighted. 
 
 
 
A 
B 
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3.5.2 A (Gly-Glu)5-FLAG-p38δ insert was successfully amplified from pcDNA3-
FLAG-p38δ 
PCR of pcDNA3-FLAG-p38δ with P003F and P003R primers yielded a product 
between 1000 and 1500 bp (Figure 3.4A). The expected size of a product amplified 
from pcDNA3-FLAG-p38δ with P003F and P003R primers is 1182 bp, including 
FLAG-p38δ, 5’ (Gly-Glu)5 linker, 5’ and 3’ DraI restriction sites and 6 extra 5’ and 
3’ nucleotides to facilitate restriction digest.  
 
Purified PCR product was sent for DNA sequence analysis by Eurofins MWG 
Operon. P003F and P003R, as well as custom sequencing primers, SeqP2 (5’-
AGCTGGATGCACTACAACCAGAC-3’) and SeqP3 (5’-
AGACATCCAGGAGCCCAATG-3’), were used to sequence the entire product. 
Combined sequence reads were aligned to NM_002754.4 and FLAG nucleotide 
sequence using Multalin [29]. The sequence generated consists of flanking 
nucleotides to facilitate restriction enzyme binding, 5’ DraI recognition sequence, 
(Gly-Glu)5, FLAG, p38δ MAPK, 3’ DraI recognition sequence and flanking 
nucleotides (Figure 3.4B). 
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Figure 3.4 PCR amplification of (Gly-Glu)5-FLAG-p38δ. (A) Agarose gel 
electrophoresis analysis of PCR product. Expected product size: 1182 bp. (B) DNA 
sequence analysis of fragment  produced by PCR amplification. Alignment with 
NM002754.4 and FLAG nucleotide sequences. NTC: no template control. 
A 
B 
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3.5.3 Troubleshooting 
Eight plasmids were prepared by miniprep from E. coli cells transformed with 
pcDNA3-MKK6b(E) vector and (Gly-Glu)5-FLAG-p38δ insert ligation reaactions. 
Plasmids were digested with HindIII and XbaI restriction endonucleases to 
determine if they contained the (Gly-Glu)5-FLAG-p38δ insert. The expected 
products from digestion of a plasmid containing the insert are 2650 bp and 5352 bp 
versus 1486 bp and 5352 bp for plasmids negative for ligation. Restriction digest 
products were analysed by agarose gel electrophoresis (Figure 3.5). A fragment 
between 2000 and 3000 bp (highlighted) indicates that this plasmid contains an 
insert of the size expected following succesful pcDNA3-MKK6b(E) vector and (Gly-
Glu)5-FLAG-p38δ insert ligation. 
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Figure 3.5. Restriction digest analysis of plasmids generated from ligation of 
pcDNA3-MKK6b(E) and (Gly-Glu)5-FLAG-p38δ. Agarose gel electrophoresis 
analysis of products of HindIII and XbaI digestion of plasmids resulting from 
ligation of pcDNA3-MKK6b(E) and (Gly-Glu)5-FLAG-p38δ. Highlighted is a 
fragment of the size expected following successful ligation. pcDNA3-MKK6b(E) 
linear plasmid (vector) served as a negative control. 
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The single plasmid determined to be positive for pcDNA3-MKK6b(E) vector and 
(Gly-Glu)5-FLAG-p38δ insert ligation (Figure 3.5) was further analysed to 
determine the orientation of the insert by digestion with SwaI and XbaI restriction 
enzymes whose recognition sites are located such that digestion of the plasmids will 
yield different sized products depending on whether the insert is present in a sense or 
anti-sense orientation. Agarose gel electrophoresis analysis of restriction digest 
products identified fragments of 6642 bp and 1360 bp indicating that the insert is 
present in a reverse orientation (Figure 3.6). 
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Figure 3.6. Restriction digest analysis to determine the orientation of the (Gly-
Glu)5-FLAG-p38δ insert. Agarose gel electrophoresis analysis of products of SwaI 
and XbaI digestion of plasmids positive for (Gly-Glu)5-FLAG-p38δ insert. 
Highlighted are fragments of the size expected if the (Gly-Glu)5-FLAG-p38δ insert 
is present in the reverse orientation (6642 bp, 1360 bp). 
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In an attempt to reduce the occurance of anti-sense orientation ligations the 
pcDNA3-MKK6b(E) vector was treated with 1 U/μl DNA shrimp alkaline 
phosphatase (SAP) (GE Healthcare, Buckinghamshire, UK) at 37°C for 1 hr to 
remove 5’ phosphates. SAP was inactivated by incubation at 65°C for 15 min. To 
address the poor level of ligation, the insert:vector ratio was increased from 3:1 and 
6:1 to 10:1 for all subsequent ligation reactions. Activity of SAP and T4 DNA 
Ligase was assesed with a number of control reactions. To examine T4 DNA Ligase 
activity, control reaction I and control reaction IV consisted of SwaI linearised 
pcDNA3-MKK6b(E) and (Gly-Glu)5-FLAG-p38δ respectively, each incubated at 
16°C overnight with T4 DNA Ligase. This resulted in re-ligation (circularisation) of 
pcDNA3-MKK6b(E) as well as self-ligation of (Gly-Glu)5-FLAG-p38δ (Figure 3.7). 
Activity of SAP was assessed using control reactions II and III. For both reactions 
SwaI linearised pcDNA3-MKK6b(E) was treated with SAP. For control reaction III, 
SwaI linearised, SAP treated pcDNA3-MKK6b(E) was then incubated as above with 
T4 DNA Ligase. Treatment with SAP prevented re-ligation of linear pcDNA3-
MKK6b(E) by T4 DNA Ligase (Figure 3.7). 
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Figure 3.7. Control reactions to assess shrimp alkaline phosphatase and T4 
DNA ligase activity. Agarose gel electrophoresis analysis of control ligation 
reactions. Control reaction I: SwaI linearised pcDNA3-MKK6b(E) + T4 DNA 
Ligase. Control reaction II: SwaI linearised pcDNA3-MKK6b(E) + SAP. Control 
Reaction III: SwaI linearised pcDNA3-MKK6b(E) + SAP + T4 DNA Ligase. 
Control reaction IV: (Gly-Glu)5-FLAG-p38δ + T4 DNA Ligase. 
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3.5.4 pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ was successfully generated 
Twenty-one plasmids prepared by miniprep from E. coli cells transformed with SAP 
treated pcDNA3-MKK6b(E) vector and (Gly-Glu)5-FLAG-p38δ insert ligation 
reactions were digested with HindIII and XbaI to determine if they contained the 
(Gly-Glu)5-FLAG-p38δ insert. A fragment between 2000 and 3000 bp (highlighted) 
indicates that these plasmids contain an insert of the size expected following 
succesful pcDNA3-MKK6b(E) vector and (Gly-Glu)5-FLAG-p38δ insert ligation 
(Figure 3.8). 
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The plasmids determined to be positive for pcDNA3-MKK6b(E) vector and (Gly-
Glu)5-FLAG-p38δ insert ligation were further analysed to identify the orientation of 
the insert by digestion with three pairs of restriction enzymes (SwaI and XbaI; BstXI 
and XhoI; BstXI and BamHI) whose recognition sites are located such that digestion 
of the plasmids will yield different sized products depending on whether the insert is 
present in a sense or anti-sense orientation (Figure 3.9). Following SwaI and XbaI 
digestion, four plasmids yielded products of 7806 bp and 196 bp (not visible on gel) 
suggesting they contain the insert in the correct orientation whereas five generated 
products of 6642 bp and 1360 bp indicating that the insert is present in a reverse 
orientation (Figure 3.9A) The four plasmids identified as containing the insert in the 
sense orientation  were also digested by BstXI and XhoI. All four plasmids yielded 
products of the size expected if the insert is orientated in the correct manner i.e. 6603 
bp and 1399 bp (Figure  3.9B). A plasmid which was believed to  contain the insert 
in  the reverse orientation was used as a control and resulted in products of 6415 bp 
and 1587 bp (Figure  3.9B*). Similarly, digestion of the four pcDNA3-MKK6b(E)-
FLAG-p38δ candidate plasmids with BstXI and BamHI generated products of the 
size expected for plasmids with the insert in the correct orientation (6762 bp and 
1240 bp) compared to the suspected negative orientation plasmid (6574 bp and 1428 
bp) (Figure 3.9C*).  
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Figure 3.9 Restriction digest analysis to determine the orientation of the (Gly-
Glu)5-FLAG-p38δ insert. Agarose gel electrophoresis analysis of products of (A) 
SwaI and XbaI, (B) BstXI and XhoI, and (C) BstXI and BamHI digestion of 
plasmids positive for (Gly-Glu)5-FLAG-p38δ insert. (A) Highlighted are fragments 
of the size expected if the (Gly-Glu)5-FLAG-p38δ insert is present in the reverse 
orientation (6642 bp, 1360 bp). (B) and (C) Highlighted are fragments of the size 
expected if the (Gly-Glu)5-FLAG-p38δ insert is present in the correct orientation (B 
1399 bp; C 1240 bp). 
 
 
A 
B C 
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The four plasmids positive for the (Gly-Glu)5-FLAG-p38δ insert in a sense 
orientation were analysed by DNA sequencing. Alignment of DNA sequence reads 
returned with the expected sequence of pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-
p38δ (Appendix I) confirmed successful ligation of pcDNA3-MKK6b(E) vector and 
(Gly-Glu)5-FLAG-p38δ insert. 
 
 
3.5.5 Expression and activity of MKK6b(E)-(Gly-Glu)5-FLAG-p38δ fusion protein 
Western blot analysis of transient transfections of KE-3 cells with the four candidate 
pcDNA3-MKK6b(E)-FLAG-p38δ plasmids demonstrated that MKK6b(E)-FLAG-
p38δ is expressed as a single, full-length polypeptide. As expected, MKK6 (38 kDa), 
p38δ MAPK (43 kDa) and FLAG (~1 kDa) are each detected at 82 kDa (Figure 3.10 
A, B and C respectively). p-p38 MAPK is also detected at 82 kDa indicating that the 
(Gly-Glu)5 linker facilitates protein folding and allows MKK6b(E) to constitutively 
phosphorylate its p38δ MAPK partner (Figure 3.10D). p-p38 MAPK is not detected 
at 43 kDa. Thus MKK6(E) expressed in the fusion protein specifically 
phosphorylates its p38δ MAPK fusion partner and does not interact with endogenous 
KE-3 p38α, -β or –γ MAPK isoforms (Figure 3.10D).  
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3.5.6 Generation of pcDNA3-MKK6b-(Gly-Glu)5-FLAG-p38δ plasmid 
A pcDNA3-MKK6b-(Gly-Glu)5-FLAG-p38δ plasmid (inactive MKK6) was created 
from pcDNA3-MKK6b(E)-FLAG-p38δ by substituting Glu151 and Glu155 with Ser 
and Thr respectively by site-directed mutagenesis using P010F: 5'-
TGGAATCAGTGGCTATTTGGTGGACTCTGTTGCTAAAACAATTGATGCAG
GTTGCAAACCATAC-3' (sense) and P010R: 5'-
GTATGGTTTGCAACCTGCATCAATTGTTTTAGCAACAGAGTCCACCAAAT
AGCCACTGATTCCA-3' (antisense) (mismatches underlined) oligonucleotides. 
This site-directed mutagenesis also introduced a second MfeI recognition site 
(CAATTG) within the plasmid sequence. Four plasmids which arose from 
transformation of the site-directed mutagenesis reaction were analysed for the 
presence of the mutations by restriction digest with MfeI. The expected products of 
MfeI digestion of plasmids containing the Ser
151
 and Thr
155
 mutations are 6354 bp 
and 1648 bp compared to a single 8002 bp product for plasmids containing Glu
151
 
and Glu
155
. Agarose gel electrophoresis of the restriction digest products indicated 
that three of the four plasmids were positive for the substitution of Glu
151
 and Glu
155
 
with Ser and Thr respectively (Figure 3.11A). Plasmids were also analysed for the 
presence of the desired mutations by DNA sequencing with SeqP6 (5’- 
TTGGATATTTCCATGAGGACGG-3’) sequencing primer. Sequence reads 
returned identified the Ser and Thr mutations in plasmids 1, 3 and 4, in agreement 
with the restriction digest results (Figure 3.11B). Plasmid 1 was used for all further 
experiments. 
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Figure 3.11 Confirmation of successful site-directed mutagenesis of pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ to generate pcDNA3-MKK6b-(Gly-Glu)5-
FLAG-p38δ. (A) Agarose gel electrophoresis analysis of products of MfeI digestion 
of plasmids following site-directed mutagenesis. Highlighted are fragments of the 
size expected following successful site-directed mutagensis (1648 bp). MfeI 
digestion of untreated pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ plasmid was 
used as a negative control. (B) DNA sequence analysis to confirm site-directed 
mutagesis. Alignment of newly synthesised plasmids with original pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ plasmid. Residues identical to the reference 
sequence (pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ) residue at the same 
position are represented by a point (•), residues which differ are in uppercase. 
Expected mutation sites following successful site-directed mutagenesis are 
highlighted. 
A 
B 
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3.5.7 Generation of control plasmid pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-
p38δDN 
A pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δDN control plasmid (non-
phosphorylatable p38δ MAPK mutant) was generated from pcDNA3-MKK6b(E)-
(Gly-Glu)5-FLAG-p38δ by changing the conservative phosphorylation motif TGY to 
AGF using P011F: 5’-GACGCCGAGATGGCTGGCTTCGTGGTGACCCG-3' 
(sense) and P011R: 5'-CGGGTCACCACGAAGCCAGCCATCTCGGCGTC-3' 
(antisense) (mismatches underlined) oligonucleotides. This site-directed mutagenesis 
also altered the BsaAI digestion profile of the plasmids. Four plasmids obtained from 
transformation of the site-directed mutagenesis reactions were analysed for the 
presence of the mutations by restriction digest with BsaAI. The expected products of 
BsaAI digestion of plasmids containing the AGF mutations are 3453, 1781, 1041, 
924 and 803 bp compared to a 3453, 1310, 1041, 924, 803 and 471 bp products for 
plasmids containing the original TGY motif. Agarose gel electrophoresis of the 
restriction digest products indicated that all four plasmids analysed were positive for 
the TGY to AGF mutation (Figure 3.12A). This was confirmed by DNA sequence 
analysis with Seq5 (5’-CTGCTGAAGCACATGCAGCATGAG-3’) sequencing 
primer. Sequence reads returned identified the AGF mutation in all four plasmids. Of 
note an extra base change was detected in one of the plasmids (Figure 3.12B). This 
plasmid was not further utilised. Plasmid 1 was used for all further experiments. 
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Figure 3.12 Confirmation of successful site-directed mutagenesis of pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ to generate pcDNA3-MKK6b(E)-(Gly-
Glu)5-FLAG-p38δDN control plasmid. (A) Agarose gel electrophoresis analysis of 
products of BsaAI digestion of plasmids following site-directed mutagenesis. 
Highlighted are unique fragments of the size expected following successful site-
directed mutagensis (1781 bp). BsaAI digestion of untreated pcDNA3-MKK6b(E)-
(Gly-Glu)5-FLAG-p38δ plasmid was used as a negative control. (B) DNA sequence 
analysis to confirm site-directed mutagesis. Alignment of newly synthesised 
plasmids with original pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ plasmid. 
Residues identical to the reference sequence (pcDNA3-MKK6b(E)-(Gly-Glu)5-
FLAG-p38δ) residue at the same position are represented by a point (•), residues 
which differ are in uppercase. Expected mutation sites following successful site-
directed mutagenesis are highlighted. 
A 
B 
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3.5.8 Expression and activity of pcDNA3-MKK6b-(Gly-Glu)5-FLAG-p38δ and 
pcDNA3-MKK6b(E)-(Gly-Glu)5FLAG-p38δDN plasmids 
Western blot analysis of transient transfections of KE-3 cells demonstrated that both 
pcDNA3-MKK6b-FLAG-p38δ and pcDNA3-MKK6b(E)-p38δDN plasmids produced 
a single polypeptide with a molecular mass of 82 kDa as expected when using a p38δ 
MAPK antibody (Figure 3.13). However, expression of pcDNA3-MKK6b(E)-
FLAG-p38δDN did not result in any detectable phosphorylation of p38 MAPK. In 
agreement with results previously reported for p38α/γ and MKK6, following 
transient transfection of KE-3 cells with pcDNA3-MKK6b-FLAG-p38δ, expression 
of phosphorylated p38 MAPK was detected at 82 kDa, similar to that observed for 
pcDNA3-MKK6b(E)-FLAG-p38δ (Figure 3.10 and Figure 3.13). As both MKK6b 
and MKK6b(E) fused to p38δ MAPK produced the same desired result, only one 
plasmid, pcDNA3-MKK6b(E)-FLAG-p38δ, was used for future experiments. 
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Figure 3.13 Western blot analysis of KE-3 cells transiently transfected with 
pcDNA3-MKK6b-(Gly-Glu)5-FLAG-p38δ and pcDNA3-MKK6b(E)-(Gly-Glu)5-
FLAG-p38δDN control plasmids. Transfected and untransfected cells were analysed 
by immunoblot using antibodies specific for p38δ and p-p38 MAPK. 30 μg protein 
lysate for each sample was loaded on a 10% SDS-PAGE gel. Membranes were 
probed with an anti-β-actin antibody as a loading control.  
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3.6 Discussion 
 
To date, functional characterisation of p38 MAPK pathways has relied heavily on 
the use of constitutively active upstream MKKs as well as pyridinyl-imidazole 
inhibitors such as SB203580 and SB202190 which specifically inhibit p38α and –β 
MAPK but have no effect on p38γ and δ MAPKs. However, this has led to the 
development of an incomplete and somewhat inaccurate understanding of p38 
MAPK signalling particularly in relation to p38γ and p38δ MAPK isoforms. The use 
of constitutively active MKKs and MKKKs does not take in to consideration the 
possibility of non-specific p38 MAPK isoform activation. To-date there are no 
specific p38δ MAPK inhibitors or direct chemical activators commercially available. 
 
Efforts by other groups to generate constitutively active p38δ MAPK mutants used 
site-directed mutagenesis of p38δ MAPK to generate mutations based on known 
activating mutations in HOG1, p38α and p38γ MAPKs [18, 19]. When expressed in 
E. coli cells, the intrinsically active p38δF324S variant reached an activity level of 
13.5% that of MKK6 activated p38δWT. Significantly, this p38δF324S active mutant 
displayed 20% phosphorylation relative to MKK6 activated p38δWT [18]. It appears 
therefore that there exists a correlation between p38 isoform activation and 
phosphorylation as the p38βD176A isoform also displayed correlated levels of 
phosphorylation (60%) and activation (60%) [18]. As E. coli cells do not express any 
MKKs the spontaneous activation of p38δF324S has been attributed 
autophosphorylation. p38δF324S exhibited a high level of autophosphorylation which 
correlated with its level of activity while p38δWT, which exhibits no basal activity, 
displayed negligible levels of autophosphorylation [18]. Autophosphorylation 
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capabilities have also been attributed to p38α MAPK mutants [20, 21]. However, 
while p38α MAPK is known to autophosphorylate in response to ZAP-70 
phosphorylation of Tyr323 in T cells or via interaction with TAB1 (TAK1 – binding 
protein 1) no evidence exists to-date which suggests that autophosphorylation is a 
natural mechanism of p38δ MAPK activation in vivo [30, 31]. Although in vivo 
expression of p38δ MAPK active mutants generated activation levels higher than 
that of MKK6 activated p38δWT, this has been attributed to a positive feedback loop 
involving autophosphorylation in combination with MKK activation as well as 
resistance to downregulation by phosphatases [19]. These processes also do not 
reflect endogenous p38δ MAPK signalling and highlight the unsuitability of p38δ 
active mutants for studying p38δ MAPK function. 
 
A number of groups have previously demonstrated the efficacy of an enzyme-
substrate fusion approach in studying the activation of MAPKs, including ERK, 
JNK, p38α MAPK and p38γ MAPK [22-24]. We show here, for the first time, that 
fusion of p38δ MAPK to its upstream kinase activator MKK6, in either the inactive 
(MKK6b) or active (MKK6b(E)) form specifically and constitutively phosphorylates 
p38δ MAPK. This fusion of two kinase partners via a peptide linker to generate a 
constitutively active form of the downstream kinase may now be considered as a 
viable alternative to the hit-and-miss approach of identifying activating mutation 
sites in individual kinases.  
 
The specific mechanisms governing the activation of p38δ MAPK by MKK6 within 
the fusion protein were outside the scope of this study and remain unclear. While 
functional components appear to be required – the MKK6-p38δDN protein in which 
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p38δ MAPK is non-phosphorylatable is inactive (Figure 3.13) – constitutive 
activation of MKK6 (MKK6b(E)) is not necessary (Figure 3.13). This result was not 
unexpected as in previous studies using MKK-MAPK fusion constructs, expression 
of wild-type kinases in the fusion protein were sufficient to induce phosphorylation 
[22-24]. Certainly, p38δ MAPK phosphorylation is not a result of cleavage of the 
fusion protein and subsequent activity of the released MKK6 module. The MKK6-
p38δ fusion protein is expressed as a single polypeptide with a molecular mass of 82 
kDa – equivalent to the combined masses of MKK6 (38 kDa), FLAG (1 kDa) and 
p38δ MAPK (43 kDa) – as demonstrated by immunoblot analysis (Figure 3.10). 
Furthermore it can be assumed that cleaved MKK6 would also phosphorylate p38α, -
β and –γ MAPK isoforms [15]. However no evidence of this was observed as p-p38 
was not detected at 38-43 kDa (Figure 3.10). 
 
Thus, the MKK6-p38δ fusion protein provides, for the first time, an opportunity to 
evaluate the function of p38δ MAPK signalling in the absence of involvement of 
other p38 MAPK isoforms  
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Chapter 4 
 
Loss of p38 mitogen-activated protein kinase 
expression promotes oesophageal squamous cell 
carcinoma proliferation, migration and 
anchorage-independent growth 
 
 
 
 
 
O'Callaghan, C., Fanning, L.J., Houston, A., Barry, O.P. 
Loss of p38 mitogen-activated protein kinase expression promotes oesophageal 
squamous cell carcinoma proliferation, migration and anchorage-independent growth 
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4.1 Abstract 
 
Oesophageal cancer is an aggressive tumour which responds poorly to both 
chemotherapy and radiation therapy and has a poor prognosis.  Thus, a greater 
understanding of the biology of oesophageal cancer is needed in order to identify 
novel therapeutic targets. Among these targets p38 MAPK isoforms are becoming 
increasingly important for a variety of cellular functions. The physiological functions 
of p38 and –β MAPKs are now well documented in contrast to –γ and - MAPKs 
which are comparatively under-studied and ill-defined. A major obstacle to 
deciphering the role(s) of the latter two p38 MAPK isoforms is the lack of specific 
chemical activators and inhibitors.  In this chapter we analysed p38 MAPK isoform 
expression in oesophageal cancer cell lines as well as human normal and tumour 
tissue. We observed specifically differential p38 MAPK expression. The role(s) of 
p38 and active (phosphorylated) p38 (p-p38) MAPK in oesophageal squamous 
cell carcinoma (OESCC) was delineated using wild type p38 MAPK as well as 
active p-p38 MAPK, generated by fusing p38 MAPK to its upstream activator 
MKK6b(E) via a decapeptide (Gly-Glu)5 linker. OESCC cell lines which are p38δ 
MAPK negative (KE-3 and -8) grew more quickly than cell lines (KE-6 and -10) 
which express endogenous p38δ MAPK. Re-introduction of p38 MAPK resulted in 
a time-dependent decrease in OESCC cell proliferation which was exacerbated with 
p-p38 MAPK. In addition we observed that p38 and p-p38 MAPK negatively 
regulated OESCC cell migration in vitro. Finally both p38 and p-p38 MAPK 
altered OESCC anchorage-independent growth.  Our results suggest that p38 and p-
p38 MAPK have a role in the suppression of OESCC. Our research may provide a 
new potential target for the treatment of oesophageal cancer.  
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4.2 Hypothesis and aims 
 
The hypothesis for this chapter is that p38δ MAPK has a role in the proliferation, 
migration and anchorage-independent growth of oesophageal squamous cell 
carcinoma (OESCC). 
 
To examine this hypothesis the aims for this chapter are as follows: 
 
 To examine p38δ MAPK expression in OESCC cell lines and human tissue. 
 
 To generate stable OESCC cell lines expressing p38δ and p-p38δ MAPK. 
 
 To evaluate the consequences of p38δ and p-p38δ MAPK expression on 
OESCC proliferation, migration, invasion and anchorage-independent 
growth. 
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4.3 Introduction 
 
Oesophageal cancer is the seventh most common cancer worldwide [1] with its five 
year survival rate being dismally low at no more than 15% [2]. Oesophageal 
squamous cell carcinoma (OESCC) is an exceptionally drug-resistant tumour. 
Despite recent advances in the detection of OESCC and the development of 
multimodal therapy [3, 4], its incidence is on the rise and outcome for patients 
remains poor [5, 6]. Thus, a greater understanding of the initiation and progression of 
OESCC is required in order to be able to identify predictive and prognostic factors 
that may in the future lead to novel therapeutic strategies. 
 
The mitogen-activated protein kinases (MAPKs) are serine/threonine kinases and 
include the extracellular-regulated kinase (ERK), c-jun NH2-terminal kinase (JNK) 
and p38 MAPK families. The p38 MAPK family consists of four members; p38 
(MAPK14) of which there are two splice variants [7], p38β (MAPK11), p38γ 
(MAPK12), and p38 (MAPK13) [8]. Although these isoforms are 60-70% identical 
in amino acid sequence they differ greatly in their tissue distribution [9], substrate 
specificity [10] and sensitivity to chemical inhibitors [11]. In recent years, we have 
gained an increased appreciation of the importance of p38 MAPK isoforms for a 
variety of cellular functions including proliferation, differentiation, transformation, 
and programmed cell death [12]. Their roles, however, are more complex than 
previously thought, with distinct members appearing to have different functions. In 
addition, the roles of p38 MAPK in various pathologic conditions remain to be 
elucidated [13].  
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To-date most of the published literature refers to the p38 MAPK family as a whole 
or indeed have focused on the first discovered isoform p38 MAPK [10, 13]. There 
is an obvious dearth of research pertaining to the latter two isoforms, p38γ and - 
MAPK, due partly to the lack of commercially available specific chemical activators 
or inhibitors for each of these isoforms [14]. In this chapter we have overcome this 
obstacle using an enzyme-substrate fusion approach for the generation of 
constitutively active p38 MAPK. We now provide new information regarding the 
role(s) of p38δ and active (phosphorylated) p38 (p-p38) MAPK in OESCC. We 
identified differential p38δ MAPK expression in OESCC. Lack of p38δ MAPK 
expression in OESCC allows for a more aggressive phenotype including increased 
proliferation, increased migration and increased capacity for anchorage independent 
growth. Restoration of p38δ MAPK expression, however, reverses these effects. 
Together, our results provide evidence for a novel role for p38δ MAPK-induced 
suppressive effects in OESCC. With survival rates being poor for patients with 
OESCC, there is an urgent need to find novel strategies to improve current therapy. 
Our work suggests isoform specific activation of p38δ MAPK as a possible potential 
approach for treatment of patients with OESCC.  
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4.4 Materials and Methods 
 
4.4.1 Specimens 
The patient cohort consisted of ten patients with OESCC of both genders ranging in 
age from 44 to 81 years. Formalin-fixed, paraffin-embedded (FFPE) 
oesophagectomy specimens from ten patients consisted of ten paired samples of 
primary tumour and metastatic lymph nodes with 10 samples of non-tumour adjacent 
tissues (NAT). All patient tumour biopsies were staged and group staged (in a 
blinded manner) histopathologically in accordance with TNM7 and performed by a 
pathologist at the Mercy University Hospital. Patient features are summarized in 
Table 4.1. 
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Table 4.1 OESCC patient features 
Patient Features     No. of patients 
Sex 
 Male      4    
  
     Female     6 
Age       Median 63 (44 to 81) years 
TNM7 stage 
 T stage 
  T3     10  
N stage 
  N1     3 
  N2     7 
   
Histological grade 
 Well differentiated    1 
 Moderately differentiated   6 
 Poorly differentiated    3 
  
Patient features are summarised based on gender, age, TNM7 stage and histological 
stage. Based on the TNM7 categorization for oesophageal cancer N1 = 1-2 lymph 
nodes and N2= 3-6 lymph nodes. 
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4.4.2 Cell culture 
The KE oesophageal cancer cell lines as well as KYSE-70, KYSE-450, OE-19, OE-
21, OE-33, OC-3 cells and stably transfected KE-3 cell lines were cultured as 
described in Chapter 2. KE cell line features are summarized in Table 2.2.  
 
 
4.4.3 Proliferation assay  
Cell viability was assessed by trypan blue (0.4% w/v) exclusion assay as previously 
described [15]. KE cells were seeded at a density of 3 x 10
4
 cells/well in a 6-well 
tissue culture plate and incubated for the times indicated. Wells were washed with 
PBS and cells were harvested with Trypsin-EDTA as in Chapter 2 and resuspended 
in the appropriate medium. A cover-slip was affixed to the haemocytometer. Equal 
volume trypan blue solution was mixed with cell suspension. 20μl trypan blue/cell 
suspension mixture was pipetted onto the haemocytometer under the cover-slip. 
Viable cells were counted in all 4 large corner squares according to Figure 4.1, using 
a Diaphot phase contrast microscope (Nikon, Tokyo, Japan). Cell concentration per 
ml was calculated as follows: 
 
Average number of cells in one large square x dilution factor (2) x 10
4
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Figure 4.1 Cell counting with a haemocytometer. Cells were counted in each of 
the four corner squares according to the following rule – count cells on top and left 
touching middle line of the perimeter of each square (√). Do not count cells touching 
the middle line at bottom and right sides (X). 
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4.4.4 Nuclear and cytosolic extraction 
Nuclear and cytoplasmic fractions were prepared using NE-PER® Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) according to 
manufacturer’s instructions. 2x106 cells were transferred to a 15ml tube and 
centrifuged at 1100 rpm for 5 min. Supernatant was discarded and cells were washed 
by resuspending in 1ml PBS. Cell suspension was transferred to a 1.5ml 
microcentrifuge tube and cells were pelleted by centrifugation at 500 x g for 3 min. 
Supernatant was discarded, leaving the cell pellet as dry as possible. Ice-cold CERI 
(supplemented with Protease Inhibitor Cocktail) was added, and the tube was 
vortexed vigorously for 15 s to fully resuspend the pellet. Following a 10 min 
incubation on ice, ice-cold CERII was added and vortexed for 5 s. Samples were 
centrifuged at a speed of 10 000 rpm for 5 min. Supernatants (cytoplasmic extract) 
were transferred to pre-chilled microcentrifuge tubes and stored at -20°C. Remaining 
insoluble fractions were resuspended in ice-cold NER by vortexing for 15 s every 10 
min, for a total of 40 min. Samples were centrifuged at 10 000 rpm for 10 min. 
Supernatants (nuclear extract) were collected in pre-chilled microcentrifuge tubes 
and stored at -20°C. Samples were stored on ice throughout the extraction procedure 
and all centrifugation steps were performed at ≤ 4°C. 
 
 
4.4.5 Stable transfection 
KE-3 cells were stably transfected with pcDNA3, pcDNA3-FLAG-p38δ, pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ, or pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-
p38δDN. Transfection procedure was as described in Chapter 3 for transient 
transfection. Twenty-four hours following transfection cells were transferred to 100 
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mm diameter dishes. Transfected cells were selected for by incubation in normal 
growth medium supplemented with 800 μg/ml geneticin. After 4-8 weeks, individual 
cell colonies were transferred to culture flasks for clone expansion. Stably 
transfected cell lines were maintained in the appropriate media supplemented 400 
μg/ml geneticin. 
 
 
4.4.6 Immunoblot analysis 
Supernatants used for immunoblotting with specific antibodies, p38α, -β, -γ and –δ, 
phospho-p38 MAPK and MKK3, MKK4, MKK6 and MKK7 antibodies were 
prepared as detailed in Chapter 2  and have previously been described by us [15, 16].   
 
 
4.4.7 Immunohistochemistry 
p38 MAPK isoform expression in FFPE OESCC and NAT sections, as well as 
expression of p38δ and p-p38 MAPK in control and stably transfected KE-3 cells 
was examined using immunohistochemistry as previously described [16]. FFPE 
OESCC and NAT sections were de-parrafinized in xylene and re-hydrated prior to 
analysis. Antigen retrieval was performed by microwave irradiation on 0.01 M 
citrate buffer, pH 6.0 (citrate acid, H2O).  
 
Endogenous peroxidase activity was quenched by incubation in 3% v/v H2O2 for 10 
min. To block non-specific binding of antibody, samples were incubated with 5% 
v/v Normal Goat Serum in 0.05M Tris Saline pH 7.6 (0.04M Trizma HCl, 0.01M 
Trizma Base, 0.15M NaCl, 0.005M KCl, pH adjusted to 7.6 with 5N HCl), 0.001% 
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w/v Saponin (NGS TS/SAP) for 1 hr at RT. Washes were performed between each 
incubation with 1% NGS TS/SAP. Primary antibodies (Table 4.2) were diluted in 
1% NGS, 0.05M Tris Buffer (0.04M Trizma HCl, 0.01M Trizma Base) – at 
concentrations specified by the manufacturer. Primary antibodies were incubated on 
coverslips overnight at 4°C in a humidified environment. A negative control was 
performed for each experiment by eliminating the primary antibody. 
 
 
Table 4.2 Primary antibodies for immunohistochemistry/immunocytochemistry. 
Target antigen  
(human) 
Molecular 
weight 
Supplier Source 
p38α MAPK 43 kDa Cell Signaling Technology Rabbit 
p38β MAPK 40 kDa Zymed Laboratories, CA, USA Mouse 
p38γ MAPK 46 kDa Upstate, Lake Placid, NY, USA Rabbit 
p38δ MAPK 43 kDa R&D Systems Rabbit 
phospho-p38 MAPK 43 kDa Cell Signaling Technology Rabbit 
 
 
Biotinylated anti-rabbit and anti-mouse secondary antibodies (Vector Laboratories, 
Burlingame, CA, USA) were diluted 1:200 in 1% NGS TS/SAP and incubated on 
samples for 45 min at RT. A preformed avidin and biotinylated horseradish 
peroxidise macromolecular complex (Vectastain® Elite® ABC Kit, Vector 
Laboratories) was applied to the samples and incubated for 45 min RT. Cells were 
stained by incubation with 3,3’-diaminobenzidine (DAB Substrate Kit for 
Peroxidase, Vector Laboratories) for 5 min in the dark. Cells were counterstained 
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with Mayer’s haematoxylin for 3 min. Coverslips were mounted to glass slides with 
aqueous mounting medium and allowed to dry overnight. 
 
Slides were examined using the brightfield view of an Olympus BX61 microscope. 
Images were captured by an Olympus DP71 camera and analysed using Olympus 
cell^F analysis image processing software (Olympus, Essex, UK). 
 
 
4.4.8 Immunocytochemistry 
p38 and p-p38 MAPK expression in control and stably transfected KE-4 cells was 
examined using immunocytochemistry. Cells were seeded at a density of 50 000 or 
80 000 cells per well of a 6-well plate with each well containing a 22mm x 22mm 
coverglass. On reaching the appropriate confluency, media was removed and cells 
were washed 3 times with PBS. Cells were fixed to coverslips by incubation in 2ml 
4% w/v paraformaldehyde for 15 min followed by three washes with PBS. Cells 
were permeabilized by incubation with 0.5% v/v Triton-X-100 in PBS for 5 min, 
followed by three washes with PBS. Antibody binding and detection was performed 
as described above for immunohistochemistry. 
 
 
4.4.9 ELISA 
A DuoSet® IC Human Phospho-p38δ (T180/Y182) sandwich enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems Europe Ltd., Abingdon, UK) was 
used according to manufacturer’s instructions to measure p38δ MAPK 
phosphorylated at T180/Y182 in cell lysates. To prepare lysates, cells were 
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resuspended at 1 x 10
7
 cells/ml in Lysis Buffer #6 (1 mM EDTA, 0.5% v/v Triton-X-
100, 5 mM NaF, 6 M urea, 10 μg/ml leupeptin, 10 μg/ml pepstatin, 100 μM PMSF, 3 
μg/ml aprotinin, 2.5 mM Na4P2O7, 1 mM sodium orthovanadate (Na3VO4)) and 
incubated on ice for 15 min. Lysates were stored at -80°C. Before use lysates were 
diluted 6-fold with IC Diluent #8 (1 mM EDTA, 0.5% v/v Triton-X-100, 5 mM NaF) 
and further serial dilutions were prepared in IC Diluent #3 (1 mM EDTA, 0.5% v/v 
Triton-X-100, 5 mM NaF, 1 M urea).  
 
Phospho-p38δ MAPK (T180/Y182) Standard was reconstituted with IC Diluent #7 
(1 mM EDTA, 0.5% v/v Triton-X-100, 5 mM NaF, 6 M urea). It was then initially 
diluted 6-fold with IC Diluent #8 before additional dilutions were prepared in IC 
Diluent #3. These dilutions generated a six point standard curve using 2-fold 
dilutions and a high standard of 10 000 pg/ml.  Phospho-38δ (T180/Y182) Capture 
Antibody was reconstituted in PBS. Phospho-38δ (T180/Y182) Detection Antibody 
was reconstituted in IC Diluent #1 (1% BSA). 
 
A 96 well microplate was coated with 100 μl per well of 1.0 μg/ml Capture Antibody 
in PBS, sealed and incubated overnight at RT. Capture Antibody was aspirated and 
wells washed three times with Wash Buffer (0.05% v/v TWEEN®20 in PBS). Plates 
were blocked by incubating with 300 μl Block Buffer (1% BSA, 0.05% NaN3, PBS) 
per well for 1 – 2 hr at RT. Aspiration/washing was repeated. 100 μl of diluted 
sample or standards was added per well, sealed and incubated for 2 hr at RT. 
Aspiration/washing was repeated. 100 μl 1.0 μg/ml Detection Antibody in IC Diluent 
#1 was added per well, sealed and incubated for 2 hr at RT. Aspiration/washing was 
repeated. 100 μl Streptavidin-HRP in IC Diluent #1 was added to each well and 
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incubated in the dark for 20 min at RT. Aspiration/washing was repeated. 100 μl 
Substrate Solution was added per well and incubated in the dark for 20 min at RT. 50 
μl Stop Solution was added per well. The absorbance of each well at 450 nm (with a 
wavelength correction of 540 nm) was measured immediately on a Sunrise
TM
 
spectrophotometric plate reader and analysed using the XRead software program. 
A standard curve was generated by plotting the Blank-corrected average absorbance 
reading for each of the standards versus their concentrations in pg/ml. The 
concentration of phospho-p38δ MAPK (T180/Y182) in each unknown sample was 
determined using this standard curve according to the following equation: 
 
       
 
where y = blank-corrected absorbance reading, m = the slope of the standard curve 
and x = concentration in pg/ml. 
 
 
4.4.10 Cell migration 
Migration of untransfected and transfected KE-3 cells was assessed using both a 
Boyden Chamber assay and a wound-healing assay as described in Chapter 2. 
 
 
4.4.11 Colony forming assay 
The role of p38 MAPK in anchorage-independent growth was assayed using a soft 
agar colony-forming assay as previously described [16]. Cells were plated at a 
density of 3 x 10
5
 cells/100-mm dish in medium containing 0.4% (w/v) agar on an 
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underlay of 0.8% (w/v) agar. After 21 days incubation colonies were stained with 
MTT as outlined in Chapter 2. 
 
 
4.4.12 siRNA 
KE-6 cells at 75% confluency were transfected with p38 MAPK small interfering 
RNA (siRNA) (Santa Cruz Biotechnology) or control siRNA-A (Santa Cruz 
Biotechnology) as recently described [17]. 24 hr before transfection, 2 x 10
5
 cells 
were seeded per well of a 6-well tissue culture plate in antibiotic-free growth 
medium. Cells were incubated with 100 nM p38δ MAPK siRNA or control siRNA-
A and 6 μl siRNA Transfection Reagent (Santa Cruz Biotechnology) in 800 μl 
serum-free, antibiotic-free medium/well for 7 hr. 1 ml normal growth medium 
containing two times the normal serum and antibiotics concentration was added per 
well and incubated for an additional 24 hr before being replaced with 2 ml normal 
growth medium. Cells were assayed (proliferation and whole cell lysates) 24, 48, 72 
and 96 hr after the addition of normal growth medium.  
 
 
4.4.13 rt-PCR 
p38δ MAPK mRNA was amplified from cellular cDNA (synthesised as described in 
Chapter 2) using DreamTaq
TM
 DNA polymerase (Fermentas, Thermo Fisher 
Scientific) and oligonucleotide primers P001F 5’- CCACGTTAAACTGCCCATCT-
3’ and P001R  5’- CCGCCACAAGCTAAAAAGAG-3’. Other reaction components 
were as listed in Table 2.6. rt-PCR was performed in a GeneAmp PCR System 2700 
 132 
 
under the conditions described in Table 2.7. rt-PCR products were analysed by 
agarose gel electrophoresis as described in Chapter 2. 
 
 
4.4.14 Proteome Profiler
TM
 antibody array 
The relative levels of phosphorylation of 26 kinases was examined in cell lysates 
using a Proteome Profiler
TM
 Human Phospho-MAPK Array (R&D Systems Europe 
Ltd.) according to manufacturer’s instructions. Cells rinsed with PBS were 
resuspended at 1 x 10
7
 cells/ml in Lysis Buffer 6. Lysates were rocked at 4°C for 30 
min then centrifuged at 14 000 x g for 5 min. Supernatants were stored at -80°C. 
Total protein concentration of samples was quantitated as described in Chapter 2. All 
incubations were performed on a platform rocker. Arrays were blocked for 1 hr at 
RT in Array Buffer 5 (a buffered protein base with preservatives). 200 μg cell lysate 
was combined with 20 μl Detection Antibody Cocktail and incubated for 1 hr at RT 
before being incubated overnight at 4°C on arrays. Three 10 min washes were 
performed between each of the remaining steps with 1X Wash Buffer. Streptavidin-
HRP, diluted 1:2000 in Array Buffer 5, was incubated on arrays for 30 min at RT. 
Chemi Reagent Mix (equal volumes Chemi Reagent 1 and 2) was pipetted evenly 
onto each membrane and incubated for 1 min before excess reagent was drained 
away. Positive signals were detected using a SYNgene G:Box Chemi XR5 Gel 
Documentation System. Pixel density of each spot was analysed using Scion Image 
software (Scion Corp., Frederick MD, USA). 
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4.5 Results 
 
4.5.1 p38, -β, -γ and - MAPK isoforms and MKK3, -4, -6 and 7 are differentially 
expressed in oesophageal cancer  
The expression of p38 MAPK as a family has previously been outlined in 
oesophageal cancer as well as other cancer types [10, 13, 18, 19].  While these 
reports refer to the p38 MAPK family, analysis of individual p38 MAPK isoform 
expression in oesophageal cancer has to date never been reported. A previous study 
by us outlining differential p38 MAPK isoform expression in renal cancer prompted 
us to investigate further the effects of individual p38 MAPK family members in 
cancer in general [20]. Using Western blot analysis we examined p38 MAPK 
isoform expression in nine OESCC cell lines (KE-3, -4, -5, -6, -8, -10, KYSE-70, 
KYSE-450 and OE-21) and three oesophageal adenocarcinoma cell lines (OC-3, OE-
19 and OE-33). We used antibodies specific for each isoform p38α, -β2, -γ and -δ 
MAPKs as previously described by us [20]. All twelve oesophageal cancer cell lines 
(squamous and adenocarcinoma) expressed p38, –β and –γ MAPKs (albeit at 
different levels) (Figure 4.2A). In contrast p38 MAPK expression was present in 
the three adenocarcinoma cell lines but absent in four of the OESCC cell lines KE-3, 
-8, KYSE-70 and OE-21 (Figure 4.2A). The specific loss of p38 MAPK isoform 
expression only has previously been reported by us in renal carcinoma (786-0) [20] 
and also observed by us in liver (Huh-7), lung (A-549) prostate (PC-3 and DU-145) 
and skin (MeWo) cancer cell lines (Figure A.1). Upstream MKK3 and -6 are thought 
to be the major protein kinases responsible for p38 MAPK activation [18] but the 
selectivity of p38 MAPK isoform activation is stimulus type and strength dependent 
[21]. We observed strong MKK3 and -4 expression for all cell lines except KE-3 and 
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-8 OESCC which were MKK3 negative. In contrast levels of MKK6 and -7 
expression were considerably lower (Figure 4.2B).  
 
Finally, analysis of p38 MAPK at the mRNA level surprisingly proved positive for 
all cell lines examined including the four OESCC cell lines that were negative for 
p38 MAPK protein expression (Figure 4.2C). Primers specific for a 292bp fragment 
of the 3’ untranslated region of p38δ MAPK mRNA amplified cDNA from all 
twelve cell lines. Other primer sets within the coding sequence yielded similar 
results. In addition DNA sequence analysis of PCR products did not identify any 
mutations such as a stop codon or a missense mutation which could possibly explain 
loss of p38 MAPK protein expression and is outlined in Chapter 6. 
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Figure 4.2 Expression of p38 MAPK isoforms, MKK3, -4, -6 and -7 in 
oesophageal cancer. (A) Western blot analysis of p38 MAPK isoform expression in 
KE-3, -4, -5, -6, -8 and -10, KYSE-70, -450, and OE-21 (oesophageal squamous cell 
carcinoma cell lines) as well as OC-3, OE-19 and OE-33 (oesophageal 
adenocarcinoma cell lines). (B) Western blot analysis of MKK3, -4, -6 and -7 in the 
same twelve cell lines. Aliquots of 30 µg of protein lysate were loaded on a 10 % 
SDS-PAGE gel and analyzed by immunoblot using antibodies specific for p38α, -β2, 
-γ and –δ MAPKs. β-actin analysis served as a loading control. The results shown 
are representative of four independent experiments. (C) Agarose gel electrophoresis 
analysis of DNA fragments produced by PCR amplification of p38δ MAPK mRNA 
from oesophageal squamous (KE3, -4, -5, -6, -8, 10, KYSE70, -450 and OE21) and 
adenocarcinoma (OC3, OE19 and -33) cell lines.  
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To investigate whether the p38 MAPK isoform expression pattern we observed in 
vitro with the OESCC cell lines could be translatable to the in vivo situation we 
analyzed the expression profile and localization of all four p38 MAPK isoforms (, -
β, –γ and -δ) in FFPE oesophagectomy specimens from ten patients with squamous 
cell carcinoma. Samples consisted of ten paired primary tumour and metastatic 
(lymph nodes) as well as corresponding NAT as outlined in Table 4.1. Samples were 
staged according to the new TNM7 categorization for oesophageal cancer (Table 
4.1) [22].  Consistent levels of p38 and –β MAPK expression was evident in all ten 
normal, primary and metastatic OESCC samples (Figure 4.3). Similarly, we did not 
observe a change in p38γ MAPK expression between normal, primary tumour and 
metastatic samples albeit the intensity of brown staining was less than that observed 
for p38 and –β MAPK (Figure 4.3). p38δ MAPK expression, however, was 
considerably different in normal versus primary tumour versus metastatic disease 
(Figure 4.3 and Table 4.3). p38δ MAPK expression was observed in both the nuclei 
and cytoplasm of nine of the ten oesophageal NAT tissue samples. However, a 
significant decrease in expression was observed in both the nuclei and cytoplasm in 
the ten primary tumour specimens as evidenced from the lighter brown staining 
compared to NAT samples in six patient samples and complete loss of expression in 
four of the samples (Figure 4.3, Table 4.3). Furthermore, eight out of the ten 
metastatic tissue specimens demonstrated complete loss of p38δ MAPK expression 
with both the nuclei and cytoplasm appearing blue in colour (Figure 4.3). This is an 
important finding considering identification of lymph node metastasis is the single 
most important prognostic factor in oesophageal cancer [1]. 
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Figure 4.3 Expression of p38α, -β, -γ and -δ MAPK isoforms in oesophageal 
human tissue. Immunohistochemical staining of p38α, -β2, -γ and -δ MAPK 
isoforms in normal, tumourigenic and metastatic (lymph node) oesophageal human 
tissue. Immunohistochemical staining was performed as outlined in Materials and 
methods. Blue arrow indicates cytoplasmic staining; black arrow indicates nuclear 
staining; white arrow indicates blue unstained nuclei and yellow arrow indicates blue 
unstained cytoplasm. Magnification is 400×. The results shown are representative of 
ten patients.   
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Table 4.3 p38 MAPK expression in patient specimens 
Diagnosis    p38 MAPK expression 
     Positive     Negative  
NAT (n=10)    9  1    
  
OESCC Primary (n=10)  6*  4  
OESCC Nodes (n=10)  2  8 
Samples obtained from ten patients consisted of ten paired primary tumour and 
metastatic lymph nodes as well as corresponding non-tumour adjacent tissues for 
analysis of p38 MAPK expression. *Denotes that p38 MAPK expression was 
considerably lower than in the corresponding NAT. 
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4.5.2 OESCC cell lines lacking endogenous p38 MAPK expression proliferate 
faster than those which express this isoform 
The results obtained for differential p38δ MAPK expression in both the oesophageal 
cell lines and the human samples prompted us to investigate further the effect(s) if 
any this particular isoform may have on the tumourigenicity of OESCC. Firstly, we 
examined whether the presence or absence of endogenous p38 MAPK expression 
could have an effect on the proliferation rate of our OESCC cell lines. Using the 
trypan blue exclusion assay we compared the proliferation rate of KE-3, and -8 cell 
lines (which do not express p38 MAPK) versus KE-6 and -10 (which express p38 
MAPK). We observed that at all time points studied (24-120 hr) both cell lines KE-3 
and -8 proliferated faster than KE-6 and -10 cells (Figure 4.4).  
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Figure 4.4 Oesophageal squamous cell carcinoma cell lines lacking endogenous 
expression of p38 MAPK have a higher proliferation rate. KE-3, and -8 cell 
lines (lacking endogenous p38 MAPK expression) and KE-6 and -10 cell lines 
(expressing endogenous p38 MAPK) were seeded (3 x 104) and counted for 24-120 
hr. The results shown are mean  S.E. of three independent experiments. 
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4.5.3 Generation of stable cell lines expressing p38δ, phosphorylated p38 (p-
p38) and p-p38δDN MAPK 
To investigate whether p38δ or active (phosphorylated) p38δ (p-p38) MAPK drives 
the observed anti-proliferative phenotype (Figure 4.4) we re-introduced wild type 
p38δ MAPK into KE-3 cells which have lost its expression. In the absence of a 
specific commercially available p38δ MAPK activator (and to investigate the 
effect(s) of active p-p38δ MAPK) we generated a constitutively active p38δ MAPK 
through enzyme substrate fusion as discussed in Chapter 3. As both MKK6b and 
MKK6b(E) fused in frame to p38 MAPK produced the same desired result 
(transient transfections Chapter 3) only one plasmid (MKK6b(E)-p38) was used for 
subsequent experiments. Western blot analysis of stable transfections of KE-3 cells 
demonstrated that pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38 produced a single 
polypeptide with a molecular mass of 82 kDa as expected when using p38 MAPK, 
p-p38 MAPK and MKK6 antibodies respectively (Figure 4.5A(i), (ii), (iii)). Western 
blot analysis of KE-3 cells stably transfected with pcDNA3-MKK6b(E)-(Gly-Glu)5-
FLAG-p38DN also produced a single polypeptide with a molecular mass of 82 kDa 
upon incubation with p38 MAPK and MKK6 antibodies (Figure 4.5A(i), (iii)) but 
did not demonstrate p38 MAPK activation (phosphorylation) (Figure 4.5A(ii)). 
Stable transfection of KE3 cells with pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ 
was also confirmed by PCR. T7 and SP6 primers specific for pcDNA3 amplified a 
2723bp fragment from genomic DNA of KE3 cells transfected with pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ and maintained in geneticin (400 μg/ml) 
supplemented medium (Figure 4.5B). 
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Figure 4.5 Generation of cell lines stably expressing p38δ, p-p38δ and p-p38δDN 
MAPK. (A) Western blot analysis of 30 g protein lysate of KE-3 cells stably 
transfected with empty vector (pcDNA3), wild type p38 MAPK, p-p38 MAPK 
and p-p38DN MAPK using antibodies specific for p38 MAPK (i), p-p38 MAPK 
(ii) and MKK6 (iii). The results shown are representative of four independent 
experiments. (B) Agarose gel electrophoresis analysis of products of PCR of 
genomic DNA from KE3 cells stably transfected with pcDNA2-MKK6b(E)-(Gly-
Glu)5-FLAG-p38δ using pcDNA3 specific T7 and SP6 primers. pcDNA3-
MKK6b(E)-(Gly-Glu)5-FLAG-p38δ plasmid DNA was used as a positive control. 
NTC: no template control. 
B 
A 
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Of note the antibody used in Figure 4.5A(ii) is a pan phospho-p38 MAPK antibody. 
To our knowledge there is no commercially available antibody to test for active 
(phosphorylated) p-p38 MAPK specifically by Western blot analysis.  Therefore, to 
confirm p38 MAPK activation we performed a sandwich ELISA which measures 
p38δ MAPK isoform phosphorylation specifically. Transfection of KE-3 cells with 
wild type p38 MAPK alone revealed activation (Figure 4.6). This is in strong 
agreement with previous reports where adenovirally expressed wild type p38 
MAPK was activated in head and neck squamous cell carcinoma [23] and human 
keratinocytes [24]. A fourfold (p<0.001) increase in activation of p38δ MAPK was 
observed following stable transfection of KE-3 cells with p-p38δ (Figure 4.6). This 
level of activation is similar to p38δ MAPK co-expressed with MKK3/MKK6 in 
HEK293 cells [25]. As expected we did not observe phosphorylation of p38 MAPK 
in cells transfected with p-p38DN (Figure 4.6). We also analysed KE-6 and KE-10 
cell lines (which express endogenous p38δ MAPK expression) but did not observe 
p38δ MAPK phosphorylation in either cell line (Figure 4.6).  
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Figure 4.6 Analysis of specific p38δ MAPK phosphorylation. Transfected and 
non-transfected KE-3, KE-6 and KE-10 cells were analysed to determine the amount 
of activated i.e. phosphorylated p38 MAPK expression using the human phospho-
p38 (T180/Y182) ELISA commercial kit. The ELISA assay was carried out 
according to manufacturer’s protocol. The results shown are mean  S.E. of three 
independent experiments. Significant (***, p<0.001) changes from control non-
transfected KE-3 cells  were determined by application of Student’s t-test. 
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To ensure specific phosphorylation of p38 MAPK only and not the other three p38 
MAPK isoforms (, -β and -γ) we performed a human phospho-MAPK antibody 
array. We did not observe phosphorylation of p38, -β or -γ MAPK in non-
transfected KE-3 cells or cells stably transfected with p38 MAPK or p-p38 MAPK 
(Figure 4.7A and B). We did, however, observe an increase (p<0.001) in 
phosphorylation in KE-3 p38 MAPK wild type transfected cells which was 
amplified in KE-3 p-p38 MAPK transfected cells (Figure 4.7A and B)  in 
agreement with our ELISA results (Figure 4.6). These results confirm 
phosphorylation of p38 MAPK only in our studies. We also observed MKK6 
phosphorylation in KE-3 p-p38 MAPK as expected (Figure 4.7A and B). A 
previous report outlined p38 MAPK induced inactivation of ERK1/2 [26] however, 
we did not find any change in ERK1/2 or indeed JNK1/2/3 (Figure 4.7A and B).  
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Finally, the physical location of a protein either in the nucleus or the cytoplasm 
directly influences its biological function. Members of the p38 MAPK family do not 
contain either a nuclear localisation signal or a nuclear export signal but their 
subcellular localisation can be regulated in part by their interacting proteins [27]. We 
compared the subcellular localization of p38 and p-p38 MAPK in KE-3 transfected 
cells with endogenous p38 MAPK expression in KE-6 cells. As expected p38 and 
p-p38 MAPK were absent from both compartments in non-transfected KE-3 cells 
(Figure 4.8A). p38 and p-p38 MAPK were detected in both the cytoplasm and the 
nucleus of KE-3 stably transfected cells (Figure 4.8A). This pattern of expression 
correlated with the subcellular localization of p38 and p-p38 MAPK in KE-6 cells 
in the presence and absence of anisomycin (30 M). To confirm our 
immunohistochemical findings cytosolic and nuclear extracts were prepared from 
transfected and non-transfected KE-3 and KE-6 cells and examined by Western blot 
analysis. The use of poly ADP ribose polymerase (PARP) as a nuclear-restricted 
marker and paxillin as a cytosolic marker ensured that there was no cross 
contamination between the subcellular fractions [16]. Similar results were observed 
demonstrating the presence of p38 and p-p38 MAPK in both the cytoplasm and 
nucleus of KE-3 and -6 cells (Figure 4.8B). 
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4.5.4 KE-3 cells transfected with p38δ and p-p38δ MAPK show reduced 
proliferation  
Uncontrolled cellular proliferation is a hallmark of cancer. To investigate if loss of 
p38δ MAPK expression specifically drives the higher growth kinetics observed in 
Figure 4.4 we compared the growth rates of KE-3 non-transfected and transfected 
cells. We observed a significant (p<0.001) time dependent decrease in the 
proliferation rate of KE-3 cells when transfected with wild type p38 MAPK 
compared with non-transfected cells and cells transfected with empty pcDNA3 
vector (Figure 4.9). This anti-proliferative effect was amplified further in KE-3 cells 
transfected with active p-p38 MAPK (Figure 4.9). KE-3 cells transfected with p-
p38DN MAPK demonstrated the same proliferation rate as non-transfected cells or 
cells transfected with pcDNA3 only (Figure 4.5A).  
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Figure 4.9 Effect of p38 and p-p38 MAPK expression on cell proliferation. 
KE-3, KE-3 pcDNA3, KE-3 p38, KE-3 p-p38 and KE-3 p-p38DN cells were 
seeded (3 X 10
4
) and counted for 24-120 hr. The results shown are mean  S.E. of 
three independent experiments. Significant (***, p<0.001) changes from control 
non-transfected KE-3 cells were determined by application of Student’s t-test.  
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To further examine the hypothesis that p38δ MAPK is anti-proliferative in OESCC 
we employed a siRNA approach using the KE-6 cell line which expresses 
endogenous p38δ MAPK (Figures. 4.2, 4.8A and B). KE-6 cells were transiently 
transfected with p38δ MAPK siRNA or control siRNA as previously described [17]. 
We observed a 51.9%  6.5% reduction in KE-6 p38δ MAPK expression at 24 hr 
following p38δ MAPK siRNA transfection which increased to 72.6%  2.6% by 96 
hr when compared to control siRNA transfected KE-6 cells (Figure 4.10A and B). 
No change in p38 MAPK expression was observed when KE-6 cells were 
transfected with control siRNA for all time points studied (24-96 hr) (only 24 hr is 
shown in Figure 4.10A). A significant (p<0.001) increase in cell proliferation was 
observed for KE-6 cells transfected with p38 MAPK siRNA compared to cells 
transfected with control siRNA for all time points studied (Figure 4.10C).  The anti-
proliferative effect was observed even in the absence of active p38 MAPK in KE-6 
cells (Figure 4.6). This effect on proliferation may be independent of its kinase 
activity as has previously been reported for p38 MAPK in regulating HeLa cell 
proliferation [28] and p38γ MAPK in rat intestinal epithelial cells [29].  
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Figure 4.10 Effect of p38δ MAPK knockdown on proliferation in a cell line 
which expresses it endogenously (Figure legend – next page). 
A 
B 
C 
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Figure 4.10 Effect of p38δ MAPK knockdown on proliferation in a cell line 
which expresses it endogenously. (A) Western blot analysis of KE-6 cells 
transiently transfected or not transfected with p38 MAPK siRNA or control siRNA 
for 24-96 hr. Cells were analysed by immunoblot using a p38 MAPK antibody. 
Aliquots of 30 g protein lysate were loaded on a 10% SDS-PAGE gel. The results 
shown are representative of three independent experiments. (B) Densitometric 
analysis was performed to analyse % knockdown of KE-6 p38 MAPK protein. (C) 
KE-6 cells (3 X 10
4
) transfected with p38 MAPK siRNA or control siRNA were 
seeded and counted for 24-96 hr. The results shown are mean  S.E. of three 
independent experiments each done in triplicate. Significant (***, p<0.001) changes 
from control siRNA transfected KE-6 cells were determined by application of 
Student’s t-test. 
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4.5.5 p38δ and p-p38δ MAPK play a role in migration and anchorage independent 
growth of KE-3 cells 
A key characteristic of cancer cells is their ability to migrate and progress from 
primary tumors to metastases in distant organs. A recent report summarizes the roles 
of p38 MAPKs in cancer invasion and metastasis [30]. This review however, as in 
previous reports documents the roles of p38 MAPK family as a whole or p38 
MAPK [10, 13]. We examined the role of p38 MAPK in OESCC cell migration 
using both a Boyden chamber assay and a wound healing assay. We observed a 66% 
 7.5% and 88.7%  1.9% decrease in migration after 24 hr for KE-3 p38δ and p-
p38δ cells respectively compared to non-transfected cells (Figure 4.11A).  In 
addition p38δ and p-p38δ MAPK induced a significant decrease in KE-3 migration 
at 24 hr (55.65%  1.5% and 75.65%  0.3% (p<0.001), respectively) and 48 hr 
(37.9%  0.8%, (p<0.01) and 82.7%  1.4%, (p<0.001) respectively) compared with 
non-transfected KE-3 cells using a wound healing assay (Figure 4.11B and C).  
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Figure 4.11 Effect of p38 and p-p38 MAPK on KE-3 cell migration. KE-3, 
KE-3 pcDNA3, KE-3 p38, KE-3 p-p38 and KE-3 p-p38DN cells were analysed 
for cell migration. (A and B) p38 and p-p38 MAPK inhibit KE-3 migration at 24hr 
(A, Boyden Chamber) and 24 and 48 hr (B, wound healing). (C) Representative 
wound healing images at 0, 24, and 48 hr. Wound healing rates decrease in p38 and 
p-p38 MAPK transfected KE-3 cells. The results shown are representative of three 
independent experiments. Significant (**, p<0.01;***, p<0.001) changes from 
control non-transfected KE-3 cells were determined by application of Student’s t-
test. 
A 
B 
C 
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Finally, to further examine the influence of p38δ and p-p38δ MAPK on the growth 
characteristics of KE-3 cells, we measured their ability to grow in an anchorage-
independent manner. Non-transfected KE-3 cells growing in soft agar for 21 days 
gave rise to 175  18 colonies/plate (Figure 4.12). This was similar to the number of 
colonies/plate that grew for cells transfected with empty vector (160  20) or p-
p38δDN (177  21) (Figure 4.12). In contrast, however, p38δ and p-p38δ MAPK 
transfected cells produced a significant (p<0.001) decrease in colony numbers in 
p38δ transfected cells (13  3) with no colonies observable for p-p38δ MAPK 
transfected cells (Figure 4.12).  
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Figure 4.12 Effect of p38 and p-p38 MAPK on KE-3 anchorage independent 
growth. Anchorage-independent growth potential of KE-3 non-transfected and 
transfected cells were measured by their ability to form colonies on soft agar. Plates 
were stained with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide to 
visualize colonies. The number of colonies per plate is shown. The results shown are 
mean  S.E. of four independent experiments.  Significant (**, p<0.01; ***, 
p<0.001) changes from control non-transfected KE-3 cells were determined by 
application of Student’s t-test. 
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4.6 Discussion 
 
Oesophageal cancer is a highly aggressive treatment-refractory disease with a high 
mortality rate [2, 5, 6]. As conventional therapy is ineffective, targeting specific 
potential molecular tumor markers may prove to be the future of oesophageal cancer 
treatment. Despite current studies of molecular targets in oesophageal cancer [31], 
we are still somewhat hindered by limited knowledge of the genes and pathways 
involved in the tumourigenesis of the oesophagus when it comes to treatment. 
 
Emerging role(s) for p38 MAPKs in different aspects of cancer has recently been 
outlined. To-date the best studied and reviewed isoform in cancer is p38 MAPK. It 
has been characterized as both a potential tumour suppressor [19, 32-34] and tumour 
promoter [23, 30]. In comparison the role(s) of p38 MAPK in cancer is largely 
uncharacterised. The limited current knowledge pertaining to p38 MAPK, however, 
also alludes to disparate role(s) for this kinase in tumour development. An oncogenic 
role for p38 MAPK has been suggested in p38-deficient mice that have reduced 
susceptibility to skin carcinogenesis [35] as well as promoting head and neck 
squamous carcinoma cell growth [23]. In contrast a very recent study outlined a role 
for p38 MAPK as a tumour suppressor in mouse fibroblasts [36]. In our study 
outlined here we show for the first time the differential expression of p38 MAPK in 
OESCC cell lines and in vivo. The loss of p38 MAPK expression provides a 
survival advantage for OESCC which demonstrates increased cell proliferation, 
migration and contact inhibition. Re-introduction of p38 MAPK, however, leads to 
reversal of these tumourigenic effects. Thus, recent evidence [36] as well as our 
present study suggests that targeting p38 MAPK may offer a powerful protection 
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against carcinogenesis. Targeting p38 MAPK isoforms or pathways for therapeutic 
purposes, however, should perhaps be strictly dependent on cell context, tumour cell 
type and tumour stage. 
 
The fusion of p38 MAPK to its upstream kinase MKK6b or active MKK6b 
(MKK6b(E)) generated a constitutively active p38 MAPK which was used as a tool 
to study its specific effect(s) in OESCC. Re-introduction of p38 MAPK (with 
subsequent activation) or active p-p38 MAPK into KE-3 OESCC attenuated cell 
proliferation, migration and anchorage-independent growth. The strength and 
duration of p38 MAPK activation has been shown to play a crucial role in 
determining cell fate. Strong activation has been shown to induce apoptosis whereas 
lower levels results in cell survival [21, 34]. In our study we observed strong anti-
proliferative, anti-migratory effects as well as effects on anchorage-independent 
growth upon re-introduction of p38 MAPK into KE-3 cells which subsequently 
became active.  These anti-tumourigenic effects were amplified further in KE-3 cells 
transfected with constitutively active p-p38 MAPK.  It is possible that owing to the 
localization of both p38 and p-p38 MAPK in the nucleus and the cytoplasm of 
OESCC that this kinase may modify its target(s) either structurally or subcellularly 
[18]. Furthermore p38 and p-p38 MAPK induced anti-tumourigenc effects in 
OESCC may arise by a combination of both phosphorylation-dependent and 
independent effects as previously described [28, 29].  
 
Although the trypan blue exclusion assay is the most commonly used procedure for 
measurement of cell viability, we recognize that it has some limitations in the depth 
of information that it can provide. Alternative cell proliferation assays such as a 
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BrDU incorporation assay which measures the rate of DNA synthesis may provide 
further insight into the effect(s) of p38δ and p-p38δ MAPK expression on OESCC 
cell proliferation. Flow cytometry using propidium iodide to measure cellular DNA 
content and thereby discriminate between cells in G1, S, G2 or M phases of the cell 
cycle could help to delineate the stage(s) at which p38δ MAPK exerts its effect(s). 
  
The Boyden chamber cell migration assay was performed without consideration of 
the effect of cell proliferation. The time allowed for cells to migrate through the 
membrane (24 hr) was much shorter than the doubling time for KE-3 cells (~48 hr) 
therefore the impact of reduced cell proliferation on migration was deemed not to be 
a factor. Further reducing the assay time or introduction of mitomycin c treatment to 
inhibit proliferation would minimize any potential cell proliferation effects. 
 
There are many paradigms in the literature of cross-talk between different MAPK 
pathways. In this instance, however, when KE-3 cells were stably transfected with 
p38 or p-p38 MAPK we did not observe changes in either p38 MAPK isoform (, 
-β and –γ), ERK1/2 or JNK1/2/3 activation levels. This is in agreement with a recent 
bio-informatics analysis of MAPK pathways which specifically identified that 
persistent activation of p38 MAPK is resistant to interaction with other MAPKs 
[37]. This lack of interference from other MAPKs will permit us to specifically study 
the effects of p38 MAPK on cell cycle control, pathway components and regulatory 
mechanisms in OESCC (Chapter 7). In addition negative feedback mechanisms have 
been shown to contribute to fine-tuning p38 MAPK activity levels. One such report 
outlines an increase in MKK6 expression and stability in p38-/- cardiomyocytes 
from transgenic mice [38]. We did not observe a correlation between the presence or 
 162 
 
absence of p38 MAPK expression in OESCC cells and MKK expression. Of 
notable exception is MKK3 whose expression is absent from KE-3 and -8 cells (both 
negative for p38 MAPK) but present in KE-4, 5, -6 and -10 cells (all positive for 
p38 MAPK). However, this pattern of expression does not hold for KYSE-70 and 
OE-21 OESCC cell lines which express MKK3 but are also negative for p38 
MAPK protein expression. 
 
Reports of the involvement of p38 MAPKs in a variety of different pathological 
conditions is continuing to increase fuelling interest in the development of potent 
and specific drugs for modulating the activity of these kinases. Presently there are a 
number of p38 MAPK inhibitors undergoing clinical trials for the treatment of 
inflammatory diseases [39, 40]. Results arising from our study demonstrate that loss 
of p38 MAPK expression in OESCC provides a more sinister phenotype with 
increased proliferation, migration and anchorage independent growth. Thus, it is 
possible that isoform specific activation (rather than inhibition) of p38 MAPK may 
provide a therapeutic benefit for patients with OESCC which express this isoform. In 
addition how p38 MAPK activators may interact and enhance the effectiveness of 
traditional therapeutics in combination therapy warrants attention.  
 
In summary, our results reveal previously undocumented p38 MAPK differential 
expression and function in OESCC. We identified a subset of OESCC cell lines as 
well as human primary and metastatic tumour samples that exhibit p38 MAPK 
protein expression downregulation. We now provide evidence that loss of expression 
of this particular isoform may be a mechanism by which OESCC cells promote 
carcinogenesis. Re-introduction of p38 MAPK into OESCC negative cell lines 
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suppressed different aspects of tumourigenesis.  Our data warrant further 
investigation to understand the important physiological and pathophysiological 
effects of p38 MAPK in OESCC and is currently in progress. This knowledge 
should identify which pathways, substrates or regulators are affected specifically by 
p38 MAPK in providing an anti-tumourigenic effect in OESCC. Armed with this 
information uncovering novel targets and the development of new therapeutics may 
be possible for this common cancer that continues to demonstrate a generally poor 
clinical outcome.  
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p38δ MAPK phenotype: an indicator of 
chemotherapeutic response in oesophageal 
squamous cell carcinoma 
 
 
 
 
 
 
 
O'Callaghan, C., Fanning, L.J., Barry, O.P.   
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal 
squamous cell carcinoma 
Anti Cancer Drugs 2015; 26(1):4655. 
(Appendix II)  
 168 
 
5.1 Abstract 
 
The previous chapter documented p38δ MAPK differential expression and function 
in OESCC. This study expands upon these findings and investigates whether p38δ 
MAPK status in OESCC can influence response(s) to cytotoxic drugs. The 
antiproliferative effect of conventional cisplatin and 5-fluorouracil (CF) treatment 
was compared with the recently reviewed triple regime of cisplatin, 5-fluorouracil 
and doxorubicin (ACF). p38δ MAPK positive and p38δ MAPK negative cell lines 
were employed using cell-growth and clonogenic assays. Key regulators of intrinsic 
and extrinsic apoptotic pathways were measured. Wound-healing assays and a 
Boyden chamber were used to investigate the effect of drug treatments on cell 
migration. Functional networks were analysed in terms of changes in MAPK 
expression. p38δ MAPK negative OESCC is less sensitive to standard CF 
chemotherapy compared with p38δ MAPK positive cells. However, following ACF 
treatment p38δ MAPK negative cells showed markedly decreased proliferation and 
cell migration, and increased apoptosis. ACF induced apoptosis through the extrinsic 
pathway involving Fas activation, caspase-8 and caspase-3 cleavage and degradation 
of PARP. Loss of mitochondrial membrane potential (ΔΨm) was observed but 
downregulation of multidomain proapoptotic proteins, as well as BH3-only proteins, 
suggests involvement of pathways other than the mitochondrial pathway. 
Interestingly, induction of p38 MAPK and ERK1/2, but not JNK1/2, was observed 
following ACF treatment. p38δ MAPK negative OESCC is more resistant to 
traditional CF treatment compared with p38δ MAPK positive OESCC. In light of 
these results, p38δ MAPK phenotyping of tumour tissue may be of considerable 
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value in deciding on an optimal therapeutic strategy for patients with p38δ MAPK 
negative OESCC. 
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5.2 Hypothesis and aims 
 
The hypothesis for this chapter is that p38δ MAPK status influences OESCC 
response to chemotherapeutic drugs. 
 
To examine this hypothesis the aims for this chapter are as follows: 
 
 To compare the sensitivity of p38δ MAPK positive and p38δ MAPK 
negative OESCC cell lines to common chemotherapeutic drug combinations. 
 
 To compare the effect(s) of different chemotherapeutic drug combinations on 
OESCC migration, invasion and recovery. 
 
 To examine the apoptotic cell death and MAPK pathways activated in p38δ 
MAPK negative OESCC by chemotherapeutic drugs.   
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5.3 Introduction 
 
Oesophageal cancer is a highly aggressive and fatal malignancy and is the seventh 
most common cancer worldwide [1]. Oesophageal squamous cell carcinoma 
(OESCC) is an exceptionally drug-resistant tumour. Although surgery is the best 
modality in terms of local control [2], outcomes following resection for OESCC 
remain unsatisfactory because of locoregional and distant failure [3]. Preoperative 
chemotherapy or chemoradiotherapy with a fluoropyrimidine/platinum combination 
– that is, a cisplatin and 5-fluorouracil (CF) regimen – has been the standard 
treatment for locally advanced disease since the 1980s. At present, multimodal 
therapy is being investigated for different stages of OESCC, even if the tumour is 
operable [4]. Preoperative chemotherapy with docetaxel plus CF (DCF) has recently 
been investigated (with or without radiotherapy) with good local control and 
pathological remission rate being recorded [4, 5]. More recently doxorubicin, 
cisplatin and 5-fluorouracil (ACF) have undergone a revival, demonstrating higher 
response rates than CF treatment, a good safety profile and promising long-term 
outcomes for patients with highly advanced oesophageal carcinoma [6-8]. 
 
The involvement of p38 MAPKs in a variety of pathological conditions is continuing 
to fuel interest in this particular family of kinases. The expression of p38 MAPKs as 
a family has previously been outlined in oesophageal cancer, as well as in other 
cancer types [9-12]. We have previously outlined for the first time the differential 
expression of individual p38 MAPK isoforms in cancer and in particular OESCC 
[13, 14]. We now know that loss of p38δ MAPK expression in OESCC affords a 
more sinister phenotype, with increased proliferation, migration and anchorage-
 172 
 
independent growth, thus identifying p38δ MAPK as a possible molecular target in 
OESCC [14].  
 
Advancing these studies a step further, this chapter evaluates whether p38δ MAPK 
status could influence cytotoxic responses to drug treatments in OESCC. Both 
negative and positive p38δ MAPK cell lines were used, isolated from patients with 
OESCC with no prior treatment, as outlined in Chapter 4. Cell viability, wound 
healing, migration and apoptosis were evaluated following standard CF treatment 
and ACF treatment. To carry out functional networks expression analysis, we also 
analysed changes in ERK1/2, JNK1/2 and p38 MAPK expression. In conclusion, this 
study indicates that p38δ MAPK status may be a predictor of response to 
chemotherapy in OESCC patients. 
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5.4 Materials and methods 
 
5.4.1 Cell culture 
The KE oesophageal squamous cancer cell lines were cultured as described in 
Chapter 2. KE cell line features are summarized in Table 2.1. 
 
 
5.4.2 Drug Treatment 
Chemotherapeutic drugs used were: 5-fluorouracil (Calbiochem, Merck KGaA, 
Darmstadt, Germany), cis-platinum (II) diammine dichloride, docetaxel, doxorubicin 
hydrochloride, hydroxyurea, methotrexate and paclitaxel, all from Sigma Aldrich. 
MAPK inhibitors were BIRB 796 (Doramapimod) (Cayman Chemical, Ann Arbor, 
MI, USA), SB203590 and U0126, both purchased from Cell Signalling Technologies 
(Hertfordshire, UK). Cells were seeded at 2 x 10
5
 cells/well of a 6-well tissue culture 
plate 24 hr before treatment. Immediately prior to treatment, growth media in all 
wells was replaced with 2 ml of fresh media. All drugs were resuspended in DMSO 
according to their product information data sheets and diluted to concentrations 
2000-fold higher than the final concentrations indicated. 1μl of each concentrated 
drug was added to the relevant well to give the desired final concentrations. Controls 
included untreated cells and cells treated with equivalent amounts of DMSO. Cells 
were incubated with chemotherapeutic drugs for 24 or 48 hr. 
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5.4.3 Cell viability  
Cell viability was assessed using the MTT assay, which depends on the ability of 
viable cells to reduce MTT to a coloured formazan product, as described in Chapter 
2. 
 
 
5.4.4 Cell migration 
Cell migration was assessed using Boyden chamber and in-vitro wound-healing 
assays as described in Chapter 2.  
 
 
5.4.5 Mitochondrial membrane potential (ΔΨm) assay 
The decline of mitochondrial membrane potential (ΔΨm) was assessed using a 
mitochondrial voltage-sensitive dye, 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazole carbocyanide iodide (JC-1), according to the manufacturer’s 
instructions [15]. The dye underwent a reversible change in fluorescence emission 
from red (i.e. aggregate forms of JC-1) to green (i.e. monomer forms of JC-1) as the 
mitochondrial membrane potential decreased. KE cells were or were not treated with 
drugs for 24 hr. Cells were then washed twice with PBS and loaded with JC-1 for 30 
min at 37°C. Images were obtained using an inverted fluorescence microscope 
(Olympus, Essex, UK). The ratio of red to green fluorescence intensity, which was 
indicative of a change in ΔΨm, was calculated using the ImageJ software. To 
measure fluorescence intensities using Image J a region was drawn around each cell 
to be measured. The same size region was drawn in an area without fluorescent 
objects to be used for background subtraction. For accuracy three selections were 
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used from around the cell. These steps were repeated for the other cells in the field of 
view that were to be measured. The data in the results window of Image J were 
copied and pasted into an excel worksheet. To calculate the corrected total cell 
fluorescence (CTCF) the following calculation was performed – Integrated Density – 
(Area of selected cell x Mean fluorescence of background readings). 
 
 
5.4.6 Immunoblot analysis 
Supernatants used for immunoblotting with specific antibodies, PARP, caspases-3, -
6, -7, -8 and 9, Puma, Bak, Bik, Bim, Bid, Bax, p38 MAPK, phospho-p38 MAPK, 
JNK1/2, phospho-JNK1/2, ERK1/2, phospho-ERK1/2, Fas and FasL were prepared 
as described in Chapter 2 and as previously described by us [13, 14].  
 
 
5.4.7 Clonogenic assay 
A clonogenic assay determines whether cells can recover from treatment. Following 
treatment, 1000 viable cells were reseeded in fresh media (without drug) in a six-
well plate (in triplicate) and allowed to grow for 14 days. Colonies were stained with 
MTT and subsequently counted using ImageJ software. 
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5.5 Results 
 
5.5.1 p38δ MAPK negative OESCC shows decreased sensitivity to 
chemotherapeutic drugs 
Monotherapy is not beneficial in the treatment of patients with oesophageal cancer 
[16]. Thus, we evaluated the cell viability of KE p38δ MAPK positive and p38δ 
MAPK negative OESCC cell lines (outlined in Chapter 4 [14]) following double 
versus triple drug treatments using a range of concentrations of cytotoxic drugs. 
Interestingly, KE-3 and KE-8 (p38δ MAPK negative cell lines) are significantly less 
sensitive to CF treatment compared with KE-4, KE-5, KE-6 and KE-10 (p38δ 
MAPK positive cell lines; Fig. 1A–C). As docetaxel has recently been added to the 
CF regime [4, 5], we investigated the effect of DCF on cell viability. There was a 
further decrease in KE-3 and KE-8 cell viability (Figure 5.1A and B). However, no 
further reduction in cell viability was observed in the KE p38δ MAPK positive cell 
lines upon DCF treatment using physiologically relevant drug concentrations (30 
μM; Figure 5.1C) [17-19]. As doxorubicin (together with CF) has recently re-
emerged as a promising drug treatment strategy for patients with oesophageal cancer 
[6-8], we also investigated its effects. Interestingly, the greatest loss in KE-3 and 
KE-8 cell viability was after triple CF plus doxorubicin (ACF) treatment (Figure 
5.1A and B). Of note, these results are comparable with the loss in cell viability seen 
in the p38δ MAPK positive cells upon CF treatment at physiological concentrations 
(Figure 5.1C). Taking the results obtained with physiological drug concentrations of 
CF (30 μM each) a step further, we investigated the appropriate triple ACF drug 
treatment concentrations for KE-3 and KE-8 cell lines. Using a range of doxorubicin 
drug concentrations, we ascertained that the best triple ACF concentration using 
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physiological concentrations of all three drugs is 30 μM each of CF and 1 μM 
doxorubicin (Figure 5.1D). No significant further decrease in cell viability was 
observed at a higher doxorubicin drug concentration of 3 μM (Figure 5.1D). 
 
As other chemotherapeutic drug combinations have also been tested for their 
efficacy in patients with OESCC, namely CF plus methotrexate [20], CF plus 
paclitaxel [20, 21] and CF plus hydroxyurea [22], we also investigated these three 
additional drug combinations again using a range of different drug concentrations. 
Interestingly, KE-3 and KE-8 showed less sensitivity to all three triple-drug 
combinations compared with ACF treatment (Figure 5.1E and F). Thus, as the 
greatest loss in KE-3 and KE-8 cell viability was observed with triple ACF treatment 
(Figure 5.1A, B and D), all subsequent experiments compared traditional CF 
treatment with ACF treatment. 
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Figure 5.1 Sensitivity of OESCC to cancer chemotherapeutic drugs is correlated 
to the presence or absence of p38δ MAPK. (Figure legend – next page)  
C D 
A B 
E F 
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Figure 5.1 Sensitivity of OESCC to cancer chemotherapeutic drugs is correlated 
to the presence or absence of p38δ MAPK. (A–F) KE cell lines (KE-3 and KE-8, 
p38δ-negative; KE-4, KE-5, KE-6 and KE-10, p38δ-positive) were seeded (2 × 105) 
in six-well plates, and cell viability was assessed using the MTT assay at 48 hr to 
determine the sensitivity of each cell line to different drug combinations. (A, B) KE-
3 and KE-8 cells were subjected to double treatment with cisplatin (3–100 μM) and 
5-fluoruracil (3–100 μM; CF), or triple treatment with cisplatin (3–100 μM), 5-
fluorouracil (3–100 μM; CF) and either docetaxel (3–100 μM) or doxorubicin (0.1–3 
μM). (C) KE-4, KE-5, KE-6 and KE-10 cells were treated either with cisplatin (3–
100 μM) and 5-fluoruracil (3–100 μM; CF), or with cisplatin (3–100 μM), 5-
fluorouracil (3–100 μM; CF) and docetaxel (3–100 μM). (D) KE-3 and KE-8 cells 
were subjected to triple treatment with constant drug concentrations of cisplatin (30 
μM) and 5-fluorouracil (30 μM; CF) plus varying drug concentrations of doxorubicin 
(0.1–3 μM). (E, F) KE-3 and KE-8 cells were subjected to triple treatment with 
cisplatin (3–100 μM), 5-fluorouracil (3–100 μM; CF) and either methotrexate (0.3–
10 μM), paclitaxel (1–30 nM) or hydroxyurea (3–100 μM). Results shown in (A–F) 
are mean ±SE of three independent experiments.  
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5.5.2 Introduction of p38δ or p-p38δ MAPK expression does not increase OESCC 
sensitivity to CF treatment 
As p38δ MAPK positive cell lines KE-4, KE-5, KE-6 and KE-10 were observed to 
be significantly more sensitive to CF treatment than p38δ MAPK negative KE-3 and 
KE-8 cell lines (Figure 5.1 A-C), we examined the effects of stably transfected p38δ 
and p-p38δ MAPK expression on KE-3 cell sensitivity to CF treatment. We found 
that the stable expression of p38δ or p-p38δ MAPK did not increase KE-3 sensitivity 
to CF treatment (Figure 5.2). In fact, a statistically significant (p<0.01) increase in 
cell viability was observed in KE-3 cells expressing p38δ and p-p38δ MAPK 
compared with non-transfected p38δ MAPK negative cells (Figure 5.2). However, 
we also observed a statistically significant (p<0.01) increase in cell viability in KE-3 
cells transfected with an empty vector (pcDNA3) following CF treatment. 
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Figure 5.2 Effect of p38δ and p-p38δ MAPK expression on KE-3 sensitivity to 
CF treatment. KE-3, KE-3 pcDNA3, KE-3 p38δ, KE-3 p-p38δDN and KE-3 p-p38δ 
cells were seeded (2 × 10
5
) in six-well plates, and cell viability was assessed using 
the MTT assay at 48 hr to determine the sensitivity of each cell line to double 
treatment with cisplatin (30 μM) and 5-fluoruracil (30 μM; CF). The results shown 
are the mean ±S.E. of two independent experiments. **p<0.01, significant changes 
from control non-transfected KE-3 cells were determined by application of Student’s 
t-test. 
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5.5.3 ACF treatment significantly delays wound healing and migration compared 
with CF treatment 
A key characteristic of cancer cells is their ability to migrate and progress from 
primary tumours to metastases in distant organs [14]. We examined whether the 
p38δ MAPK status of OESCCs could influence their wound healing and cell 
migration following drug treatment. Double CF treatment of KE-6 and KE-10 (p38δ 
MAPK positive cells) for 48 hr brought about a significant delay in wound healing, 
with a 60.0 ± 7 and 66.0 ± 1.2% loss in wound healing, respectively, compared with 
untreated cells (Figure 5.3A and B). In contrast, CF treatment did not impair the 
ability of KE-3 and KE-8 cells to migrate into the wound (Figure 5.3A and B). Triple 
ACF treatment, however, significantly delayed the wound-healing ability of KE-3 
and KE-8 cell lines, with a 72.8 ± 2.5 and 84.0 ± 3.9% loss in wound healing at 48 
hr, respectively. There was a further 15 ± 5.8% loss in wound healing upon ACF 
treatment, compared with CF treatment alone, of KE-6 cells but no significant 
change in KE-10 cells (Figure 5.3A and B). Doxorubicin (300 nM) alone did not 
have any significant effect on the wound-healing ability of either p38δ MAPK 
positive or p38δ MAPK negative cells (Figure 5.3A and B). Further, we compared 
the migration of p38δ MAPK positive and p38δ MAPK negative cells following CF 
versus ACF treatment using a Boyden chamber assay. Double CF treatment induced 
a significant (78.7 ± 5.2 and 78.7 ± 7.8%, respectively) decrease in cell migration of 
KE-6 and KE-10 cells at 24 hr; however, no significant change in cell migration was 
observed upon CF treatment of KE-3 and KE-8 cells (Figure 5.3C). In contrast, triple 
ACF treatment of KE-3 and KE-8 significantly decreased their cell migration by 
75.9 ± 2.4 and 81.3 ± 6.9%, respectively (Figure 5.3C). 
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Figure 5.3 Effect of chemotherapeutic cytotoxic drugs on wound healing and 
migration of KE p38δ MAPK positive and negative cell lines. (Figure legend – 
next page) 
A 
B 
C 
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Figure 5.3 Effect of chemotherapeutic cytotoxic drugs on wound healing and 
migration of KE p38δ MAPK positive and negative cell lines. KE-6 and KE-10 
cells (p38δ MAPK positive), as well as KE-3 and KE-8 cells (p38δ MAPK 
negative), were analysed for (A, B) wound healing and (C) cell migration following 
treatment with cisplatin (3 μM) and 5-fluoruracil (3 μM; CF), doxorubicin (Dox; 300 
nM) alone or cisplatin (3 μM), 5-fluorouracil (3 μM) and doxorubicin (300 nM; 
triple treatment; ACF). (A) Representative wound-healing images at 0 and 48 hr with 
or without drug treatment. The results shown in (A) are representative of three 
independent experiments, whereas the results shown in (B) and (C) are the mean 
±SE of three independent experiments. ***p<0.001, **p<0.01, significant changes 
from control untreated cells were determined by application of Student’s t-test. 
. 
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5.5.4 Triple ACF treatment decreases mitochondrial membrane potential and 
activates extrinsic pathways in p38δ MAPK negative OESCCs 
Initially, we investigated the involvement of the mitochondria in OESCC apoptosis 
using the JC-1 cationic dye. It selectively enters the mitochondria and reversibly 
changes in colour from red to green as the membrane potential decreases [15]. KE-6 
and KE-10 cells show a marked decrease in ΔΨm following CF and ACF treatment 
(Figure 5.4A and B). Similar losses in ΔΨm in KE-3 and KE-8 cells were observed 
only upon ACF treatment (Figure 5.4A and B). Doxorubicin alone did not alter the 
ΔΨm of KE-6 and KE-10 cells, but it did produce a significant (p < 0.01) decrease in 
the ΔΨm of KE-3 and KE-8, comparable to CF treatment (Figure 5.4A and B). 
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Figure 5.4 Effect of chemotherapeutic drug treatment on the mitochondrial 
membrane potential (ΔΨm) of p38δ-negative OESCCs. (A) The mitochondrial 
membrane potential (ΔΨm) of KE cells before and after treatment with cisplatin (30μM) 
and 5-fluorouracil (30μM; CF), doxorubicin (1μM; Dox) or cisplatin (30μM), 5-
fluorouracil (30μM) and doxorubicin (1μM; ACF) for 24 hr. Representative images 
(red/green mixed channels) show the changes in mitochondrial ΔΨm in KE cells, 
detected using JC-1 dye. Red fluorescence indicates high membrane potential and 
functional capacity in mitochondria, whereas green cytoplasmic fluorescence is 
indicative of inactive mitochondria. (B) Decreased red/green fluorescence ratio suggests 
a decrease in ΔΨm. The results shown in A are representative of four independent 
experiments, whereas the results shown in B are the mean ±S.E. of four independent 
experiments. ***p<0.001, **p<0.01, significant changes from control untreated cells 
were determined by application of Student’s t-test. 
A 
B 
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To further investigate the effects of CF-induced versus ACF-induced apoptosis in 
KE p38δ MAPK negative cells, intrinsic (mitochondrial) and extrinsic (Fas) 
apoptotic pathways were investigated. Expression of the relevant apoptosis-related 
proteins was examined by Western blot analysis. To investigate the role of the 
intrinsic mitochondrial pathway we examined the expression levels of Bcl-2 family 
members including multidomain proapoptotic proteins Bak and Bax, as well as BH3-
only proapoptotic proteins Puma, Bik, Bid and Bim. Interestingly CF treatment 
downregulated all Bcl-2 proapoptotic members examined, with further reductions in 
expression being observed in the presence of ACF treatment (Figure 5.5A). The 
mitochondrial apoptotic pathway-related caspase-9 was not cleaved (Figure 5.5A). 
 
To investigate whether CF and ACF activate the extrinsic apoptotic pathway, we 
examined the expression levels of death receptor signalling-related proteins 
including Fas, caspase-3 and caspase-8 and PARP. Alterations in the expression of 
Fas and FasL, members of the tumour necrosis family, have been reported previously 
in OESCC with Fas-activated apoptosis being shown to limit the growth of OESCCs 
[23, 24]. We observed an increase in Fas expression when both KE-3 and KE-8 cells 
were treated with ACF, but not on CF treatment, implicating the involvement of the 
extrinsic death pathway. The expression level of FasL was very low in both cell 
lines, and there was no appreciable change after treatment with CF or ACF (Figure 
5.5B). We observed that ACF (but not CF) treatment of KE-3 and KE-8 cell lines 
activated (cleaved) caspase-3 and caspase-8, as well as activated (cleaved) their 
substrate PARP, producing the 85 kDa proteolytic fragment indicative of caspase 
activation and apoptosis (Figure 5.5B). The extrinsic apoptotic pathway-related 
caspases-6 and caspase-7 were not cleaved upon CF or ACF treatment (Figure 5.5B). 
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5.5.5 Triple ACF treatment induces p38 and ERK1/2 but not JNK1/2 MAPK 
activation in p38δ MAPK negative OESCC 
To gain further insight into CF-induced versus ACF-induced cytotoxic effects, we 
analysed MAPK expression. We observed p38 MAPK phosphorylation upon ACF 
treatment but not CF treatment (Figure 5.6). CF induced ERK1/2 phosphorylation, 
which was further enhanced with ACF treatment (Figure 5.6). In contrast, JNK1/2 
activation was not observed following either CF or ACF treatment (Figure 5.6). 
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Figure 5.6 MAPK activation in KE-3 and KE-8 cells following 
chemotherapeutic drug treatment. Western blot analysis of the three different 
MAPKs (p38 MAPK, JNKs and ERKs) following treatment with cisplatin (30 μM) 
and 5-fluoruracil (30 μM; CF), or following triple treatment with cisplatin (30 μM), 
5-fluorouracil (30 μM) and doxorubicin (1 μM; ACF) for 24 hr. The results shown 
are representative of four independent experiments. 
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To assess whether p38 and ERK1/2 MAPK activation is causal to the actions of the 
chemotherapeutics we used specific pharmacological inhibitors of p38 MAPK and 
MEK. Interestingly, both SB203590 (20 μM) and BIRB 796 (5 μM), inhibitors of 
p38α and p38β MAPK (but not p38γ and p38δ MAPK) [18, 25] did not prevent the 
antiproliferative effects of either CF or ACF (Figure 5.7). In fact, in agreement with 
recent reports (with similar cytotoxic drug combinations), p38 MAPK blockade 
enhanced the cytotoxic effects of ACF treatment significantly (but not CF treatment) 
at 24 hr (Figure 5.7) [18, 19]. The enhanced antiproliferative effect of p38 MAPK 
inhibition observed at 24 hr with ACF was not obvious at 48 hr because of the high 
level of cell death at this time point (Figure 5.7). The specific MEK inhibitor U0126 
(20 μM) [26] brought about a significant abolition of the effects of both CF and ACF 
drug treatments in both cell lines, indicating that ERK1/2 may be directly involved 
in drug-induced cytotoxicity (Figure 5.7). 
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Figure 5.7 Involvement of MAPKs in CF and ACF induced cell death. KE-3 and 
KE-8 cells were treated with SB203580 (20 μM), BIRB796 (5μM) or U0126 (20 
μM) followed by double treatment with cisplatin (30 μM) and 5-fluoruracil (30 μM; 
CF), or triple treatment with cisplatin (30 μM), 5-fluorouracil (30 μM; CF) and 
doxorubicin (1 μM; ACF). Cell viability was assessed using the MTT assay as 
described in Chapter 2. Results shown are the mean ± S.E. of four independent 
experiments. ***p< 0.001, **p<0.01, *p< 0.05, significant changes from CF treated 
or ACF-treated cells were determined by application of Student’s t-test. 
.  
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5.5.6 Recovery of KE-3 and KE-8 cells following drug treatments 
One of the most important parameters for the efficacy of chemotherapeutic drug 
treatments is the long-term effect on cell viability. Thus, we evaluated the effects of 
CF, doxorubicin alone and ACF treatment on the capacity of KE-3 and KE-8 cells to 
recover in assays of clonogenic growth. All three different drug treatments had a 
significant effect on the recovery of both KE-3 and KE-8 cell lines (Figure 5.8A and 
B). However, of note, cell recovery following ACF treatment was never observed, 
whereas colonies – that is, cell recovery – were observed following treatment with 
CF or doxorubicin alone (Figure 5.8A and B). 
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Figure 5.8 Recovery of KE-3 and KE-8 cells following chemotherapeutic drug 
withdrawal. The ability of p38δ-negative OESCC cell lines KE-3 and KE-8 to 
recover after drug withdrawal was assessed with a colony formation assay 
(clonogenic assay). KE-3 and KE-8 cells were or were not treated (Unt) with 
cisplatin (30 μM) and 5-fluorouracil (30 μM; CF), doxorubicin (1 μM; Dox) alone or 
the combination of all three drugs (ACF) for 48 hr. Viable, adherent cells were 
counted and reseeded (1000 cell/well) in a six-well plate (in triplicate) in the absence 
of drug. (A) Fourteen days later, colonies were stained with MTT. Each well shown 
is a representative image of nine similar wells (three independent experiments). (B) 
Colonies were counted using ImageJ software. ***p< 0.001, **p< 0.01, *p<0.05, 
significant changes from untreated cells were determined by application of Student’s 
t-test. 
A 
B 
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5.6 Discussion 
 
The purpose of this chapter was to determine whether differences in the OESCC 
p38δ MAPK phenotype could influence the chemosensitivity of OESCC to 
conventional CF versus ACF drug combinations. 
 
Single-agent response rates of 10–25% remain poor for oesophageal cancer [16]. 
Further, the use of double CF is of limited effectiveness in the treatment of patients 
with OESCC, with respect to improving overall survival time and patient quality of 
life [3, 8]. Triple ACF combination therapy was first reported as far back as 1983 
[27], but of late it has sparked renewed interest [4, 8]. Doxorubicin is an effective, 
widely used chemotherapeutic agent in the treatment of a variety of solid tumours 
and malignant haematologic diseases [28]. There are now reports documenting the 
usefulness and, importantly, the safety of ACF therapy for the treatment of advanced 
oesophageal carcinoma [7, 8, 29]. Despite the absence of phase III clinical trials, 
ACF is currently used in the clinical setting for treatment of patients with OESCC 
[8]. 
 
All three drugs in this study, cisplatin, 5-fluorouracil and doxorubicin, used as 
monotherapy or double therapy have been reported to induce intrinsic apoptosis in 
oesophageal cancer [17, 30]. We examined typical markers of both intrinsic and 
extrinsic apoptotic cell death in p38δ MAPK negative cell lines. Although we 
observed mitochondrial depolarization following ACF treatment, there was no 
subsequent caspase-9 activation. Interestingly, we also observed downregulation of 
Bcl-2 multidomain, as well as BH-3 proapoptotic proteins. However, decreased 
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expression of these intrinsic pathway proteins is in agreement with a recent report on 
oxaliplatin-induced apoptosis in squamous oesophageal cancer cell lines [31]. 
Potentially, the presence of Bcl-2 multidomain and BH3-only proapoptotic 
molecules may be an important predictor of p38δ MAPK negative OESCC response 
to combination therapy without being directly involved. Our findings suggest that 
ACF suppresses cell growth in p38δ MAPK negative OESCC through extrinsic 
apoptotic pathway activation of the Fas death receptor, with caspase-8 and caspase-3 
cleavage and subsequent degradation of PARP. Further analysis of cell death 
following ACF treatment could have been performed by assessing DNA 
fragmentation using TUNEL or by measuring cytochrome c release. The 
identification of cells in the various stages of apoptosis could have been achieved 
using propidium iodide/Annexin V staining to further discriminate between healthy, 
early apoptotic, necrotic and dead cells. 
 
Although p38δ MAPK status appears to be a predictor of OESCC response to 
conventional CF therapy, the expression of p38δ MAPK alone does not appear to be 
responsible for the increased sensitivity of p38δ MAPK positive KE-4, KE-5, KE-6 
and KE-10 cells to CF treatment. Introduction of p38δ and p-p38δ MAPK in cells 
which lack endogenous expression of this isoform failed to increase their sensitivity 
to CF treatment. It is unclear from our studies why KE-3 cells expressing p38δ or p-
p38δ MAPK did not demonstrate increased sensitivity to CF treatment. A possible 
explanation is that transfected p38δ MAPK may not activate the same signalling 
pathways as endogenous p38δ MAPK in response to cytotoxic drug treatment. 
Comparison of the subcellular localisation of transfected and endogenous p38δ 
MAPK following CF treatment as well as identification of the signalling pathways 
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activated downstream of p38δ MAPK could provide further insight into this 
differential sensitivity. There are many reports linking MAPK involvement 
following exposure to mechanistically different chemotherapeutic drugs [32]. 
However, their suppression and activation and indeed the absence of any role in 
apoptosis have been attributed to all three MAPKs [32-34]. Thus, the activation of 
MAPKs by chemotherapeutic drugs and the subsequent consequences of MAPK 
activation appear to be very much cell-type specific [33]. Although we observed p38 
MAPK activation upon ACF treatment, our findings with the p38 MAPK 
pharmacological inhibitors do not support a direct role for p38 MAPK activity in 
drug-induced cytotoxicity. In contrast, ERK1/2 activation may play a more direct 
role as its inhibition by U0126 can partly reverse the antiproliferative effects of both 
CF and ACF treatments. 
 
The increased antiproliferative and proapoptotic effects of ACF treatment over CF 
treatment in this study suggest that the former may be considered as mainstay 
treatment of patients with p38δ MAPK negative OESCC. It remains to be 
investigated whether patients with p38δ MAPK negative OESCC may benefit more 
from ACF treatment compared with classical CF treatment, and whether or not ACF 
treatment can influence overall survival. Further investigations into the mechanistic 
strategies underpinning p38δ MAPK negativity related loss in drug sensitivity are 
warranted. The clonogenic assay is a valuable tool in gauging long-term 
consequences of single, double and triple chemotherapy in p38δ MAPK negative 
OESCC. This assay closely mirrors the clinical situation in which patients are treated 
with chemotherapeutic drugs in a pulsed rather than a continuous manner. Two 
weeks post-treatment, ACF-treated p38δ MAPK negative OESCC cells never 
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recovered. Although we observed a statistically significant reduction in colony 
formation on CF double or doxorubicin treatment, cell recovery was always 
observed, clearly demonstrating resistance. In general, the MTT assay demonstrated 
lower cytotoxic activity than the clonogenic assay with these drugs. Of note, a high 
degree of correlation between both assays is not always apparent, and it may be 
influenced by both cell type and anticancer drug type [35-37]. Thus, unlike ACF 
treatment, the limited efficacy of CF or doxorubicin alone could provide an 
opportunity for cancer persistence in patients with p38δ MAPK negative OESCC. 
 
In summary, the present study indicates that p38δ MAPK may be a significant 
predictor of treatment response in patients with p38δ-negative OESCC. p38δ MAPK 
phenotyping of pre-treatment biopsy may potentially be a useful predictor of 
response to chemotherapy and ultimately prognosis in OESCC patients. Our data 
support the value of known p38δ MAPK status in the decision process used to 
inform the optimal treatment of patients with OESCC. 
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Chapter 6  
 
Differential MAPK13 promoter methylation in 
oesophageal squamous cell carcinoma  
 
 
 
 
 
 
 
 
 
 
Note: This chapter does not represent a complete body of work. Due to both time and 
financial constraints, the research presented here is unfinished. The experiments 
required to complete this study will be discussed further in Chapter 8. 
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6.1 Abstract 
 
Previous chapters have characterised p38δ MAPK function as a tumour suppressor in 
OESCC and outlined the effects its lack of expression has on OESCC response(s) to 
chemotherapeutic drugs. The differential expression of p38δ MAPK in OESCC has 
important consequences for chemosensitivity as p38δ MAPK negative OESCC is 
more resistant to traditional CF treatment compared with p38δ MAPK positive 
OESCC. Loss of p38δ MAPK expression is also a mechanism by which OESCC 
proliferation, migration and anchorage-independent growth is increased.  This new 
study investigated how loss of p38δ MAPK expression is achieved in OESCC. p38δ 
mRNA expression was detected in all cell lines regardless of p38δ MAPK protein 
status. gDNA sequence analysis did not identify any loss of function causing 
genomic mutations. Differential epigenetic control of p38δ MAPK expression was 
also investigated. We outline here for the first time differential MAPK13 promoter 
methylation in OESCC. Our results suggest that epigenetic regulation may be 
responsible for suppression of p38δ MAPK expression and promotion of 
tumourigenesis in OESCC. 
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6.2 Hypothesis and aims 
 
The hypothesis for this chapter is that the differential expression of p38δ in OESCC 
is caused by genetic mutation or differential epigenetic regulation of p38δ MAPK 
expression. 
 
To examine this hypothesis the aims for this chapter are as follows: 
 
 To examine p38δ MAPK mRNA expression in OESCC cell lines. 
 
 To examine p38δ MAPK DNA sequence in p38δ MAPK negative OESCC 
for a mutation which would explain loss of p38δ MAPK expression. 
 
 To examine the methylation status of CpG sites in the p38δ promoter in 
OESCC cell lines.  
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6.3 Introduction 
 
Previous chapters have documented the differential expression of p38δ MAPK in 
OESCC and the consequences of p38δ MAPK expression on OESCC 
tumourigenicity and response to cytotoxic drugs. Loss of p38δ MAPK expression 
contributes to a pro-oncogenic phenotype in OESCC and affords a level of resistance 
to conventional cisplatin and 5-fluorouracil treatment [1, 2]. Re-introduction  of p38δ 
and p-p38δ MAPK expression resulted in a decrease in OESCC cell proliferation, 
migration and anchorage-independent growth [1]. These results demonstrated 
significant tumour suppressive functions for p38δ MAPK in OESCC. Loss of p38δ 
MAPK expression can therefore be considered as a significant pro-survival 
mechanism in OESCC. In general, loss or inactivation of tumour suppressor genes 
occurs via genetic changes such as point mutations and deletions or by epigenetic 
regulation [3]. This chapter sheds light on some mechanism(s) by which the loss of 
p38δ MAPK expression may occur in OESCC.  
 
At the genomic level, point mutations, insertions and deletions of genetic material 
are common mechanisms by which expression of tumour suppressor genes are 
inactivated. The somatic mutation rate for OESCC is higher than in breast 
carcinoma, with C.G  T.A transitions the most common, followed by C.G  G.C 
transversions [4, 5]. Point mutations can be responsible for converting a codon into a 
premature stop codon or replacing an essential amino acid thereby abolishing or 
reducing the production of a functioning gene product. Point mutations can also 
cause aberrant RNA splicing, again abolishing the function of the gene [6]. The 
tumour suppressor p53 is frequently mutated in OESCC and p53 mutated 
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oesophageal cancer is recognised as being resistant to conventional chemotherapy [7, 
8]. Insertion or deletion of even a single nucleotide can cause a frameshift in the 
coding sequence which could explain the loss of p38δ MAPK protein expression.  
 
As well as mutations and chromosomal abnormalities, cancer genomes are also 
characterised by epigenetic changes such as aberrant DNA methylation. DNA 
methylation occurs in cytosines which precede guanines i.e. CpG dinucleotides and 
is essential for normal maintenance of tissue-specific gene expression [9]. In 
comparison with normal cells, cancer cells display global DNA hypomethylation, 
particularly in repetitive DNA sequences and introns which mediates genome 
instability [10]. This is coupled with specific hypermethylation of tumour suppressor 
genes which is responsible for gene silencing as DNA methylation inhibits 
transcription factor binding to promoter regions [11]. Hypermethylation of CpG-rich 
regions in gene promoters (known as CpG islands) is in fact one of the most 
common epigenetic changes to occur in tumours. Interestingly, it is found in almost 
all types of human neoplasms and gene inactivation by epigenetic silencing is at least 
as common as the classic coding-region mutation based disruption of tumour 
suppressor genes [12, 13]. This form of epigenetic regulation is increasingly 
implicated in the development and progression of many cancers, including 
oesophageal carcinomas where tumour suppressor genes involved in the cell cycle 
such as p16
INK4b
 and p14
ARF
 are frequently hypermethylated [3, 11]. Notably, 
promoter hypermethylation has previously been implicated in the epigenetic 
silencing of p38δ MAPK in different cancer types. In malignant pleural 
mesothelioma and primary cutaneous melanoma MAPK13 promoter methylation is 
associated with decreased p38δ MAPK mRNA and protein expression [14, 15]. 
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Restoration of p38δ MAPK expression in melanoma cells decreases proliferation 
[14].  
 
In this study mRNA and gDNA sequences from p38δ MAPK protein positive and 
negative cell lines were compared in order to identify any of the genetic 
abnormalities discussed above which may explain the differential loss of p38δ 
MAPK expression. Possible epigenetic regulation of p38δ MAPK expression was 
investigated using methylation-specific PCR (MSP) and bisulfite sequencing PCR 
(BSP) analysis of CpG islands in the MAPK13 promoter region.   
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6.4 Materials and methods 
 
6.4.1 Cell culture  
KE cell lines as well as KYSE-70, KYSE-450, OE21 and OC-1 were cultured as 
described in Chapter 2. KE cell line features are summarized in Table 2.2.   
 
 
6.4.2 PCR/rt-PCR 
p38δ MAPK mRNA was amplified from cellular cDNA (synthesised as described in 
Chapter 2) using DreamTaq
TM
 DNA polymerase (Fermentas, Thermo Fisher 
Scientific, Waltham, MA, USA) and oligonucleotide primers P009F (5’- 
CGAGATCGGGTGCCCGGGAT-3’) or P002F (5’-CCGGAAAAAGGGCTTCTAC 
AA) and P001R (5’- CCGCCACAAGCTAAAAAGAG-3’). A 748bp fragment of 
MAPK13, corresponding to positions 2189-2936 (GenBank accession no. 
NC_000006.12), was amplified from gDNA (isolated as described in Chapter 2) 
using Platinum® Taq DNA Polymerase (Life Technologies, Grand Island, NY, 
USA) and oligonucleotide primers P009F (5’- CGAGATCGGGTGCCCGGGAT-3’) 
and P017R (5’- TCAGCTTCTTGATGGCCACCTTCTC-3’). All other reaction 
components were as listed in Table 2.6. PCR and rt-PCR were performed in a 
GeneAmp PCR System 2700 under the conditions described in Table 2.7. PCR and 
rt-PCR products were analysed by agarose gel electrophoresis as described in 
Chapter 2. 
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6.4.3 Quantitative rt-PCR 
Nucleic acid isolation 
Total cellular RNA was isolated from KE-3, KE-6, KE-8, KYSE-70, KYSE-450, 
OE-21 and OC-1 cells as outlined in Chapter 2.  
 
QuantiFast® Probe Assay 
p38δ MAPK mRNA expression was quantitated using a Qiagen QuantiFast® Probe 
Assay with one-step rt-PCR and simultaneous detection of GAPDH. 100 ng RNA 
was added to genomic DNA removal reaction mix (QuantiFast Master Mix 1) in a 
96-well PCR plate and incubated for 5 min at RT. rt-PCR reaction mix (QuantiFast 
Master Mix 2, MAPK13 QuantiFast Probe Assay, GAPDH QuantiFast Probe Assay, 
ROX dye solution, QuantiFast RT Mix) was added to PCR plate and reactions 
underwent thermal cycling according to the conditions outlined in Table 6.1 in an 
ABI 7500 Real-Time PCR System (Applied Biosystems, Life Technologies, Grand 
Island, NY, USA). All quantification experiments included a no template control 
(NTC), for detection of contamination and a no reverse transcriptase control to test 
for contaminating gDNA. 
 
 
Table 6.1 One-step qrt-PCR reaction conditions 
Step Temperature °C Time Cycles 
Reverse Transcription 50 20 min  
PCR initial activation 95 5 min  
Denaturation 95 15 s 45 
Annealing/extension* 60 30 s 
*Fluorescence data collection 
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Data analysis 
Data analysis was performed using the ΔΔCT method according to the formula below 
[16] and aided by the SABiosciences data analysis website 
www.SABiosciences.com/pcrarraydataanalysis.php. Baseline was set automatically. 
Cycle threshold value was set in the linear exponential phase of the amplification 
plot and kept the same across all experiments. 
 
ΔΔCT = ΔCT Sample(CT
MAPK13 
- CT
GAPDH
) – ΔCT Control(CT
MAPK13 
- CT
GAPDH
) 
 
 
6.4.4 Sodium bisulfite conversion 
The methylation status of DNA was determined using sodium bisulfite conversion 
with an EpiMark® Bisulfite Conversion Kit (New England BioLabs, Hertfordshire, 
UK) according to manufacturer’s instructions. Incubation of the target DNA with 
sodium bisulfite results in the conversion of all unmethylated cytosines to uracils, 
leaving the methylated bases intact (Figure 6.1). 
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Figure 6.1 Overview of bisulfite conversion. 5-methylcytosines remain unchanged 
while unmethylated cytosines are deaminated to uracil as a result of treatment with 
sodium bisufite. 
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1 μg gDNA was combined with a sodium metabisulfite mixture and mixed gently by 
pipetting. The bisulfite conversion reaction was performed in a GeneAmp PCR 
System 2700 under the conditions outlined in Table 6.2. 
 
 
Table 6.2 Bisulfite conversion reaction conditions 
Step Temperature °C Time 
Denaturation 95 5 min 
Incubation 65 30 min 
Denaturation 95 5 min 
Incubation 65 60 min 
Denaturation 95 5 min 
Incubation 65 90 min 
Hold 18-20 up to 12 hr 
 
 
On completion of the conversion reaction, DNA Binding Buffer was added to the 
mixture and mixed briefly. Samples were loaded on to an EpiMark spin column and 
centrifuged at 15 000 x g for 1 min. Following a wash step, Desulphonation Reaction 
Buffer was added to each column and incubated at RT for 15 min. Columns were 
centrifuged at 15 000 x g for 1 min before two further wash steps. Bisulfite 
converted DNA was eluted in 40 μl Elution Buffer. 
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6.4.5 Methylation specific PCR (MSP) 
MSP is a method of assessing the methylation status of a group of CpG sites using 
individual pairs of primers specific for methylated (M) versus unmethylated (U) 
DNA [17]. MSP primers (Table 6.3) were designed within a CpG island in the 
MAPK13 promoter region (Figure 6.2) with the aid of MethPrimer, an online 
program for designing bisulfite-conversion-based primers 
(http://www.urogene.org/methprimer/) [18]. Specificity of the assay was ensured by 
the presence of two CpG pairs in each primer. 
 
 
Table 6.3 Primers for MSP 
Specificity Primer Sequence (5’→3’) Tm° 
M M01F TTTGTTTGGATTTATTAGTTTCGTC 54.8 
M01R GAACCTATCCAACCCTACGCT 59.8 
U U01F GTTTGGATTTATTAGTTTTGTTGT 52.5 
U01R CAAACCTATCCAACCCTACACT 58.4 
 
 
MSP amplicons were analysed by agarose gel electrophoresis and subsequently 
confirmed by sequencing analysis as described in Chapter 2. 
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6.4.6 Bisulfite sequencing PCR (BSP) 
Primer sequences were designed using MethPrimer [18] to amplify a fragment of a 
CpG island in the MAPK13 promoter region of bisulfite converted DNA regardless 
of methylation status (Figure 6.2). Oligonucleotide primers BSP01F (5’-
TTGGGAGTTGGTTAGAAATGTA-3’) and BSP01R (5’-AACAATACTTCCCAA 
TTCCCT-3’) were used to amplify a 270 bp fragment, from bisulfite converted DNA 
with Platinum® Taq DNA Polymerase. Other reaction components were as listed in 
Table 2.6. BSP was performed in a GeneAmp PCR System 2700 under the 
conditions described in Table 2.7. PCR products were analysed by agarose gel 
electrophoresis as per Chapter 2 and subsequently sequenced to determine the 
average methylation status for each of the four CpG dinucleotides present in the 
amplicon. 
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Figure 6.2 Representative diagram of MAPK13 promoter region CpG sites. 
Each vertical line represents a single CpG site. Transcription start site (0), exons 
(grey arrows), location of methylation specific PCR assay (black bar, MSP) and 
location of bisulfite sequencing PCR (striped bar, BSP) are indicated. Adapted from 
RefGene [19]. 
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6.4.7 5’-aza-2’-deoxycitidine treatment 
5’-aza-2’-deoxycitidine was dissolved at 50 mg/ml in DMSO. KE-3 cells were 
treated with 2μM 5’-aza-2’-deoxycitidine (Decitabine, Sigma Aldrich Ireland Ltd, 
Arklow, Ireland) or DMSO (control) for 96 hr. Culture medium was replaced with 
medium containing fresh 5’-aza-2’-deoxycitidine or DMSO every 24 hr.   
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6.5 Results  
 
6.5.1 p38δ MAPK mRNA is present in all OESCC cell lines 
As discussed in Chapter 4, primers specific for a fragment within the 3’ untranslated 
region of p38δ MAPK mRNA amplified cDNA from all oesophageal squamous and 
adenocarcinoma cell lines examined regardless of their p38δ MAPK protein status 
(Figure 4.1C). However, the region amplified by this primer pair (P001F and P001R) 
does not span an exon-exon boundary and gDNA contamination of the template is 
possible. Intron-spanning primer sets within the p38δ MAPK coding region 
consistently strongly amplified cDNA from p38δ MAPK protein positive cell lines 
KE-4, -5, -6, 10, KYSE-450, OC-3, OE-19 and -33, as well as from p38δ MAPK 
protein negative cell lines OE21 and OC1 (Figure 6.3A and B). Varying levels of 
amplicon were observed from KE-3, KE-8 and KYSE-70 (p38δ MAPK protein 
negative) cells, depending on the primer pair used. Primers specific for a 1575 bp 
portion of p38δ mRNA (P002F and P001R) weakly amplified cDNA from KE-8 and 
KYSE-70 cells but not from KE-3 cells (Figure 6.3A). PCR with a primer pair 
specific for a 1605 bp region of p38δ mRNA (P009F and P001R) did not yield any 
detectable product from KYSE-70 cDNA but did weakly amplify cDNA from KE-3 
and KE-8 cells (Figure 6.3B). 
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6.5.2 p38δ MAPK translation start site sequence is intact in OESCC cell lines 
As p38δ MAPK mRNA was detected in all cell lines examined (Figure 6.3), the 
possibility of a genetic abnormality at the transcriptional level was discounted. 
Therefore, the p38δ MAPK translation start site was amplified and sequenced in 
order to identify any potential mutations such as the presence of a premature stop 
codon or a mutated start codon which could possibly explain the absence of p38 
MAPK protein expression in KE-3, KE-8 and KYSE-70 cells. The translation start 
site of p38 MAPK was amplified from gDNA with specific primers P009F and 
P017R. All cell lines examined were positive for the 748 bp fragment, including KE-
3, KE-8 and KYSE-70 cell lines which were negative for p38δ MAPK protein 
expression (Figure 6.4A). PCR products were analysed by DNA sequencing and the 
returned sequence reads were compared with the MAPK13 reference sequence 
(NC_000006.12). Differences in the first ~10 bases of the sequence read were 
ignored as these peaks tend to be poorly resolved in the electropherogram. The p38δ 
MAPK ATG start codon was found to be intact in all cell lines examined i.e. KE-3, 
KE-8, KYSE-70, OE-21, OC-1 (p38δ MAPK negative) and KYSE-450 (p38δ 
MAPK positive) (Figure 6.4B(i)). Any mutations identified were deemed to be silent 
or located within a non-coding (intron) region (Figure 6.4B(ii) and (iii) respectively). 
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Figure 6.4 MAPK13 translation start site is intact in OESCC cell lines. (A) 
Agarose gel electrophoresis analysis of DNA fragments produced by PCR 
amplification of MAPK13 exon 1 from p38δ MAPK protein positive (KYSE-450) 
and p38δ MAPK protein negative (KE-3, KE-8, KYSE-70, OE-21, OC-1) OESCC. 
(B) DNA sequence analysis of PCR products. Residues identical to the reference 
sequence (MAPK13 NC_000006.12) residue at the same position are represented by 
a point (•), residues which differ are in uppercase. 
A 
B 
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6.5.3 p38δ MAPK mRNA expression is downregulated in OESCC cell lines which 
lack p38δ protein expression 
In the absence of any detectable mutations at the genomic level, differential p38δ 
MAPK mRNA expression remained the most likely cause of p38δ MAPK protein 
loss. Therefore p38δ MAPK mRNA expression was further analysed. Quantitive 
real-time PCR was used to determine the relative levels of p38δ MAPK mRNA 
expression in each of the OESCC cell lines being studied. p38δ MAPK mRNA 
expression was found to be highest in p38δ MAPK protein positive cells KE-6 and 
KYSE-450, although there was a significant (p<0.01) difference between the two 
cell lines (Figure 6.5). p38δ MAPK mRNA expression was similarily and 
significantly (p<0.001) downregulated in p38δ MAPK protein negative cell lines 
KE-3, KE-8 and KYSE-70 when compared with both KE-6 and KYSE-450 p38δ 
MAPK protein positive cells (Figure 6.5). OE-21 and OC-1 (both p38δ MAPK 
protein negative) demonstrated intermediate levels of p38δ MAPK mRNA 
expression yet still with significant (p<0.001 and p<0.01) decreases from KE-6 and 
KYSE-450 expression (Figure 6.5). 
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Figure 6.5 Relative p38δ MAPK mRNA expression in OESCC. p38δ MAPK 
mRNA levels in p38δ MAPK protein negative OESCC cell lines KE-3, KE-8, 
KYSE-70, OE-21 and OC-1 were compared with p38δ MAPK protein positive KE-6 
and KYSE-450 cells. GAPDH was measured as an internal control. Relative values 
were calculated by normalizing 2
-ΔΔCT
. Results shown are the mean ± S.E. of three 
independent qrt-PCR experiments. ***p<0.001, **p<0.01, significant changes in 
p38δ MAPK expression from (black) KE-6 and (blue) KYSE-450 cells were 
determined by application of Student’s t-test. 
 
. 
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6.5.4 MAPK13 promoter is differentially methylated in OESCC 
As a genetic mutation had been ruled out as an explanation for the differential loss of 
p38δ MAPK in OESCC, epigenetic regulation of p38δ MAPK expression was 
considered. DNA methylation was detected by MSP in KE-3, KE-8, KYSE-70 and 
OC-1 OESCC (Figure 6.6A (M)). In contrast, no substantial DNA methylation was 
identified in KE-6, KYSE-450 and OE-21 cells (Figure 6.6A (M)). Furthermore, 
unmethylated DNA was poorly amplified in KE-3, KE-8 and KYSE-70 cells (Figure 
6.6A (U)). This is indicative of the presence of MAPK13 promoter hypermethylation 
in p38δ MAPK protein negative OESCC, with the exception of the OE-21 cell line. 
 
BSP was used for further validation and analysis of MAPK13 promoter methylation 
density in OESCC. The methylation status of four individual CpG sites within a 
MAPK13 promoter region CpG island was analysed. Comparison of DNA sequence 
reads of PCR products with in silico bisulfite-converted MAPK13 reference 
sequence (NC_000006.12) identified differential CpG methylation in OESCC 
(Figure 6.5B). Unmethylated CpG cytosines (C) in the MAPK13 reference sequence 
are converted to uracil (T). Identical residues at the equivalent positions in the PCR 
products indicates the CpG residue is not methylated in that particular cell line while 
the presence of unconverted C residues is indicative of DNA methylation at that 
individual CpG site (Figure 6.6B).  
 
Of the four MAPK13 promoter region CpG sites analysed by BSP, only one was 
found to be methylated in KE-6 and KYSE-450 p38δ MAPK protein positive 
OESCCs (Figure 6.6B and C). Conversely, DNA methylation was detected at all 
four CpG sites in KE-3, KE-8 and KYSE-70 p38δ MAPK protein negative OESCCs 
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(Figure 6.6B and C). In p38δ MAPK protein negative OE-21 and OC-1, DNA 
methylation was identified at one and two CpG sites respectively (Figure 6.6B and 
C) 
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Figure 6.6 MAPK13 promoter methylation analysis. (A) Agarose gel 
electrophoresis analysis of MAPK13 MSP products. (B) DNA sequence analysis of 
MAPK13 CpG island BSP products. Residues identical to the reference sequence 
(MAPK13 NC_000006.12) residue at the same position are represented by a point 
(•), residues which differ are in uppercase. (C) Representative BSP analysis of CpG 
methylation. An unmethylated cytosine is depicted as a white circle, a methylated 
cytosine as a black circle. 
A 
B 
C 
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6.5.5 Treatment with 5’aza-2’deoxycitidine does not induce p38δ MAPK mRNA 
expression in KE-3 OESCC cells 
5’-aza-2’-deoxycitidine is an epigenetic modifier. It demethylates or hemi-
demethylates DNA by inhibiting DNA methyltransferase activity. KE-3 cells were 
treated with 5’-aza-2’-deoxycitidine and the effect on p38δ MAPK expression was 
analysed by qrt-PCR. No significant change in p38δ MAPK mRNA expression was 
detected between 5’-aza-2’-deoxycitidine and DMSO (control) treated cells (Figure 
6.7). Of note, these results were obtained from a single preliminary experiment – no 
replicates were performed.   
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Figure 6.7 Relative p38δ MAPK mRNA expression in KE-3 cells following 5’-
aza-2’-deoxycitidine treatment. p38δ MAPK mRNA level in KE-3 cells following 
treatment for 96 hr with 2μM 5’aza-2’-deoxycitidine was compared with DMSO 
treated KE-3 cells. GAPDH expression was measured as an internal control. Relative 
values were calculated by normalizing to KE-3 + DMSO 2
-ΔΔCT
. Results shown are 
the mean ± S.E of 3 replicate wells in a single qrt-PCR experiment. 
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6.6 Discussion 
 
Tumour suppressor gene function can be lost in a variety of ways in order for cancer 
cells to gain the capacity for uncontrolled proliferation, migration and escape from 
apoptosis. These include somatic mutations, including insertions, deletions or point 
mutations, and/or epigenetic changes such as DNA methylation or histone 
deacetylation. p38δ MAPK displays tumour suppressor functions in OESCC – its 
loss promotes proliferation, migration, anchorage-independent growth and resistance 
to conventional chemotherapy [1, 2]. p38δ MAPK expression is absent at the protein 
level in OESCC cell lines KE-3, KE-8, KYSE-70, OE-21 and OC-1. In this study we 
outline how this inactivation of p38δ MAPK expression may occur in OESCC. 
 
The results presented here indicate that this loss of protein expression cannot be 
attributed to a genetic mutation or deletion. p38δ MAPK mRNA is expressed in all 
OESCC cell lines, regardless of p38δ MAPK protein status. Furthermore, no 
mutations were identified in exon 1 of the coding region which would prevent or 
disrupt translation from mRNA to protein. However, differential mRNA expression 
levels were observed between p38δ MAPK protein positive and protein negative cell 
lines. The highest levels of p38δ MAPK mRNA expression were observed in p38δ 
protein positive cell lines KE-6 and KYSE-450. Significantly lower levels of p38δ 
MAPK mRNA were detected in p38δ MAPK protein negative cell lines. This 
suggests that the absence of p38δ MAPK protein expression in these cells may be 
attributed to p38δ MAPK mRNA expression failing to reach the threshold required 
to achieve a detectable level of protein synthesis.   
 
 229 
 
Our results show that the downregulation of p38δ MAPK mRNA expression in KE-
3, KE-8, KYSE-70, OE-21 and OC-1 cells is most likely caused by MAPK13 
promoter hypermethylation. The MAPK13 promoter regions of the OESCC cell lines 
with the lowest levels of p38δ MAPK mRNA expression (KE-3, KE-8 and KYSE-70 
p38δ protein negative cells) are highly methylated, as demonstrated by both MSP 
and BSP analysis. Conversely, in p38δ MAPK protein positive cell lines KE-6 and 
KYSE-450, in which p38δ MAPK mRNA expression was significantly higher 
(p<0.001), a decreased incidence of DNA methylation was detected by both MSP 
and BSP. OC-1 cells also expressed significantly higher (p<0.001) levels of p38δ 
MAPK mRNA than KE-3, KE-8 and KYSE-70 cells despite the fact that they are 
also p38δ MAPK protein negative. Interestingly however, the MAPK13 promoter 
was also found to be hypermethylated in this cell line when compared with p38δ 
MAPK protein positive cells (two CpG sites methylated versus one CpG site 
methylated). There appears to be an inverse correlation therefore between MAPK13 
promoter methylation and p38δ MAPK mRNA expression in OESCC. Of note, 
methylation of the specific CpG sites examined here may not be the critical 
determinants of MAPK13 expression but rather these results reflect a general pattern 
of MAPK13 promoter methylation. This would explain why the OE21 cell line does 
not appear to fit this model of p38δ MAPK epigenetic regulation – the loss of p38δ 
MAPK expression in the OE21 cell line may be caused by MAPK13 promoter 
methylation at a critical CpG site not included in this analysis.  
 
Confirmation of epigenetic silencing of p38δ MAPK in OESCC could be achieved 
with further experimentation. The DNA methyltransferase inhibitor 5’-aza-2’-
deoxycitidine causes passive demethylation and has been shown to reactivate 
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epigenetically silenced genes [14, 20]. Although the preliminary experiment outlined 
here did not detect activation of p38δ MAPK expression following 5’-aza-2’-
deoxycitidine treatment, it is possible that conditions used (2μM 5’-aza-2’-
deoxycitidine for 96 hr) were not sufficient to induce DNA demethylation. Examples 
in the literature use concentrations of 5’-aza-2’-deoxycitidine as high as 10μM as 
well as numerous time-points to achieve DNA demethylation [21, 22]. CpG island 
demethylation following 5’-aza-2’-deoxycitidine treatment was not assessed in this 
study but could be confirmed using BSP before proceeding with analysis of p38δ 
MAPK mRNA expression.   Increased p38δ MAPK mRNA expression in KE-3, KE-
8, KYSE-70, OE-21 and OC-1 cells following 5’-aza-2’-deoxycitidine treatment 
would confirm that p38δ MAPK is epigenetically regulated in OESCC and that the 
MAPK13 promoter methylation identified above is associated with loss of p38δ 
MAPK expression. This was found to be the case in melanoma cells where a nearly 
undetectable level of MAPK13 expression was increased significantly upon 
treatment with 5’-aza-2’-deoxycitidine [14]. Importantly, introduction of p38δ 
MAPK expression in melanoma cell lines exhibiting MAPK13 promoter 
hypermethylation resulted in decreased proliferation, particularly when a 
constitutively active form of p38δ MAPK was used [14]. This is consistent with our 
results outlined in Chapter 4 and further strengthens the argument for the tumour 
suppressive functions of this gene [1]. 
 
The implication of MAPK13 promoter methylation in promoting tumourigenesis in 
OESCC could have therapeutic implications. Epigenetic alterations, as opposed to 
genetic mutations can be pharmacologically reversed. 5’-aza-2’-deoxycitidine (as 
decitabine) is in fact used as a treatment for myelodysplastic syndromes and 
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leukaemia [23, 24]. 5’-aza-2’-deoxycitidine acts as a cytidine analog during DNA 
replication but cannot be methylated by DNMT1 and instead causes degredation of 
DNMT1 and reduces methylation in rapidly dividing cancer cells [25]. Histone 
deacetylation is another mechanism by which gene expression can be repressed. 
Methyl domain binding proteins bound to methylated CpG sites recruit histone 
deacetylases (HDAC) to the histone, further inhibiting transcription [26]. HDAC 
inhibitors have also demonstrated antitumour effects in various cancers. 
Suberanilohydroxanic acid (Vorinostat) is used in the treatment of T cell 
lymphomas. It causes hyperacetylation of not only histones but also p53 and hsp90, 
thereby inducing apoptosis [27]. The HDAC inhibitor Trichostatin A has recently 
been shown to suppress proliferation and promote apoptosis in OESCC [28]. HDAC 
inhibitors can also induce the expression of cancer-testis antigens (CTAs), thereby 
increasing the immunogenicity of cancer cells [29]. Furthermore, HDAC inhibitors 
can promote demethylation by downregulation of DNMT1. The combination of a 
HDAC inhibitor and a demethylating agent has been found to have synergistic 
effects [30]. Potential lies in the combination of epigenetic and non-epigenetic 
therapies. The re-expression of tumour suppressor genes by epigenetic drugs 
weakens the ability of cancer cells to withstand cytotoxic treatment, thereby 
lowering the dose of chemotherapeutic drug required to induce cell death [30]. 
Another potential clinical use of the findings presented here is as a prognostic tool. 
DNA methylation analysis techniques would facilitate the sensitive and quantitative 
detection of a hypermethylated MAPK13 promoter in biopsy specimens. As we have 
seen in Chapter 5, pre-treatment identification of p38δ MAPK status may be useful 
in determining the optimal treatment and predicting response in OESCC patients.  
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Chapter 7 
 
Investigation into the contribution of p38δ (and 
p-p38δ) MAPK to the cell cycle in OESCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This chapter does not represent a complete body of work. Due to both time and 
financial constraints, the research presented here is unfinished. The experiments 
required to complete this study will be discussed further in Chapter 8. 
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7.1 Abstract 
 
We have previously shown that p38δ MAPK negative OESCC cells proliferate more 
quickly than cells which endogenously express p38δ MAPK. Introduction, however, 
of p38δ MAPK expression in p38δ MAPK negative OESCC cells caused a 
significant decrease in the rate of cell proliferation. This effect was further enhanced 
by constitutive expression of phosphorylated p38δ MAPK (Chapter 4). Cell 
proliferation arises from a particular balance between cell division and cell death 
which is tightly controlled by the cell cycle. While the p38 MAPK pathway can both 
positively and negatively regulate cell division (depending on cell type and stimulus) 
the specific contribution of the individual p38 MAPK isoforms has not been 
elucidated. This chapter aims to uncover how the cell cycle is influenced by the 
introduction of p38δ MAPK and p-p38δ MAPK in reducing OESCC proliferation. 
The effects of p38δ MAPK and p-p38δ MAPK on the expression of 84 cell cycle 
regulated genes was examined using an RT
2
 Profiler human cell cycle PCR array.  
  
 236 
 
7.2 Hypothesis and aims 
 
The hypothesis for this chapter is that p38δ (and p-p38δ) MAPK negatively regulates 
cell cycle progression by influencing the expression of a cell cycle associated 
gene(s). 
 
To examine this hypothesis the aims for this chapter are as follows: 
 
 To compare the expression of cell cycle associated genes in p38δ MAPK 
negative and p38δ MAPK positive OESCC cell lines. 
 
 To compare the expression of cell cycle associated genes in p38δ MAPK 
negative and p-p38δ MAPK positive OESCC cell lines.  
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7.3 Introduction 
 
The p38 MAPK family has long been recognised as a regulator of cell growth since 
overexpression of mammalian p38α MAPK in yeast was found to significantly slow 
proliferation [1]. In recent years p38α MAPK has been shown to regulate cell cycle 
progression and checkpoint controls by a number of mechanisms in both G1/S and 
G2/M phases of the cell cycle (Figure 7.1). Depending on cell-type and the activating 
signal, p38α can either activate G1/S phase arrest or promote progression through the 
checkpoint [2]. p38α MAPK activation promotes proliferation and progression 
through the cell cycle in a variety of mammalian cells by regulating the activity of 
transcription factors such as NF-κB, ATF-1, ATF-2, CREB and C/EBP family 
members [3]. On the other hand, arrest of NIH3T3 cells at G1/S phase of the cell 
cycle by Cdc42 has been shown to be dependent on p38α MAPK activation [4]. 
Interestingly, expression of Cdc42 in MEFs is associated with downregulation of 
p38δ MAPK activity and progression of MEFs through G1/S, highlighting the 
significance of the cell type in determining the specific role of p38 MAPK signalling 
[5]. Osmotic shock also induces G1/S phase arrest in Mori human fibroblast via p38 
activation [6].  
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Figure 7.1 Schematic diagram of p38 MAPK pathway regulation of the cell 
cycle. The four phases of the eukaryotic cell cycle are the Gap-1 phase (G1), DNA 
synthesis (S phase), Gap-2 phase (G2) and the mitotic phase (M). p38α MAPK is 
known to both inhibit and promote progression through the G1/S phase checkpoint 
(CP), depending on the cell type and/or stimulus. Several reports identify p38α 
MAPK as an inhibitor of G2/M transition and progression through M-phase. p38β 
MAPK prevents entry into M phase when DNA replication is incomplete. p38γ 
induces G2 arrest in response to γ-irradiation. p38δ MAPK induces G1 phase arrest 
through p53 and p21 in keratinocytes.  
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Several mechanisms have been proposed for p38α MAPK mediated G1/S arrest. 
These involve well characterised p38α MAPK substrates such as p53, p21 and 
HMG-box transcription factor 1 [6-8] or downregulation of cyclin D expression and 
protein stability [9-11]. p38α MAPK has also been identified as a mediator of G2 
arrest induced by environmental stimuli such as UV irradiation. p38α MAPK is 
responsible for the phosphorylation of Cdc25B which increases its affinity for 14-3-3 
proteins and ultimately its inactivation. Inhibition of p38α MAPK abolishes the G2 
delay induced by UV irradiation [12]. p38α MAPK is also activated in M phase 
arrest by disruption of the spindle with nocodazole [13]. In contrast, Fas receptor 
stimulation results in p38 MAPK mediated phosphorylation of the G1/S transition 
regulator retinoblastoma protein (Rb). Phosphorylation of Rb reverts Rb-regulated 
growth suppression by causing it to dissociate from E2F, thereby increasing E2F 
transcriptional activity. 
 
Specific roles for p38β and -γ MAPKs in cell cycle control have also been described. 
p38β MAPK (in combination with p38α MAPK) is responsible for inhibiting entry 
into M phase when DNA replication is ongoing or has stalled by keeping cyclin 
B1/cyclin dependent kinase (CDK) -1 complexes inactive [14]. p38γ MAPK plays a 
critical role in γ-irradiation induced G2 arrest. Activation of p38γ in response to γ-
irradiation is mediated by ATM and leads to regulation of the G2 checkpoint via 
activation of Chk2 and Cdc25C [15] 
 
Despite the significant roles p38α, -β, and –γ MAPK signalling play in the cell cycle, 
a clear function for p38δ MAPK in cell cycle control has yet to be defined. There is 
increasing evidence however which suggests that p38δ MAPK negatively regulates 
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cell cycle progression. p38δ MAPK has been shown to be involved in the induction 
of G1 phase arrest in response to selenoprotein W depletion [16]. MKK-4 activated 
p38δ MAPK phosphorylates p53 on Ser-33. Phosphorylated p53 is protected from 
proteosomal degradation and accumulates in the nucleus where it activates 
expression of the cyclin-dependent kinase inhibitor (CDKI) p21. p21 expression is 
then responsible for inducing G1 phase arrest [16]. p38δ MAPK has also recently 
been implicated in the suppression of keratinocyte proliferation. PKCδ-induced p38δ 
MAPK activation was shown to be responsible for the upregulation of p53 
expression (rather than phosphorylation) which in turn induced p21 expression [17]. 
 
To elucidate the specific contribution of p38δ to cell cycle progression in OESCC we 
compared the expression of 84 cell cycle regulated genes in p38δ positive (KE-6), 
p38δ negative (KE-3) and p-p38δ positive (KE-3 pcDNA3-MKK6b(E)-(Gly-Glu)5-
FLAG-p38δ) oesophageal squamous carcinoma cell lines using an RT2 Profiler 
human cell cycle PCR array (Qiagen, Manchester, UK). Genes analysed by the array 
include positive and negative regulators of the cell cycle, phase transitions, 
checkpoints, and DNA replication. The complete list of genes and their functional 
categories are outlined in Table 7.1. 
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Table 7.1 RT
2
 Profiler Human Cell Cycle PCR array gene table 
Gene Description Category 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 2/6 
ANAPC2 Anaphase promoting complex subunit 2 1/3/6 
ATM Ataxia telangiectasia mutated 5/7 
ATR Ataxia telangiectasia and Rad3 related 5/6 
AURKA Aurora kinase A 6 
AURKB Aurora kinase B 4 
BCCIP BRCA2 and CDKN1A interacting protein 3/6 
BCL2 B-cell CLL/lymphoma 2 6 
BIRC5 Baculoviral IAP repeat containing 5 3 
BRCA1 Breast cancer 1, early onset 5/7 
BRCA2 Breast cancer 2, early onset 5/6 
CASP3 Caspase 3, apoptosis-related cysteine peptidase 5/7 
CCNA2 Cyclin A2 3/5 
CCNB1 Cyclin B1 3/6 
CCNB2 Cyclin B2 4/6 
CCNC Cyclin C 6 
CCND1 Cyclin D1 1/6 
CCND2 Cyclin D2 6 
CCND3 Cyclin D3 6 
CCNE1 Cyclin E1 1/6 
CCNF Cyclin F 4/6 
CCNG1 Cyclin G1 3 
CCNG2 Cyclin G2 5 
CCNH Cyclin H 3/6 
CCNT1 Cyclin T1 3/6 
CDC16 Cell division cycle 16 homolog (S. cerevisiae) 4/6 
CDC20 Cell division cycle 20 homolog (S. cerevisiae) 4/6 
CDC25A Cell division cycle 25 homolog A (S. pombe) 1/3/5 
CDC25C Cell division cycle 25 homolog C (S. pombe) 4/5/6 
CDC34 Cell division cycle 34 homolog (S. cerevisiae) 1/5 
CDC6 Cell division cycle 6 homolog (S. cerevisiae) 2/4/6 
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CDK1 Cyclin-dependent kinase 1 4/5/6 
CDK2 Cyclin-dependent kinase 2 5/6 
CDK4 Cyclin-dependent kinase 4 1/6 
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 3/6 
CDK5RAP1 CDK5 regulatory subunit associated protein 1 3 
CDK6 Cyclin-dependent kinase 6 1/6 
CDK7 Cyclin-dependent kinase 7 3/6 
CDK8 Cyclin-dependent kinase 8 6 
CDKN1A Cyclin-dependent kinase inhibitor 1B (p21, Cip1) 5/6 
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 1/5/6 
CDKN2A Cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4) 
5 
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 
5/7 
CDKN3 Cyclin-dependent kinase inhibitor 3 1/3/5 
CHEK1 CHK1 checkpoint homolog (S. pombe) 5 
CHEK2 CHK2 checkpoint homolog (S. pombe) 5 
CKS1B CDC28 protein kinase regulatory subunit 1B 3/6 
CKS2 CDC28 protein kinase regulatory subunit 2 3 
CUL1 Cullin 1 1/5 
CUL2 Cullin 2 1/5 
CUL3 Cullin 3 1/5 
E2F1 E2F transcription factor 1 1/6 
E2F4 E2F transcription factor 4, p107/p130-binding 6 
GADD45A Growth arrest and DNA-damage-inducible, alpha 5/6 
GTSE1 G-2 and S-phase expressed 1 3 
HUS1 HUS checkpoint homolog (S. pombe) 5 
KNTC1 Kinetochore associated 1 5/6 
KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 3 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 5 
MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) 5 
MCM2 Minichromosome maintenance complex component 2 2 
MCM3 Minichromosome maintenance complex component 3 2 
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MCM4 Minichromosome maintenance complex component 4 2 
MCM5 Minichromosome maintenance complex component 5 2 
MDM2 Mdm2 p53 binding protein homolog (mouse) 5 
MKI67 Antigen identified by monoclonal antibody Ki-67 6 
MNAT1 Menage a trois homolog 1, cyclin H assembly factor 
(Xenopus laevis) 
3 
MRE11A MRE11 meiotic recombination 11 homolog A (S. 
cerevisiae) 
4 
NBN Nibrin 5 
RAD1 RAD1 homolog (S. pombe) 5 
RAD17 RAD17 homolog (S. pombe) 5 
RAD51 RAD51 homolog (S. cerevisiae) 4 
RAD9A RAD9 homolog A (S. pombe) 5/6 
RB1 Retinoblastoma 1 5/6 
RBBP8 Retinoblastoma binding protein 8 5 
RBL1 Retinoblastoma-like 1 (p107) 7 
RBL2 Retinoblastoma-like 2 (p130) 7 
SERTAD1 SERTA domain containing 1 3 
SKP2 S-phase kinase-associated protein 2 (p45) 1/6 
STMN1 Stathmin 1 4 
TFDP1 Transcription factor  Dp-1 6 
TFDP2 Transcription factor  Dp-2 (E2F dimerization partner 2) 6 
TP53 Tumour protein p53 5/7 
WEE1 WEE1 homolog (S. pombe) 2/5/6 
 Categories of function gene grouping: 1, G1 phase and G1/S transition; 2, S phase 
and DNA replication; 3, G2 phase and G2/M transition; 4, M phase; 5, cell cycle 
checkpoint and cell cycle arrest; 6, regulation of cell cycle; 7, negative regulation of 
cell cycle (www.sabiosciences.com)  
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7.4 Materials and methods 
 
7.4.1 Cell culture  
KE-3 and KE-6 cell lines as well as stably transfected KE-3 pcDNA3-MKK6b(E)-
(Gly-Glu)5-FLAG-p38δ (KE-3 p-p38δ) cells were cultured as described in Chapter 2.  
 
 
7.4.2 Cell cycle gene expression analysis 
 
Nucleic acid isolation 
Total cellular RNA was isolated from KE-3, KE-6 and KE-3 p-p38δ cells using an 
RNeasy Mini Kit (Qiagen, Manchester, UK) as outlined in Chapter 2.  
 
cDNA synthesis 
500ng high quality RNA (A260/A280 1.8 to 2.0, A260/A230 > 1.7 ) was converted into 
cDNA using an RT
2
 First Strand cDNA kit according to manufacturer’s instructions 
(Qiagen, Manchester, UK). Each RNA sample was combined with genomic DNA 
elimination mix (Buffer GE) and incubated for 5 min at 42°C before being placed on 
ice for ≥ 1 min. Reverse transcription mix (Buffer BC3, Control P2, RE3 Reverse 
Transcriptase Mix) was added to each genomic DNA elimination reaction and 
incubated at 42°C for 15 min. The reaction was stopped by incubating at 95°C for 5 
min. RNase-free H2O was added to each reaction and reactions were placed on ice 
before proceeding immediately with the RT
2
 Profiler PCR array assay. 
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RT
2
 Profiler PCR array 
Cell cycle gene expression in KE-3, KE-6 and KE-3 p-p38δ cells was determined 
using the Cell Cycle RT
2
 Profiler PCR array (PAHS-020Z) according to the 
manufacturer’s instructions (Qiagen, Manchester, UK). RT2 SYBR Green Mastermix 
was centrifuged for 15 s to bring contents to the bottom of the tube. The cDNA 
synthesis reaction was combined with RT
2
 SYBR Green Mastermix and RNase-free 
H2O in a loading reservoir before being dispensed into each well of the RT
2
 Profiler 
PCR array. 
 
RT
2
 Profiler PCR array layout is outlined in Figure 7.2. As well as the 84 cell cycle 
focused genes, arrays included five housekeeping genes to enable normalization of 
data. In addition, one well in each array contained a gDNA control (GDC) to 
specifically detect nontranscribed genomic DNA contamination. Reverse 
transcription controls (RTC; 3 replicate wells per array) tested the efficiency of the 
RT
2
 First Strand Kit reverse-transcription reaction by detecting template synthesised 
from the kits built-in external RNA control. Finally, the efficiency of the PCR 
reaction itself was tested in 3 replicate wells containing a predispensed artificial 
DNA sequence and the assay which detects it (positive PCR control, PPC).  
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RT
2
 Profiler PCR array plates were sealed with optical adhesive film (Applied 
Biosystems, Life Technologies, Grand Island, NY, USA). Arrays underwent thermal 
cycling according to the conditions outlined in Table 7.2 in an ABI 7500 Real-Time 
PCR System (Applied Biosystems, Life Technologies, Grand Island, NY, USA).  
 
Table 7.2 RT
2
 Profiler PCR array reaction conditions 
Step Temperature °C Time Cycles 
Activation of HotStart DNA Taq 
Polymerase 
95 10 min 1 
 95 15 s 40 
Fluorescence data collection 60 1 min 
 
 
Data analysis 
Data analysis was performed using the ΔΔCT method according to the formula below 
[18] and aided by the SABiosciences data analysis website 
www.SABiosciences.com/pcrarraydataanalysis.php. Baseline was set automatically. 
Cycle threshold value was set in the linear exponential phase of the amplification 
plot and kept the same across all arrays. 
 
ΔΔCT = ΔCT Sample(CT
GOI 
- CT
HKG
) – ΔCT Control(CT
GOI 
- CT
HKG
) 
 
where GOI is the gene of interest and HKG is the housekeeping genes used for 
normalization. 
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CT values >35 for the gDNA control wells were considered acceptable as the level of 
gDNA contamination was too low to affect gene expression profiling results. RTC 
values were analysed by calculating  
 
   ΔCT = AVG CT
RTC
 – AVG CT
PPC 
 
A value <5 was considered acceptable as an indication that no inhibition of the 
reverse transcription reaction had occurred. For PPC wells an average CT
PPC
 value of 
20 ± 2 on each array and variation ≤2 cycles between arrays was accepted.  
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7.5 Results 
 
7.5.1 Relative cell cycle gene expression in p38δ MAPK negative (KE-3) versus 
p38δ MAPK positive (KE-6) OESCC 
p38δ MAPK negative cells proliferate at a significantly faster rate than p38δ MAPK 
positive cells (Chapter 4) [19]. In order to identify the pathway(s) responsible for 
differential regulation of proliferation in p38δ MAPK negative and p38δ MAPK 
positive OESCC, this study compared the relative expression of 84 cell cycle 
associated genes (Table 7.1) between KE-3 (p38δ MAPK negative) and KE-6 (p38δ 
MAPK positive) OESCC cells. Two criteria were used to define a meaningful 
difference in gene expression between the KE-3 and KE-6 groups: the average 
relative expression in three independent experiments must be (1) increased or 
decreased by ≥ 2-fold and (2) must be statistically significant following application 
of Student’s t-test (p<0.05). Figure 7.3 displays a scatter plot analysis of the results 
obtained from the RT
2
 Profiler PCR array. Thirty cell cycle associated genes 
demonstrated at least a 2-fold difference in gene expression between the p38δ 
MAPK negative and p38δ MAPK positive cells. Downregulation was observed in 
nine genes, while twenty-one genes appeared to be upregulated in the p38δ MAPK 
negative KE-3 cells (Figure 7.3). Fold regulation of the 21 genes which satisfied the 
dual criteria outlined above are listed in Table 7.3. 
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Figure 7.3 Relative expression comparison for 84 cell cycle associated genes 
between p38δ MAPK negative (KE-3) and p38δ MAPK positive (KE-6) 
OESCC. Depicted is a log10 transformation plot of the normalized relative 
expression level of each gene between KE-3 (y-axis) and KE-6 (x-axis) cells. Dotted 
lines indicate a 2-fold change in gene expression threshold. Results shown are mean 
fold change of mRNA expression from three independent experiments. 
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Table 7.3 Changes in fold regulation for cell cycle associated genes between 
p38δ MAPK negative (KE-3) and p38δ MAPK positive (KE-6) OESCC 
Gene Fold Regulation KE-3/KE-6 p value 
CCND2 101.42 0.038890 
CCNG1 6.22 0.015122 
ATM 5.21 0.003923 
MRE11A 3.86 0.043477 
CUL1 3.40 0.034541 
CCNE1 3.23 0.047776 
BIRC5 2.72 0.000828 
CHEK1 2.66 0.036834 
KPNA2 2.54 0.028599 
WEE1 2.44 0.045845 
CUL2 2.29 0.020438 
BCCIP 2.16 0.045158 
CDC16 2.12 0.020739 
BCL2 -2.27 0.003914 
ATR -2.28 0.000936 
RB1 -3.18 0.002726 
CDKN1A -6.52 0.000011 
CCND1 -8.36 0.000138 
CDKN1B -9.41 0.000597 
CDK6 -19.48 0.000204 
CCNC -25.95 0.000229 
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7.5.2 Relative cell cycle gene expression in p-p38δ MAPK positive versus p38δ 
MAPK negative KE-3 OESCC 
Introduction of p-p38δ MAPK expression in KE-3 cells significantly decreases the 
rate of proliferation (Chapter 4) [19]. The second RT
2
 Profiler PCR experiment was 
designed to identify any changes in cell cycle gene expression induced by expression 
of p-p38δ MAPK in KE-3 cells. The relative expression of 84 cell cycle associated 
genes (Table 7.1) was compared between stably transfected KE-3 p-p38δ cells and 
p38δ MAPK negative KE-3 cells. The dual criteria for meaningful changes in gene 
expression outlined above were also applied here. Of the 84 genes examined in the 
array, seven demonstrated at least a 2-fold difference in gene expression between 
KE-3 p-p38δ and WT KE-3 cells. Of these seven differentially expressed genes one 
(CDK6) appeared to be upregulated in p-p38δ expressing cells while six were 
downregulated (ANAPC2, CCNT1, CDKN2B, MCM3, MREIIA, WEE1) (Figure 
7.4). All genes analysed by the RT
2
 Profiler PCR array failed to satisfy the dual 
criteria as none of the alterations in gene expression observed were found to be 
statistically significant. 
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Figure 7.4 Relative expression comparison for 84 cell cycle associated genes 
between KE-3 p-p38δ MAPK and KE-3 cells. Depicted is a log10 transformation 
plot of the normalized relative expression level of each gene between KE-3 (x-axis) 
and KE-3 p-p38δ (y-axis) cells. Dotted lines indicate a 2-fold change in gene 
expression threshold. Results shown are mean fold change of mRNA expression 
from three independent experiments. 
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7.6 Discussion 
 
A key mechanism by which p38α MAPK is thought to control cell cycle progression 
is through the D-type cyclins [9-11]. Induction of cyclin D1, -2 and -3 expression is 
an early event during G1 to S phase transition. Co-expression of MKK3 and p38α 
MAPK in CCL39 cells significantly inhibited cyclin D1 expression while inhibition 
of p38α MAPK activity with SB203580 enhanced cyclin D1 mRNA and protein 
levels [10]. In this study we did not observe any increase in cyclin D1 expression 
between in p38δ MAPK negative cells compared with p38δ MAPK positive cells. In 
fact, there was a significant (p<0.001) 8-fold decrease in cyclin D1 expression 
detected between p38δ MAPK positive KE-6 cells and p38δ MAPK negative KE-3 
cells. On the other hand, cyclin D2 expression was significantly (p<0.05) 
upregulated by >100-fold in p38δ MAPK negative KE-3 cells. This suggests that 
while p38α MAPK may regulate the cell cycle through inhibition of cyclin D1, p38δ 
MAPK may act preferentially on cyclin D2. The lack of p38δ MAPK expression in 
KE-3 cells therefore removes inhibition of cyclin D2 expression. Cyclins E1 and G1 
are also significantly upregulated in KE-3 cells compared to KE-6 cells (3-fold and 
6-fold respectively, p<0.05). These cyclins may also play a role in driving the 
increased proliferation observed in KE-3 cells. 
 
The decreased expression of CDKIs, negative regulators of G1 to S phase transition, 
is another mechanism by which p38δ MAPK may exert its effects on cell 
proliferation in KE-3 cells. The expression of both CDKN1B (p27) and CDKN1A 
(p21), is significantly downregulated (>9-fold and >6-fold respectively, p<0.001) in 
p38δ MAPK negative KE-3 cells compared with p38δ MAPK positive KE-6 cells. 
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Induction of p21 expression in keratinocytes has previously been shown to be 
mediated by p38δ MAPK activation of p53 expression [17]. However we did not 
observe any changes in p53 expression between KE-6 and KE-3 cells.  It is possible 
that reduced phosphorylation of p53 protein in the absence of p38δ MAPK rather 
than decreased mRNA is responsible for the decrease in p21 expression in KE-3 
cells, as has been previously described [16]. The significant differences in the rates 
of proliferation of KE-3 and KE-6 cells observed in Chapter 4 may therefore be the 
result of decreased p53 and p21-mediated G1 phase arrest in the p38δ MAPK-
negative KE-3 cells. 
 
It is important to note that not all differences in gene expression between KE-3 and 
KE-6 cells can be attributed to differential p38δ MAPK expression. As KE-3 and 
KE-6 cells are separate cell lines arising from distinct individuals, the differing gene 
expression profiles could be caused by other factors such as different karyotypes and 
gene copy numbers. 
 
The absence of statistically significant changes in cell cycle gene expression between 
KE-3 p-p38δ and WT KE-3 cells was somewhat surprising as the differences in 
proliferation between these cells is so striking (Figure 4.8). The 84 genes analysed 
by the array represent a subset of human genes which are involved in the cell cycle. 
Changes in expression of cell cycle associated genes which are not included in the 
array may be responsible for the effect of p38δ and p-p38δ MAPK on KE-3 
proliferation. Furthermore it is possible that the effect of (p-)p38δ MAPK expression 
on proliferation may not be occurring at a transcriptional level but rather is a result 
of altered kinase activity. Further research into the role of p38δ MAPK signalling in 
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OESCC would benefit from the use of kinase profiling analysis. By using arrays 
which measure differences in kinase phosphorylation levels rather than expression, 
the signalling pathway responsible for the differences in proliferation between p38δ 
MAPK negative and p38δ/p-p38δ MAPK positive cells could be delineated. 
 
In this study, differentially expressed genes were defined as those with a fold change 
in expression between two groups of ≥2 and a p value of <0.05. The advantage of 
this approach is that it integrates the concepts of statistically significant differences 
in gene expression (based on p value) and a biologically meaningful difference in 
expression (fold change). However, depending on the choice of fold change 
threshold and statistical significance cut-off, alternative interpretations of the array 
data set are possible. Quantitative rt-PCR analysis of individual differentially 
expressed genes would be beneficial to validate the RT
2 Profiler PCR array gene 
expression results. Western blots or ELISA may also be performed to determine 
whether the observed differences in gene expression represent changes at the protein 
level.   
 257 
 
7.7 References 
 
1. Han, J., et al., A MAP kinase targeted by endotoxin and hyperosmolarity in 
mammalian cells. Science, 1994. 265(5173): p. 808-11. 
2. Ambrosino, C. and A.R. Nebreda, Cell cycle regulation by p38 MAP kinases. 
Biol Cell, 2001. 93(1-2): p. 47-51. 
3. Ono, K. and J. Han, The p38 signal transduction pathway: activation and 
function. Cell Signal, 2000. 12(1): p. 1-13. 
4. Molnar, A., et al., Cdc42Hs, but not Rac1, inhibits serum-stimulated cell 
cycle progression at G1/S through a mechanism requiring p38/RK. J Biol 
Chem, 1997. 272(20): p. 13229-35. 
5. Philips, A., et al., Differential effect of Rac and Cdc42 on p38 kinase activity 
and cell cycle progression of nonadherent primary mouse fibroblasts. J Biol 
Chem, 2000. 275(8): p. 5911-7. 
6. Kishi, H., et al., Osmotic shock induces G1 arrest through p53 
phosphorylation at Ser33 by activated p38MAPK without phosphorylation at 
Ser15 and Ser20. J Biol Chem, 2001. 276(42): p. 39115-22. 
7. Kim, G.Y., et al., The stress-activated protein kinases p38 alpha and JNK1 
stabilize p21(Cip1) by phosphorylation. J Biol Chem, 2002. 277(33): p. 
29792-802. 
8. Xiu, M., et al., The transcriptional repressor HBP1 is a target of the p38 
mitogen-activated protein kinase pathway in cell cycle regulation. Mol Cell 
Biol, 2003. 23(23): p. 8890-901. 
9. Casanovas, O., et al., Osmotic stress regulates the stability of cyclin D1 in a 
p38SAPK2-dependent manner. J Biol Chem, 2000. 275(45): p. 35091-7. 
10. Lavoie, J.N., et al., Cyclin D1 expression is regulated positively by the 
p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem, 
1996. 271(34): p. 20608-16. 
11. Kida, A., et al., Glycogen synthase kinase-3beta and p38 phosphorylate 
cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent 
degradation in hematopoietic cells. Oncogene, 2007. 26(46): p. 6630-40. 
12. Bulavin, D.V., et al., Initiation of a G2/M checkpoint after ultraviolet 
radiation requires p38 kinase. Nature, 2001. 411(6833): p. 102-7. 
13. Takenaka, K., T. Moriguchi, and E. Nishida, Activation of the protein kinase 
p38 in the spindle assembly checkpoint and mitotic arrest. Science, 1998. 
280(5363): p. 599-602. 
14. Llopis, A., et al., The stress-activated protein kinases p38alpha/beta and 
JNK1/2 cooperate with Chk1 to inhibit mitotic entry upon DNA replication 
arrest. Cell Cycle, 2012. 11(19): p. 3627-37. 
15. Wang, X., et al., Involvement of the MKK6-p38gamma cascade in gamma-
radiation-induced cell cycle arrest. Mol Cell Biol, 2000. 20(13): p. 4543-52. 
 258 
 
16. Hawkes, W.C. and Z. Alkan, Delayed cell cycle progression in selenoprotein 
W-depleted cells is regulated by a mitogen-activated protein kinase kinase 4-
p38/c-Jun NH2-terminal kinase-p53 pathway. J Biol Chem, 2012. 287(33): p. 
27371-9. 
17. Saha, K., et al., p38δ Regulates p53 to Control p21Cip1 Expression in 
Human Epidermal Keratinocytes. Journal of Biological Chemistry, 2014. 
18. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods, 2001. 25(4): p. 402-8. 
19. O'Callaghan, C., et al., Loss of p38delta mitogen-activated protein kinase 
expression promotes oesophageal squamous cell carcinoma proliferation, 
migration and anchorage-independent growth. Int J Oncol, 2013. 43(2): p. 
405-15. 
 
 
  
 259 
 
 
Chapter 8 
 
General Discussion 
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8.1 Discussion 
 
Interestingly, the p38 family of kinases can both positively and negatively regulate a 
host of cellular processes such as proliferation, migration and apoptosis [1]. The 
dysregulation of these normal cell functions is critical for malignant transformation 
and as a result significant roles for the p38 MAPK signalling pathway in cancer have 
previously been outlined [2]. However, these roles are generally attributed to the best 
characterised isoform, p38α MAPK. The individual contributions by the other 
isoforms, particularly p38δ MAPK, remain unclear. Depending on cell type, p38α 
MAPK can act as either a tumour promoter or a tumour suppressor [3, 4]. The 
limited information available pertaining to p38δ MAPK would appear to suggest 
similar dual roles. p38δ MAPK has been shown to promote proliferation and 
invasion in HNSCC [5]. Furthermore, it is required for the development of skin 
carcinoma and lung tumourigenesis in mice, clearly demonstrating a pro-oncogenic 
role for this isoform [6]. On the other hand, p38δ MAPK has been characterised as a 
tumour suppressor in MEFs where p38δ−/− MEFs displayed increased migration and 
impaired contact inhibition compared to WT MEFs [7]. Similarly, in melanoma cells 
and brain metastases of TNBC, introduction of p38δ MAPK expression significantly 
reduces cell proliferation [8, 9].  
 
The findings we present in this thesis support some of the studies which suggest an 
anti-tumourigenic role for p38δ MAPK. We have established that p38δ MAPK 
functions as a tumour suppressor in OESCC. The loss of p38δ MAPK expression 
which we observed in 50% of OESCC cell lines and in vivo appears to be a 
significant event which contributes to the tumourigenicity of OESCC. Importantly, 
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we have demonstrated in our studies that re-introduction of p38δ MAPK can reverse 
these oncogenic effects. Expression of p38δ MAPK reduces not only OESCC 
proliferation but also impairs cell migration and the capacity for anchorage-
independent growth. Of note, these anti-proliferative and anti-migratory effects were 
further enhanced upon expression of p-p38δ MAPK. As we observed some 
phosphorylation of p38δ MAPK in KE-3 cells transfected with WT p38δ MAPK (as 
demonstrated by ELISA analysis of specific p38δ MAPK phosphorylation), it is 
possible that activation and/or expression of p38δ MAPK is driving the anti-
tumourigenic effects observed in transfected KE-3 cells.  
 
Recent documented roles for p38δ MAPK in human diseases ranging from 
neurodegenerative disorders to diabetes is fuelling increased interest in the 
development of p38δ MAPK specific inhibitors [10]. Based on our research findings 
focusing on the identification of specific p38δ MAPK activators is also warranted. 
The PP1 and PP2A serine/threonine protein phosphatase inhibitor OA can 
specifically activate p38δ MAPK (without affecting p38α, -β, or –γ MAPKs) in 
keratinocytes [11, 12]. Attempts by our group to replicate these results in OESCC 
have to-date been unsuccessful. Based on our research findings we observed that 
activated p-p38δ MAPK (more so than simply expression of p38δ MAPK) can 
further decrease proliferation, migration and anchorage-independent growth in 
OESCC. Thus, future development of specific p38δ MAPK activators may present a 
potential future therapeutic strategy in the treatment of p38δ MAPK positive 
OESCC. Furthermore, the identification of specific p38δ MAPK activators, as well 
as inhibitors, could also afford us the opportunity to delineate novel p38δ MAPK 
functions. The lack of such compounds has to date been the main limiting factor in 
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the future studies of p38δ MAPK. This may in turn identify further diseases where 
p38δ MAPK could be a potential therapeutic target. 
 
Neoadjuvant chemotherapy, alone or in combination with chemoradiotherapy, is 
now considered the standard approach for locally advanced oesophageal cancer. 
Unfortunately, OESCC is a particularly drug-resistant disease [13]. Single-drug 
treatments yield poor response rates of 10-25%. Although the combination of 
fluoropyrimidine and platinum agents can achieve greater tumour reduction, it has 
little effect on overall survival time and recurrence is common [14, 15]. Meta-
analyses of neoadjuvant therapy trials indicate that patient response to chemotherapy 
is variable regardless of clinical stage and 60-70% of patients do not respond well to 
neoadjuvant treatments [16, 17]. Very recently, a number of biomarkers which may 
predict patient response to neoadjuvant therapy in oesophageal cancer have been 
identified by examining gene expression patterns, single nucleotide polymorphisms 
(SNPs) and microRNAs (miRNAs) (reviewed by [13]). Several gene expression 
microarray studies have highlighted different gene expression patterns which can 
discriminate between oesophageal cancer patients which respond to treatment and 
those which are resistant with a high degree of sensitivity and specificity [18-20]. 
However, while gene expression profiling for breast cancer has now translated to use 
in the clinical setting, further research is required to develop such a clinically useful 
predictive test for oesophageal cancer [21]. The association between SNPs in genes 
involved in DNA base excision repair and oesophageal cancer patient response to 
chemo- and radiotherapy has also been investigated. Particular SNPs in the XRCC1 
and ERCC1 genes have been found to be predictive of therapy response [22, 23]. As 
above, further validation studies for the predictive potential of SNPs in oesophageal 
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cancer are required. Abnormal expression patterns for microRNAa (miRNAs), short 
non-coding RNA sequences which inhibit mRNA translation, have been detected in 
oesophageal cancers [24]. Several miRNAs have been identified as having 
prognostic value in oesophageal cancer. miR-296 is of particular interest as it is 
significantly differentially expressed between treatment responsive and non-
responsive patient groups and its inhibition increases oesophageal cancer cell 
sensitivity to chemotherapy [25]. However, while clinical trials evaluating miRNA 
biomarkers in breast and ovarian carcinomas are ongoing [26], the clinical 
application of miRNAs as predictive markers in oesophageal cancer remains to be 
examined. 
 
Interestingly our research adds to the list of biomarkers making p38δ MAPK a new 
possible predictive marker for patient response to chemotherapy in OESCC. As well 
as the conventional combination of cisplatin and 5-fluorouracil (CF), we have 
outlined a greater response of OESCC to the triple combination of doxorubicin, 
cisplatin and 5-fluorouracil (ACF). Although such triple therapy is not considered as 
standard treatment, it is presently used for patients with OESCC in Japan and its 
efficacy and safety is well reported [27-29]. Thus, further investigation is warranted 
on a more global scale to determine whether ACF treatment can provide greater 
benefits for p38δ MAPK negative OESCC patients compared with CF treatment, 
particularly in terms of overall survival. Based on our results p38δ MAPK 
phenotyping of tumour tissue may prove useful in determining the optimal treatment 
strategy in individual OESCC patients.  
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Aberrant DNA methylation has previously been reported in oesophageal cancer and 
is associated with the silencing of tumour suppressors and cell cycle regulatory genes 
[30]. We detected hypermethylation of the MAPK13 promoter in three of the four 
p38δ MAPK negative cell lines examined when compared with p38δ MAPK positive 
cell lines. For the fourth cell line we examined only a portion of the CpG sites 
present in the MAPK13 promoter. Thus, is possible that these cells are also 
epigenetically regulated by hypermethylation but at a different location in the 
MAPK13 promoter. Redesigning of primers used for BSP to amplify an alternative 
region of the MAPK13 promoter could identify differential methylation of CpG sites 
in these cells. Alternatively, other methods of detecting DNA methylation are 
available, such as bisulfite melting curve analysis which would assess DNA 
methylation across the promoter region rather than at individual CpG sites [31]. 
Aberrant methylation of the MAPK13 promoter region has previously been reported 
in mesothelioma and melanoma therefore epigenetic control of p38δ MAPK is a 
likely explanation for its differential expression in OESCC [8, 32]. 
 
Presently, we are unable to definitively confirm epigenetic regulation of p38δ 
MAPK in OESCC. Epigenetic silencing of p38δ MAPK has been outlined in 
melanoma cells where 5’-aza-2’-deoxycitidine treatment induced a significant 
increase in p38δ MAPK expression [8]. Our attempts to induce p38δ MAPK 
expression in hypermethylated cells with 5’-aza-2’-deoxycitidine treatment were not 
successful mainly due to inadequate optimisation. We could not determine the 
methylation status of MAPK13 promoter sites following 5’-aza-2’-deoxycitidine 
treatment. As a result, we cannot comment on whether p38δ MAPK expression 
remained unchanged because 5’aza-2’-deoxycitidine treatment was not effective in 
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demethylating DNA or because the observed DNA methylation is not causing 
epigenetic regulation. At this juncture further experimentation is warranted to 
confirm differential epigenetic control of p38δ MAPK expression in OESCC. 
Importantly, research of this nature this could have significant consequences in the 
clinical setting. DNA methylation biomarkers are increasingly considered as viable 
tools for the early detection, diagnosis and prognosis of cancer [33]. Comparison of 
MAPK13 promoter methylation in normal oesophageal, primary tumour and 
metastatic tissue could provide interesting insights into the potential usefulness of 
aberrant MAPK13 promoter methylation analysis as a biomarker for OESCC.  
Presently, 5’-aza’2-deoxycitidine has proven effective in the treatment of leukaemia 
and myelodyplastic syndromes. Therefore, induction of p38δ MAPK expression 
using demethylating agents should be evaluated as a potential treatment strategy in 
p38δ MAPK negative OESCC.   
 
As the yeast p38 MAPK homolog HOGI is an important regulator of the cell cycle, a 
role for p38 MAPK signalling in cell cycle control has been extensively studied [34]. 
p38α MAPK and to an extent p38β and –γ MAPKs, have clearly defined roles in 
regulating cell cycle progression. However, a role(s) for p38δ MAPK is clearly 
lacking. Given the significant pro-proliferative effect that loss of p38δ MAPK has in 
OESCC  it may be assumed that p38δ MAPK is a negative regulator of the cell cycle 
[35-37]. The difference in human cell cycle gene expression that we observed 
between p38δ MAPK negative and positive cell lines provides a number of potential 
mechanisms by which loss of p38δ promotes cell cycle progression and proliferation. 
Interestingly, increased expression of cyclins, namely cyclin D2, E1 and G1 was 
detected in p38δ MAPK negative cells when compared with OESCC cells which 
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endogenously express p38δ MAPK. As p38α MAPK is a known negative regulator 
of cyclin D1 expression, in a similar fashion, expression of p38δ MAPK may 
decrease the expression of cyclin D2, E1 and/or G1 [38]. Therefore lack of this 
regulation in p38δ MAPK negative cells may be responsible for driving the 
increased proliferation of these cells. Another possible explanation for increased 
OESCC proliferation in the absence of p38δ MAPK expression is the 
downregulation of cyclin-dependent kinase inhibitors. Previous reports have 
identified specific roles for p38δ MAPK in controlling p21 expression by 
upregulating either p53 expression or activation [36, 37]. We observed a significant 
decrease in p21 expression in p38δ MAPK negative cells and although no 
corresponding reduction in p53 expression was detected, decreased p53 
phosphorylation in the absence of p38δ MAPK could be responsible. Although 
further experimentation is clearly needed to define the mechanisms involved in a role 
for p38δ MAPK in OESCC cell cycle control, our research findings have alluded to 
some potential pathways.  
 
Interestingly, and somewhat surprisingly, we found no differences in cell cycle gene 
expression between p38δ MAPK negative and transfected p-p38δ MAPK positive 
cells, despite the significant differences in their rates of proliferation. Thus, it may be 
possible that p-p38δ MAPK is exerting its effects on OESCC cells at a kinase rather 
than a transcriptional level. This assumption is also based on our ELISA evidence (in 
Chapter 4) which demonstrates that WT p38δ MAPK is phosphorylated when 
transfected into KE-3 cells. Future research would benefit from examining the signal 
transduction pathways activated by introduction of p38δ and p-p38δ MAPK 
expression using peptide microarrays (Pamgene, Hertogenbosch, The Netherlands). 
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These arrays facilitate kinome analysis in cell lysates by immoblilizing 144 peptides 
derived from known human kinase phosphorylation sites on a microarray. Peptide 
phosphorylation by cell lysates is measured in real-time by a fluorescently labelled 
anti-phosphotyrosine antibody [39]. Using these arrays to compare the kinomes of 
p38δ MAPK negative, p38δ MAPK positive and p-p38δ MAPK positive cells may 
prove worthwhile in contributing to our current understanding of p38δ MAPK 
signalling and further advance our knowledge of its specific roles in OESCC. 
 
While our findings to date pertain to the role(s) of p38δ MAPK in OESCC, it is 
important to note that they may be also translatable to other cancer types. We have 
previously reported that renal carcinoma cells fail to express p38δ MAPK [40] and 
we have also observed loss of p38δ MAPK expression in liver, prostate and lung 
carcinomas (Figure A.1). Thus, it is possible that loss of p38δ MAPK is also 
promoting tumourigenicity in these cancers. However, of note p38α MAPK has been 
characterised as both a tumour promoter and a tumour suppressor, depending on the 
cell type [3-5, 41]. Experimental evidence to date provided by us and others suggests 
that p38δ MAPK function appears to be similarly context-dependent. Thus, whether 
p38δ MAPK plays a pro- or anti-oncogenic role may be cancer type specific.  
 
In final summation of our work, loss of p38δ MAPK expression, possibly due to 
MAPK13 promoter methylation, confers a selective advantage in OESCC 
progression. This may possibly be related to increased cyclin expression and/or 
downregulation of cyclin-dependent kinase inhibitors. The increased tumourigenicity 
observed in p38δ MAPK negative OESCC, combined with reduced sensitivity to 
conventional chemotherapy (CF), results in a highly aggressive, treatment resistant 
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disease. Interestingly, the absence of p38δ MAPK may potentially be an important 
predictor of increased sensitivity to the triple chemotherapeutic combination of ACF. 
Introduction of p38δ MAPK, and especially p-p38δ MAPK in OESCC cells (which 
lack endogenous expression) has significant anti-tumourigenic effects. It is 
unfortunate that to date there are no pharmacological agents currently available 
which specifically activate p38δ MAPK. Future development of such activators 
could potentially be an important therapeutic strategy in the treatment of p38δ 
positive OESCC. Importantly, our research findings presented in this thesis may also 
be translatable to other cancer types which are also p38δ MAPK negative. Thus, 
p38δ MAPK may therefore in the near future be considered as a new potential 
therapeutic target not only for OESCC but also for a host of other malignancies. 
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8.2 Future directions 
 
The role of p38δ MAPK in the cell cycle remains unclear. It would be beneficial to 
delineate the point in the cell cycle at which p38δ and p-p38δ MAPK is exerting an 
effect. This may provide additional potential targets for the treatment of OESCC. 
Future studies exploring the function of p38δ MAPK in the cell cycle should focus 
on validating the data presented in this thesis but also examine cell cycle components 
and pathways not included in our analysis. Assessment of the signal transduction 
pathways activated by p38δ and p-p38δ MAPK expression using peptide microarrays 
should also be considered.  
 
This thesis presents opportunities for further research in the continuation of the 
studies outlined in Chapters 6 and 7. Future experimentation arising from this thesis 
should focus initially on generating further knowledge in these areas. Additional 
research is warranted to create a greater understanding of the epigenetic mechanisms 
controlling p38δ MAPK expression in OESCC. Analysis of p38δ MAPK 
methylation in OESCC tumour tissue as well as re-establishment of p38δ MAPK 
expression in OESCC cell lines through treatment with epigenetic drugs would 
provide valuable information regarding the epigenetic regulation of this isoform in 
OESCC. Subsequent analysis of the effects on cell proliferation and 
chemotherapeutic drug sensitivity could provide a basis for the consideration of 
epigenetic drugs as a treatment option for p38δ MAPK negative OESCC. 
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Opportunities for translational research also arise from the findings presented in this 
thesis. The potential for p38δ MAPK to act as a predictive biomarker for treatment 
response in OESCC should be explored further. The comparison of p38δ MAPK 
expression in OESCC patient tumour samples with treatment response and outcome 
data would be advantageous for the continuation of this research. The Cancer 
Genome Atlas (TCGA) currently contains exome, SNP, methylation, mRNA, 
miRNA and clinical data for 185 oesophageal carcinoma samples [42, 43]. Analysis 
of the data available on TCGA could provide useful information relating to p38δ 
MAPK methylation and expression in OESCC as well as providing further insights 
into the prospective use of p38δ MAPK as a predictor of patient response. 
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pcDNA3-MKK6b(E) 
     1 GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATG  
 
    61 CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG  
 
   121 CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGC  
 
   181 TTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT  
 
   241 GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATA  
 
   301 TGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC  
 
   361 CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC  
 
   421 ATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT  
 
   481 ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT  
 
   541 ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA  
 
   601 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG  
 
   661 ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC  
 
   721 AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCG  
 
   781 GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA  
 
   841 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTGGCACG  
 
   901 AGGAGCTTTTAGCTGCCAGCCCTGGCCCATCATGTAGCTGCAGCACAGCCTTCCCTAACG  
        >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
        MKK6b(E) 
 
   961 TTGCAACTGGGGGAAAAATCACTTTCCAGTCTGTTTTGCAAGGTGTGCATTTCCATCTTG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1021 ATTCCCTGAAAGTCCATCTGCTGCATCGGTCAAGAGAAACTCCACTTGCATGAAGATTGC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1081 ACGCCTGCAGCTTGCATCTTTGTTGCAAAACTAGCTACAGAAGAGAAGCAAGGCAAAGTC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1141 TTTTGTGCTCCCCTCCCCCATCAAAGGAAAGGGGAAAATGTCTCAGTCGAAAGGCAAGAA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1201 GCGAAACCCTGGCCTTAAAATTCCAAAAGAAGCATTTGAACAACCTCAGACCAGTTCCAC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
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 1261 ACCACCTCGAGATTTAGACTCCAAGGCTTGCATTTCTATTGGAAATCAGAACTTTGAGGT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1321 GAAGGCAGATGACCTGGAGCCTATAATGGAACTGGGACGAGGTGCGTACGGGGTGGTGGA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1381 GAAGATGCGGCACGTGCCCAGCGGGCAGATCATGGCAGTGAAGCGGATCCGAGCCACAGT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1441 AAATAGCCAGGAACAGAAACGGCTACTGATGGATTTGGATATTTCCATGAGGACGGTGGA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1501 CTGTCCATTCACTGTCACCTTTTATGGCGCACTGTTTCGGGAGGGTGATGTGTGGATCTG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1561 CATGGAGCTCATGGATACATCACTAGATAAATTCTACAAACAAGTTATTGATAAAGGCCA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1621 GACAATTCCAGAGGACATCTTAGGGAAAATAGCAGTTTCTATTGTAAAAGCATTAGAACA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1681 TTTACATAGTAAGCTGTCTGTCATTCACAGAGACGTCAAGCCTTCTAATGTACTCATCAA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1741 TGCTCTCGGTCAAGTGAAGATGTGCGATTTTGGAATCAGTGGCTATTTGGTGGACGAAGT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1801 TGCTAAAGAAATTGATGCAGGTTGCAAACCATACATGGCCCCTGAAAGAATAAACCCAGA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1861 GCTCAACCAGAAGGGATACAGTGTGAAGTCTGACATTTGGAGTCTGGGCATCACGATGAT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1921 TGAGTTGGCCATCCTTCGATTTCCCTATGATTCATGGGGAACTCCATTTCAGCAGCTCAA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1981 ACAGGTGGTAGAGGAGCCATCGCCACAACTCCCAGCAGACAAGTTCTCTGCAGAGTTTGT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2041 TGACTTTACCTCACAGTGCTTAAAGAAGAATTCCAAAGAACGGCCTACATACCCAGAGCT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
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  2101 AATGCAACATCCATTTTTCACCCTACATGAATCCAAAGGAACAGATGTGGCATCTTTTGT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2161 AAAACTGATTCTTGGAGACTAAAAAGCAGTGGACTTAATCGGTTGACCCTACTGTGGATT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2221 GGTGGGTTTCGGGGTGAAGCAGGTTCACTACAGCATCAATAGAAAGTCATCTTTGAGATA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2281 ATTTAACCCTGCCTCTCAGAGGGTTTTCTCTCCCAATTTTCTTTTTACTCCCCCTCTTAA  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2341 GGGGGCCTTGGAATCTATAGTATAGAATGAACTGTCTAGAGGGCCCTATTCTATAGTGTC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2401 ACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTG  
 
  2461 TTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTT  
 
  2521 CCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGG  
 
  2581 GTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGG  
 
  2641 ATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATC  
 
  2701 CCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGA  
 
  2761 CCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCG  
 
  2821 CCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGAT  
 
  2881 TTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTG  
 
  2941 GGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATA  
 
  3001 GTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATT  
 
  3061 TATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAAT  
 
  3121 TTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTC  
 
  3181 CCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAA  
 
  3241 AGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAA  
 
  3301 CCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATT  
 
  3361 CTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCT  
 
  3421 CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGC  
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  3481 TCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTC  
 
  3541 GCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTAT  
 
  3601 TCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGT  
 
  3661 CAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAAC  
 
  3721 TGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTG  
 
  3781 TGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGC  
 
  3841 AGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAA  
 
  3901 TGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATC  
 
  3961 GCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACG  
 
  4021 AAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCG  
 
  4081 ACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAA  
 
  4141 ATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGG  
 
  4201 ACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCT  
 
  4261 TCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTC  
 
  4321 TTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAA  
 
  4381 CCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAAT  
 
  4441 CGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTT  
 
  4501 CGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCAC  
 
  4561 AAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCAT  
 
  4621 CAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATG  
 
  4681 GTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGC  
 
  4741 CGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGC  
 
  4801 GTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAAT  
 
  4861 CGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCAC  
 
  4921 TGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGT  
 
  4981 AATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCA  
 
  5041 GCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCC  
 
  5101 CCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACT  
 
 279 
 
  5161 ATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT  
 
  5221 GCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATG  
 
  5281 CTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCA  
 
  5341 CGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAA  
 
  5401 CCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC  
 
  5461 GAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAG  
 
  5521 AAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG  
 
  5581 TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCA  
 
  5641 GCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTC  
 
  5701 TGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAG  
 
  5761 GATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATA  
 
  5821 TGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGAT  
 
  5881 CTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACG  
 
  5941 GGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGC  
 
  6001 TCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGC  
 
  6061 AACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTC  
 
  6121 GCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTC  
 
  6181 GTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATC  
 
  6241 CCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAA  
 
  6301 GTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCAT  
 
  6361 GCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATA  
 
  6421 GTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACA  
 
  6481 TAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAG  
 
  6541 GATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTC  
 
  6601 AGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGC  
 
  6661 AAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATA  
 
  6721 TTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTA  
 
  6781 GAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC  
 
 280 
 
pcDNA3-FLAG-p38δ 
     1 GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATG  
 
    61 CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG  
 
   121 CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGC  
 
   181 TTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT  
 
   241 GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATA  
 
   301 TGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC  
 
   361 CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC  
 
   421 ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT  
 
   481 ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT  
 
   541 ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA  
 
   601 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG  
 
   661 ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC  
 
   721 AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCG  
 
   781 GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA  
 
   841 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGC  
 
   901 GTTTAAACTTAAGCTTCCATGGACTACAAGGACGACGATGACAAGATGAGCCTCATCCGG  
                            >>>>>>>>>>>>>>>>>>>>>>>> 
                            FLAG 
                                                    >>>>>>>>>>>>>>> 
                                                    p38δ MAPK 
 
   961 AAAAAGGGCTTCTACAAGCAGGACGTCAACAAGACAGCCTGGGAGCTGCCCAAGACCTAC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1021 GTGTCCCCGACGCACGTCGGCAGCGGGGCCTATGGCTCCGTGTGCTCGGCCATCGACAAG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1081 CGGTCAGGGGAGAAGGTGGCCATCAAGAAGCTGAGCCGACCCTTTCAGTCCGAGATCTTC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1141 GCCAAGCGCGCCTACCGGGAGCTGCTGCTGCTGAAGCACATGCAGCATGAGAACGTCATT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1201 GGGCTCCTGGATGTCTTCACCCCAGCCTCCTCCCTGCGCAACTTCTATGACTTCTACCTG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
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  1261 GTGATGCCCTTCATGCAGACGGATCTGCAGAAGATCATGGGGATGGAGTTCAGTGAGGAG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1321 AAGATCCAGTACCTGGTGTATCAGATGCTCAAAGGCCTTAAGTACATCCACTCTGCTGGG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1381 GTCGTGCACAGGGACCTGAAGCCAGGCAACCTGGCTGTGAATGAGGACTGTGAACTGAAG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1441 ATTCTGGATTTTGGGCTGGCGCGACATGCAGACGCCGAGATGACTGGCTACGTGGTGACC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1501 CGCTGGTACCGAGCCCCCGAGGTGATCCTCAGCTGGATGCACTACAACCAGACAGTGGAC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1561 ATCTGGTCTGTGGGCTGTATCATGGCAGAGATGCTGACAGGGAAAACTCTGTTCAAGGGG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1621 AAAGATTACCTGGACCAGCTGACCCAGATCCTGAAAGTGACCGGGGTGCCTGGCACGGAG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1681 TTTGTGCAGAAGCTGAACGACAAAGCGGCCAAATCCTACATCCAGTCCCTGCCACAGACC  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1741 CCCAGGAAGGATTTCACTCAGCTGTTCCCACGGGCCAGCCCCCAGGCTGCGGACCTGCTG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1801 GAGAAGATGCTGGAGCTAGACGTGGACAAGCGCCTGACGGCCGCGCAGGCCCTCACCCAT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1861 CCCTTCTTTGAACCCTTCCGGGACCCTGAGGAAGAGACGGAGGCCCAGCAGCCGTTTGAT  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1921 GATTCCTTAGAACACGAGAAACTCACAGTGGATGAATGGAAGCAGCACATCTACAAGGAG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  1981 ATTGTGAACTTCAGCCCCATTGCCCGGAAGGACTCACGGCGACGAAGTGGCATGAAGCTG  
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2041 TAATAAGAATTCGGATCCACTAGTCCAGTGTGGTGGAATTCTGCAGATATCCAGCACAGT  
       >>> 
       p38δ MAPK 
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  2101 GGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTT  
 
  2161 CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTG  
 
  2221 CCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGT  
 
  2281 GTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACA  
 
  2341 ATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCT  
 
  2401 GGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGG  
 
  2461 TGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTT  
 
  2521 TCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGCA  
 
  2581 TCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGG  
 
  2641 GTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG  
 
  2701 AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCT  
 
  2761 CGGTCTATTCTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATG  
 
  2821 AGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTG  
 
  2881 TGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGT  
 
  2941 CAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGC  
 
  3001 ATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTC  
 
  3061 CGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGG  
 
  3121 CCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCC  
 
  3181 TAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGA  
 
  3241 CAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCG  
 
  3301 CTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATG  
 
  3361 CCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGT  
 
  3421 CCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGG  
 
  3481 GCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTAT  
 
  3541 TGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTAT  
 
  3601 CCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCG  
 
  3661 ACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCG  
 
  3721 ATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGC  
 283 
 
 
  3781 TCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGC  
 
  3841 CGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTG  
 
  3901 TGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCG  
 
  3961 GCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCA  
 
  4021 TCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGAC  
 
  4081 CGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGA  
 
  4141 AAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGA  
 
  4201 TCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAA  
 
  4261 ATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTG  
 
  4321 TGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTA  
 
  4381 GAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAAT  
 
  4441 TCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAG  
 
  4501 CTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTG  
 
  4561 CCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTC  
 
  4621 TTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATC  
 
  4681 AGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAA  
 
  4741 CATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTT  
 
  4801 TTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTG  
 
  4861 GCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCG  
 
  4921 CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG  
 
  4981 CGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTC  
 
  5041 CAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAA  
 
  5101 CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGG  
 
  5161 TAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCC  
 
  5221 TAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC  
 
  5281 CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGG  
 
  5341 TTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTT  
 
  5401 GATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGT  
 284 
 
 
  5461 CATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA  
 
  5521 ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA  
 
  5581 GGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGT  
 
  5641 GTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCG  
 
  5701 AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGA  
 
  5761 GCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA  
 
  5821 AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGG  
 
  5881 CATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATC  
 
  5941 AAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCC  
 
  6001 GATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCA  
 
  6061 TAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAAC  
 
  6121 CAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACG  
 
  6181 GGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTC  
 
  6241 GGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCG  
 
  6301 TGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAAC  
 
  6361 AGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCAT  
 
  6421 ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATA  
 
  6481 CATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAA  
 
  6541 AGTGCCACCTGACGTC  
  
 285 
 
pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ 
     1 GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATG 
 
    61 CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG 
 
   121 CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGC 
 
   181 TTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT 
 
   241 GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATA  
 
   301 TGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC 
 
   361 CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC 
 
   421 ATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT 
 
   481 ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT 
 
   541 ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA 
 
   601 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG 
 
   661 ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC 
 
   721 AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCG 
 
   781 GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA 
 
   841 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTGGCACG 
                                                                  > 
                                                            MKK6b(E) 
 
   901 AGGAGCTTTTAGCTGCCAGCCCTGGCCCATCATGTAGCTGCAGCACAGCCTTCCCTAACG 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
   961 TTGCAACTGGGGGAAAAATCACTTTCCAGTCTGTTTTGCAAGGTGTGCATTTCCATCTTG 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1021 ATTCCCTGAAAGTCCATCTGCTGCATCGGTCAAGAGAAACTCCACTTGCATGAAGATTGC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1081 ACGCCTGCAGCTTGCATCTTTGTTGCAAAACTAGCTACAGAAGAGAAGCAAGGCAAAGTC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1141 TTTTGTGCTCCCCTCCCCCATCAAAGGAAAGGGGAAAATGTCTCAGTCGAAAGGCAAGAA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1201 GCGAAACCCTGGCCTTAAAATTCCAAAAGAAGCATTTGAACAACCTCAGACCAGTTCCAC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
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  1261 ACCACCTCGAGATTTAGACTCCAAGGCTTGCATTTCTATTGGAAATCAGAACTTTGAGGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1321 GAAGGCAGATGACCTGGAGCCTATAATGGAACTGGGACGAGGTGCGTACGGGGTGGTGGA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1381 GAAGATGCGGCACGTGCCCAGCGGGCAGATCATGGCAGTGAAGCGGATCCGAGCCACAGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1441 AAATAGCCAGGAACAGAAACGGCTACTGATGGATTTGGATATTTCCATGAGGACGGTGGA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1501 CTGTCCATTCACTGTCACCTTTTATGGCGCACTGTTTCGGGAGGGTGATGTGTGGATCTG 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1561 CATGGAGCTCATGGATACATCACTAGATAAATTCTACAAACAAGTTATTGATAAAGGCCA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1621 GACAATTCCAGAGGACATCTTAGGGAAAATAGCAGTTTCTATTGTAAAAGCATTAGAACA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1681 TTTACATAGTAAGCTGTCTGTCATTCACAGAGACGTCAAGCCTTCTAATGTACTCATCAA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1741 TGCTCTCGGTCAAGTGAAGATGTGCGATTTTGGAATCAGTGGCTATTTGGTGGACGAAGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1801 TGCTAAAGAAATTGATGCAGGTTGCAAACCATACATGGCCCCTGAAAGAATAAACCCAGA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1861 GCTCAACCAGAAGGGATACAGTGTGAAGTCTGACATTTGGAGTCTGGGCATCACGATGAT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1921 TGAGTTGGCCATCCTTCGATTTCCCTATGATTCATGGGGAACTCCATTTCAGCAGCTCAA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  1981 ACAGGTGGTAGAGGAGCCATCGCCACAACTCCCAGCAGACAAGTTCTCTGCAGAGTTTGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2041 TGACTTTACCTCACAGTGCTTAAAGAAGAATTCCAAAGAACGGCCTACATACCCAGAGCT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
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  2101 AATGCAACATCCATTTTTCACCCTACATGAATCCAAAGGAACAGATGTGGCATCTTTTGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       MKK6b(E) 
 
  2161 AAAACTGATTCTTGGAAAATTTAAAGGCGAGGGCGAGGGCGAGGGCGAGGGCGAGATGGA 
       >>>>>>>>>>>>>>>>>>>>>>                                    >> 
       MKK6b(E)                                                FLAG 
                                >>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
                                (Gly-Glu)5 
 
  2221 CTACAAGGACGACGATGACAAGATGAGCCTCATCCGGAAAAAGGGCTTCTACAAGCAGGA 
       >>>>>>>>>>>>>>>>>>>>>> 
       FLAG 
                             >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
                             p38δ MAPK 
 
  2281 CGTCAACAAGACAGCCTGGGAGCTGCCCAAGACCTACGTGTCCCCGACGCACGTCGGCAG 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2341 CGGGGCCTATGGCTCCGTGTGCTCGGCCATCGACAAGCGGTCAGGGGAGAAGGTGGCCAT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2401 CAAGAAGCTGAGCCGACCCTTTCAGTCCGAGATCTTCGCCAAGCGCGCCTACCGGGAGCT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2461 GCTGCTGCTGAAGCACATGCAGCATGAGAACGTCATTGGGCTCCTGGATGTCTTCACCCC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2521 AGCCTCCTCCCTGCGCAACTTCTATGACTTCTACCTGGTGATGCCCTTCATGCAGACGGA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2581 TCTGCAGAAGATCATGGGGATGGAGTTCAGTGAGGAGAAGATCCAGTACCTGGTGTATCA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2641 GATGCTCAAAGGCCTTAAGTACATCCACTCTGCTGGGGTCGTGCACAGGGACCTGAAGCC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2701 AGGCAACCTGGCTGTGAATGAGGACTGTGAACTGAAGATTCTGGATTTTGGGCTGGCGCG 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2761 ACATGCAGACGCCGAGATGACTGGCTACGTGGTGACCCGCTGGTACCGAGCCCCCGAGGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2821 GATCCTCAGCTGGATGCACTACAACCAGACAGTGGACATCTGGTCTGTGGGCTGTATCAT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
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  2881 GGCAGAGATGCTGACAGGGAAAACTCTGTTCAAGGGGAAAGATTACCTGGACCAGCTGAC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  2941 CCAGATCCTGAAAGTGACCGGGGTGCCTGGCACGGAGTTTGTGCAGAAGCTGAACGACAA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3001 AGCGGCCAAATCCTACATCCAGTCCCTGCCACAGACCCCCAGGAAGGATTTCACTCAGCT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3061 GTTCCCACGGGCCAGCCCCCAGGCTGCGGACCTGCTGGAGAAGATGCTGGAGCTAGACGT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3121 GGACAAGCGCCTGACGGCCGCGCAGGCCCTCACCCATCCCTTCTTTGAACCCTTCCGGGA 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3181 CCCTGAGGAAGAGACGGAGGCCCAGCAGCCGTTTGATGATTCCTTAGAACACGAGAAACT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3241 CACAGTGGATGAATGGAAGCAGCACATCTACAAGGAGATTGTGAACTTCAGCCCCATTGC 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3301 CCGGAAGGACTCACGGCGACGAAGTGGCATGAAGCTGTAATAATTTAAATCAGTGGACTT 
       >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 
       p38δ MAPK 
 
  3361 AATCGGTTGACCCTACTGTGGATTGGTGGGTTTCGGGGTGAAGCAGGTTCACTACAGCAT 
 
  3421 CAATAGAAAGTCATCTTTGAGATAATTTAACCCTGCCTCTCAGAGGGTTTTCTCTCCCAA 
 
  3481 TTTTCTTTTTACTCCCCCTCTTAAGGGGGCCTTGGAATCTATAGTATAGAATGAACTGTC 
 
  3541 TAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTG 
 
  3601 TGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGG 
 
  3661 AAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGA 
 
  3721 GTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGG 
 
  3781 AAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAA 
 
  3841 CCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGG 
 
  3901 GTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTT 
 
  3961 TCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATC 
 
  4021 GGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTG 
 289 
 
 
  4081 ATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGA 
 
  4141 CGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACC 
 
  4201 CTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAA 
 
  4261 AAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTT 
 
  4321 AGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCA 
 
  4381 ATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAA 
 
  4441 GCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCC 
 
  4501 TAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATG 
 
  4561 CAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTG 
 
  4621 GAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATC 
 
  4681 AAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTC 
 
  4741 CGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCT  
 
  4801 CTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCG  
 
  4861 ACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCA 
 
  4921 CGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGC 
 
  4981 TGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGA 
 
  5041 AAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCC 
 
  5101 CATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTC 
 
  5161 TTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCG 
 
  5221 CCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCT 
 
  5281 GCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGC 
 
  5341 TGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGC 
 
  5401 TTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGC 
 
  5461 AGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGA 
 
  5521 AATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTT 
 
  5581 CTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCG 
 
  5641 CGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGG 
 
  5701 TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTC 
 290 
 
 
  5761 TAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTC 
 
  5821 TAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCT 
 
  5881 CACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATG 
 
  5941 AGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCT 
 
  6001 GTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGG 
 
  6061 GCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC 
 
  6121 GGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGG 
 
  6181 AAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT 
 
  6241 GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCA 
 
  6301 GAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCT 
 
  6361 CGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTC 
 
  6421 GGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGT 
 
  6481 TCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATC 
 
  6541 CGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC 
 
  6601 CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG 
 
  6661 GTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCC 
 
  6721 AGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAG 
 
  6781 CGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA 
 
  6841 TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGAT 
 
  6901 TTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAG 
 
  6961 TTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAAT 
 
  7021 CAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCC 
 
  7081 CGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGAT 
 
  7141 ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAG 
 
  7201 GGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTG 
 
  7261 CCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC 
 
  7321 TACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCA 
 
  7381 ACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGG 
 291 
 
 
  7441 TCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC 
 
  7501 ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTA 
 
  7561 CTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTC 
 
  7621 AATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACG 
 
  7681 TTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACC 
 
  7741 CACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGC 
 
  7801 AAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAAT 
 
  7861 ACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAG 
 
  7921 CGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCC 
 
  7981 CCGAAAAGTGCCACCTGACGTC 
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p38𝛿 mitogen activated protein kinase (MAPK) is a unique stress responsive protein kinase. While the p38 MAPK family as a
whole has been implicated in a wide variety of biological processes, a specific role for p38𝛿 MAPK in cellular signalling and its
contribution to both physiological and pathological conditions are presently lacking. Recent emerging evidence, however, provides
some insights into specific p38𝛿MAPK signalling. Importantly, these studies have helped to highlight functional similarities as well
as differences between p38𝛿MAPK and the othermembers of the p38MAPK family of kinases. In this reviewwe discuss the current
understanding of the molecular mechanisms underlying p38𝛿 MAPK activity. We outline a role for p38𝛿 MAPK in important
cellular processes such as differentiation and apoptosis as well as pathological conditions such as neurodegenerative disorders,
diabetes, and inflammatory disease. Interestingly, disparate roles for p38𝛿MAPK in tumour development have also recently been
reported. Thus, we consider evidence which characterises p38𝛿 MAPK as both a tumour promoter and a tumour suppressor. In
summary, while our knowledge of p38𝛿MAPK has progressed somewhat since its identification in 1997, our understanding of this
particular isoform in many cellular processes still strikingly lags behind that of its counterparts.
1. p38 Isoform Evolution
The first and now archetypal member of the p38 MAPK fam-
ily, p38𝛼 MAPK, was identified by four independent groups
in 1994. It was isolated as a 38 kDa protein rapidly tyrosine
phosphorylated in response to lipopolysaccharide stimula-
tion [1], as a molecule that binds pyridinyl-imidazole drugs
which inhibit the synthesis of proinflammatory cytokines
[2] and as an activator of MAPK activated protein kinase 2
(MAPKAP-K2/MK2) and small heat shock proteins in cells
stimulated with heat shock or interleukin- (IL-) 1 [3, 4].
This was followed by the subsequent identification of p38𝛽
MAPK in the same year, p38𝛾 MAPK in 1996, and lastly
p38𝛿 MAPK in 1997 [5–9]. The product of the S. cerevisiae
HOG1 gene, an important component of osmoregulation
and the cell cycle, was found to be a homologue of p38
MAPK [10]. This conservation from yeast to mammals is
significant as it indicates that the p38 family is responsible
for critical cellular processes. A study of the evolutionary
history of MAPKs suggests that each p38 MAPK family
member evolved from a single ancestor. In fact it appears
that MAPK12 (p38𝛾) arose from a tandem duplication of
MAPK11 (p38𝛽) on chromosome 22 while MAPK14 (p38𝛼)
and MAPK13 (p38𝛿) subsequently resulted from a single
segmental duplication of the MAPK11-MAPK12 gene unit on
chromosome 6 [11]. These gene duplications appear to have
occurred before the species separation of nematodes but after
the species separation of arthropods. Interestingly, unlike
the other p38 isoforms, MAPK13 has not been identified
in teleosts [11]. This indicates that a MAPK13 gene deletion
event may have occurred subsequent to gene duplication in
the evolution of these species. Duplicated genes are generally
assumed to be functionally redundant at the time of origin
and are eventually silenced. The evolutionary preservation of
the four p38 MAPK isoforms therefore suggests functional
differentiation of the individual family members.Thus, while
the majority of research to date has focused on p38𝛼 and
p38𝛽 MAPKs, each isoform is an important kinase in its
own right with distinct cellular functions. This review aims
to highlight components of the previously neglected p38𝛿
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MAPK signalling pathway and emphasises recent progress
in our understanding of p38𝛿MAPK involvement in diverse
physiological as well as pathological processes.
The use of pyridinyl-imidazole inhibitors has largely
driven the advancement in our understanding of p38𝛼 and
p38𝛽 MAPK signalling, functions, and substrates. Both
p38𝛼 and p38𝛽 MAPK are highly sensitive to inhibition by
SB203580, SB202190, andnewer compounds such as L-167307
[2, 5, 12]. In contrast, the observation that p38𝛿 MAPK is
insensitive to inhibition by pyridinyl-imidazole compounds
has hindered its study in cellular events [7, 9].The differential
sensitivity to these drugs can be attributed to amino acid
sequence variability at the ATP binding pocket where these
compounds bind competitively, facilitated by interactions
with nearby amino acids. Thr106 of p38𝛼 and p38𝛽 MAPK
has been identified as the major determinant for imidazole
inhibitor specificity as it orientates the drug to interact with
His107 and Leu108 thereby preventing ATP binding [13]. The
equivalent residue in p38𝛿 MAPK is a methionine (Met),
the large side chain of which prevents binding of these
inhibitors. In fact, substitution ofMet106 in p38𝛿MAPKwith
Thr was found to confer some sensitivity to inhibition by
SB203580 [14]. Conversely, p38𝛼 MAPK mutants in which
Thr106 is replaced with Met displayed reduced sensitivity to
inhibition by SB203580 [15]. It is unfortunate that no potent
p38𝛿 MAPK specific inhibitor has been identified to date.
Although the diaryl urea compound BIRB796 allosterically
inhibits p38𝛿 MAPK at high concentrations, it is also a
powerful inhibitor of p38𝛼, -𝛽, and -𝛾 MAPK [16]. While
varying the concentration of BIRB796 and combining it with
SB203580 may be of some use in identifying p38𝛿 MAPK
specific signalling pathways, the possible influence of the
other p38 MAPK isoforms, in particular p38𝛾 MAPK, must
be considered when interpreting any results.
2. p38𝛿MAPK Expression and Activation
Unsurprisingly, p38𝛿 MAPK shares highly similar protein
sequences with the other p38 MAPK isoforms. It displays
61%, 59%, and 65% amino acid identity to p38𝛼, -𝛽, and
-𝛾MAPKs, respectively [7]. Differences in sequence between
p38𝛿MAPKand the other p38MAPK familymembers can be
observed in the ATP binding pocket. This has consequences
for inhibitor sensitivity and contributes to substrate speci-
ficity. On the other hand, the greatest sequence similarities
lie in the highly conserved kinase domains, where the four
isoforms share >90% amino acid identity [17]. Within kinase
subdomain VIII (of XI), p38𝛿 MAPK possesses a TGY
dual phosphorylation motif which is the hallmark of p38
MAPKs and is conserved among all known mammalian p38
isoforms [7–9, 18]. p38𝛿 MAPK has a distinct distribution
profile in human tissue that is relatively limited compared
to that of p38𝛼 and p38𝛽 MAPK isoforms which are largely
ubiquitously expressed [8]. High levels of p38𝛿 mRNA have
been detected in endocrine tissues such as salivary, pituitary,
prostate, and adrenal glands, while more modest levels are
expressed in the stomach, colon, trachea, pancreas, skin,
kidney, and lung [8]. This differential expression in different
cell and tissue types is indicative of a specific biological effect
of p38𝛿 MAPK activation in these cell types, distinct from
that of the other p38 family members.
The murine p38𝛿 MAPK amino acid sequence is 92%
identical to the human sequence and the adultmouse displays
a broadly similar pattern of p38𝛿 MAPK expression to that
seen in human tissue, that is, lung, testis, kidney, and gut
epithelium [18]. Murine p38𝛿 MAPK expression varies at
different stages in the developing mouse embryo. At 9.5 days
it is primarily expressed in the developing gut and septum
transversum, while by 15.5 days its expression expands to
most developing epithelia [18].This suggests that p38𝛿MAPK
has a role in embryonic development. However, knock-out of
p38𝛿MAPK results in mice which are both viable and fertile
and exhibit a normal phenotype [19]. Moreover, while p38𝛽-
and p38𝛾-null mice as well as p38𝛾/p38𝛿 double knockout
(KO) mice are also phenotypically normal [19, 20], genetic
ablation of p38𝛼 MAPK is embryonic lethal at day 10.5–11.5
[21]. Functional redundancy among the p38 isoforms is a
likely explanation with p38𝛼, -𝛽, or -𝛾 compensating for the
loss of p38𝛿 MAPK activity during development. However,
it appears that p38𝛼 MAPK plays a critical role in early
development where its loss cannot be overcome.
p38𝛼, -𝛽, and -𝛾 MAPK isoforms are activated by
alterations in the physical and chemical properties of the
extracellular environment with diverse triggers including
environmental stress signals, inflammatory cytokines, and
mitogenic stimuli [1, 5, 6, 22]. Using transiently expressed
epitope-tagged p38𝛿 MAPK, a similar activation profile has
been defined for p38𝛿 MAPK [7–9]. It is strongly activated
by environmental alterations in osmolarity, ultraviolet (UV)
irradiation, and oxidation. It is also moderately activated by
chemical stressors and proinflammatory cytokines including
arsenite, anisomycin, tumour necrosis factor- (TNF-) 𝛼, and
IL-1. Despite their similar activation profiles, differences in
the levels of activation of p38𝛿 MAPK and the other p38
MAPK isoforms have been reported. For example, while
hyperosmolarity appears to stimulate both p38𝛼 andp38𝛿 to a
similar degree, under hypoosmotic conditions, p38𝛼MAPK
is more strongly activated than p38𝛿 MAPK [7]. A range of
MAP3Ks have been implicated in the activation of the p38
MAPK pathway, including MLKs (mixed-lineage kinases),
TAK1 (transforming growth factor𝛽 activated kinase 1), ASK1
(apoptosis signal-regulating kinase 1), TAO (thousand-and-
one amino acid), DLK1 (dual-leucine-zipper-bearing kinase
1) MEKKs, and ZAK1 (leucine zipper and sterile-𝛼 motif
kinase 1) (Figure 1). To date their individual contribution to
p38𝛿 MAPK signalling in particular is not yet understood
[23–28]. Further upstream of the MAP3Ks is a complex
network involving members of the Ras/Rho family of small
GTP-binding proteins and heterotrimeric G-protein coupled
receptors [29, 30]. This adds to the diversity of signalling
from various stimuli contributing to the crosstalk between
p38 MAPKs and other signalling pathways.
The upstream direct activators responsible for dual phos-
phorylation of the p38 MAPK TGY motif are the MAPK
kinases (MKKs). p38𝛿MAPK is unique as it can be activated
by four separate MKKs: the p38 MAPK specific MKK3
and MKK6 and also the JNK MKKs-4 and -7 [7–9, 18].
International Journal of Cell Biology 3
p38𝛿
P
P
MKK3/MKK4/MKK6
ASK1, TAK1, MLKs, 
TAO, MEKKs
GPCRs, RhoGTPases, 
STE20 kinases
UV irradiation, 
oxidation, cytokines, 
anisomycin, arsenite, 
Stathmin
P
eEF2K
P
eEF2X
PRKD1
P
Diabetes
Neurodegenerative
disease
Migration
Inflammation
Proliferation
differentiation
apoptosis
Transcription
Translation
P P
Cancer
H2O2
AP1
ATF2
C/EBP
c-myb
Elk1
p53
SAP-1
SAP-2
TonEBP
Tau
Figure 1: Schematic representation of the current understanding of p38𝛿MAPK signalling and activation. A variety of extracellular stimuli
can activate theMAPK signalling pathway resulting in dual phosphorylation of p38𝛿MAPK. Known substrates of active p38𝛿MAPK include
transcription factors, structural proteins, kinases, and translation repressors. Phosphorylated substrates affect several cellular processes and
contribute to the pathogenesis of diseases such as cancer, diabetes, and neurodegenerative and inflammatory conditions.
However, information regarding the specific contributions
of these individual MKKs to p38𝛿 MAPK activation in
different cell types and under diverse conditions is lacking.
Current evidence suggests that activation of p38𝛿 MAPK is
significantly influenced by both the nature and the strength of
the stimulus as well as the cell type involved. This may be the
result of varying levels of expression of upstream components
of the MAPK signalling cascade in different cell types. For
example, MKK3 is the major direct activator of p38𝛿MAPK
phosphorylation in response to UV radiation, hyperosmotic
shock, and TNF𝛼 in mouse embryonic fibroblast (MEF) cells
[31]. It also appears to be the primary kinase responsible for
p38𝛿 MAPK activation in response to transforming growth
factor-𝛽1 (TGF-𝛽1) as MKK3 deficiency impairs endogenous
p38𝛿 activation by TGF-𝛽1 in murine glomerular mesangial
cells [32]. On the other hand, MKK6 was identified as the
major activator of p38𝛿MAPK in KB (HeLa) cells subjected
to IL-1, anisomycin, or osmotic stress [9]. Furthermore,
MKK7 is reported to be responsible for the activation of p38𝛿
MAPK in 293T cells under peroxide stress, mediated by the
scaffolding action of islet brain-2 [33]. Further complicating
the current understanding of p38𝛿 MAPK activation is the
likelihood that, in some cases, the cooperation of two MKKs
may be necessary. While MKK4 preferentially phosphory-
lates JNK on Tyr, MKK7 preferentially phosphorylates JNK
onThr [34–36].Therefore it must be considered possible that
the combined activity of these two MKKs may be required
to fully phosphorylate p38𝛿 MAPK on both the Tyr and
the Thr residues. Interestingly, two reports outline a MKK-
independent mechanism of activation for p38𝛼 MAPK via
autophosphorylation [37, 38]. While autophosphorylation
activity is detected in intrinsically active p38𝛿 mutants [39,
40], no such pathway has been observed which activates the
endogenous p38𝛿MAPK isoform.
An important factor in determining the biological con-
sequences of p38𝛿 MAPK phosphorylation is the strength
and duration of the activation signal. p38𝛿 MAPK activa-
tion is largely transient with activation and downregulation
occurring within minutes of stimulation [17]. This is due to
the regulatory action of protein phosphatases which again
appears to be cell-type specific. While MAPK phosphatase
1 inactivates p38𝛿 MAPK in HEK293FT cells, it does not
interact with p38𝛿 MAPK in the NIH3T3 cell line [41,
42]. The protein serine/threonine phosphatases PP1 and
PP2A have also been shown to be involved in p38𝛿 MAPK
phosphorylation as okadaic acid (OA), a PP1/PP2A inhibitor,
causes increased p38𝛿 MAPK activity in human epidermal
keratinocytes [43].
3. Novel p38𝛿MAPK Substrates
While p38 MAPKs are proline-directed kinases, substrate
specificity is also determined by docking domains both in
the MAPK itself and in the target protein [44]. Therefore,
although p38𝛿 MAPK substrate specificity overlaps to some
extent with that of p38𝛼, -𝛽, and -𝛾MAPKs, there are a num-
ber of notable differences. Common substrates of p38MAPKs
include MBP, PHAS-1, and transcription factors ATF2, SAP1,
Elk-1, and p53 (Figure 1). In contrast, however, substrates
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Table 1: Known p38𝛿MAPK substrates and their biochemical functions.
Substrate Function Consequences of phosphorylation
AP1 Transcription factor Activation of transcription, involucrin expression, keratinocytedifferentiation [58]
ATF2 Transcription factor Activation of transcription [7, 9]
C/EBP Transcription factor Keratinocyte differentiation [59]
c-myb Transcription factor c-myb degradation [109]
eEF2K Inhibitory kinase eEF2 activation, protein synthesis [53]
Elk1 Transcription factor Activation of transcription [7, 9]
p53 Transcription factor p21 expression, G1 phase arrest [9, 110]
PHAS-1 Translation repressor Dissociation from eIF4E, activation of translation [7]
PRKD1 Serine-threonine kinase Inhibition of PRKD1 activity [72]
SAP-1 Transcription factor Activation of transcription [9]
SAP-2 Transcription factor Activation of transcription [9]
Stathmin Microtubule protein Cytoskeleton reorganisation [50]
Tau Microtubule protein Microtubule assembly, tau self-aggregation [46]
TonEBP/OREBP Transcription factor Impaired TonEBP/OREBP transcriptional activity [41]
AP1: activator protein 1; ATF2: activating transcription factor 2; C/EBP: CCAAT (cytosine-cytosine-adenosine-adenosine-thymidine)-enhancer-binding
protein; myb: myeloblastosis; eEF2K: eukaryotic elongation factor 2 kinase; eEF2: eukaryotic elongation factor 2; PHAS-1: phosphorylated heat- and acid-stable
protein 1; PRKD1: protein kinase D 1; SAP: serum response factor accessory protein; eIF4E: eukaryotic translation initiation factor 4E.
such as MAPK activated protein kinase 2 (MAPKAP-K2)
and MAPKAP-K3 which are the major downstream kinases
of p38𝛼 and p38𝛽 MAPK are not phosphorylated by p38𝛿
MAPK [7–9, 45] (Table 1).
3.1. Tau. At the time p38𝛿 MAPK was first described the
microtubule-associated protein tau was identified as a strong
in vitro substrate for p38𝛿 MAPK [46]. Tau is a component
of the cytoskeleton network and under normal conditions
it stabilises microtubule assembly by binding to 𝛽-tubulin.
Phosphorylation of tau at T50 by p38𝛿MAPK causes it to be
functionally modified and enhances its capacity to promote
microtubule assembly.This effect is seen in neuroblastoma in
response to osmotic shock where tau T50 phosphorylation
occurs soon after p38𝛿MAPK activation, aiding the adaptive
response of neurons to changes in osmolarity [46]. It appears,
however, that subsequent hyperphosphorylation of tau at
additional sites causes it to dissociate from the cytoskeleton,
thereby promoting its self-assembly [47]. This aggregation
destabilises the microtubule network and contributes to
the development of neurofibrillary tangles [48]. Notably,
Alzheimer’s disease and other neurodegenerative disorders
known as tauopathies are characterised by the aggregation
in the brain of these neurofilament structures [49]. There
is therefore a clearly defined role for p38𝛿 MAPK in the
pathogenesis of neurodegenerative disease, making it a good
potential therapeutic target for these disorders.
3.2. Stathmin. There is further evidence of a role for
p38𝛿 MAPK in cytoskeleton regulation as the microtubule-
associated protein stathmin has also been characterised as a
good p38𝛿 MAPK substrate in vitro and in transfected cells
exposed to osmotic shock [50]. The normal physiological
role of stathmin is to sequester free tubulin and increase
depolymerisation of microtubules [51, 52]. It is possible
that phosphorylation of stathmin by p38𝛿 MAPK blocks its
ability to destabilise microtubules and as a result promotes
microtubule polymerisation and enhances cell survival under
stress conditions.
3.3. eEF2K. In response to anisomycin stimulation, p38𝛿
MAPK has been shown to be the main p38 MAPK isoform
which phosphorylates eukaryotic elongation factor 2 kinase
(eEF2K) [53]. Phosphorylation of eEF2K on Ser359 inacti-
vates the kinase and as a result removes its inhibitory phos-
phorylation of eEF2. eEF2 in turn promotes the movement of
the ribosome along mRNA during translation [54]. This sug-
gests that, by inhibiting eEF2K and consequently activating
eEF2, p38𝛿MAPK is responsible for driving the translation of
proteins associatedwith stress responses. Consistent with this
hypothesis is the observation that theMKK3/6-p38𝛿MAPK-
eEF2K pathway in myeloid cells is implicated in the produc-
tion of the proinflammatory cytokine TNF𝛼 in bacterial LPS
induced acute liver disease [55].These differences in substrate
specificity in combination with its unique tissue distribution
profile demonstrate that despite similarities in stimuli the
consequences of p38𝛿MAPK can potentially be significantly
different to those of the other p38 MAPK isoforms.
4. p38𝛿MAPK Function and New Roles in
Human Disease
Since the discovery of p38𝛿 MAPK in 1997 it has been
implicated in a range of diverse physiological events, namely,
differentiation, apoptosis, and cytokine production (Fig-
ure 1). The greatest understanding of its involvement in these
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cellular processes has been achieved from work using ker-
atinocytes and the majority of these studies have previously
been reviewed [56, 57]. Research is now emerging which
establishes p38𝛿 MAPK as a regulator of these processes in
other cell types. As a result in the past five years p38𝛿MAPK
has also been implicated in the pathogenesis of diabetes,
inflammatory diseases, and cancer. This progress has been
achieved with the development of p38𝛿 MAPK KO mouse
models which are proving to be a useful tool in elucidating
novel roles for p38𝛿MAPK in vivo.
4.1. Differentiation and Psoriasis. A number of different
studies have identified a role for p38𝛿 MAPK in ker-
atinocyte differentiation, a process critical for the precise
control of normal epidermal homeostasis. p38𝛿 MAPK
induces keratinocyte differentiation by regulating the expres-
sion of involucrin, a marker of keratinocyte terminal
differentiation [58–60]. p38𝛿 MAPK activation by 12-O-
tetradecanoylphorbol-13-acetate (TPA), calcium, OA, or
green tea polyphenol corresponds with increased involucrin
promoter activity, mRNA, and protein expression, as well as
increased levels and activity of AP1 and C/EBP transcription
factors [58, 59, 61]. Importantly, these responses are observed
in the presence of a p38𝛼/𝛽MAPK inhibitor. In addition p38𝛾
MAPK is poorly expressed in keratinocytes [60] confirming a
specific role for p38𝛿MAPK. Involucrin expression can also
be further upregulated in keratinocytes coexpressing p38𝛿
MAPK and PKC𝜂, -𝛿 or 𝜀 isoforms [59]. Of note cholesterol-
depleting agents and overexpression of MKK6/MKK7 have
previously been shown to induce involucrin expression via
activation of p38𝛼 MAPK [60, 62, 63]. This highlights
the significance of the stimulus type in determining p38
MAPK isoform activation. A further role for p38𝛿 MAPK
in keratinocyte differentiation was recently identified. p38𝛿
MAPK can regulate expression of ZO-1, an epidermal tight
junction membrane protein associated with keratinocyte
differentiation [64]. Inhibition of p38𝛿 MAPK results in
depletion of ZO-1 protein in calcium induced differentiating
keratinocytes while other junction proteins remain unaf-
fected [64]. Psoriasis is a benign, chronic inflammatory skin
condition that is characterised by hyperproliferation and dif-
ferentiation of keratinocytes as well as increased expression
of inflammatory cytokines. Given the significant role p38𝛿
MAPK plays in keratinocyte differentiation, it is no surprise
that aberrant p38𝛿 MAPK signalling has been implicated in
the pathogenesis of psoriasis. Expression of theMAPK13 gene
is commonly upregulated in psoriasis [65]. Furthermore, an
increase in p38𝛿 (as well as -𝛼 and -𝛽) MAPK activity has
been detected in psoriatic lesions compared to nonlesional
psoriatic skin. After treatment for psoriasis, phosphorylated
p38 MAPK levels return to those of uninvolved skin [66].
Further to its role in keratinocyte differentiation p38𝛿
MAPK is also implicated in hematopoiesis. In human pri-
mary erythroid cells, p38𝛿MAPKmRNA is only expressed in
late-stage differentiation where along with p38𝛼 MAPK it is
increasingly activated [67].Thismay suggest a functional role
for p38𝛿 MAPK in erythrocyte membrane remodelling and
enucleation. Interestingly, an increase in p38𝛿MAPKmRNA
and protein expression is observed as blood monocytes
differentiate to macrophages [68]. This suggests a role for
p38𝛿MAPK in functions gained by mature macrophages. A
possible candidate is phagocytosis given that the microtubule
associated protein stathmin is such a strong p38𝛿 MAPK
substrate.
Most recently, p38𝛿 MAPK has been identified as a
component of differentiation in bone repair [69]. In bone
cell differentiation during wound healing, wild type (WT)
monocytes differentiate to calcifying/bone-formingmonoos-
teophils upon treatment with the peptide LL-37. p38𝛿MAPK
protein and mRNA is highly expressed in monoosteophils
compared to undifferentiated monocytes. Monocytes from
p38𝛿 MAPK KO mice are incapable of this differentiation,
suggesting a critical role for p38𝛿MAPK in this process [69].
4.2. Apoptosis and Diabetes. As well as its significant role
in keratinocyte differentiation, p38𝛿 MAPK has also been
identified as a regulator of keratinocyte apoptosis. This dual
functional role may be attributed to the overlap of differ-
entiation and apoptosis signalling pathways [70]. As well
as inducing involucrin expression [61], OA simultaneously
causes disruption of mitochondrial membrane potential and
caspase-dependent apoptosis [43]. Overexpression of p38𝛿
MAPK enhances this OA driven apoptotic morphology. This
response is specific to p38𝛿MAPKactivation as it occurred in
the presence of the p38𝛼/𝛽 MAPK inhibitor SB203580 [43].
Furthermore, p38𝛿 MAPK coexpressed with either MEK6
or PKC𝛿, both upstream p38 MAPK activators, elicited an
apoptotic response similar to that induced by OA but in the
absence of an external stimulus. This was also independent
of SB203580, again ruling out a contribution from other p38
MAPK isoforms [71]. Interestingly, concurrent p38𝛿 MAPK
activation and inactivation of the proproliferative MAPK
ERK1/2 were observed with OA stimulation and PKC𝛿/p38𝛿
MAPK coexpression [43, 61, 71]. In fact a reduction in ERK1/2
activation appears to be critical for apoptosis as its con-
stitutive activation inhibited PKC𝛿/p38𝛿 MAPK mediated
apoptosis [71]. Therefore, it is likely that a specific balance
between prosurvival ERK1/2 and proapoptotic p38𝛿 MAPK
is essential in determining keratinocyte fate. In regulating
this balance, p38𝛿MAPK and ERK1/2 form a complex that is
translocated to the nucleus upon stimulation by PKC𝛿. This
nuclear localisation facilitates ERK1/2 inactivation by nuclear
phosphatases, whilemaintaining p38𝛿MAPK activation [71].
A role for p38𝛿 MAPK in apoptosis has recently been
demonstrated in vivo using p38𝛿 MAPK KO mice. Mice
deficient in p38𝛿 MAPK displayed a fivefold lower rate
of pancreatic 𝛽 cell death in response to oxidative stress
than WT mice and are afforded protection against insulin
resistance induced by a high-fat diet [72]. This would appear
to link p38𝛿MAPK to the pathogenesis of diabetes mellitus,
a disease characterised by reduced insulin sensitivity and
a decrease in insulin-producing pancreatic 𝛽 cells [72].
Increased p38 MAPK pathway activity has indeed been
observed in both type 1 and type 2 diabetes and is correlated
with late complications of hyperglycemia, including neuropa-
thy and nephropathy [73, 74]. p38𝛿 MAPK specifically has
6 International Journal of Cell Biology
also been implicated in the regulation of insulin secretion.
Phosphorylation by p38𝛿 MAPK negatively regulates the
activity of protein kinaseD1 (PKD1), a knownpositive regula-
tor of neuroendocrine cell secretion [72]. Thus, pronounced
activation of PKD1 has been observed in pancreatic 𝛽 cells
lacking p38𝛿MAPK. As p38𝛿MAPK is normally quite highly
expressed in the pancreas this can contribute to heightened
insulin secretion and improved glucose tolerance in p38𝛿
MAPK-null mice [72]. The pivotal role p38𝛿 MAPK plays
in integrating insulin secretion and survival of pancreatic 𝛽
cells makes it an attractive potential therapeutic target for the
treatment of human diabetes.
4.3. Cytokine Production and Inflammatory Diseases. One
of the pathways by which p38𝛼 MAPK was discovered
was via its identification as a regulator of proinflammatory
cytokine biosynthesis [2].Thus, its role in cytokine signalling
and cytokine-dependent inflammatory diseases is well char-
acterised. Consequently, some recent research using p38𝛿
MAPKKOmouse models has focused on identifying specific
roles for p38𝛿 MAPK in inflammation. A study of p38𝛿
MAPK KO mice as well as myeloid-restricted deletion of
p38𝛿MAPK in mice has shown that p38𝛿MAPK is required
for the recruitment of neutrophils to sites of inflammation
[75]. p38𝛿MAPKand its downstream target PKD1 conversely
regulate PTEN activity to control neutrophil extravasation
and chemotaxis. The accumulation of neutrophils at inflam-
matory sites is known to trigger inflammation-induced acute
lung injury (ALI) which can cause acute respiratory distress
syndrome (ARDS), a condition with a high mortality rate
[76]. Therefore, abnormal p38𝛿-PKD1 signalling may play an
important role in both ALI and ARDS in humans.
Rheumatoid arthritis is a typical example of an inflamma-
tory disease involving chronic synthesis of proinflammatory
cytokines which result in synovial hyperplasia and joint
destruction [77]. While p38𝛿MAPK (along with -𝛼, -𝛽, and
-𝛾) is expressed in the synovium of rheumatoid arthritis
patients its level of activation is lower than that of the four
other p38 MAPK isoforms [78]. Despite this low level of
activation new research has identified p38𝛿 MAPK as an
essential component of joint damage in a collagen-induced
model of arthritis. p38𝛾/𝛿−/−mice displayed reduced arthritis
severity compared to WT mice [79]. The decrease in joint
destructionwas associatedwith lower expression of IL-1𝛽 and
TNF𝛼 as well as a reduction in T cell proliferation, IFN𝛾, and
IL-17 production. Lack of either p38𝛾 or p38𝛿 MAPK alone
yielded intermediate effects, suggesting significant roles for
both isoforms in arthritis pathogenesis.
Proinflammatory cytokines also play a significant role in
the pathogenesis of inflammatory airway diseases, including
asthma, chronic obstructive pulmonary disease (COPD), and
cystic fibrosis.While increasedmucus production is linked to
the morbidity and mortality of such diseases the underlying
molecular mechanisms remain somewhat unclear [80]. The
critical driver of mucus production is thought to be IL-13
production by immune cells which results in mucin gene
expression [81, 82]. In the last few years p38𝛿 MAPK has
been implicated in the signalling pathway responsible for
controlling IL-13 driven excess mucus production. Increased
MAPK13 gene expression is evident in the lungs of patients
with severe COPD [83]. Novel inhibitors with increased
activity against p38𝛿 MAPK blocked mucus production by
IL-13 in human airway epithelial cells [83]. Thus, in patients
with hypersensitivity airway diseases there exists a potential
opportunity for therapeutic intervention should specific p38𝛿
MAPK inhibitors become clinically available.
5. p38𝛿MAPK and Cancer
In recent years, the function of the p38 MAPK signalling
pathway in malignant transformation has been intensively
studied. As a result, the best characterised isoform, p38𝛼
MAPK, has been identified as both a tumour promoter [84–
86] and a tumour suppressor [87–89]. Recent studies have
now also implicated p38𝛿 MAPK in cancer development
and progression. Like p38𝛼MAPK, p38𝛿MAPK would also
appear to have both pro- and antioncogenic roles, depending
on the cell type studied.
Interest in p38𝛿 MAPK as a potential tumour promoter
is based on the evidence that p38𝛿 MAPK expression and
activation are significantly increased in a variety of carcinoma
cell lines such as human primary cutaneous squamous
carcinoma cells [65], head and neck squamous carcinoma
cells and tumours [85], cholangiocarcinoma, and liver cancer
cell lines [90]. p38𝛿 MAPK was first shown to promote a
malignant phenotype (over eight years ago) in head and neck
squamous cell carcinoma (HNSCC) [85]. It was shown to
regulate HNSCC invasion and proliferation through control-
ling expression of matrix metalloproteinase-1 and -13 [85, 91].
Moreover the expression of dominant-negative p38𝛿MAPK
impaired the ability of cutaneous HNSCC cells to implant in
the skin of immunodeficiency mice as well as inhibiting the
growth of xenografts [85].
p38𝛿MAPK-null mice have been utilised to demonstrate
that p38𝛿 MAPK is required for the development of
multistage chemical skin carcinogenesis in vivo. When
compared with WT mice, p38𝛿 MAPK-deficient mice
displayed reduced susceptibility to 7, 12-dimethylbenz(a)
anthracene/12-O-tetradecanoylphorbol-13-acetate induced
skin carcinoma with a significant delay in tumour
development [92]. Furthermore, both tumour numbers
and size were significantly decreased compared with WT
mice [92]. This decreased carcinogenesis was associated with
reduced levels of proproliferative ERK1/2-AP1 signalling and
decreased activation of signal transducer and activator of
transcription 3 (Stat3) [92]. The ERK1/2-AP1 pathway is a
key cancer promoting cascade previously implicated in skin
carcinogenesis [93, 94]. Stat3 meanwhile is an oncogenic
transcription factor involved in chemical and UVB-induced
transformation [95]. It is also proproliferative and plays
a role in angiogenesis and invasion [96, 97]. Therefore
p38𝛿 MAPK promotion of proliferation via Stat3 may be a
significant mechanism in the promotion of carcinogenesis
by p38𝛿 MAPK. Similarly, p38𝛿 MAPK KO mice have
reduced susceptibility to development of K-ras driven
lung tumorigenesis. Compared with WT mice, p38𝛿−/−/K-
RasG12D+/− mice displayed significantly decreased tumour
numbers, average tumour volume, and total tumour volume
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per lung [92]. This is in contrast to p38𝛼 MAPK-deficient
mice which display hyperproliferation of lung epithelium
and increased K-Ras-induced lung tumour development
[88]. This highlights once again the distinct and often
opposing functions of the individual p38 MAPK isoforms.
Further evidence for a specific role of p38𝛿MAPK in pro-
moting cancer progression has most recently been demon-
strated in cholangiocarcinoma (CC) [90]. p38𝛿 MAPK
expression is upregulated in CCwhen compared with normal
biliary tract tissue. Knockdown, however, of p38𝛿 MAPK
expression by siRNA transfection significantly inhibited
motility and invasiveness of CC cells. In contrast, overex-
pression of p38𝛿 MAPK in these cells results in enhanced
invasive behaviour. Significantly, p38𝛿 MAPK may prove to
be a useful marker for the differential diagnosis of CC over
hepatocellular carcinoma where it lacks expression [90].
In contrast to the relatively well characterised role of
p38𝛿MAPK as a tumour promoter an increasing number of
reports since 2011 outline its activity as a tumour suppressor.
The first indication of a tumour suppressive role for p38𝛿
MAPKwas observed in mouse embryonic fibroblasts (MEF).
p38𝛿−/− (and p38𝛾−/−)MEFs displayed increased cellmotility
compared to WT cells [98]. Furthermore, while WT fibrob-
lasts ceased to proliferate after reaching 100% confluency,
p38𝛿−/− MEFs continued to grow, forming foci rather than
a monolayer [98]. This deregulation of contact inhibition is
significant as it is a hallmark of malignant transformation
[99]. Our own recent studies have also identified a role for
p38𝛿MAPK in the control of oesophageal squamous cell car-
cinoma (OESCC)migration, invasion and contact inhibition,
processes which are crucial for the progression of primary
tumours to distant metastases [100]. Reintroduction of p38𝛿
MAPK into OESCC cells which lack endogenous expression
significantly impaired cell proliferation, migration, and inva-
sion as well as significantly reducing the number of colonies
formed on soft agar compared to WT. These effects were
further enhanced in cells transfected with a constitutively
active form of p38𝛿MAPK [100]. Furthermore, p38𝛿MAPK
expression appears to influence the chemosensitivity of
OESCC to apoptosis. Our recent study indicates that OESCC
cells expressing p38𝛿MAPK are significantly more sensitive
to cisplatin and 5-fluorouracil combination therapy than
p38𝛿 MAPK-deficient cells [101]. These findings are signifi-
cant as they suggest that p38𝛿MAPKmay be a useful predic-
tor of response to chemotherapy in OESCC patients. Further
supporting the hypothesis that loss of p38𝛿 MAPK confers
a survival advantage, p38𝛿 MAPK expression was found
to be downregulated in brain metastases of triple-negative
breast cancer (TNBC). Abolition of p38𝛿 MAPK expression
in TNBC induced cell growth, while overexpression of p38𝛿
MAPK in brain metastases reduced growth rates [102].
Cancer genomes are increasingly associated with epige-
netic alterations whereby tumour suppressor genes exhibit
promoter hypermethylation. Interestingly, hypermethylation
of the MAPK13 gene promoter region has recently been
characterised in both malignant pleural mesothelioma [103]
and primary cutaneous melanoma [104]. This methylation is
associated with downregulation of p38𝛿 MAPK mRNA and
protein expression. Melanoma cell lines displaying MAPK13
gene promotermethylation donot express significant levels of
p38𝛿MAPKwhen compared to fibroblasts, melanocytes, and
melanoma cell lines with unmethylated MAPK13 promoters.
Furthermore, treatment ofmelanoma cells with the demethy-
lating agent 5-aza-2󸀠-deoxycytidine significantly increases
the expression of the MAPK13 gene [104, 105]. Importantly,
reestablishment of p38𝛿MAPK expression inmelanoma cells
with MAPK13 hypermethylation suppresses cell prolifera-
tion. The effect was further enhanced upon expression of
a constitutively active form of p38𝛿 MAPK. Interestingly,
however, overexpression of p38𝛿MAPK or its constitutively
active form in cells in which MAPK13 was not epigenetically
silenced only marginally affected proliferation [104].
6. Conclusions and Future Directions for p38𝛿
MAPK Research
p38𝛿 MAPK is a unique stress-responsive protein kinase.
It is mainly activated by environmental stresses, including
UV radiation, osmotic shock, and oxidative stress, to illicit
an adaptive response within the cell. This is mediated
through phosphorylation of substrates involved in cytoskele-
ton organisation such as tau and stathmin, as well as tran-
scription factors responsible for the expression of stress-
responsive genes [106, 107]. Since the discovery of the p38
MAPK family in the mid-nineties they have increasingly
been associated with cellular processes such as proliferation,
differentiation, development, apoptosis, and migration [108].
Research to date has generally focused on the first two iso-
forms to be discovered. It is now becoming increasingly clear
however that conclusions drawn fromp38𝛼MAPK (and to an
extent p38𝛽MAPK) studies cannot be automatically applied
to the p38𝛾 and p38𝛿 MAPK isoforms due to their different
expression patterns, substrate specificities, and sensitivity
to chemical inhibitors. Studies carried out in the last few
years have led to some small advances in our knowledge of
the regulation of p38𝛿 MAPK and its physiological roles.
In particular, the development of p38𝛿 MAPK KO mouse
models has yielded a greater understanding of the conse-
quences of p38𝛿 MAPK signalling in vivo. Roles for p38𝛿
MAPK in important cellular processes such as differentiation
and apoptosis have been identified [69, 72]. As a result,
p38𝛿 MAPK is now implicated in a variety of pathological
conditions including inflammatory diseases, diabetes, and
cancer [72, 75, 92, 98]. Most importantly, p38𝛿 MAPK may
now be considered as a potential therapeutic target for the
treatment of these disorders.
The implication of p38𝛿MAPK in a wide range of human
diseases should strengthen future research interest in this
isoform. The main limiting factors to the further study of
p38𝛿 MAPK functions, however, are the lack of specific
inhibitors and activators. Fuelled by the prospect of therapeu-
tic benefit for patients with diabetes or inflammatory disease,
for example, the search formore potent and specific inhibitors
of p38𝛿MAPK is ongoing [83]. These may not only provide
potential treatments for the conditions outlined here but
could also afford us the opportunity to delineate specific p38𝛿
MAPK functions in the absence of involvement from other
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p38MAPK isoforms.This in turnmay identify other diseases
where p38𝛿 MAPK could be a potential therapeutic target.
In this review we also present important and interesting
observations which suggest that focusing on identification
of specific p38𝛿 MAPK activators is also warranted. This
may in the future translate to the development of novel
therapeutic strategies for patients with OESCC ormelanoma.
Whether considering the possible therapeutic benefits of
p38𝛿 MAPK inhibitors or activators it is important to heed
the diversity and important role(s) of p38𝛿MAPK signalling
in normal physiological processes. In conclusion, uncovering
some of the physiological as well as pathological roles of
p38𝛿MAPK since its discovery almost twenty years ago has
been somewhat successful. However, based on our current
knowledge continued focused research on this particular
isoform is necessary if p38𝛿 is to translate into a novel
therapeutic target for a range of diverse human diseases.
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Abstract. Oesophageal cancer is an aggressive tumour which 
responds poorly to both chemotherapy and radiation therapy 
and has a poor prognosis. Thus, a greater understanding of the 
biology of oesophageal cancer is needed in order to identify 
novel therapeutic targets. Among these targets p38 MAPK 
isoforms are becoming increasingly important for a variety of 
cellular functions. The physiological functions of p38α and -β 
are now well documented in contrast to -γ and -δ which are 
comparatively under-studied and ill-defined. A major obstacle 
to deciphering the role(s) of the latter two p38 isoforms is the 
lack of specific chemical activators and inhibitors. In this study, 
we analysed p38 MAPK isoform expression in oesophageal 
cancer cell lines as well as human normal and tumour tissue. We 
observed specifically differential p38δ expression. The role(s) of 
p38δ and active (phosphorylated) p38δ (p-p38δ) in oesophageal 
squamous cell carcinoma (OESCC) was delineated using wild-
type p38δ as well as active p-p38δ, generated by fusing p38δ to 
its upstream activator MKK6b(E) via a decapeptide (Gly-Glu)5 
linker. OESCC cell lines which are p38δ-negative (KE-3 and -8) 
grew more quickly than cell lines (KE-6 and -10) which express 
endogenous p38δ. Re-introduction of p38δ resulted in a time-
dependent decrease in OESCC cell proliferation which was 
exacerbated with p-p38δ. In addition, we observed that p38δ 
and p-p38δ negatively regulated OESCC cell migration in vitro. 
Finally both p38δ and p-p38δ altered OESCC anchorage-inde-
pendent growth. Our results suggest that p38δ and p-p38δ have 
a role in the suppression of OESCC. Our research may provide 
a new potential target for the treatment of oesophageal cancer.
Introduction
Oesophageal cancer is the seventh most common cancer 
worldwide (1) with its 5-year survival rate being dismally 
low at ≤15% (2). Oesophageal squamous cell carcinoma 
(OESCC) is an exceptionally drug-resistant tumour. Despite 
recent advances in the detection of OESCC and the develop-
ment of multimodal therapy (3,4), its incidence is on the rise 
and outcome for patients remains poor (5,6). Thus, a greater 
understanding of the initiation and progression of OESCC is 
required in order to be able to identify predictive and prog-
nostic factors that may in the future lead to novel therapeutic 
strategies.
The mitogen-activated protein kinases (MAPKs) are 
serine/threonine kinases and include the extracellular-
regulated kinase (ERK), c-jun NH2-terminal kinase (JNK) 
and p38 MAPK families. The p38 MAPK family consists 
of four members; p38α (MAPK14) of which there are two 
splice variants (7), p38β (MAPK11), p38γ (MAPK12) and 
p38δ (MAPK13) (8). Although these isoforms are 60-70% 
identical in amino acid sequence they differ greatly in their 
tissue distribution (9), substrate specificity (10) and sensitivity 
to chemical inhibitors (11). In recent years, we have gained an 
increased appreciation of the importance of p38 isoforms for a 
variety of cellular functions including proliferation, differen-
tiation, transformation and programmed cell death (12). Their 
roles, however, are more complex than previously thought, 
with distinct members appearing to have different functions. 
In addition, the roles of p38 in various pathologic conditions 
remain to be elucidated (13).
To-date most of the published literature refers to the 
p38 family as a whole or indeed have focused on the first 
discovered isoform p38α (10,13). There is an obvious dearth 
of research pertaining to the latter two isoforms, p38γ and 
-δ, due partly to the lack of commercially available specific 
chemical activators or inhibitors for each of these isoforms 
(14). In the present study we have overcome this obstacle 
using an enzyme-substrate fusion approach for the generation 
of constitutively active p38δ. We now provide new informa-
tion regarding the role(s) of p38δ and active (phosphorylated) 
p38δ (p-p38δ) in OESCC. We identified differential p38δ 
expression in OESCC. Lack of p38δ expression in OESCC 
allows for a more aggressive phenotype including increased 
proliferation, increased migration and increased capacity for 
anchorage-independent growth. Restoration of p38δ expres-
sion, however, reverses these effects. Together, our results 
provide evidence for a novel role for p38δ-induced suppressive 
effects in OESCC. With survival rates being poor for patients 
with OESCC, there is an urgent need to find novel strategies to 
Loss of p38δ mitogen-activated protein kinase expression 
promotes oesophageal squamous cell carcinoma proliferation, 
migration and anchorage-independent growth
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improve current therapy. Our study suggests isoform specific 
activation of p38δ as a possible potential approach for treat-
ment of patients with OESCC.
Materials and methods
Reagents. All chemicals and cell culture reagents were 
purchased from Sigma-Aldrich (Wicklow, Ireland), enzymes 
from New England BioLabs (Hertfordshire, UK) and primary 
antibodies from Cell Signaling Technologies (Hertfordshire, 
UK), unless otherwise stated.
Specimens. The patient cohort consisted of ten patients with 
OESCC of both genders ranging in age from 44 to 81 years. 
Formalin-fixed, paraffin-embedded (FFPE) oesophagectomy 
specimens from ten patients consisted of ten paired samples of 
primary tumour and metastatic lymph nodes with 10 samples 
of non-tumour adjacent tissues (NAT). Patient features are 
summarized in Table IA.
Cell culture. The KE oesophageal cancer cell lines (kind 
gifts from Professor T. Fujii, Kurume University School of 
Medicine, Japan) (15-17) as well as KYSE-70, OE-19, OE-21 
and OE-33 (ATCC, Rockville, MD, USA) were cultured in 
RPMI-1640 supplemented with 10% FCS, 100 µg/ml strep-
tomycin and 100 U/ml penicillin. KE cell line features are 
summarized in Table IB. The metastatic oesophageal cancer 
cell line, OC-3 [a kind gift from Cork Cancer Research Centre, 
(Biosciences Institute, National University of Ireland, Cork, 
Ireland] (18) was cultured in DMEM supplemented with 
10% FCS, 100 µg/ml streptomycin and 100 U/ml penicillin. 
KYSE-450 cells (ATCC, Rockville, MD, USA) were main-
tained in 45% RPMI-1640/45% Ham's F-12 nutrient mixture 
supplemented with 10% FCS, 100 µg/ml streptomycin and 
100 U/ml penicillin.
Proliferation assay. KE cells were plated at a density of 
3x104 cells/well in a 6-well tissue culture plate. Cell viability 
was assessed by trypan blue (0.4% w/v) exclusion assay at the 
indicated times (18).
Nuclear and cytosolic extraction. Nuclear and cytosolic 
fractions were isolated from 2x106 cells using the NE-PER 
Isolation kit (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer's instructions.
Generation of MKK6b-p38δ MAPK, MKK6b(E)-p38δ MAPK 
and MKK6b(E)-p38δDN MAPK fusion proteins. p38δ 
(pcDNA3-FLAG-p38δ) and constitutively active MKK6b 
[pcDNA3-MKK6b(E)] plasmids were a kind gift from 
Professor J. Han (Scripps Research Institute, La Jolla, CA, 
USA) and have previously been described (19). To construct 
the pcDNA3-MKK6b(E)-FLAG-p38δ (p-p38δ) fusion plasmid 
the TAA stop codon of MKK6b(E) was replaced with a unique 
SwaI restriction sequence using a QuikChange Lightening 
Site-Directed Mutagenesis kit (Agilent Technologies) (5'-CAT 
CTTTTGTAAAACTGATTCTTGGAGAATTTAAATCAG 
TGGACTTAATCGGTTGACCCTACTG-3'; 5'-CAGTAG 
GGTCAACCGATTAAGTCCACTGATTTAAATTCTCCAA 
GAATCAGTTTTACAAAAGATG-3'). A PCR generated 
Table I. Patient characteristics, and cell lines used.
A, OESCC patient features
Patient features No. of patients
Gender
 Male   4
 Female   6
Age, median (years) 63 (44-81)
TNM7 stage
 T stage
  T3 10
 N stage
  N1   3
  N2   7
Histological grade
 Well differentiated   1
 Moderately differentiated   6
 Poorly differentiated   3
B, KE (OESCC) cell line features
KE features
Gender
 Male KE-3, -4, -5, -6
 Female KE-8, -10
Age, median (years) 67 (50-71)
TNM7 stage
 T stage
  T1 KE-10
  T3 KE-3, -5, -6, -8
  T4 KE-4
 N stage
  N0 KE-5
  N1 KE-3, -4, -6, -8, -10
Histological grade
 Well differentiated KE-5, -6
 Moderately differentiated KE-3, -10
 Poorly differentiated KE-4, -8
C, p38δ MAPK expression in patient specimens
 p38δ MAPK expression -----------------------------------------------------
Diagnosis Positive  Negative
NAT (n=10) 9 1
OESCC primary (n=10) 6a 4
OESCC nodes (n=10) 2 8
A, Patient features and B, KE features are summarised based on 
gender, age, TNM7 stage and histological stage. Based on the 
TNM7 categorization for oesophageal cancer N1=1-2 lymph nodes 
and N2=3-6 lymph nodes. C, Samples obtained from ten patients 
consisted of ten paired primary tumour and metastatic lymph nodes 
as well as corresponding non-tumour adjacent tissues for analysis of 
p38δ expression. ap38δ expression was considerably lower than in 
the corresponding NAT.
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DraI-DraI fragment encoding FLAG-p38δ with a 5' (Gly-Glu)5 
linker (5'-CCGCGCTTTAAAGGCGAGGGCGAGGG 
CGAGGGCGAGGGCGAGATGGACTACAAGGACGAC 
GAT-3'; 5'-TTGATCTTTAAATTATTACAGCTTCATG 
CCACTTCGT-3') to facilitate folding as previously described 
(20) was ligated to SwaI linearised pcDNA3-MKK6b(E) with 
T4 DNA ligase. The pcDNA3-MKK6b-FLAG-p38δ plasmid 
(inactive MKK6b) was created by the substitution of Glu151 and 
Glu155 with Ser and Thr respectively by site-directed muta-
genesis (5'-TGGAATCAGTGGCTATTTGGTGGACTCTGT 
TGCTAAAACAATTGATGCAGGTTGCAAACCATAC-3'; 
5'-GTATGGTTTGCAACCTGCATCAATTGTTTTAGCAA 
CAGAGTCCACCAAATAGCCACTGATTCCA-3'). The 
pcDNA3-MKK6b(E)-FLAG-p38δDN (dominant negative) 
(p-p38δDN) plasmid was created by substituting Thr180 and 
Tyr182 of p38δ with Ala and Phe respectively by site-directed 
mutagenesis (5'-GACGCCGAGATGGCTGGCTTCGTGG 
TGACCCG-3'; 5'-CGGGTCACCACGAAGCCAGCCAT 
CTCGGCGTC-3'). DNA sequence analysis confirmed the 
integrity of all plasmids.
Stable transfection. KE-3 cells were transfected using 
Lipofectamine™ 2000 reagent (Life Technologies™) and a 
total of 4 µg of plasmid DNA according to the manufacturer's 
instructions. Twenty-four hours following transfection cells 
were transferred to 100-mm diameter dishes and transfected 
cells were selected in growth medium containing 800 µg/
ml Geneticin. After 4-8 weeks, individual cell colonies were 
transferred for clone expansion.
Immunoblot analysis. Supernatants used for immunoblotting 
with specific antibodies, p38α and -δ, phospho-p38 MAPK 
and MKK6 antibodies (New England Biolabs), p38γ (Upstate) 
and p38β2 antibody (Zymed Laboratories Inc.) have previously 
been described by us (18,21). Chemiluminescent detection was 
performed using SuperSignal® WestDura Extended Duration 
Substrate (Pierce Biotechnology) and bands were visualized 
using a Syngene G:Box ChemiXR5 Gel Documentation 
System.
Immunohistochemistry. This was performed as previously 
described by us (21). Briefly, FFPE OESCC and NAT sections 
were de-parrafinized in xylene and re-hydrated prior to anal-
ysis. Antigen retrieval was performed by microwave irradiation 
in 0.01 M citrate buffer, pH 6.0. In addition cultured cells 
grown on coverslips were fixed in 2-4% paraformaldehyde and 
permeabilised with 0.5% Triton-X-100. Samples were blocked 
with 5% NGS in TS/SAP. Slides were incubated with primary 
antibody overnight at 4˚C. Antibody binding was localized 
using a biotinylated secondary antibody, avidin-conjugated 
HRP and DAB substrate, contained within the Vectastain 
ABC detection kit (Vector Laboratories, Burlingame, CA, 
USA). Slides were counterstained with hematoxylin.
ELISA. Cell lysates were analysed for p38δ phosphorylation 
at T180/Y182 using the R&D Systems DuoSet® IC Human 
phospho-p38δ (T180/Y182) sandwich ELISA (DYC2124-5) 
according to the manufacturer's instructions. Absorbance was 
read at 450 nm on a Tecan Sunrise spectrophotometric plate 
reader and analysed using the XRead software program.
Boyden chamber cell migration assay. Cells were plated 
in starvation medium at a density of 3x104 cells/well into a 
96-well plate of the upper chamber. The bottom chamber 
contained 10% FCS as the chemoattractant. Cells were left 
migrate for 24 h through the matrigel filter (8 mm). Migrated 
cells were treated with MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (5 mg/ml) and absorbance 
read at 540 nm to calculate viable cell numbers as previously 
described (21).
Wound-healing assay. Cell migration was assessed by in vitro 
wound-healing assay as previously described (22). A linear 
wound track was made by use of a sterile tip through confluent 
cells. Cells migrating into the wound were captured under 
a phase-contrast microscope 24 and 48 h after wounding. 
Migration was determined using the ImageJ program as an 
average closed area of the wound relative to the initial wound 
area at 24 and 48 h after wounding.
Colony forming assay. The role of p38δ in anchorage-inde-
pendent growth was assayed using a soft agar colony-forming 
assay as previously described (21). Cells were plated at a 
density of 3x105 cells/100-mm dish in medium containing 
0.4% (w/v) agar on an underlay of 0.8% (w/v) agar. After a 
21-day incubation colonies were stained with MTT (5 mg/ml) 
overnight and counted.
siRNA. KE-6 cells at 75% confluency in antibiotic-free media 
were transfected with 100 nM p38δ MAPK siRNA or control 
siRNA-A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
according to the manufacturer's instructions and as recently 
described (23).
RT-PCR. First-st rand cDNA was synthesised using 
SuperScript® VILO™ cDNA Synthesis kit (Life Technologies) 
from total RNA isolated from cells using an Illustra RNASpin 
Mini kit (GE Healthcare, Buckinghamshire, UK) according to 
the manufacturer's instructions. p38δ mRNA was amplified 
from cellular cDNA under the following conditions: ddH2O, 
1X DreamTaq buffer, 0.2 mM dNTPs, 0.25 µM p38δ forward 
primer: 5'-CCACGTTAAACTGCCCATCT-3', 0.25 µM p38δ 
reverse primer: 5'-CCGCCACAAGCTAAAAAGAG-3', 1 µl 
cDNA and 1 U DreamTaq DNA polymerase (Thermo Fisher 
Scientific; Waltham, MA, USA). RT-PCR products were anal-
ysed by agarose gel electrophoresis.
Proteome Profiler™ antibody array. The relative levels of 
phosphorylation of 26 kinases was examined in cell lysates 
using a Proteome Profiler Human Phospho-MAPK array 
(R&D Systems, Abingdon, UK) according to the manufac-
turer's instructions. Following chemiluminescent detection, 
pixel density of each spot was analysed using Scion image 
software.
Ethics. The research was approved by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals.
Statistical analysis. Results are expressed as mean ± SE. 
Statistical comparisons were made by using analysis of 
variance with subsequent application of Student's t-test, as 
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appropriate. GraphPad InStat 3 software was used also for 
statistical analysis.
Results
p38α, -β, -γ and -δ isoforms and MKK3, -4, -6 and 7 are 
differentially expressed in oesophageal cancer. The expres-
sion of p38 as a family has previously been outlined in 
oesophageal cancer as well as other cancer types (10,13,24,25). 
While these reports refer to the p38 family, analysis of indi-
vidual p38 isoform expression in oesophageal cancer has to 
date never been reported. A previous study by us outlining 
differential p38 isoform expression in renal cancer prompted 
us to investigate further the effects of individual p38 family 
members in cancer in general (26). Using western blot analysis 
we examined p38 MAPK isoform expression in nine OESCC 
cell lines (KE-3, -4, -5, -6, -8, -10, KYSE-70, KYSE-450 and 
OE-21) and three oesophageal adenocarcinoma cell lines 
(OC-3, OE-19 and OE-33). We used antibodies specific for 
each isoform p38α, -β2, -γ and -δ as previously described by us 
(26). All twelve oesophageal cancer cell lines (squamous and 
adenocarcinoma) expressed p38α, -β and -γ (albeit at different 
levels) (Fig. 1A). In contrast p38δ expression was present in 
the three adenocarcinoma cell lines but absent in four of the 
OESCC cell lines KE-3, -8, KYSE-70 and OE-21 (Fig. 1A). 
The specific loss of p38δ isoform expression only has previ-
ously been reported by us in renal carcinoma (786-0) (26) and 
also observed by us in liver (Huh-7), lung (A-549) prostate 
(PC-3 and DU-145) and skin (MeWo) cancer cell lines (Barry 
et al, unpublished data). Upstream MKK3 and -6 are thought 
to be the major protein kinases responsible for p38 activation 
(24) but the selectivity of p38 isoform activation is stimulus 
type and strength dependent (27). We observed strong MKK3 
and -4 expression for all cell lines except KE-3 and -8 OESCC 
which were MKK3 negative. In contrast levels of MKK6 
and -7 expression were considerably lower (Fig. 1B).
Finally, analysis of p38δ at the mRNA level surprisingly 
proved positive for all cell lines examined including the four 
OESCC cell lines that were negative for p38δ protein expres-
sion (Fig. 1C). Primers specific for a 292-bp fragment of the 
3'-untranslated region of p38δ mRNA amplified cDNA from 
all twelve cell lines. Other primer sets within the coding 
sequence yielded similar results (data not shown). In addition 
DNA sequence analysis of PCR products did not identify any 
mutations such as a stop codon or a missense mutation which 
could possibly explain loss of p38δ protein expression (data 
not shown).
To investigate whether the p38 isoform expression pattern 
we observed in vitro with the OESCC cell lines could be 
translatable to the in vivo situation we analyzed the expres-
sion profile and localization of all four p38 isoforms (α, 
-β, -γ and -δ) in FFPE oesophagectomy specimens from 
ten patients with squamous cell carcinoma. Samples consisted 
of ten paired primary tumour and metastatic (lymph nodes) 
as well as corresponding non-tumour adjacent tissues (NAT) 
as outlined in Table IA. Samples were staged according to the 
new TNM7 categorization for oesophageal cancer (Table IA) 
(28). Consistent levels of p38α and -β expression was evident 
in all ten normal, primary and metastatic OESCC samples 
(Fig. 1D). Similarly, we did not observe a change in p38γ 
expression between normal, primary tumour and metastatic 
samples albeit the intensity of brown staining was less than that 
Figure 1. Expression of p38 MAPK isoforms, MKK3, -4, -6 and -7 in oesophageal cancer. (A) Western blot analysis of p38 isoform expression in KE-3, -4, -5, 
-6, -8 and -10, KYSE-70, -450 and OE-21 (oesophageal squamous cell carcinoma cell lines) as well as OC-3, OE-19 and OE-33 (oesophageal adenocarcinoma 
cell lines). (B) Western blot analysis of MKK3, -4, -6 and -7 in the same twelve cell lines. Aliquots of 30 µg of protein lysate were loaded on a 10% SDS-PAGE 
gel and analyzed by immunoblotting using antibodies specific for p38α, -β2, -γ and -δ. β-actin analysis served as a loading control. The results shown are 
representative of four independent experiments. (C) Agarose gel electrophoresis analysis of DNA fragments produced by PCR amplification of p38δ mRNA 
from oesophageal squamous (KE3, -4, -5, -6, -8, 10, KYSE70, -450 and OE21) and adenocarcinoma (OC3, OE19 and -33) cell lines. (D) Immunohistochemical 
staining of p38α, -β2, -γ and -δ isoforms in normal, tumourigenic and metastatic (lymph node) oesophageal human tissue. Immunohistochemical staining was 
performed as outlined in Materials and methods. Blue arrow indicates cytoplasmic staining; black arrow indicates nuclear staining; white arrow indicates blue 
unstained nuclei and yellow arrow indicates blue unstained cytoplasm. Magnification, x400. The results shown are representative of ten patients.
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observed for p38α and -β (Fig. 1D). p38δ expression, however, 
was considerably different in normal vs primary tumour vs 
metastatic disease (Fig. 1D and Table IC). p38δ expression 
was observed in both the nuclei and cytoplasm of nine of the 
ten oesophageal NAT tissue samples. However, a significant 
decrease in expression was observed in both the nuclei and 
cytoplasm in the ten primary tumour specimens as evidenced 
from the lighter brown staining compared to NAT samples in 
six patient samples and complete loss of expression in four of 
the samples (Fig. 1D and Table IC). Furthermore, eight out 
of the ten metastatic tissue specimens demonstrated complete 
loss of p38δ expression with both the nuclei and cytoplasm 
appearing blue in colour (Fig. 1D). This is an important 
finding considering identification of lymph node metastasis 
is the single most important prognostic factor in oesophageal 
cancer (1).
OESCC cell lines lacking endogenous p38δ MAPK expres-
sion proliferate faster than those which express this isoform. 
The results obtained for differential p38δ expression in both 
the oesophageal cell lines and the human samples prompted 
us to investigate further the effect(s) if any this particular 
isoform may have on the tumourigenicity of OESCC. Firstly, 
we examined whether the absence or presence of endogenous 
p38δ expression could have an effect on the proliferation rate 
of our OESCC cell lines. Using the trypan blue exclusion 
assay we compared the proliferation rate of KE-3 and -8 cell 
lines (which do not express p38δ) versus KE-6 and -10 (which 
express p38δ). We observed that at all time-points studied 
(24-120 h) both cell lines KE-3 and -8 proliferated faster than 
KE-6 and -10 cells (Fig. 2).
Generation of active (phosphorylated) p38δ (p-p38δ) MAPK 
fusion proteins. To investigate whether p38δ or active (phos-
phorylated) p38δ (p-p38δ) drives the observed anti-proliferative 
phenotype (Fig. 2) we re-introduced wild-type p38δ into KE-3 
cells which have lost its expression. In the absence of a specific 
commercially available p38δ activator [and to investigate the 
effect(s) of active (p-p38δ)] we generated a constitutively 
active p38δ through enzyme substrate fusion as previously 
described for JNK (Fig. 3A) (20). Western blot analysis of 
stable transfections of KE-3 cells demonstrated that pcDNA3-
MKK6b-(Gly-Glu)5-FLAG-p38δ (data not shown) as well as 
pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ both produced 
a single polypeptide with a molecular mass of 82 kDa as 
expected when using p38δ, p-p38 and MKK6 antibodies, 
respectively (Fig. 3B). As both MKK6b and MKK6b(E) fused 
in frame to p38δ produced the same desired result only one 
plasmid (MKK6b(E)-p38δ) was used for subsequent experi-
ments. Western blot analysis of KE-3 cells stably transfected 
with pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δDN also 
produced a single polypeptide with a molecular mass of 
82 kDa upon incubation with p38δ and MKK6 antibodies 
(Fig. 3Bi and iii) but did not demonstrate p38 activation (phos-
phorylation) (Fig. 3Bii). Of note the antibody used in Fig. 3Bii 
is a pan phospho-p38 antibody. To our knowledge there is no 
commercially available antibody to test for active (phosphory-
lated) p-p38δ specifically by western blot analysis. Therefore, 
to confirm p38δ activation we performed a sandwich ELISA 
which measures p38δ isoform phosphorylation specifically. 
Transfection of KE-3 cells with wild-type p38δ alone revealed 
activation (Fig. 3C). This is in strong agreement with previous 
reports where adenovirally expressed wild-type p38δ was 
activated in head and neck squamous cell carcinoma (29) 
and human keratinocytes (30). A 4-fold (p<0.001) increase in 
activation of p38δ was observed following stable transfection 
of KE-3 cells with p-p38δ (Fig. 3C). This level of activation 
is similar to KE-3 p38δ transfected cells upon activation with 
anisomycin (30 µM) (data not shown). As expected we did 
not observe phosphorylation of p38δ in cells transfected with 
p-p38δDN (Fig. 3C). We also analysed KE-6 and KE-10 cell 
lines (which express endogenous p38δ expression) but did not 
observe p38δ phosphorylation in either cell line (Fig. 3C).
To ensure specific phosphorylation of p38δ only and not 
the other three p38 isoforms (α, -β and -γ) we performed a 
human phospho-MAPK antibody array (R&D Systems). We 
did not observe phosphorylation of p38α, -β or -γ in non-
transfected KE-3 cells or cells stably transfected with p38δ or 
p-p38δ (Fig. 3D and E). We did, however, observe an increase 
(p<0.001) in phosphorylation in KE-3 p38δ wild-type trans-
fected cells which was amplified in KE-3 p-p38δ transfected 
cells (Fig. 3D and E) in agreement with our ELISA results 
(Fig. 3C). These results confirm phosphorylation of p38δ only 
in our studies. We also observed MKK6 phosphorylation in 
KE-3 p-p38δ as expected (Fig. 3D and E). A previous report 
outlined p38δ induced inactivation of ERK1/2 (31) however, 
we did not find any change in ERK1/2 or indeed JNK1/2/3 
(Fig. 3D and E).
Finally, the physical location of a protein either in the 
nucleus or the cytoplasm directly influences its biological 
function. Members of the p38 family do not contain either a 
nuclear localisation signal (NLS) or a nuclear export signal 
(NES) but their subcellular localisation can be regulated in part 
by their interacting proteins (32). We compared the subcellular 
localization of p38δ and p-p38 in KE-3 transfected cells with 
endogenous p38δ expression in KE-6 cells. As expected p38δ 
Figure 2. Oesophageal squamous cell carcinoma cell lines lacking endog-
enous expression of p38δ MAPK have a higher proliferation rate. KE-3 and 
-8 cell lines (lacking endogenous p38δ expression) and KE-6 and -10 cell 
lines (expressing endogenous p38δ expression) were seeded (3x104) and 
counted for 24-120 h. The results shown are mean ± SE of three independent 
experiments.
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Figure 3. Generation of active p38δ (p-p38δ) MAPK fusion proteins. (A) A schematic representation of MKK6b-p38δ or MKK6b(E)-p38δ MAPK fusion 
protein. The coding region of p38δ was fused in frame to the 3'-end of the stop codon-less MKK6b or MKK6b(E) through a peptide linker (Gly-Glu)5. 
(B) Western blot analysis of KE-3 cells stably transfected with empty vector (pcDNA3), wild-type p38δ, p-p38δ and p-p38δDN. Cells were analysed by immu-
noblot using antibodies specific for p38δ (i), p-p38 (ii) and MKK6 (iii). Aliquots of 30 µg protein lysate for each cell line were loaded on a 10% SDS-PAGE 
gel. The results shown are representative of four independent experiments. (C) Transfected and non-transfected KE-3, KE-6 and KE-10 cells were analysed to 
determine the amount of activated i.e., phosphorylated p38δ expression using the human phospho-p38δ (T180/Y182) ELISA commercial kit (R&D Systems). 
The ELISA assay was carried out according to the manufacturer's protocol. The results shown are mean ± SE of three independent experiments. Significant 
(***p<0.001) changes from control non-transfected KE-3 cells. (D) The human phospho-MAPK array shows the effects of stably transfecting KE-3 cells with 
p38δ and p-p38δ. Arrays were incubated with 200 µg of cell lysate. (E) Corresponding pixel density for p38α, -β, -δ and -γ, MKK-6, ERK1/2 and JNK1/2/3 
phosphorylation in non-transfected and transfected KE-3 cells. (F) Immunohistochemical subcellular localization of p38δ and p-p38 in KE-3 non-transfected 
cells and cells transfected with p38δ and p-p38δ. KE-6 cells were or were not treated with anisomycin (30 µM). (G) Nuclear and cytoplasmic localization of 
p38δ and p-p38 in KE-3 and KE-6 cells. The results shown are representative of four independent experiments (F and G).
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and p-p38 were absent from both compartments in non-trans-
fected KE-3 cells (Fig. 3F). p38δ and p-p38 were detected in 
both the cytoplasm and the nucleus of KE-3 stably transfected 
cells (Fig. 3F). This pattern of expression correlated with the 
subcellular localization of p38δ and p-p38 in KE-6 cells in the 
presence and absence of anisomycin (30 µM). To confirm our 
immunohistochemical findings cytosolic and nuclear extracts 
were prepared from transfected and non-transfected KE-3 and 
KE-6 cells and examined by western blot analysis. The use of 
PARP as a nuclear-restricted marker and Paxillin as a cyto-
solic marker ensured that there was no cross contamination 
between the subcellular fractions (21). Similar results were 
observed demonstrating the presence of p38δ and p-p38 in 
both the cytoplasm and nucleus of KE-3 and -6 cells (Fig. 3G).
KE-3 cells transfected with p38δ and p-p38δ MAPK show 
reduced proliferation. Uncontrolled cellular proliferation is a 
hallmark of cancer. To investigate if loss of p38δ expression 
specifically drives the higher growth kinetics observed in 
Fig. 2 we compared the growth rates of KE-3 non-transfected 
and transfected cells. We observed a significant (p<0.001) 
time-dependent decrease in the proliferation rate of KE-3 cells 
when transfected with wild-type p38δ compared with non-
transfected cells and cells transfected with empty pcDNA3 
vector (Fig. 4A). This anti-proliferative effect was amplified 
further in KE-3 cells transfected with active p-p38δ (Fig. 4A). 
KE-3 cells transfected with p-p38δDN demonstrated the same 
proliferation rate as non-transfected cells or cells transfected 
with pcDNA3 only (Fig. 4A).
To further examine the hypothesis that p38δ is anti-
proliferative in OESCC we employed a siRNA approach using 
the KE-6 cell line which expresses endogenous p38δ (Figs. 1, 
3F and G). KE-6 cells were transiently transfected with p38δ 
siRNA or control siRNA as previously described (23). We 
Figure 4. Effect of p38δ and p-p38δ MAPK expression on cell proliferation. (A) KE-3, KE-3 pcDNA3, KE-3 p38δ, KE-3 p-p38δ and KE-3 p-p38δDN cells were 
seeded (3x104) and counted for 24-120 h. The results shown are mean ± SE of three independent experiments. Significant (***p<0.001) changes from control 
non-transfected KE-3 cells. (B) Western blot analysis of KE-6 cells transiently transfected or not transfected with p38δ siRNA or control siRNA for 24-96 h. 
Cells were analysed by immunoblotting using a p38δ antibody. Aliquots of 30 µg protein lysate were loaded on a 10% SDS-PAGE gel. The results shown are 
representative of three independent experiments. (C) Densitometric analysis was performed to analyse % knockdown of KE-6 p38δ protein. (D) KE-6 cells 
(3x104) transfected with p38δ siRNA or control siRNA were seeded and counted for 24-96 h. The results shown are mean ± SE of three independent experi-
ments each done in triplicate. Significant (***p<0.001) changes from control siRNA transfected KE-6 cells.
O'CALLAGHAN et al:  A NOVEL INVESTIGATION OF p38δ MAPK IN OESOPHAGEAL CANCER412
observed a 51.9±6.5% reduction in KE-6 p38δ expression 
at 24 h following p38δ siRNA transfection which increased 
to 72.6±2.6% by 96 h when compared to control siRNA 
transfected KE-6 cells (Fig. 4B and C). No change in p38δ 
expression was observed when KE-6 cells were transfected 
with control siRNA for all time-points studied (24-96 h) (only 
24 h is shown in Fig. 4B). A significant (p<0.001) increase in 
cell proliferation was observed for KE-6 cells transfected with 
p38δ siRNA compared to cells transfected with control siRNA 
for all time-points studied (Fig. 4D). The anti-proliferative 
Figure 5. Effect of p38δ and p-p38δ MAPK on KE-3 cell migration and anchorage-independent growth. KE-3, KE-3 pcDNA3, KE-3 p38δ, KE-3 p-p38δ and 
KE-3 p-p38δDN cells were analysed for cell migration (A-C) and anchorage-independent growth D). (A and B) p38δ and p-p38δ inhibit KE-3 migration at 
24 h (A, Boyden Chamber) and 24 and 48 h (B, wound healing). (C) Representative wound healing images at 0, 24 and 48 h. Wound healing rates decrease in 
p38δ and p-p38δ transfected KE-3 cells. The results shown are representative of three independent experiments. (D) Anchorage-independent growth potential 
of KE-3 non-transfected and transfected cells were measured by their ability to form colonies on soft agar. Plates were stained with 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide to visualize colonies. The number of colonies per plate is shown. The results shown are mean ± SE of four independent 
experiments (A, B and D). Significant (**p<0.01; ***p<0.001) changes from control non-transfected KE-3 cells.
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effect was observed even in the absence of active p38δ in 
KE-6 cells (Fig. 3C). This effect on proliferation may be inde-
pendent of its kinase activity as has previously been reported 
for p38α in regulating HeLa cell proliferation (33) and p38γ in 
rat intestinal epithelial cells (34).
p38δ and p-p38δ MAPK play a role in migration and 
anchorage-independent growth of KE-3 cells. A key charac-
teristic of cancer cells is their ability to migrate and progress 
from primary tumours to metastases in distant organs. A 
recent report summarizes the roles of p38 MAPKs in cancer 
invasion and metastasis (35). This review, however, as in 
previous reports documents the roles of p38 family as a whole 
or p38α (10,13). We examined the role of p38δ in OESCC 
cell migration using both a Boyden chamber assay and a 
wound healing assay. We observed a 66±7.5 and 88.7±1.9% 
decrease in migration after 24 h for KE-3 p38δ and p-p38δ 
cells respectively compared to non-transfected cells (Fig. 5A). 
In addition p38δ and p-p38δ induced a significant decrease in 
KE-3 migration at 24 h [55.65±1.5 and 75.65±0.3% (p<0.001), 
respectively] and 48 h [37.9±0.8, (p<0.01) and 82.7±1.4%, 
(p<0.001) respectively] compared with non-transfected KE-3 
cells using a wound healing assay (Fig. 5B and C). Finally, 
to further examine the influence of p38δ and p-p38δ on the 
growth characteristics of KE-3 cells, we measured their ability 
to grow in an anchorage-independent manner. Non-transfected 
KE-3 cells growing in soft agar for 21 days gave rise to 175±18 
colonies/plate (Fig. 5D). This was similar to the number of 
colonies/plate that grew for cells transfected with empty vector 
(160±20) or p-p38δDN (177±21) (Fig. 5D). In contrast, however, 
p38δ and p-p38δ transfected cells produced a significant 
(p<0.001) decrease in colony numbers in p38δ transfected 
cells (13±3) with no colonies observable for p-p38δ transfected 
cells (Fig. 5D).
Discussion
Oesophageal cancer is a highly aggressive treatment-refrac-
tory disease with a high mortality rate (2,5,6). As conventional 
therapy is ineffective, targeting specific potential molecular 
tumour markers may prove to be the future of oesophageal 
cancer treatment. Despite current studies of molecular targets 
in oesophageal cancer (36), we are still somewhat hindered by 
limited knowledge of the genes and pathways involved in the 
tumourigenesis of the oesophagus when it comes to treatment.
Emerging role(s) for p38 MAPKs in different aspects of 
cancer has recently been outlined. To-date the best studied and 
reviewed isoform in cancer is p38α. It has been characterized 
as both a potential tumour suppressor (25,37-39) and tumour 
promoter (29,35). In comparison the role(s) of p38δ in cancer 
is largely uncharacterised. The limited current knowledge 
pertaining to p38δ, however, also alludes to disparate role(s) 
for this kinase in tumour development. An oncogenic role 
for p38δ has been suggested in p38δ-deficient mice that have 
reduced susceptibility to skin carcinogenesis (40) as well as 
promoting head and neck squamous carcinoma cell growth 
(29). In contrast a very recent study outlined a role for p38δ 
as a tumour suppressor in mouse fibroblasts (41). In our 
study outlined here we show for the first time the differential 
expression of p38δ in OESCC cell lines and in vivo. The loss 
of p38δ expression provides a survival advantage for OESCC 
which demonstrates increased cell proliferation, migration and 
contact inhibition. Re-introduction of p38δ, however, leads to 
reversal of these tumourigenic effects. Thus, recent evidence 
(41) as well as our present study suggests that targeting p38δ 
may offer a powerful protection against carcinogenesis. 
Targeting p38 MAPK isoforms or pathways for therapeutic 
purposes, however, should perhaps be strictly dependent on 
cell context, tumour cell type and tumour stage.
The fusion of p38δ to its upstream kinase MKK6b or 
active MKK6b [MKK6b(E)] generated a constitutively active 
p38δ which was used as a tool to study its specific effect(s) 
in OESCC. Re-introduction of p38δ (with subsequent acti-
vation) or active p-p38δ into KE-3 OESCC attenuated cell 
proliferation, migration and anchorage-independent growth. 
The strength and duration of p38 activation has been shown 
to play a crucial role in determining cell fate. Strong activa-
tion has been shown to induce apoptosis whereas lower levels 
results in cell survival (27,39). In our study we observed strong 
anti-proliferative, anti-migratory effects as well as effects on 
anchorage-independent growth upon re-introduction of p38δ 
into KE-3 cells which subsequently became active. These 
antitumourigenic effects were amplified further in KE-3 cells 
transfected with constitutively active p-p38δ. It is possible that 
owing to the localization of both p38δ and p-p38δ in the nucleus 
and the cytoplasm of OESCC that this kinase may modify its 
target(s) either structurally or subcellularly. We are presently 
researching whether they are in free form or docked with 
specific cytoplasmic or nuclear partners (24). Furthermore, 
p38δ and p-p38δ induced antitumourigenic effects in OESCC 
may arise by a combination of both phosphorylation-dependent 
and independent effects as previously described (33,34).
There are many paradigms in the literature of cross-talk 
between different MAPK pathways. In this instance, however, 
when KE-3 cells were stably transfected with p38δ or p-p38δ 
we did not observe changes in either p38 isoform (α, -β and -γ), 
ERK1/2 or JNK1/2/3 expression (data not shown) or activa-
tion levels. This is in agreement with a recent bio-informatics 
analysis of MAPK pathways which specifically identified 
that persistent activation of p38δ is resistant to interaction 
with other MAPKs (42). This lack of interference from other 
MAPKs permits us to specifically study the effects of p38δ on 
cell cycle control, pathway components and regulatory mecha-
nisms in OESCC which is currently ongoing in our laboratory. 
In addition negative feedback mechanisms have been shown to 
contribute to fine-tuning p38 MAPK activity levels. One such 
report outlines an increase in MKK6 expression and stability 
in p38α-/- cardiomyocytes from transgenic mice (43). We did 
not observe a correlation between the presence or absence of 
p38δ expression in OESCC cells and MKK expression. Of 
notable exception is MKK3 whose expression is absent from 
KE-3 and -8 cells (both negative for p38δ) but present in KE-4, 
-5, -6 and -10 cells (all positive for p38δ). However, this pattern 
of expression does not hold for KYSE-70 and OE-21 OESCC 
cell lines which express MKK3 but are also negative for p38δ 
protein expression.
Reports of the involvement of p38 MAPKs in a variety 
of different pathological conditions is continuing to increase 
fuelling interest in the development of potent and specific 
drugs for modulating the activity of these kinases. Presently 
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there are a number of p38 inhibitors undergoing clinical trials 
for the treatment of inflammatory diseases (44,45). Results 
arising from our study demonstrate that loss of p38δ expres-
sion in OESCC provides a more sinister phenotype with 
increased proliferation, migration and anchorage-independent 
growth. Thus, it is possible that isoform specific activation 
(rather than inhibition) of p38δ may provide a therapeutic 
benefit for patients with OESCC which express this isoform. 
In addition, how p38δ activators may interact and enhance 
the effectiveness of traditional therapeutics in combination 
therapy warrants attention.
In conclusion, our results reveal previously undocumented 
p38δ differential expression and function in OESCC. We iden-
tified a subset of OESCC cell lines as well as human primary 
and metastatic tumour samples that exhibit downregulation of 
p38δ protein expression. We now provide evidence that loss of 
expression of this particular isoform may be a mechanism by 
which OESCC cells promote carcinogenesis. Re-introduction 
of p38δ into OESCC negative cell lines suppressed different 
aspects of tumourigenesis. Our data warrant further inves-
tigation to understand the important physiological and 
pathophysiological effects of p38δ in OESCC and is currently 
in progress. This knowledge should identify which pathways, 
substrates or regulators are affected specifically by p38δ in 
providing an antitumourigenic effect in OESCC. Armed with 
this information uncovering novel targets and the develop-
ment of new therapeutics may be possible for this common 
cancer that continues to demonstrate a generally poor clinical 
outcome.
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p38δ MAPK phenotype: an indicator of chemotherapeutic
response in oesophageal squamous cell carcinoma
Carol O’Callaghana, Liam J. Fanningb and Orla P. Barrya
We recently documented p38δ differential expression and
function in oesophageal squamous cell carcinoma
(OESCC). This study expands upon these findings and
investigates whether p38δ status in OESCC can influence
response(s) to cytotoxic drugs. The antiproliferative effect of
conventional cisplatin and 5-fluorouracil (CF) treatment was
compared with the recently reviewed triple regime of
cisplatin, 5-fluorouracil and doxorubicin (ACF). p38δ-
positive and p38δ-negative cell lines were employed using
cell-growth and clonogenic assays. Key regulators of
intrinsic and extrinsic apoptotic pathways were measured.
Wound-healing assays and a Boyden chamber were used to
investigate the effect of drug treatments on cell migration.
Functional networks were analysed in terms of changes in
MAPK expression. p38δ-negative OESCC is less sensitive
to standard CF chemotherapy compared with p38δ-positive
cells. However, following ACF treatment p38δ-negative cells
showed markedly decreased proliferation and cell
migration, and increased apoptosis. ACF induced apoptosis
through the extrinsic pathway involving Fas activation,
caspase-8 and caspase-3 cleavage and degradation of
PARP. Loss of mitochondrial membrane potential (ΔΨm)
was observed but downregulation of multidomain
proapoptotic proteins, as well as BH3-only proteins,
suggests involvement of pathways other than the
mitochondrial pathway. Interestingly, induction of p38 and
ERK1/2, but not JNK1/2, was observed following ACF
treatment. p38δ-negative OESCC is more resistant to
traditional CF treatment compared with p38δ-positive
OESCC. In light of these results, p38δ phenotyping of
tumour tissue may be of considerable value in deciding on
an optimal therapeutic strategy for patients with p38δ-
negative OESCC. Anti-Cancer Drugs 00:000–000 © 2014
Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
Oesophageal cancer is a highly aggressive and fatal
malignancy and is the seventh most common cancer
worldwide [1]. Oesophageal squamous cell carcinoma
(OESCC) is an exceptionally drug-resistant tumour.
Although surgery is the best modality in terms of local
control [2], outcomes following resection for OESCC
remain unsatisfactory because of locoregional and
distant failure [3]. Preoperative chemotherapy or chemo-
radiotherapy with a fluoropyrimidine/platinum combina-
tion – that is, a cisplatin and 5-fluorouracil (CF) regimen –
has been the standard treatment for locally advanced
disease since the 1980s. At present, multimodal therapy
is being investigated for different stages of OESCC, even
if the tumour is operable [4]. Preoperative chemotherapy
with docetaxel plus CF (DCF) has recently been inves-
tigated (with or without radiotherapy) with good local
control and pathological remission rate being recorded [4,
5]. More recently doxorubicin, cisplatin and 5-fluorouracil
(ACF) have undergone a revival, demonstrating higher
response rates than CF treatment, a good safety profile
and promising long-term outcomes for patients with
highly advanced oesophageal carcinoma [6–8].
The involvement of p38 MAPKs in a variety of patholo-
gical conditions is continuing to fuel interest in this par-
ticular family of kinases. It consists of four isoforms: p38α
(MAPK14), p38β (MAPK11), p38γ (MAPK12) and p38δ
(MAPK13), which to date remains the least studied iso-
form [9]. The expression of p38 as a family has previously
been outlined in oesophageal cancer, as well as in other
cancer types [10–13]. We recently outlined for the first
time the differential expression of individual p38 isoforms
in cancer and in particular OESCC [14,15]. We now know
that loss of p38δ expression in OESCC affords a more
sinister phenotype, with increased proliferation, migration
and anchorage-independent growth, thus identifying
p38δ as a possible molecular target in OESCC [15].
Advancing our studies a step further we evaluated whe-
ther p38δ status could influence cytotoxic responses to
drug treatments in OESCC. We used both negative and
positive p38δ cell lines isolated from patients with
OESCC with no prior treatment, as previously outlined
by us [15]. Cell viability, wound healing, migration and
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apoptosis were evaluated following standard CF treat-
ment and ACF treatment. To carry out functional net-
works expression analysis, we also analysed changes in
ERK1/2, JNK1/2 and p38 MAPK expression. In conclu-
sion, our study indicates that p38δ status may be a pre-
dictor of response to chemotherapy in OESCC patients.
Materials and methods
Reagents
All chemicals and cell culture reagents were purchased
from Sigma Aldrich (Wicklow, Ireland) and primary anti-
bodies from Cell Signalling Technologies (Hertfordshire,
UK), unless otherwise stated.
Cell culture
The KE oesophageal squamous cancer cell lines were a
kind gift from Professor T. Fujii, Kurume University
School of Medicine, Japan [15–18]. Cells were cultured in
RPMI-1640 supplemented with 10% foetal calf serum,
100 µg/ml streptomycin and 100U/ml penicillin. KE cell
line features have been summarized previously by us [15].
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide assay
Cell viability was assessed using the 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
assay, which depends on the ability of viable cells to
reduce MTT to a coloured formazan product, as described
previously [19].
Boyden chamber cell migration in-vitro assay
Cells were plated in starvation medium at a density of
3× 104 cells/well onto a 96-well plate of the upper
chamber. The bottom chamber contained 10% foetal calf
serum as the chemoattractant. Cells were left to migrate
for 24 h through the matrigel filter (8 μm) and stained as
previously described [19].
Wound-healing assay
Cell migration was assessed using an in-vitro wound-
healing assay as previously described [20]. Cells migrat-
ing into the wound were photographed under a phase-
contrast microscope 48 h after wounding. Migration was
determined using the ImageJ (National Institutes of
Health, Bethesda, Maryland, USA) program as an average
closed area of the wound relative to the initial wound area
at 48 h after wounding.
Mitochondrial membrane potential (ΔΨm) assay
The decline of mitochondrial membrane potential (ΔΨm)
was assessed using a mitochondrial voltage-sensitive dye,
5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazole car-
bocyanide iodide (JC-1), according to the manufacturer’s
instructions [21]. The dye underwent a reversible change
in fluorescence emission from red (i.e. aggregate forms of
JC-1) to green (i.e. monomer forms of JC-1) as the mito-
chondrial membrane potential decreased. Briefly, KE cells
were or were not treated with drugs for 24 h. Cells were
then washed twice with PBS and loaded with JC-1 for
30min at 37°C. Images were obtained using an inverted
fluorescence microscope (Olympus, Southend-on-Sea,
UK). The ratio of red to green fluorescence intensity,
which was indicative of a change in ΔΨm, was calculated
using the ImageJ software.
Immunoblot analysis
Supernatants used for immunoblotting with specific anti-
bodies, PARP, caspases-3 and 8, Puma, Bak, Bik, Bim, Bid,
Bax, p38, phospho-p38, JNK1/2, phospho-JNK1/2,
ERK1/2 and phospho-ERK1/2 (New England Biolabs,
Hertfordshire, UK), as well as Fas and FasL (Santa Cruz
Biotechnology, Santa Cruz, California, USA), have pre-
viously been described by us [14,15]. Chemiluminescence
detection was performed using SuperSignal WestDura
Extended Duration Substrate (Pierce Biotechnology,
Rockford, Illinois, USA), and bands were visualized using a
Syngene G:Box ChemiXR5 Gel Documentation System
(Syngene, Cambridge, UK). Images were quantified using
ImageJ software.
Colony formation assay
A colony formation assay determines whether cells can
recover from treatment. Following treatment, viable cells
were reseeded in fresh media (without drug) in a six-well
plate (in triplicate) and allowed to grow for 14 days.
Colonies were stained with MTT and subsequently
counted using ImageJ software.
Statistical analysis
Statistical comparisons were made by analysis of variance
with subsequent application of Student’s t-test, as
appropriate. The non-parametric Mann–Whitney U-test
pairwise comparisons were also performed. As the results
obtained using both methods were in agreement, only
results for the Student’s t-test are shown.
Results
p38δ MAPK-negative OESCC shows decreased
sensitivity to chemotherapeutic drugs
Monotherapy is not beneficial in the treatment of
patients with oesophageal cancer [22]. Thus, we eval-
uated the cell viability of KE p38δ-positive and p38δ-
negative OESCC cell lines (differential p38δ expression
was recently reported by us [15]) following double versus
triple drug treatments using a range of concentrations of
cytotoxic drugs. Interestingly, KE-3 and KE-8 (p38δ-
negative cell lines) are significantly less sensitive to CF
treatment compared with KE-4, KE-5, KE-6 and KE-10
(p38δ-positive cell lines; Fig. 1a–c). As docetaxel has
recently been added to the CF regime [4,5], we inves-
tigated the effect of DCF on cell viability. There was a
further decrease in KE-3 and KE-8 cell viability (Fig. 1a
and b). However, no further reduction in cell viability
was observed in the KE p38δ-positive cell lines upon
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DCF treatment using physiologically relevant drug con-
centrations (30 μmol/l; Fig. 1c) [23–25]. As doxorubicin
(together with CF) has recently re-emerged as a pro-
mising drug treatment strategy for patients with oeso-
phageal cancer [6–8], we also investigated its effects.
Interestingly, the greatest loss in KE-3 and KE-8
cell viability was after triple CF plus doxorubicin
(ACF) treatment (Fig. 1a and b). Of note, these results
are comparable with the loss in cell viability seen in the
p38δ-positive cells upon CF treatment at physiological
concentrations (Fig. 1c). Taking the results we obtained
with physiological drug concentrations of CF (30 μmol/l
each) a step further, we investigated the appropriate tri-
ple ACF drug treatment concentrations for KE-3 and
KE-8 cell lines. Using a range of doxorubicin drug con-
centrations, we ascertained that the best triple ACF
concentration using physiological concentrations of all
three drugs is 30 μmol/l each of CF and 1 μmol/l doxor-
ubicin (Fig. 1d). No significant further decrease in
cell viability was observed at a higher doxorubicin drug
concentration of 3 μmol/l (Fig. 1d).
As other chemotherapeutic drug combinations have also
been tested for their efficacy in patients with OESCC,
namely CF plus methotrexate [26], CF plus paclitaxel
[26,27] and CF plus hydroxyurea [28], we also investi-
gated these three additional drug combinations again
using a range of different drug concentrations.
Interestingly, KE-3 and KE-8 showed less sensitivity to
all three triple-drug combinations compared with ACF
treatment (Fig. 1e and f). Thus, as the greatest loss in
KE-3 and KE-8 cell viability was observed with triple
ACF treatment (Fig. 1a, b and d), all subsequent
experiments compared traditional CF treatment with
ACF treatment.
ACF treatment significantly delays wound healing and
migration compared with CF treatment
A key characteristic of cancer cells is their ability to
migrate and progress from primary tumours to metastases
in distant organs [15]. We examined whether the p38δ
status of OESCCs could influence their wound healing
and cell migration following drug treatment. Initially, we
identified the highest concentration of drug(s) that does
not lead to loss of cell viability – that is, 3 μmol/l of each
drug for CF and 300 nmol/l doxorubicin (data not shown).
Double CF treatment of KE-6 and KE-10 (p38δ-positive
cells) for 48 h brought about a significant delay in wound
healing, with a 60.0 ± 7 and 66.0 ± 1.2% loss in wound
healing, respectively, compared with untreated cells
(Fig. 2a and b). In contrast, CF treatment did not impair
the ability of KE-3 and KE-8 cells to migrate into the
wound (Fig. 2a and b). Triple ACF treatment, however,
significantly delayed the wound-healing ability of KE-3
and KE-8 cell lines, with a 72.8 ± 2.5 and 84.0 ± 3.9%
loss in wound healing at 48 h, respectively. There was a
further 15 ± 5.8% loss in wound healing upon ACF
treatment, compared with CF treatment alone, of KE-6
cells but no significant change in KE-10 cells (Fig. 2a and
b). Doxorubicin (300 nmol/l) alone did not have any
significant effect on the wound-healing ability of either
p38δ-positive or p38δ-negative cells (Fig. 2a and b).
Further, we compared the migration of p38δ-positive and
p38δ-negative cells following CF versus ACF treatment
using a Boyden chamber assay. Double CF treatment
induced a significant (78.7 ± 5.2 and 78.7 ± 7.8%, respec-
tively) decrease in cell migration of KE-6 and KE-10 cells
at 24 h; however, no significant change in cell migration
was observed upon CF treatment of KE-3 and KE-8 cells
(Fig. 2c). In contrast, triple ACF treatment of KE-3 and
KE-8 significantly decreased their cell migration by
75.9 ± 2.4 and 81.3 ± 6.9%, respectively (Fig. 2c).
Triple ACF treatment decreases mitochondrial membrane
potential and activates extrinsic pathways in p38δ negative
OESCCs
Initially, we investigated the involvement of the mito-
chondria in OESCC apoptosis using the JC-1 cationic
dye. It selectively enters the mitochondria and reversibly
changes in colour from red to green as the membrane
potential decreases [21]. KE-6 and KE-10 cells show a
marked decrease in ΔΨm following CF and ACF treat-
ment (Fig. 3a and b). Similar losses in ΔΨm in KE-3 and
KE-8 cells were observed only upon ACF treatment
(Fig. 3a and b). Doxorubicin alone did not alter the ΔΨm
of KE-6 and KE-10 cells, but it did produce a significant
(P< 0.01) decrease in the ΔΨm of KE-3 and KE-8,
comparable to that on CF treatment (Fig. 3a and b).
To further investigate the effects of CF-induced versus
ACF-induced apoptosis on KE p38δ-negative cells, intrinsic
(mitochondrial) and extrinsic (Fas) apoptotic pathways were
investigated. Expression of the relevant apoptosis-related
proteins was examined by western blot analysis. To inves-
tigate the role of the intrinsic mitochondrial pathway we
examined the expression levels of Bcl-2 family members
including multidomain proapoptotic proteins Bak and Bax,
as well as BH3-only proapoptotic proteins Puma, Bik, Bid
and Bim. Interestingly CF treatment downregulated all Bcl-
2 proapoptotic members examined, with further reductions
in expression being observed in the presence of ACF
treatment (Fig. 3c). The mitochondrial apoptotic pathway-
related caspase-9 was not cleaved (data not shown).
To investigate whether CF and ACF activate the
extrinsic apoptotic pathway, we examined the expression
levels of death receptor signalling-related proteins
including Fas, caspase-3 and caspase-8 and PARP.
Alterations in the expression of Fas and FasL, members
of the tumour necrosis family, have been reported pre-
viously in OESCC with Fas-activated apoptosis being
shown to limit the growth of OESCCs [29,30]. We
observed an increase in Fas expression when both KE-3
and KE-8 cells were treated with ACF, but not on CF
treatment, implicating the involvement of the extrinsic
4 Anti-Cancer Drugs 2014, Vol 00 No 00
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death pathway. The expression level of FasL was very
low in both cell lines, and there was no appreciable
change after treatment with CF or ACF (Fig. 3d). We
observed that ACF (but not CF) treatment of KE-3 and
KE-8 cell lines activated (cleaved) caspase-3 and caspase-
8, as well as activated (cleaved) their substrate PARP,
producing the 85 kDa proteolytic fragment indicative
of caspase activation and apoptosis (Fig. 3d). The
extrinsic apoptotic pathway-related caspases-6 and
caspase-7 were not cleaved upon CF or ACF treatment
(data not shown).
Triple ACF treatment induces p38 and ERK1/2 but not
JNK1/2 MAPK activation in p38δ-negative OESCC
To gain further insight into CF-induced versus ACF-
induced cytotoxic effects, we analysed MAPK expres-
sion. We observed p38 phosphorylation upon ACF
treatment but not CF treatment (Fig. 4a). CF induced
ERK1/2 phosphorylation, which was further enhanced
with ACF treatment (Fig. 4a). In contrast, JNK1/2 acti-
vation was not observed following either CF or ACF
treatment (Fig. 4a).
To assess whether p38 and ERK1/2 activation is causal to
the actions of our chemotherapeutics we used specific
pharmacological inhibitors of p38 and MEK. Interestingly,
both SB203590 (20 micromolar) and BIRB 796 (5 micro-
molar), inhibitors of p38α and p38β (but not p38γ and
p38δ) [24,31] did not prevent the antiproliferative effects of
either CF or ACF (Fig. 4b). In fact, in agreement with
recent reports (with similar cytotoxic drug combinations),
p38 blockade enhanced the cytotoxic effects of ACF
treatment significantly (but not CF treatment) at 24 h
(Fig. 4b) [24,25]. The enhanced antiproliferative effect of
p38 inhibition observed at 24 h with ACF was not obvious
at 48 h because of the high level of cell death at this time
point (Fig. 4b). The specific MEK inhibitor U0126 (20
micromolar) [32] brought about a significant abolition of
the effects of both CF and ACF drug treatments in both
cell lines, indicating that ERK1/2 may be directly involved
in drug-induced cytotoxicity (Fig. 4b).
Recovery of KE-3 and KE-8 cells following drug
treatments
One of the most important parameters for the efficacy of
chemotherapeutic drug treatments is the long-term effect
Fig. 2
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on cell viability. Thus, we evaluated the effects of CF,
doxorubicin alone and ACF treatment on the capacity of
KE-3 and KE-8 cells to recover in assays of clonogenic
growth. All three different drug treatments had a sig-
nificant effect on the recovery of both KE-3 and KE-8
cell lines (Fig. 5a and b). However, of note, cell
recovery following ACF treatment was never observed,
whereas colonies – that is, cell recovery – were observed
following treatment with CF or doxorubicin alone
(Fig. 5a and b).
Discussion
In this study, we focused on OESCCs, as this cell phe-
notype shows differential p38δ expression [15]. Loss of
this important serine/threonine kinase confers greater
tumourgenicity and may be a mechanism by which
OESCC promotes carcinogenesis [15]. The purpose of
this study was to determine whether differences in the
OESCC p38δ phenotype could influence the chemo-
sensitivity of OESCC to conventional CF versus ACF
drug combinations.
Single-agent response rates of 10–25% remain poor for
oesophageal cancer [22]. Further, the use of double CF is
of limited effectiveness in the treatment of patients with
OESCC, with respect to improving overall survival time
and patient quality of life [3,8]. Triple ACF combination
therapy was first reported as far back as 1983 [33], but of
late it has sparked renewed interest [4,8]. Doxorubicin is
an effective, widely used chemotherapeutic agent in the
treatment of a variety of solid tumours and malignant
haematologic diseases [34]. There are now reports doc-
umenting the usefulness and, importantly, the safety of
ACF therapy for the treatment of advanced oesophageal
carcinoma [7,8,35]. Despite the absence of phase III
clinical trials, ACF is currently used in the clinical setting
for treatment of patients with OESCC [8].
All three drugs in this study, cisplatin, 5-fluorouracil and
doxorubicin, used as monotherapy or double therapy
have been reported to induce intrinsic apoptosis in
oesophageal cancer [23,36]. We examined typical mar-
kers of both intrinsic and extrinsic apoptotic cell death
in our p38δ-negative cell lines. Although we observed
Fig. 4
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5-fluorouracil (30 μmol/l) and doxorubicin (1 μmol/l; ACF) for 24 h. The results shown in (a) are representative of four independent experiments,
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mitochondrial depolarization following ACF treatment,
there was no subsequent caspase-9 activation.
Interestingly, we also observed downregulation of Bcl-2
multidomain, as well as BH-3 proapoptotic proteins.
However, decreased expression of these intrinsic path-
way proteins is in agreement with a recent report on
oxaliplatin-induced apoptosis in squamous oesophageal
cancer cell lines [37]. Potentially, the presence of Bcl-2
multidomain and BH3-only proapoptotic molecules may
be an important predictor of p38δ-negative OESCC
response to combination therapy without being directly
involved. Our findings suggest that ACF suppresses cell
growth in p38δ-negative OESCC through extrinsic
apoptotic pathway activation of the Fas death receptor,
with caspase-8 and caspase-3 cleavage and subsequent
degradation of PARP.
There are many reports linking MAPK involvement
following exposure to mechanistically different che-
motherapeutic drugs [38]. However, their suppression
Fig. 5
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Recovery of KE-3 and KE-8 cells following chemotherapeutic drug withdrawal. The ability of p38δ-negative OESCC cell lines KE-3 and KE-8 to
recover after drug withdrawal was assessed with a colony formation assay (clonogenic assay). KE-3 and KE-8 cells were or were not treated (Unt)
with cisplatin (30 μmol/l) and 5-fluorouracil (30 µmol/l; CF), doxorubicin (1 μmol/l; Dox) alone or the combination of all three drugs (ACF) for 48 h.
Viable, adherent cells were counted and reseeded (1000 cell/well) in a six-well plate (in triplicate) in the absence of drug. (a) Fourteen days later,
colonies were stained with MTT. Each well shown is a representative image of nine similar wells (three independent experiments). (b) Colonies were
counted using ImageJ software. ***P<0.001, **P<0.01, *P<0.05, significant changes from untreated cells. MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide; OESCC, oesophageal squamous cell carcinoma.
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and activation and indeed the absence of any role in
apoptosis have been attributed to all three MAPKs [38
–40]. Thus, the activation of MAPKs by chemother-
apeutic drugs and the subsequent consequences of
MAPK activation appear to be very much cell-type spe-
cific [39]. Although we observed p38 activation upon
ACF treatment, our findings with the p38 pharmacolo-
gical inhibitors do not support a direct role for p38 MAPK
activity in drug-induced cytotoxicity. In contrast, ERK1/2
activation may play a more direct role as its inhibition
through MEK can partly reverse the antiproliferative
effects of both CF and ACF treatments.
The increased antiproliferative and proapoptotic effects
of ACF treatment over CF treatment in our study suggest
that the former may be considered as mainstay treatment
of patients with p38δ-negative OESCC. It remains to be
investigated whether patients with p38δ-negative
OESCC may benefit more from ACF treatment com-
pared with classical CF treatment, and whether or not
ACF treatment can influence overall survival. Further
investigations into the mechanistic strategies under-
pinning p38δ-negativity related loss in drug sensitivity
are warranted. The clonogenic assay is a valuable tool in
gauging long-term consequences of single, double and
triple chemotherapy in p38δ-negative OESCC. This
assay closely mirrors the clinical situation in which
patients are treated with chemotherapeutic drugs in a
pulsed rather than a continuous manner. After 2 weeks of
treatment, our ACF-treated p38δ-negative OESCC cells
never recovered. Although we observed a statistically
significant reduction in colony formation on CF double or
doxorubicin treatment, cell recovery was always
observed, clearly demonstrating resistance. In general,
the MTT assay demonstrated lower cytotoxic activity
than the clonogenic assay with these drugs. Of note, a
high degree of correlation between both assays is not
always apparent, and it may be influenced by both cell
type and anticancer drug type [41–43]. Thus, unlike ACF
treatment, the limited efficacy of CF or doxorubicin
alone could provide an opportunity for cancer persistence
in patients with p38δ-negative OESCC.
In summary, the present study indicates that p38δ may
be a significant predictor of treatment response in
patients with p38δ-negative OESCC. p38δ genotyping of
pretreatment biopsy may potentially be a useful predictor
of response to chemotherapy and ultimately prognosis in
OESCC patients. Our data support the value of known
p38δ status in the decision process used to inform the
optimal treatment of patients with OESCC.
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1. Introduction 
Renal cell carcinoma (RCC) is the third leading cause of death among urological tumours, 
annually afflicts about 150, 000 people globally and causes nearly 78, 000 deaths (Jemal et al., 
2008; Zbar et al., 2003). RCC is an epithelial tumour consisting of several different 
histological subtypes of which clear cell RCC is the prototypical. Traditionally treatment has 
been via surgery and immunotherapy. Surgical resection is appropriate for some patient 
cohorts including those with isolated metastases. However, recurrence is common even 
when the primary and metastatic sites have been aggressively resected (Couillard & deVere 
White, 1993). RCC is highly unresponsive to standard chemotherapy and the use of cytokine 
therapy with interleukin (IL)-2 or interferon (IFN)-ǂ is associated with low rates of response 
and high rates of toxicity (Oudard et al., 2007). Thus, development of new therapies 
continues to be crucial to improve outcomes in patients with RCC. 
The increased understanding of the molecular structure and aberrant activity of signalling 
pathways  in RCC has lead to a flurry of research activity in the arena of targeted therapies 
namely anti-angiogenic vascular endothelial growth factor (VEGF) and the mammalian 
target of rapamycin (mTOR), both of which are involved in the pathogenesis of RCC 
(Mulders, 2009). These advancements in an obvious therapeutic gap have significantly 
improved the progression free survival (PFS) of patients with RCC. Despite the explosion in 
drug development during the past five years, however, PFS for patients with metastatic 
RCC (mRCC) still remains poor as none of the current targeted therapies possess the 
capacity to induce remission. In addition these drugs provide dose-limiting toxic side effects 
and so we are still faced with a considerable task in developing newer safer therapeutics for 
use as either first line agents or in combination with existing ones.  
2. Targeted therapy for RCC 
As the understanding of the molecular biology underlying RCC has increased, various 
components of growth and angiogenic signal transduction pathways have been identified as 
rational targets for therapeutic intervention in the treatment of patients with RCC and 
mRCC. The VEGF/VEGF receptor (VEGFR) pathway is one such target. VEGF expression is 
induced under hypoxic conditions triggering several mechanisms that promote 
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angiogenesis (Ellis & Hicklin, 2008). Members of the VEGF family namely VEGF-A, -B, -C 
and –D regulate angiogenesis through binding to the related family of receptor tyrosine 
kinases (RTKs): VEGF receptors (VEGFR)-1, -2 and -3.  The VEGFR consists of an 
extracellular ligand binding site, a transmembrane ǂ-helical domain and an intracellular 
protein-tyrosine kinase region. Once activated, phosphorylated tyrosine residues on these 
receptor kinases provide high-affinity binding sites for components of the Raf/MEK/ERK 
(MAP Kinase) and PI3K/AKT signalling pathways which mediate cell growth and 
angiogenesis. Inhibition of the pathway involving VEGF-A activation of VEGFR-2 has 
undergone the most extensive investigation in recent years. This pathway mediates the 
formation and preservation of the blood vessel network which is vital for tumour cell 
survival and proliferation (Casanovas et al., 2005). In RCC, VEGF is also a powerful tumour 
growth factor. RCCs over-express the different VEGFRs and also produce as paracrine and 
autocrine growth factors, large amounts of VEGF (Qian et al., 2009). In tumours the VEGF 
isoforms –C and –D have been shown to activate the VEGFR3 receptor and to initiate the 
development and maintenance of a lymphatic system (He et al., 2005). Targeting this process 
in cancer treatment is now in the early stages of development. Presently, different 
therapeutic avenues exist for inhibiting the activation of receptor tyrosine kinases (RTKs). 
Monoclonal antibodies (mAbs) against growth factor ligands, or antibody fragments against 
RTK ligand-binding domain, can prevent binding of growth factors, thus attenuating RTK 
activity. Alternatively, the protein kinase can be targeted. Drugs that bind reversibly to the 
ATP-binding site within the kinase domain or to a small pocket that is immediately adjacent 
to the ATP-binding site are used to block the enzymatic activity of the kinase. Due to 
similarities within the amino acid structure of the kinase domain, ATP-competitive 
inhibitors can have cross reactivity with other structurally related kinases.   
2.1 VEGF- antibody therapy/ligand competitors 
2.1.1 Bevacizumab 
Bevacizumab is an i.v. administered humanized monoclonal IgG1 antibody that targets and 
neutralises all major isoforms of circulating VEGF (Presta et al., 1997). By binding with high 
affinity to VEGF, bevacizumab inhibits its interaction with tyrosine kinase receptors thereby 
preventing the initiation of an angiogenic signal (Figure 1). This weakens existing 
microvasculature and production of new vasculature is inhibited. The loss of vascularisation 
eventually leads to tumour cell death (Jain, 2005). 
Bevacizumab is used in the treatment of a wide range of cancer types including RCC, colon, 
brain and lung cancers. It was approved in 2009 for the first-line treatment of patients with 
advanced RCC or mRCC in combination with IFN-ǂ. FDA approval came as a result of the 
phase III AVOREN trial. RCC patients following previous nephrectomy were randomized to 
receive either bevacizumab plus IFN-ǂ or placebo plus IFN-ǂ (Escudier et al., 2007a). The 
addition of bevacizumab to IFN-ǂ significantly improved both the overall response rate 
(ORR) (30.6 vs. 12.4%, P<0.0001) and PFS (10.2 vs. 5.4 months). Subgroup analysis, however, 
indicated that the advantage in PFS related only to favourable and intermediate risk patients 
and not to the poor risk group. The final overall survival (OS) results reported no significant 
difference between the bevacizumab and control groups (23.3 vs. 21.3 months). However, 
these findings may have been influenced by the fact that 63% of patients in the placebo plus 
IFN-ǂ group and 55% of patients in the bevacizumab plus IFN-ǂ group received second-line 
therapy with other agents (Escudier et al., 2010). 
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Fig. 1. Schematic representation of the signalling pathways contributing to angiogenesis  
and cell proliferation in RCC and the targeted agents which inhibit them. HIF activation 
upregulates the expression of VEGF, PDGF, EGF and Ang-2. Binding of these ligands to 
their receptors induces downstream activation of MAPK signalling, resulting in 
angiogenesis. Abbreviations; VHL: Von Hippel Lindau; HIF: hypoxia-inducible factor; 
mTOR: mammalian target of rapamycin; PI3K: phosphoinositol-3 kinase; VEGF(R): vascular 
endothelial growth factor (receptor); PDGF(R): platelet-derived growth factor (receptor); 
EGF(R): epidermal growth factor (receptor); TGF-ǃ: transforming growth factor beta;  
Ang-2: angiopoietin 2. Inhibitory arrows (┤) show clinically available or in development 
therapeutic agents for the treatment of RCC and mRCC. 
2.1.2 Aflibercept 
Aflibercept is an engineered fusion protein designed to interact with all isoforms of VEGF 
and to placental growth factor (PLGF), thereby preventing them from binding to VEGFRs. It 
is composed of the extracellular domain 2 of VEGFR1 and extracellular domain 3 of 
VEGFR2 fused to an Fc segment of human IgG1 (Wulff et al., 2002). Aflibercept appears to 
have a greater affinity for VEGF than bevacizumab, resulting in a more complete 
obstruction of VEGF signalling. This together with the fact that aflibercept binds to PLGF 
while bevacizumab does not, may explain why preclinical studies have shown aflibercept to 
be more effective than bevacizumab (Kim et al., 2002). 
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2.2 Receptor tyrosine kinase inhibitors (RTKIs) 
The intracellular kinase activity of growth factor receptors also provides an attractive target 
for therapeutic intervention. Three receptor tyrosine kinase inhibitors are currently available 
for the treatment of clear cell RCC and many more are in development (Figure 1). By 
targeting the intracellular tyrosine kinase domain of multiple growth factor receptors these 
drugs inhibit not only the VEGF pathway but also the platelet derived growth factor (PDGF) 
pathway as well as other kinases critical for proliferation and angiogenesis. 
2.2.1 Sorafenib 
Sorafenib was the first multi-targeted kinase inhibitor approved for the treatment of patients 
with cytokine-refractory advanced RCC or mRCC. It is a potent small molecule dual-action 
inhibitor, first identified in in vitro assays as an inhibitor of Ras signalling. Sorafenib also 
inhibits VEGFRs and PDGFRs (Wilhelm et al., 2004). As multiple kinases are inhibited by 
sorafenib it is difficult to determine the relative contribution of each target to the anti-
tumour activity of this drug. Preclinical studies in a variety of cancer models suggest 
sorafenib acts on both tumour cells and tumour vasculature by inhibiting cellular 
proliferation and angiogenesis pathways (Wilhelm et al., 2008). 
Sorafenib’s approval by the FDA in 2005 was as a result of a phase III trial namely; 
Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET). All 
participants had advanced RCC and had experienced disease progression in spite of the 
then standard cytokine therapy. Patients were randomly assigned to receive sorafenib or 
placebo (Escudier et al., 2007b). At the first interim analysis the ORR was 10% for sorafenib 
compared with 2% for placebo. Also, sorafenib treated patients had a significant PFS 
advantage of 5.5 months versus 2.8 months for the placebo group. At this point those 
patients initially assigned to receive placebo were allowed to switch to sorafenib, potentially 
obscuring differences in end point results. In fact the final analysis of all patients registered 
in the trial did not show a statistically significant difference in the OS of the initial intent-to-
treat population (17.8 vs. 15.2 months in sorafenib and placebo treated patients, 
respectively). However, a secondary analysis was performed in which patients who crossed 
over to sorafenib after initial treatment with placebo were censored. This demonstrated a 
significant benefit for sorafenib treatment with a median OS of 17.8 months compared to 
14.3 months for placebo (Escudier et al., 2009). In terms of side effect profile sorafenib 
treated patients reported fewer adverse effects and a better overall quality of life than those 
receiving IFN-ǂ. Both hypertension and skin toxicity, in general, are common manifestations 
of toxicity with multiple tyrosine kinase inhibitors, with incidences of 17% and 40% 
respectively, outlined in the TARGET trial. Other adverse effects associated with sorafenib 
treatment are diarrhea (Escudier et al., 2007b), and an additive loss of muscle mass above 
that usually observed in patients with advanced cancer (Antoun et al., 2010). 
2.2.2 Sunitinib 
Sunitinib is a RTKI designed to prevent cells from responding to the elevated level of pro-
angiogenic signals associated with RCC. It is an orally available, small molecule, multi-
targeted kinase inhibitor with activity against VEGFRs, PDGFRs, fms-like tyrosine kinase 
receptor-3 (FLT-3) and stem cell factor receptor (c-KIT). Sunitinib is classified as an ATP 
competitive inhibitor. It received accelerated approval by the FDA in 2006 based on 
responses in patients with mRCC who had failed cytokine therapy. Regular approval was 
obtained in 2007 as a result of a phase III study evaluating sunitinib as a first-line therapy 
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compared with IFN-ǂ. Results of the trial demonstrated a considerable advantage for 
sunitinib over IFN-ǂ and both OS rates and PFS were significantly higher for the sunitinib 
treated group (Motzer et al., 2007a; Motzer et al., 2009). Sunitinib is now the standard of care 
for initial therapy of good to moderate prognosis mRCC patients. OS of over two years is a 
marked improvement on the one year OS rates observed before the advent of targeted 
kinase inhibitor therapy (Motzer et al., 2009).  
As sunitinib inhibits multiple kinases and therefore blocks several signalling pathways, 
numerous side effects are associated with treatment. These, however, are favourable when 
compared to the significant toxicity profile associated with the previous therapeutic option 
for RCC i.e. immunotherapy. In the phase III trial which led to the approval of sunitinib, 
slightly different toxicity profiles were observed between the two treatment groups. 
Sunitinib treated patients more commonly experienced diarrhea, hypertension, hand-foot 
syndrome, neutropenia and thrombocytopenia while fatigue occurred more commonly in 
the IFN-ǂ group. Overall, however, patients who received sunitinib reported a better quality 
of life compared to patients treated with IFN-ǂ. 
2.2.3 Pazopanib 
Pazopanib is the latest multiple kinase inhibitor approved for the first-line treatment of 
patients with advanced RCC. It inhibits signalling by VEGFRs, PDGFRs, and c-KIT by 
competitively binding to the ATP enzymatic pocket of the RTK. Pazopanib differs from 
sunitinib and sorafenib as the range of targets it potently inhibits is narrower. FDA approval 
followed a phase III trial involving clear cell (or predominately clear cell) RCC patients with 
no previous treatment history (54%), or who had progressed following a single prior 
cytokine treatment (46%) (Sternberg et al., 2010). Patients were randomized to receive either 
pazopanib or placebo daily. In the overall population the primary end point of PFS was 
significantly higher in the pazopanib group compared to placebo (9.2 vs. 4.2 months). The 
ORR for the pazopanib group was 30%. Although a non-significant improvement in median 
OS of 22.9 months for the pazopanib group versus 20.5 months for the placebo group was 
reported, this analysis had been confounded by the early and high level of patient cross-
over from placebo to pazopanib upon progression (Sternberg, 2010). 
The toxicity profile associated with pazopanib treatment is similar to both sunitinib and 
sorafenib. The most common effects observed include hypertension, diarrhea, nausea, hair 
depigmentation and asthenia. Clinical trials cannot easily be compared, however, as evident 
from a phase III trial of pazopanib which demonstrated lower incidence of hand-foot 
syndrome, diarrhea and asthenia compared with sunitinib and sorafenib. Conversely, the 
incidence of hypertension associated with pazopanib treatment in the phase III trial is high 
(40%) when compared to sunitinib and sorafenib trials (Lang & Harrison, 2010).  
2.2.4 In development 
The new generation of RTKIs in development for the treatment of RCC display greater 
potency and selectivity for VEGFRs compared to the established kinase inhibitors 
discussed above. It is hoped that this increased potency and high specificity will give rise 
to enhanced anti-tumour activity. Furthermore, the absence of off-target (non-VEGFR) 
inhibition may result in less toxicity than is normally associated with kinase inhibitors in 
general. 
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2.2.5 Axitinib (AG-013736) 
Axitinib is an orally available RTKI. Picomolar concentrations are sufficient for axitinib to 
inhibit VEGFRs, while it inhibits PDGFR-ǃ and c-KIT at low nanomolar concentrations (Hu-
Lowe et al., 2008). In this study and others (Inai et al., 2004) axitinib in mouse models has 
demonstrated anti-tumour, anti-angiogenic and anti-metastatic properties as well as having 
an ability to induce central necrosis. Axitinib is now being looked at for the second-line 
treatment of advanced RCC. In a phase II trial of patients with cytokine-refractory mRCC 
(Rixe et al., 2007), axitinib displayed an ORR of 44.2% and median PFS of 15.7 months, 
greater than any agent investigated for mRCC treatment to-date. However, this efficacy has 
not been examined in comparative trials with other targeted agents.  
2.2.6 Cediranib (AZD2171) 
Cediranib is an ATP-competitive inhibitor of RTKs and like axitinib is a potent inhibitor of 
VEGFRs and PDGFR-ǃ at subnanomolar concentrations (Gomez-Rivera et al., 2007; Takeda 
et al., 2007). In a recent placebo controlled phase II trial, a median PFS of 12.1 months was 
observed in patients treated with cediranib compared to 2.7 months for those who received 
placebo. Furthermore, the mean change in tumour size in patients receiving cediranib was a 
20% decrease versus a mean increase of 19% for patients randomized to placebo (Bhargava 
& Robinson, 2011). 
2.2.7 Tivozanib (AV-951) 
Tivozanib is an orally active RTKI and is selective for VEGFRs at picomolar concentrations 
(Nakamura et al., 2006). In a phase II trial, clear cell RCC patients who had undergone 
nephrectomy displayed an ORR of 32% to 1.5 mg tivozanib daily. The median PFS for 
patients was 14.8 months (Bhargava et al., 2010). This potency combined with the selectivity 
of tivozanib for VEGFRs reduces the inhibition of off-target kinases, resulting in less 
toxicity. The most common side effects reported in this trial were hypertension and 
dysphonia while incidences of other toxicities usually associated with RTKIs (fatigue, 
diarrhea and hand-foot syndrome) were low. The occurrence of fewer toxicities together 
with the specificity of tivozanib allows it to be safely combined at full dose and scheduled 
with another targeted agent. For example, preliminary results of a phase I trial combining 
tivozanib and the mTOR inhibitor temsirolimus in mRCC patients reported no dose limiting 
toxicities (Fishman et al., 2009). 
2.2.8 Regorafenib 
Regorafenib is a potentially significant multi-kinase inhibitor in that it inhibits the 
traditional targets of VEGFRs, PDGF-ǃ and fibroblast growth factor (FGF)-1, as well as the 
endothelium specific receptor tyrosine kinase Tie-2. The inhibition of targets both within 
and external to the VEGF axis may offer valuable therapeutic advantages when it comes to 
avoiding resistance and enhancing the efficacy of targeted therapy. A phase II trial of 
regorafenib in mRCC patients showed that those receiving regorafenib had a 27% partial 
response and a 42% stable disease rate (Eisen et al., 2009).  
2.2.9 Dovitinib (TKI258) 
Dovitinib is also a promising agent targeting VEGFRs, PDGFRs, FLT3 as well as FGF 
receptors namely FGFR3. This is significant as not only does the FGF angiogenic signalling 
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pathway provide a potential mechanism of resistance to VEGF therapy, activating mutations 
or upregulation of FGF/FGFRs have been identified in RCC (Emoto et al., 1994). Members 
of the FGF family are involved in proliferation, differentiation and migration of a range of 
cell types. A phase II study of dovitinib in previously treated advanced RCC or mRCC 
patients has reported results which include a median PFS and OS of 6.1 and 16 months, 
respectively (Angevin et al., 2011). 
3. Targeting EGFR 
Disruption of EGF signalling is a popular therapeutic mechanism in a number of cancer 
types. As the expression of ligands of the EGFR (including EGF and the angiogenesis 
promoting transforming growth factor (TGF)-ǃ) is upregulated by VHL inactivation, the 
validity of this approach in clear cell RCC was explored in a number of trials. In single-agent 
EGFR inhibitor trials, gefitinib (a selective EGFR TKI) and cetuximab (a recombinant mouse-
human mAb) were administered as monotherapy. Neither agent demonstrated a complete 
or partial response (Staehler et al., 2005). In a randomized phase II trial, clear cell RCC 
patients received either bevacizumab or bevacizumab plus the EGFR inhibitor erlotinib. The 
results showed identical median PFS and ORR between the two groups (Bukowski et al., 
2007). EGFR inhibition therefore does not appear to be a viable approach for the treatment 
of clear cell RCC. A possible reason for this may be the rarity of EGFR mutations in RCC, 
when compared to other cancers (Dancey, 2004). Furthermore, the activators of EGFR 
signalling which are upregulated in RCC can also initiate VEGFR signalling, making the 
inhibition of EGFR alone insufficient to disrupt tumour proliferation and angiogenesis. 
4. Targeting PDGF 
Members of the PDGF family include PDGF-A, -B, -C and –D and mediate their effects 
through binding to PDGFR-ǂ and –ǃ leading to the activation of various signalling 
pathways giving rise to tumour growth (Guo et al., 2003; Pietras et al., 2003). High levels of 
PDGF-D has been shown to be associated with RCC and its progression has been linked to 
PDGF-D/PDGFR-ǃ signalling and PDGFR-ǂ expression (Sulzbacher et al., 2003). Although 
there is not a wealth of data published on PDGF and PDGFR in RCC there are currently 
many drugs either clinically available or in development that target this RTK as outlined 
above and in Figure 1. 
5. Limitations of currently available targeted agents 
Comparison of the relative benefit of each targeted treatment in advanced RCC and mRCC 
is exceptionally difficult. Trials conducted targeting RTKs involved varied patient 
populations with differences in prior treatment status, prognosis and histology of RCC. 
According to Flaherty & Puzanov the easiest comparison is ORR. This comparison identifies 
two groups: bevacizumab and sorafenib generate a response rate of ≤10%, while sunitinib 
and pazopanib induce a response in ≥30% of patients. However, this does not reflect any 
clinical benefit as higher response rates do not appear to be associated with improved PFS 
or OS (Flaherty & Puzanov, 2010).  
Resistance is a major problem with both older and newer therapies as well as mono and 
poly therapies. Few complete responses are associated with any of the targeted therapies 
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discussed. All patients will eventually develop resistance and progress, usually within 8 to 
16 months (Sosman & Puzanov, 2009). A number of mechanisms have been described 
outlining how resistance can occur. Sorafenib, sunitinib and pazopanib therapy is associated 
with a significant increase in VEGF production (Deprimo et al., 2007; Kumar et al., 2007; 
Veronese et al., 2006). Resistance may occur if the increase in VEGF reaches a threshold that 
can overcome the inhibition. Another hypothesis has been examined in animal models of 
tumour angiogenesis. These models outline that the inhibition of VEGF or VEGFR leads to 
upregulation of PDGF and basic FGF (bFGF) production by tumours activating alternative 
pathways for angiogenic signalling (Fernando et al., 2008). Despite the overlap of targets 
and inevitable resistance, however, RCC tumours do not appear to be totally cross-resistant 
to sequential therapy with different agents. In a phase II study, patients who had progressed 
on sunitinib underwent treatment with sorafenib. Objective responses resulted in 10% of 
patients with a median PFS of 16 weeks (Di Lorenzo et al., 2009). A possible explanation is 
that when the initial inhibitor is removed (once resistance has occurred and the tumour has 
progressed), cells revert back to VEGF signalling.  
Presently, it is hoped that combination therapies for the treatment of patients with RCC will 
see improvements in PFS, ORR and OS greater than those seen with any single agent. There 
are two options for the combination of targeted therapies i.e. vertical blockade and horizontal 
blockade. Vertical blockade involves targeting several steps along a single signalling pathway. 
This is an attractive option in treatment of RCC combining drugs which inhibit hypoxia-
inducible factor (HIF) translation, VEGF or VEGFR. This approach could provide an 
opportunity to overcome the resistance associated with increased levels of VEGF. A phase I 
trial evaluated the potential benefit of combining sorafenib with bevacizumab in mRCC 
patients (Sosman, 2008). Due to toxicity, the dosage of both agents had to be reduced from 
their usual levels to half the recommended dose of bevacizumab and one-quarter the usual 
dose of sorafenib. Despite this a 50% response rate was observed, a vast improvement on the 
10-15% achieved with full doses of each agent alone. The combination strategy of horizontal 
blockade entails simultaneously targeting more than one signalling pathway crucial for 
tumour cell survival and proliferation. Horizontal blockade is an appealing option as 
combining VEGFR inhibitors with other tyrosine kinase inhibitors may prove useful in 
preventing resistance by the mechanism of alternative angiogenic pathways. 
6. PI3K/AKT/mTOR signalling pathway 
The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin-
pathway (PI3K/AKT/mTOR-pathway) is one of the most common aberrant pathways 
activated in cancer, regulating many known oncogenic pathways including apoptosis, 
proliferation and cell migration  (Carracedo & Pandolfi, 2008; Klein & Levitzki, 2009; Inoki 
et al., 2005). Activation of PI3K occurs at the cell membrane in response to several RTKs 
including the EGFR, the insulin-like growth factor receptor (IGFR) and the PDGFR leading 
to the production of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3). 
Levels of PIP3 are tightly regulated by the tumour suppressor phosphatase and tensin 
homolog (PTEN), serving as the negative regulator of the PI3K/AKT/mTOR pathway. AKT 
is recruited to the cell membrane by PIP3 and phosphorylated to its fully activated form by 
phosphoinositide dependent protein kinase 1 (PDK1). Activated AKT can directly activate 
mTOR by phosphorylation or indirectly through inactivation of the tuberous sclerosis 
complex 2 (TSC2) which normally inhibits mTOR (Figure 2).  
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mTOR is a 290kDa serine/threonine protein kinase and is highly conserved from fungi to 
mammals. It forms multimolecular complexes and plays a key role in diverse signalling events 
such as growth, proliferation, survival, angiogenesis and protein synthesis (Dowling et al., 
2010).  mTOR responds to a range of diverse stimuli including growth factors, cytokines, and 
hormones but also acts as an important sensor of cellular stresses imposed by hypoxia, pH or 
osmotic alterations, heat shock, oxidative stress and DNA damage. Defects in signalling 
components upstream of mTOR including excessive growth factor receptor activation or 
mutation correlates with a more aggressive tumour and a worse prognosis (Faivre et al., 2006). 
mTOR exists as two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2) (Figure 2). Regulation of mTOR activation is controlled by two components of the 
tuberous sclerosis complex (TSC) comprising TSC1 (hamartin) and TSC2 (tuberin). When they 
heterodimerise mTOR is inhibited and can no longer phosphorylate downstream substrates 
(Dancey, 2005). Phosphorylation of TSC2 by AKT, however, promotes dissociation of the 
TSC1/TSC2 complex which activates the guanosine triphosphate Rheb. Rheb activity 
subsequently activates mTORC1. mTORC1 is bound to raptor (regulatory-associated protein 
of mTOR), mLST8 (mammalian lethal with sec 13 protein 8), also known as GǃL and PRAS40 
(proline-rich AKT substrate 40kDa) which is phosphorylated by AKT causing its dissociation 
from raptor and its subsequent activation. mTORC2 complexes with rictor (rapamycin-
insensitive companion of mTOR), mSIN1, mLST8 and Protor-1 or Protor-2. Both complexes 
phosphorylate the hydrophobic motifs of AGC kinase family members. mTORC1 
phosphorylates S6K and the inhibitory binding protein 4E-BP1 at Thr37 and Thr 46 which acts 
as a priming event essential for the phosphorylation of Ser65 and Thr70 leading to the release 
of eIF4E and subsequent assembly of the eIF4F complex (Gingras et al., 2001).  Activation of 
S6K in turn leads to phosphorylation of inhibitory sites (Ser636 and 639) on the insulin 
receptor substrate-1 (IRS-1), thereby suppressing IRS-1 mediated activation of the PI3K/AKT 
pathway. mTORC2 activation leads to phosphorylation of AKT, SGK1 and PKC which control 
cell survival and cytoskeletal organization (Figure 2). 
mTORC1 is frequently dysregulated in cancer (Guertin & Sabatini, 2007). Loss or 
inactivation of tumour suppressors such as p53, liver kinase B1 (LKB1), PTEN and TSC1/2 
which antagonise PI3K-dependent activation of mTORC1 can promote tumourigenesis via 
increased signalling through mTORC1 (Sabatini, 2006; Shaw et al., 2004). Moreover, 
increased levels and/or phosphorylation of downstream targets of mTORC1 have been 
reported in various human malignancies in which they correlate with tumour 
aggressiveness and poor prognosis (Guertin & Sabatini, 2007; Mamane et al., 2006). 
Collectively these studies suggest that aberrant mTORC1 signalling is linked to 
dysregulated control in cancer and for this reason the spotlight has been shone on mTORC1 
as a possible therapeutic target for anti-cancer therapy. 
6.1 mTOR and RCC 
As outlined above the signalling network controlled by the PI3K/AKT/mTOR axis is very 
often found to be dysregulated in human malignancy. There is a wealth of data to support 
the notion that signalling through mTOR is dysregulated in RCC. This makes this cancer 
type in particular an attractive target for mTOR inhibitor therapy. RCC demonstrates 
increased phosphorylation of AKT, S6K1 and mTOR as well as increased expression of 
PTEN and disrupted TSC complexes (Pantuck et al., 2007). mTOR activation ultimately 
leads to increased production of angiogenic factors leading to a highly vascularised tumour 
which is evident in RCC.  
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Fig. 2. Schematic representation of mTOR signalling, phosphatidylinositide 3’OH-
kinase/AKT/mTOR signalling, Wnt/ǃ-catenin signalling, HGF signalling and core NOTCH 
signalling pathways. In relation to growth factor signalling, PI3K activates downstream 
mTORC1 giving rise to HIF-1ǂ activation, which in turn switches on gene expression 
required for angiogenesis and cell proliferation in endothelial cells. HGF binding to MET 
leads to its phosphorylation and subsequent recruitment of adapter proteins such as Gab1, 
Gab2, SHC, STAT3 and PI3K with downstream activation of Ras/MAPK and PI3K/AKT 
pathways. Wnt pathway activation leads to hypophosphorylated ǃ-catenin where it 
translocates into the nucleus and forms a complex with TCF. Ligand binding to the Notch 
receptor leads to release of the intracellular domain (ICD) of Notch. Notch ICD 
subsequently translocates into the nucleus, where it forms a complex with essential cofactors 
such as the transcription factor CSL. This complex mediates the transcription of target genes 
such as HES and HEY. Abbreviations; RTK: receptor tyrosine kinase; PI3K: 
phosphatidylinositol 3-kinase; PDK1: phosphoinositide dependent protein kinase 1; PTEN: 
phosphatase and tensin homolog; mTOR: mammalian target of rapamycin; TSC: tuberous 
sclerosis complex; mLST8: mammalian lethal with sec 13 protein 8; PRAS40: prolin-rich AKT 
substrate 40 kDa; IRS-1: insulin receptor substrate-1; VHL: von Hippel-Lindau; HIF: hypoxia 
inducible factor; TCF; T cell factor; HGF: hepatocyte growth factor; CSL: CBF1, Suppressor 
of hairless, Lag-1; HES: hairy enhancer of split; Hey: hairy enhancer of split related with 
YRPW. Inhibitory arrows (┤) show clinically available or in development therapeutic targets 
for the treatment of RCC and mRCC. 
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mTOR inhibitors were originally developed as immunosuppressants for patients 
undergoing transplantation with rapamycin (also known as sirolimus or Rapamune®) being 
the first mTOR inhibitor identified. Clinical experience and subsequent trials identified the 
anti-proliferative (Schmelzle & Hall, 2000) and anti-angiogenic (Del Bufalo et al., 2006) 
properties of these agents in various cancer types, including RCC. This is of particular 
clinical importance as RCC demonstrates significant uncontrolled angiogenesis. More 
specifically mTORC1 activity is inhibited by rapamycin and associated analogs 
(temsirolimus, everolimus and ridaforolimus) which are collectively termed rapalogs. 
mTORC2, however, is largely insensitive to rapalogs, although prolonged treatment may be 
able to reduce mTORC2 activity in some cell types (Sarbassov et al., 2006). 
6.1.1 mTOR inhibitors-rapamycin 
Rapamycin is a naturally occurring macrolide triene antibiotic that acts as a specific, 
allosteric inhibitor of mTORC1 (Hay & Sonenberg, 2004). Rapamycin either associates with 
the immunophilin FKBP12 (FK 506-binding protein of 12 kDa) and the resulting complex 
interacts with the FRB (FKBP12-rapamycin binding) domain located in the C-terminus of 
mTOR or directly to FRB. This binding prevents the binding of mTORC1 to raptor which is 
thought to uncouple it from its substrates 4E-BPs and S6Ks (Oshiro et al., 2004). The ability 
of rapamycin to suppress both cellular proliferation and growth through its interaction with 
mTORC1 indicated that it could be used as an anti-cancer agent (Faivre et al., 2006). This 
lead to the development of rapamycin analogs (rapalogs) which display the same 
pharmacodynamics as the parent drug but have improved pharmacokinetic properties.  
6.1.2 Temsirolimus 
Temsirolimus (Torisel®), also known as CCI-779, is a macrocyclic lactone and a water-
soluble ester prodrug of rapamycin. It is administered by i.v. injection, is rapidly cleared 
from the plasma and is converted by CYP4503A4/5 into rapamycin. It binds with high 
affinity to the immunophilin FKBP12 and selectively inhibits mTORC1 with no effect on 
mTORC2 (Le Tourneau et al., 2008). Inhibition of mTORC1 kinase activity results in 
decreased phosphorylation of S6K and 4E-BP1. In addition by inhibiting mTORC1 it has 
been shown to reduce expression of HIF-1ǂ and -2ǂ which leads to decreased VEGF and 
PDGF expression (Thomas et al., 2006). Thus, the clinical efficacy of temsirolimus reflects 
bimodal phamacodynamics resulting in null signalling of RTK cascades and inhibition of 
protein synthesis can result in inhibition of cell cycle and tumourigenesis. Temsirolimus was 
approved as first-line therapy for patients with mRCC in the US and Europe in May 2007 
demonstrating improved efficacy in poor-prognosis patients in comparison with IFN-ǂ 
(Hudes et al., 2009). The efficacy of temsirolimus in the second-line setting remains unclear. 
However, recently it has demonstrated disease control rate of 70% and overall median time 
to progression of four months in intermediate to poor-prognosis patients with VEGF-
refractory mRCC (Mackenzie et al., 2011).  Side effects of the drug include diarrhoea, 
asthenia stomatitis, rash, nausea, anorexia, hypertension, dyspnea, hyperglycaemia, 
hypercholesterolemia and anemia.  
6.1.3 Temsirolimus plus immunotherapy combination  
Temsirolimus was first investigated as combination therapy with IFN-ǂ in phase I/II study 
(Motzer et al., 2007b). This study revealed that the combination of the two had an accepted 
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safety profile and displayed anti-tumour activity in patients with mRCC. A pivotal phase III 
trial was also carried out comparing temsirolimus or temsirolimus plus IFN-ǂ with IFN-ǂ 
alone in patients with mRCC. In summary, the median OS time was significantly longer 
with temsirolimus alone than with IFN-ǂ alone (10.9 months versus 7.3 months, 
respectively), and combination therapy with temsirolimus and IFN-ǂ did not lead to a 
significantly longer median OS time than with IFN-ǂ alone (8.4 months versus 7.3 months, 
respectively) (Hudes et al., 2007).  
6.1.4 Temsirolimus plus anti-angiogenics combination 
Phase I studies examining the efficacy of temsirolimus with sunitinib have not shown 
sufficient safety to-date. Trials using temsirolimus in combination with sunitinib and 
temsirolimus in combination with sorafenib were discontinued owing to significant toxicity 
(Patel et al., 2009). The efficacy of temsirolimus plus bevacizumab has also been studied but 
again based on toxicity profiles a phase II trial has indicated that this combination cannot be 
recommended for patients with mRCC (Negrier et al., 2011). In summary, the combined 
usage of temsirolimus and anti-angiogenic agents has proved disappointing to date, phase 
III trials are still continuing whose results may shed light on possible best practice for 
combination therapy in the near future.    
6.2 Everolimus 
Everolimus (Afinitor®) is an orally bioavailable hydroxyethyl ester of rapamycin. Like 
temsirolimus it is an inhibitor of mTORC1 and was approved on March 30th, 2009 for 
patients suffering from advanced RCC following failure when treated with previous TKI 
therapy (de Reijke et al., 2009). It has now become the standard second-line agent after the 
approved first-line drugs sunitinib and/or sorafenib (Soulieres, 2009).  
6.2.1 Everolimus plus anti-angiogenics combination 
The combination of everolimus and the VEGFR TKIs are showing promise in initial studies. 
A phase II study of everolimus plus sorafenib has been prompted following successful 
completion of a phase I trial with the combination of both demonstrating acceptable toxicity 
and evidence of anti-tumour activity in patients with previously untreated mRCC 
(Harzstark et al., 2011). Similarly, a phase II trial of everolimus plus sunitinib is warranted 
following successful maximum-tolerated dose of everolimus plus sunitinib in patients with 
mRCC (Kroog et al., 2009). In contrast, everolimus plus imatinib is not recommended for 
future studies following results from a phase II study in previously treated patients with 
mRCC as the combination did not demonstrate a three month PFS rate of 49%, which did 
not meet the specified criteria for continuation (Ryan et al., 2011). Finally, in a phase II trial 
with two different mRCC patient cohorts, one with and one without prior TKI treatment, 
everolimus plus bevacizumab was active and well tolerated (Hainsworth et al., 2010). This 
regimen which uses full doses of each agent, is being evaluated as first-line therapy in a 
phase II study, RECORD (Renal Cell Cancer Treatment With Oral RAD 001 Given Daily)-2. 
6.3 Ridaforolimus 
The mTOR inhibitor, ridaforolimus (formerly deforolimus), is yet another promising 
rapamycin analog in RCC treatment but not yet approved. Ridaforolimus (also known as 
AP23573), a non-prodrug of rapamycin, has demonstrated prominent anti-proliferative 
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activity against a range of cancers (Hartford et al., 2009). The most common side effects 
associated with ridaforolimus to-date include stomatitis, fatigue, diarrhoea and 
thrombocytopenia. Important additional information such as OS and the safety profile of 
ridaforolimus has yet to be identified. 
6.4 Combination therapy 
At present there are numerous ongoing and planned studies evaluating the efficacy of both 
temsirolimus and everolimus with other targeted therapies including VEGF ligand 
competitors, VEGFR inhibitors, AKT inhibitors, p70S6R inhibitors, tubulin inhibitors, IGF-
1R antagonists and Bcr-ABL antagonists (Pal & Figlin, 2011). Information pertaining to the 
successes associated with these exploratory trials is limited at present. 
6.5 New mTOR inhibitors  
Presently, temsirolimus and everolimus are approved for the treatment of mRCC. Despite 
their efficacy there are some drawbacks including resistance but also the fact that they are 
both specific mTORC1 inhibitors that lack activity against mTORC2. This allows the latter to 
activate AKT. Indeed, increased activation i.e. phosphorylation of AKT has been 
documented in tumour biopsies isolated from patients treated with rapalogs (O'Reilly et al., 
2006). In addition the crosstalk with other pathways such as MEK/ERK on AKT could limit 
the efficacy of mTOR inhibitors. There are reports of newer drugs targeting mTORC2 as well 
as MAPK interacting pathways. New mTOR inhibitors are not rapalogs but are small 
molecule inhibitors resembling TKIs. They bind competitively and reversibly to the mTOR-
ATP binding pocket blocking the enzymatic activity of the kinase. Compounds such as 
PP242, Torin1, WYE-354, WYE-125132 (WYE-132) and Ku-006379 suppress both mTORC1 
and mTORC2 displaying more dramatic effects on cell growth, proliferation and cell cycle 
than rapamycin. This has been attributed to suppression of mTORC2 mediated AKT 
phosphorylation at Ser 473 and greater inhibition of 4E-BP1 phosphorylation (Thoreen et al., 
2009). Active site mTOR inhibitors have the potential to be potent anti-cancer drugs as they 
inhibit mTORC2 activity which rapamycin and its analogs do not but also because they 
counteract the activation of AKT which can occur as a result of rapamycin-mediated 
disruption of the mTOR/S6K/IRS-1 negative feedback loop. To-date these potentially 
effective cancer therapeutic agents have yet to be investigated in patients with RCC or 
mRCC. 
7. Targeting mTOR upstream moieties – PI3K 
PI3K is a lipid kinase that converts phosphatidylinositol bisphosphate to PIP3. PI3K further 
recruits PDK1 and AKT to the cell membrane where PDK1 activates AKT. Because of its 
location upstream of mTOR, it has become another attractive target for treatment of patients 
with RCC to be used solely or in combination with existing mTOR inhibitors.  Recently, 
activation of the PI3K pathway has been shown to be directly linked to adverse clinical 
outcomes in patients with RCC (Merseburger et al., 2008). The PI3K inhibitor prototypes 
wortmannin and LY294002 have been shown to decrease AKT activation and significantly 
reduce cell growth in vitro particularly in PTEN-null or PI3K-overexpressing RCCs with the 
latter also demonstrating in vivo tumour regression (Sourbier et al., 2006). Given that PI3K is 
highly expressed in RCC metastases, which are themselves radioresistant, newer generation 
PI3K inhibitors such as PX-866, with better bioavailability and less toxicity, may show utility 
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as radiosensitizers in RCC metastases. Another chemotherapeutic drug, PI-103, has recently 
been shown to independently inhibit both PI3Kǂ and mTOR (Fan et al., 2006) thereby 
overcoming a potential disadvantage of rapamycin in the treatment of AKT-dependent 
tumors. In fact GDC-0941 which is derived from PI-103 has demonstrated improved 
bioavailability and partial response in breast and ovarian cancer patients.  Ongoing studies 
using PI3K and dual PI3K/mTOR inhibitors such as SAR245408, SAR245408, NVP-BKM120 
and NVP-BEZ235 modified for clinical use are ongoing (Maira et al., 2008). These have yet to 
be tested in patients with RCC. 
7.1 PDK1 
Similar to PI3K, a key mediator of AKT activation, PDK1 is poised to respond to targeted 
inhibition with blockade of AKT signalling (Figure 2). Both highly specific inhibitors, such 
as AR-12 (Arno), and inhibitors with dual function on PDK1/PI3K or PDK1/AKT are in 
development (Najafov et al., 2010).  These targets present another potentially robust way to 
render the AKT pathway completely inhibited, mitigating the confounding issues of 
inhibition of each of the AKT family members. 
7.2 AKT 
AKT, also known as protein kinase B (PKB), can be activated by a number of mechanisms 
including PIP3 activation of PDK1 at Thr308 and at Ser473 by mTORC2 (Figure 2). 
Decreased expression of the inhibitory PTEN can also activate AKT (Hara et al., 2005). Upon 
phosphorylation (p-)AKT is known to interact with a large set of substrates, including 
mTOR and through inactivation of the TSC impacts many key cellular processes such as cell 
cycle progression and apoptosis, both of which play a vital role in oncogenesis. Recently, p-
AKT expression was shown to be correlated with pathologic variables and survival, with 
higher levels of cytoplasmic p-AKT expression compared with nuclear p-AKT in primary 
RCC  (Pantuck et al., 2007).  Recently, a specific p-AKT (S473) inhibitor, WYE-132, has been 
tested on RCC cell lines and achieved complete regression of A498 large tumours when 
administered with bevacizumab (Yu et al., 2010). 
8. Targeting downstream moieties-HIF-1α 
RCC is closely linked to mutations in the von Hippel-Lindau (VHL) gene. A deletion of one 
allele of VHL has been identified in >90% of patients with sporadic clear cell RCC (Gnarra et 
al., 1994). The remaining VHL allele is also commonly inactivated by a deletion event or 
altered methylation (Nickerson et al., 2008). In normal cell conditions, the VHL protein is a 
direct inhibitor of the activity of a key regulator of responses to hypoxia i.e.  HIF. HIFs are 
heterodimers and contain an ǂ and a ǃ subunit. VHL targets the HIF-ǂ isoform for 
proteasomal degradation. This prevents it from translocating to the nucleus and binding to 
HIF-ǃ which would result in the induction of over 200 target genes that contain hypoxia-
response elements in their promoters. The best described of the numerous HIF targets are 
growth factors which promote angiogenesis and proliferation (Figures 1 and 2). Under 
hypoxic conditions, VHL itself is degraded. This stabilizes HIF-ǂ within the cell and allows 
it to accumulate in the nucleus. Here it initiates the expression of genes which promote cell 
survival and growth. The effects of biallelic inactivation of the VHL gene in clear cell RCC 
cells mirror those which result from VHL degradation in response to hypoxia. Expression of 
HIF targets such as VEGF, PDGF, and TGF-ǃ are upregulated.  
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The VHL gene product, pVHL, is an E3 ubiquitin ligase that promotes the proteasomal 
degradation of HIF-1ǂ, -2ǂ and -3ǂ. Consequently, renal carcinomas with mutations in VHL 
have high steady-state levels of HIF expression. Functional studies show that HIF is 
sufficient for transformation caused by loss of VHL, thereby establishing HIF as the primary 
oncogenic driver in kidney cancers (Maranchie et al., 2002). mTOR increases the translation 
of HIF-1 and HIF-2 which in turn can drive the expression of angiogenic factors such as 
VEGF, PDGF-ǃ, bFGF and TGF-ǂ. Thus, much interest has recently focused on targeting one 
or both HIF factor signals for cancer therapy. EZN-2968 is an RNA antagonist that 
specifically binds and inhibits HIF-1ǂ mRNA in vitro and in vivo (Greenberger et al., 2008). 
In this study it proved to be a potent, selective, and durable antagonist of HIF-1 mRNA and 
protein expression resulting in reduced prostate and glioblastoma tumor cell growth. Its 
efficacy in RCC has not yet been investigated. In contrast, targeting heat shock protein 
90(HSP90) with 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) 
which reduces levels of HIF-1ǂ in the setting of VHL loss has shown promising results in 
clinical trials including patients with RCC (Kummar et al., 2010; Ronnen et al., 2006). 
Furthermore, YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (an agent originally 
developed for circulatory disorders) and YC-1 analogs, 1, 3-disubstituted selenolo[3,2-
c]pyrazole derivatives have now been found to repress HIF-1 activity and inhibit renal 
cancer tumour growth (Chou et al., 2010). Lastly, PX-478 (S-2-amino-3-[4'-N,N,-bis(2-
chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride) an inhibitor of 
constitutive and hypoxia-induced HIF-1ǂ levels and thus HIF-1 activity has proven efficacy 
in vitro with different RCC cell lines (Koh et al., 2008).  
8.1 HIF-2α 
HIF-2ǂ, also referred to as endothelial PAS domain protein 1 shares 48% homology with HIF-
1ǂ. Current knowledge pertaining to the regulation of HIF-2ǂ is somewhat lacking when 
compared with HIF-1ǂ. However, the tumourigenic role of HIF-2ǂ has been studied most 
extensively in RCC. Both in vitro and in vivo studies with human kidney tumours suggest that 
HIF-2ǂ is more oncogenic than HIF-1ǂ (Maranchie et al., 2002; Raval et al., 2005).  RCC 
tumours express either HIF-1ǂ and HIF-2ǂ or HIF-2ǂ alone, leaving HIF-2ǂ expression as a 
common point of VHL mutated cancers. Moreover, consistent with this data, HIF-1ǂ 
expression has been shown to decrease in advanced lesions as HIF-2ǂ expression increases 
(Mandriota et al., 2002). Resulting from these observations HIF-2ǂ is now being studied as the 
more important isoform for therapeutic intervention of RCC. Although several potentially 
important drugs targeting HIF-1ǂ have been described (as outlined above) reports of HIF-2ǂ 
are few. One potentially effective drug that needs further investigation is emetine, a protein 
synthesis inhibitor that blocks the translocation of peptidyl-tRNA from the acceptor site to the 
donor site on the riboosome. Emetine is not a novel drug (in fact it has been around for almost 
a century) but has been used for the treatment of bacterial, viral and amoeba Entamoeba 
histolytica infections as well as being used as an antiemetic  (Zhou et al., 2005). It has been 
shown to induce HIF-2ǂ downregulation in the setting of VHL loss in RCC cell lines. Further 
analysis of this drug is necessary for its efficacy in the in vivo setting of RCC. 
9. HIF targets-Ror2 
Regulated receptor tyrosine kinase-like orphan receptor 2 (Ror2) is a member of a family of 
orphan RTKs. Ror2 is found heavily phosphorylated in the kidney of RCC patients and is 
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expressed highly in human RCC cell lines indicating a role for Ror2 in the pathology of RCC 
(Wright et al., 2009). In fact suppressed expression of Ror2 results in reduced expression of 
matrix metalloproteinase (MMP)-2, whose upregulation correlates with advanced stages of 
RCCs (Slaton et al., 2001). Thus, Ror2 represents a promising therapeutic target for patients 
with RCC. Although the direct target of Ror2 kinase activity has yet to be deciphered, it does 
appear to act as a mediator of Wnt signals in the further activation of tumour cell signalling 
events (Figure 2). There are currently no clinically available drugs targeting Ror2 for the 
treatment of RCC. 
9.1 Carbonic anhydrase IX 
Carbonic anhydrase IX (CAIX), a hypoxia-induced protein, is unique in that it is a cell 
surface protein that is present in human tumours but absent from normal tissue (Figure 2). It 
is found to be highly expressed in clear cell RCC and is associated with grade (Genega et al., 
2010). Currently, CAIX is being pursued as a prognostic indicator, diagnostic tool and a 
future potential targeted therapy for the treatment of RCC. Presently, there exists a chimeric 
antibody (cG250) used for its localisation, but also for direct antibody-dependent cellular 
cytotoxicity (ADCC). Thus, it has progressed through phase 1 (Davis et al., 2007), phase 2 
(Bleumer et al., 2004), and is presently undergoing a phase 3 trial (NCT00087022) in patients 
with RCC.  In addition, cG250 accumulation in RCC lesions is extremely high and so is 
being investigated as a strategy to deliver tumour-sterilising radiation doses with cG250 as a 
carrier molecule (Divgi et al., 2004). Furthermore, preliminary research with dendritic cells 
loaded with CAIX-derived peptides have shown to activate the cellular and humoral 
immune system in patients with cytokine refractory RCC (Uemura et al., 2006). Large 
prospective trials, however, are required to establish dendritic cell vaccination with CAIX–
derived peptides or indeed direct vaccination with these peptides.  
9.2 Angiopoietins and Tie-2 
Angiopoietin/Tie-2 signalling pathways are important together with VEGF/VEGFR in the 
process of vascular endothelial growth for angiogenesis (Figure 1). Due to the highly 
vascular nature of RCC identifying new anti-angiogenic agents is highly desirable in an 
effort to try and treat this largely refractory cancer. One such target is Tie-2, an endothelium-
specific tyrosine kinase, which serves as a receptor for the family of angiopoietin ligands, 
angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), pro-angiogenic targets of HIF 
transcriptional activity. Binding of the former induces autophosphorylation of Tie-2, the 
latter antagonizes the actions of Ang-1 by competitively binding to Tie-2 without activating 
it.  Ang-1 plays an important role in the assembly of newly formed vasculature and in the 
maintenance of vascular integrity. The role of Ang-2 in angiogenesis is highly dependent on 
the presence of other angiogenic factors, particularly VEGF.  Tie-2 expression has been 
shown to correlate with angiopoietin-2 expression in RCC tumours (Liu et al., 2008).   
Development of therapeutic drugs targeting the Angiopoietin/Tie-2 pathway differ 
somewhat. They may be direct inhibitors of the tyrosine kinase i.e. to target Tie-2, selective 
and non-selective traps to target Ang-1 or -2, or systemic delivery of angiopoietins to induce 
their anti-tumour effects (Huang et al., 2010). Tie-2 kinase inhibitors include CEP-11981 and 
CE-245677, the former is currently being evaluated in an open label phase 1 trial in patients 
with advanced solid tumours. The latter tested in a phase I trial has been discontinued 
owing to unacceptable side effects. There are currently two angiopoietin traps in clinical 
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development. AMG-386 is an anti-angiopoietin peptibody which inhibits the interaction 
between ligands Ang-1 and -2 with the Tie-2 receptor. It is currently undergoing phase II 
trials in combination with sorafenib and sunitinib for the treatment of RCC (Huang et al., 
2010). The second compound PF-4856884 (also known as CVX-060) selectively targets Ang-2 
and in a phase I study demonstrated a significant reduction in RCC tumour blood flow. The 
mild side effect profile of both of these drugs provides an attractive basis for their 
combination with other anti-angiogenic or chemotherapeutic agents.  
9.3 Notch 
Notch signalling controls a variety of processes, involving cell fate specification, 
differentiation, proliferation, and survival (Artavanis-Tsakonas et al., 1999). Mammals have 
four Notch proteins, namely Notch 1-4, that function as receptors for five Notch ligands – 
Jagged1 and 2, and the delta-like ligands (DLL)-1, -3 and -4. Ligand binding leads to at least 
three subsequent proteolytic cleavages that release the intracellular domain (ICD) of Notch. 
Notch ICD subsequently translocates into the nucleus, where it forms a complex with 
essential cofactors such as c-promoter binding factor 1 (CBF1), mastermind-like 1 (MAML1) 
and the transcription factor CSL. This complex mediates the transcription of target genes 
such as that encoding Deltex, genes in the hairy enhancer of split (HES) and HES-related 
families of basic helix-loop-helix transcription factors, and others (Figure 2). Aberrant 
signalling within this pathway has previously been reported in multiple malignancies 
(Miele et al., 2006) including RCC with elevated Notch 1, 3 and Jagged-1 mRNAs (Rae et al., 
2000; Sjolund et al., 2008).  Elevated expression of DLL-4 has also been reported in RCCs 
with reduction of such basal expression having considerable effects on endothelial function 
important in tumour angiogenesis (Patel et al., 2005). Interestingly, Notch signalling can 
lead to either tumour progression or suppression depending on the cellular context (Nicolas 
et al., 2003, Xia et al., 2001). However, in the context of RCC, Notch signalling inhibition has 
lead to inhibition of RCC growth thus indicating a potential novel therapeutic pathway in 
RCC. Presently, there is strong evidence for signalling crosstalk between Notch and HIF-1ǂ. 
Cleaved Notch ICD and HIF-1ǂ appear to play an important point between the two 
signalling cascades (Gustafsson et al., 2005). Moreover, there is recent evidence to support 
Notch signalling linking AKT and hypoxia in melanomas (Bedogni et al., 2008). Whether 
this interaction is pertinent to RCC has yet to be investigated. Inhibition of Notch signalling 
as a strategy for cancer treatment has been proposed in numerous studies (Nickoloff et al., 
2003). Two approaches have been identified; selective strategies involving antisense, mAbs 
and RNA interference; nonselective strategies involving soluble or cell-associated Notch 
decoys, Ǆ-secretase inhibitors, intracellular MAML1 decoys and Ras signalling inhibitors 
(Miele et al., 2006). Currently it is too early to evaluate the true efficacy of these strategies 
and of the different drugs involved but what is known from present findings is that Notch 
inhibition in cancer deserves a thorough investigation including in patients with RCC. 
9.4 Wnt/β-catenin signalling 
Wnts are a family of secreted glycoproteins that regulate a wide range of cellular functions 
such as growth, differentiation, migration and polarity (Moon et al., 2004). Wnt signalling is 
controlled by the transcriptional coactivator ǃ-catenin, which is emerging as a key molecule 
in the pathogenesis of renal cancer. In normal quiescent cells, ǃ-catenin is bound to casein 
kinase 1, glycogen synthase kinase 3ǃ (GSK3), adenomatosis polyposis coli protein and axin. 
This complex controls ǃ-catenin phosphorylation targeting it for proteosomal degradation. 
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Wnt positively regulates ǃ-catenin, preventing its phosphorylation, ubiquitination and 
degradation. Thus, upon Wnt pathway activation hypophosphorylated ǃ-catenin 
translocates into the nucleus and forms a complex with the DNA binding protein T cell 
factor (TCF) (Figure 2). The ǃ-catenin/TCF complex activates transcription of a wide range 
of genes including growth promoting genes such as VEGF (Easwaran et al., 2003) as well as 
the MYC oncogene which shows copy number amplification in RCC (Beroukhim et al., 
2009). Wnt can also mediate its effect on cell growth and tumour promotion by activating 
the mTOR pathway (Inoki et al., 2006). TSC2 is phosphorylated by GSK3 for its activation 
and subsequent inhibition of mTOR. Wnt activates mTOR pathway by inhibiting GSK3.  
There are several papers outlining the involvement of Wnt signalling in RCC. 
Overexpression of ǃ-catenin can induce renal tumours in mice (Sansom et al., 2005). In some 
RCC tumours the APC gene promoter is aberrantly hypermethylated providing a 
mechanism by which ǃ-catenin is liberated  (Battagli et al., 2003). ǃ-catenin is also degraded 
by the E3-ubiquitin ligase activity of VHL and so loss of VHL in RCC has been shown to 
enable HGF-driven oncogenic ǃ-catenin signalling (Peruzzi et al., 2006). In a recent article 
further evidence for the activation of Wnt signalling in RCC was outlined when a deletion of 
CXXC4 a gene coding for Idax, an inhibitor of this pathway, was identified in aggressive 
RCC (Kojima et al., 2009). In addition, various Wnt antagonists such as secreted-Frizzled 
receptor proteins, Dickkopf 2 and Wnt inhibitory factor 1 were found to be hypermethylated 
and thus silenced in RCC (Awakura et al., 2008; Hirata et al., 2009; Kawakami et al., 2009). It 
is also possible that loss of VHL could lead to the combined de-repression of HIFs and ǃ-
catenin which could also lead to RCC (Linehan et al., 2009). Finally, Jade-1 (gene for 
apoptosis and differentiation in epithelia) has been identified as a VHL-interacting protein 
which brings about ǃ-catenin degradation. Thus, Jade-1 is thought to function as a renal 
tumour suppressor (Chitalia et al., 2008). Loss of VHL can bring about a reduction in Jade-1 
levels with subsequent increases in ǃ-catenin levels, providing another caveat by which loss 
of VHL can promote renal tumourigenesis. In summary Wnt signalling has a dual role in the 
pathogenesis of RCC. It induces transcription through activation of ǃ-catenin but also 
activates mTOR signalling driving cellular growth. Thus, Wnt signalling and ǃ-catenin 
provide attractive targets for therapeutic intervention in RCC. At present there are no 
clinically available drugs targeting this pathway in RCC but may become available in the 
near future.  
10. HGF/MET signalling 
Kidney tissue is an abundant source of hepatocyte growth factor (HGF) a stromal cell-derived 
cytokine involved in cell proliferation, tissue regeneration, tumour growth and tumour 
invasion through the HGF/scatter factor (SF):c-MET pathway (Cantley et al., 1994). HGF 
binding to MET leads to its phosphorylation and subsequent recruitment of adapter proteins 
such as Gab1, Gab2, SHC, STAT3 and PI3K with downstream activation of Ras/MAPK and 
PI3K/AKT pathways (Figure 2) resulting in RCC growth and metastasis (Eder et al., 2009). 
Different studies have shown that HGF and its receptor c-MET are overexpressed in RCC and 
play a significant role in the progression of RCC (Horie et al., 1999; Natali et al., 1996). 
Moreover, VHL-negative RCC cells exhibit cell invasion and branching morphogenesis in 
response to HGF (Koochekpour et al., 1999). c-MET has also been shown to be constitutively 
phosphorylated in RCC and high levels of serum HGF/SF in RCC patients are associated with 
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reduced survival (Tanimoto et al., 2008). Presently, MET is being targeted in clinical trials for 
the treatment of RCC (Giubellino et al., 2009). Strategies involve preventing c-MET 
autophosphorylation; prevention of HGF binding to c-MET and lastly targeting the signalling 
cascade of activated c-MET (Toschi & Janne, 2008). One such investigational drug is AMG 102, 
a fully human mAb that blocks HGF/SF binding to c-EMT and blocks signalling events 
driving tumour proliferation, migration, invasion and survival (Figure 2). Reports of a phase II 
trial with AMG 102 identified that although the drug brought about tumour burden reduction 
and long-term disease stability, it was unclear from the study whether this drug is capable of 
tumour growth inhibition in a histologically diverse population of patients with mRCC 
(Schoffski et al., 2010). Other drugs currently in development include foretinib (GSK1363089) 
an oral multi kinase inhibitor of MET and VEGFRs (Kataoka et al., 2011), ARQ 197, a selective 
non-ATP competitive inhibitor of MET (Adjei et al., 2011) and a range of orally available c-
MET kinase inhibitors namely (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-
yl-1H-pyrazol-4-yl)-pyridin-2-ylamine (PF02341066) and 2-[4-(3-quinolin-6-ylmethyl-3H-
[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol (PF04217903) (Yamazaki et al., 2011). 
The efficacy of these drugs have yet to be investigated in patients with RCC. Thus, further 
investigations of these potentially effective therapeutic drugs is warranted at this time. 
11. Conclusions and future directions 
RCC is similar to other cancer types in that it is asymptomatic initially with a lack of early 
warning signs. This results in a high percentage of patients presenting with metastasis at 
diagnosis or indeed relapse following nephrectomy. RCC is also known for its unpredictable 
clinical behaviour. Historically RCC and mRCC has been associated with treatment 
resistance and poor prognosis. However, with ever increasing knowledge of angiogenesis 
and aberrant signalling pathways in patients with RCC recent basic and clinical 
developments has exerted a substantial impact on outcomes for patients with mRCC.  
Throughout the past fifteen years there has been an increased understanding of the tumour 
biology of RCC. There is now a myriad of treatment options available making the treatment 
of RCC and mRCC immensely complex. Sequential therapy with targeted agents is currently 
the standard of care while combination therapies are still under active investigation. 
Combination therapies can provide additive or synergistic effects resulting from more 
complete blockade of the many aberrant signalling cascades outlined above. This approach 
can also prevent or delay the development of resistance that would eventually arise with 
single-agent therapy owing to signalling pathway redundancy. Despite recent 
advancements, however, current chemotherapeutics can only increase the overall survival of 
patients from weeks to months and unfortunately cannot cure RCC. Combination regimes 
have many drawbacks and in many instances have not proven beneficial in terms of inferior 
efficacy and excessive toxicity. It is also clear from the multitude of described and ongoing 
clinical trials that patient response to targeted agents is not universal. Thus, we have 
reached the stage where there is compelling need to identify new combinations with the 
goal of providing maximal efficacy with manageable toxicity. Increased knowledge of 
mechanisms of disease, drug resistance, new targets and new targeted agents may 
eventually provide optimal strategies for patients with RCC and mRCC. 
Another area of note to improve the treatment of patients with RCC and mRCC is the 
identification of genetic and epigenetic markers as promising biomarkers (Pal et al., 2010; 
Vickers & Heng 2010) . This may indicate the suitability of a patient to treatment with one 
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agent above another and also the optimal sequential or combination of therapies. Many RCC 
biomarkers have been examined over the past decade and include VHL gene mutation, 
plasma VEGF, tissue and plasma VEGFRs, tissue HIF and tissue and serum CAIX as 
outlined already in this report. Others include B7-H1 a cell surface glycoprotein that acts as 
a negative regulator of anti-tumoural T cell-mediated immunity and whose high levels of 
expression in patients with RCC has been associated with shorter survival (Vickers & Heng, 
2010).   Another prognostic biomarker includes neutrophil gelatinase-associated lipocalin 
(NGAL). NGAL is elevated in a number of cancers and has been linked to MMP-9, which is 
involved in the degradation of the extracellular matrix and therefore invasion and 
metastasis. Thus, lower levels of NGAL is associated with longer PFS in RCC patients 
(Vickers & Heng, 2010). Despite growing research in this area, however, there are currently 
no biomarkers used in the clinical management of patients with RCC.  Future studies such 
as the NIH funded Cancer Genome Atlas project may provide further insight into the 
genome, mRNA and micro RNA transcriptome and methylome of RCC revealing the 
pathways and networking that is aberrant in RCC and thus aid in the identification of new 
biomarkers and therapeutic agents. Furthermore, the use of increasingly sophisticated 
integrative multivariate models which incorporate both molecular and genetic information 
will ultimately aid in the development of curative, non-toxic personalised therapies. Thus, 
research is ongoing and newer improved technologies hold promise in the expansion of our 
knowledge of pathogenesis and determinants of outcome. In summary, in the future 
researchers and clinicians alike will have to unite and develop a workable cohesive strategy 
to optimise use of available agents as well as those undergoing clinical trials and identify 
optimal strategies for the successful treatment of patients with RCC. 
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